{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "a03d8e3e",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import sys\n",
    "from selenium.webdriver.support.ui import WebDriverWait\n",
    "from selenium.webdriver.common.by import By\n",
    "from selenium.webdriver.support import expected_conditions as EC\n",
    "from selenium.webdriver import ActionChains\n",
    "import selenium\n",
    "from selenium import webdriver\n",
    "from selenium.webdriver.common.keys import Keys\n",
    "import time\n",
    "from webdriver_manager.chrome import ChromeDriverManager"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "946d4391",
   "metadata": {},
   "outputs": [],
   "source": [
    "driver=webdriver.Chrome()\n",
    "driver.get(\"https://acrabstracts.org/meetings/acr-convergence-2021/?viewby=sessions\")\n",
    "driver.maximize_window()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 156,
   "id": "e78751f0",
   "metadata": {},
   "outputs": [],
   "source": [
    "# /html/body/div[2]/div/div/div/main/div/div[2]/dl[1]/dd/h5/a\n",
    "# /html/body/div[2]/div/div/div/main/div/div[2]/dl[2]/dd/h5/a\n",
    "# /html/body/div[2]/div/div/div/main/div/div[2]/dl[27]/dd/h5/a\n",
    "# /html/body/div[2]/div/div/div/main/div/div[2]/dl[55]/dd/h5/a\n",
    "# /html/body/div[2]/div/div/div/main/div/div[2]/dl[160]/dd/h5/a\n",
    "# /html/body/div[2]/div/div/div/main/div/div[2]/dl[171]/dd/h5/a\n",
    "# /html/body/div[2]/div/div/div/main/div/div[2]/dl[128]/dd/h5/a"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "81f7b0d8",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1\n",
      "2\n",
      "3\n",
      "4\n",
      "5\n",
      "6\n",
      "7\n",
      "8\n",
      "9\n",
      "10\n",
      "11\n",
      "12\n",
      "13\n",
      "14\n",
      "15\n",
      "16\n",
      "17\n",
      "18\n",
      "19\n",
      "20\n",
      "21\n",
      "22\n",
      "23\n",
      "24\n",
      "25\n",
      "26\n",
      "27\n",
      "28\n",
      "29\n",
      "30\n",
      "31\n",
      "32\n",
      "33\n",
      "34\n",
      "35\n",
      "36\n",
      "37\n",
      "38\n",
      "39\n",
      "40\n",
      "41\n",
      "42\n",
      "43\n",
      "44\n",
      "45\n",
      "46\n",
      "47\n",
      "48\n",
      "49\n",
      "50\n",
      "51\n",
      "52\n",
      "53\n",
      "54\n",
      "55\n",
      "56\n",
      "57\n",
      "58\n",
      "59\n",
      "60\n",
      "61\n",
      "62\n",
      "63\n",
      "64\n",
      "65\n",
      "66\n",
      "67\n",
      "68\n",
      "69\n",
      "70\n",
      "71\n",
      "72\n",
      "73\n",
      "74\n",
      "75\n",
      "76\n",
      "77\n",
      "78\n",
      "79\n",
      "80\n",
      "81\n",
      "82\n",
      "83\n",
      "84\n",
      "85\n",
      "86\n",
      "87\n",
      "88\n",
      "89\n",
      "90\n",
      "91\n",
      "92\n",
      "93\n",
      "94\n",
      "95\n",
      "96\n",
      "97\n",
      "98\n",
      "99\n",
      "100\n",
      "101\n",
      "102\n",
      "103\n",
      "104\n",
      "105\n",
      "106\n",
      "107\n",
      "108\n",
      "109\n",
      "110\n",
      "111\n",
      "112\n",
      "113\n",
      "114\n",
      "115\n",
      "116\n",
      "117\n",
      "118\n",
      "119\n",
      "120\n",
      "121\n",
      "122\n",
      "123\n",
      "124\n",
      "125\n",
      "126\n",
      "127\n",
      "128\n"
     ]
    }
   ],
   "source": [
    "links=[]\n",
    "i=1\n",
    "while(i<=128):\n",
    "    try:\n",
    "        el=driver.find_element(By.XPATH,'/html/body/div[2]/div/div/div/main/div/div[2]/dl['+str(i)+']/dd/h5/a')\n",
    "        links.append(el.get_attribute('href'))\n",
    "        print(i)\n",
    "    except:\n",
    "        print(\"error\",i)\n",
    "    i+=1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "94e7df2e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['https://acrabstracts.org/sessions/antiphospholipid-syndrome-poster-00690083-2021',\n",
       " 'https://acrabstracts.org/sessions/b-cell-biology-targets-in-autoimmune-inflammatory-disease-poster-00010010-2021',\n",
       " 'https://acrabstracts.org/sessions/epidemiology-public-health-poster-i-covid-19-vaccination-00840117-2021',\n",
       " 'https://acrabstracts.org/sessions/fibromyalgia-other-clinical-pain-syndromes-poster-01180127-2021',\n",
       " 'https://acrabstracts.org/sessions/health-services-research-poster-i-lupus-inflammatory-arthritis-more-01280148-2021',\n",
       " 'https://acrabstracts.org/sessions/imaging-of-rheumatic-diseases-poster-01490182-2021',\n",
       " 'https://acrabstracts.org/sessions/miscellaneous-rheumatic-inflammatory-diseases-poster-i-01830209-2021',\n",
       " 'https://acrabstracts.org/sessions/osteoarthritis-clinical-poster-i-02100224-2021',\n",
       " 'https://acrabstracts.org/sessions/patient-outcomes-preferences-attitudes-poster-i-impact-02250240-2021',\n",
       " 'https://acrabstracts.org/sessions/pediatric-rheumatology-clinical-poster-i-jia-02410265-2021',\n",
       " 'https://acrabstracts.org/sessions/psychologysocial-sciences-poster-02660267-2021',\n",
       " 'https://acrabstracts.org/sessions/ra-diagnosis-manifestations-outcomes-poster-i-cardiovascular-pulmonary-disease-02680295-2021',\n",
       " 'https://acrabstracts.org/sessions/ra-etiology-pathogenesis-poster-00110045-2021',\n",
       " 'https://acrabstracts.org/sessions/sjgrens-syndrome-basic-clinical-science-poster-02960322-2021',\n",
       " 'https://acrabstracts.org/sessions/sle-diagnosis-manifestations-outcomes-poster-i-diagnosis-03230356-2021',\n",
       " 'https://acrabstracts.org/sessions/spondyloarthritis-including-psa-basic-science-poster-00460068-2021',\n",
       " 'https://acrabstracts.org/sessions/spondyloarthritis-including-psa-diagnosis-manifestations-outcomes-poster-i-clinical-aspects-of-axial-spondyloarthritis-03570386-2021',\n",
       " 'https://acrabstracts.org/sessions/systemic-sclerosis-related-disorders-clinical-poster-i-03870413-2021',\n",
       " 'https://acrabstracts.org/sessions/vasculitis-anca-associated-poster-04140436-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-immunological-complications-of-therapy-04370440-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-muscle-biology-myositis-myopathies-04410444-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-osteoporosis-metabolic-bone-disease-basic-clinical-science-04450448-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-spondyloarthritis-including-psa-diagnosis-manifestations-outcomes-i-04490452-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-health-services-research-04620465-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-imaging-of-rheumatic-diseases-04660469-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-ra-etiology-pathogenesis-04580461-2021',\n",
       " 'https://acrabstracts.org/sessions/plenary-i-04530457-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-fibromyalgia-other-clinical-pain-syndromes-04740477-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-sle-animal-models-04700473-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-osteoarthritis-clinical-04780483-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-professional-education-04840487-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-spondyloarthritis-including-psa-treatment-i-emerging-therapies-04880491-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-healthcare-disparities-in-rheumatology-04920495-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-systemic-sclerosis-related-disorders-clinical-04960501-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-vasculitis-non-anca-associated-related-disorders-05020507-2021',\n",
       " 'https://acrabstracts.org/sessions/cytokines-cell-trafficking-poster-05080516-2021',\n",
       " 'https://acrabstracts.org/sessions/epidemiology-public-health-poster-ii-inflammatory-arthritis-ra-spa-gout-05600593-2021',\n",
       " 'https://acrabstracts.org/sessions/genetics-genomics-proteomics-poster-05170533-2021',\n",
       " 'https://acrabstracts.org/sessions/healthcare-disparities-in-rheumatology-poster-05940622-2021',\n",
       " 'https://acrabstracts.org/sessions/measures-measurement-of-healthcare-quality-poster-06230659-2021',\n",
       " 'https://acrabstracts.org/sessions/metabolic-crystal-arthropathies-basic-clinical-science-poster-i-06600682-2021',\n",
       " 'https://acrabstracts.org/sessions/muscle-biology-myositis-myopathies-poster-06830722-2021',\n",
       " 'https://acrabstracts.org/sessions/osteoarthritis-clinical-poster-ii-07230738-2021',\n",
       " 'https://acrabstracts.org/sessions/patient-outcomes-preferences-attitudes-poster-ii-measurements-07390763-2021',\n",
       " 'https://acrabstracts.org/sessions/patient-perspectives-poster-pp01pp09-2021',\n",
       " 'https://acrabstracts.org/sessions/pediatric-rheumatology-clinical-poster-ii-sle-jdm-juvenile-scleroderma-07640785-2021',\n",
       " 'https://acrabstracts.org/sessions/ra-diagnosis-manifestations-outcomes-poster-ii-miscellaneous-aspects-of-ra-07860812-2021',\n",
       " 'https://acrabstracts.org/sessions/ra-treatments-poster-i-comparative-effectiveness-biosimilars-withdrawal-the-real-world-08130845-2021',\n",
       " 'https://acrabstracts.org/sessions/research-methodology-poster-08460854-2021',\n",
       " 'https://acrabstracts.org/sessions/sle-animal-models-poster-05340540-2021',\n",
       " 'https://acrabstracts.org/sessions/sle-diagnosis-manifestations-outcomes-poster-ii-manifestations-08550896-2021',\n",
       " 'https://acrabstracts.org/sessions/spondyloarthritis-including-psa-diagnosis-manifestations-outcomes-poster-ii-imaging-in-spondyloarthritis-08970907-2021',\n",
       " 'https://acrabstracts.org/sessions/spondyloarthritis-including-psa-treatment-poster-i-axial-spondyloarthritis-09080939-2021',\n",
       " 'https://acrabstracts.org/sessions/systemic-sclerosis-related-disorders-basic-science-poster-05410559-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-antiphospholipid-syndrome-09480951-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-osteoarthritis-joint-biology-basic-science-09400943-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-spondyloarthritis-including-psa-basic-science-09440947-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-vasculitis-anca-associated-09520955-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-infection-related-rheumatic-disease-09620965-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-t-cell-biology-targets-in-autoimmune-inflammatory-disease-09660969-2021',\n",
       " 'https://acrabstracts.org/sessions/plenary-ii-09560961-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-pediatric-rheumatology-clinical-09740979-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-ra-diagnosis-manifestations-outcomes-i-bugs-drugs-09800983-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-sle-etiology-pathogenesis-09700973-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-sjgrens-syndrome-basic-clinical-science-09840987-2021',\n",
       " 'https://acrabstracts.org/sessions/patient-perspectives-pp10pp13-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-epidemiology-public-health-i-risk-in-rheumatic-diseases-09880991-2021',\n",
       " 'https://acrabstracts.org/sessions/epidemiology-public-health-poster-iii-other-rheumatic-musculoskeletal-diseases-10221060-2021',\n",
       " 'https://acrabstracts.org/sessions/health-services-research-poster-ii-care-models-and-innovation-10611082-2021',\n",
       " 'https://acrabstracts.org/sessions/innate-immunity-poster-09921006-2021',\n",
       " 'https://acrabstracts.org/sessions/miscellaneous-rheumatic-inflammatory-diseases-poster-ii-clinical-features-diagnostics-10831117-2021',\n",
       " 'https://acrabstracts.org/sessions/osteoarthritis-clinical-poster-iii-11181134-2021',\n",
       " 'https://acrabstracts.org/sessions/osteoporosis-metabolic-bone-disease-basic-clinical-science-poster-11351149-2021',\n",
       " 'https://acrabstracts.org/sessions/patient-educationcommunity-programs-poster-11501152-2021',\n",
       " 'https://acrabstracts.org/sessions/patient-outcomes-preferences-attitudes-poster-iii-patient-preferences-11531169-2021',\n",
       " 'https://acrabstracts.org/sessions/pediatric-rheumatology-basic-science-poster-10071013-2021',\n",
       " 'https://acrabstracts.org/sessions/professional-education-poster-11701195-2021',\n",
       " 'https://acrabstracts.org/sessions/ra-animal-models-poster-10141021-2021',\n",
       " 'https://acrabstracts.org/sessions/ra-diagnosis-manifestations-outcomes-poster-iii-prediction-biomarkers-treatment-response-11961222-2021',\n",
       " 'https://acrabstracts.org/sessions/ra-treatments-poster-ii-pros-biomarkers-systemic-inflammation-12231256-2021',\n",
       " 'https://acrabstracts.org/sessions/sle-diagnosis-manifestations-outcomes-poster-iii-outcomes-12571303-2021',\n",
       " 'https://acrabstracts.org/sessions/spondyloarthritis-including-psa-diagnosis-manifestations-outcomes-iii-comorbidities-extra-muskuloskeletal-manifestations-related-conditions-13041328-2021',\n",
       " 'https://acrabstracts.org/sessions/spondyloarthritis-including-psa-treatment-poster-ii-psoriatic-arthritis-i-13291363-2021',\n",
       " 'https://acrabstracts.org/sessions/systemic-sclerosis-related-disorders-clinical-poster-ii-13641390-2021',\n",
       " 'https://acrabstracts.org/sessions/vasculitis-non-anca-associated-related-disorders-poster-i-giant-cell-arteritis-polymyalgia-rheumatica-13911419-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-sle-diagnosis-manifestations-outcomes-i-covid-19-vaccine-experience-translational-science-14201423-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-innate-immunity-14301433-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-systemic-sclerosis-related-disorders-basic-science-14341437-2021',\n",
       " 'https://acrabstracts.org/sessions/plenary-iii-14241429-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-clinical-epidemiology-14461451-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-cytokines-cell-trafficking-14381441-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-ra-treatments-ii-new-findings-in-established-therapies-14421445-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-miscellaneous-rheumatic-inflammatory-diseases-new-insights-into-therapies-mechanisms-of-disease-14521457-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-sle-treatment-new-agents-old-agents-14581463-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-reproductive-issues-in-rheumatic-disorders-14641467-2021',\n",
       " 'https://acrabstracts.org/sessions/immunological-complications-of-therapy-poster-15161529-2021',\n",
       " 'https://acrabstracts.org/sessions/infection-related-rheumatic-disease-poster-15301564-2021',\n",
       " 'https://acrabstracts.org/sessions/late-breaking-posters-l01-l15-2021',\n",
       " 'https://acrabstracts.org/sessions/metabolic-crystal-arthropathies-basic-clinical-science-poster-ii-15651583-2021',\n",
       " 'https://acrabstracts.org/sessions/orthopedics-low-back-pain-rehabilitation-poster-15841588-2021',\n",
       " 'https://acrabstracts.org/sessions/osteoarthritis-joint-biology-basic-science-poster-14681479-2021',\n",
       " 'https://acrabstracts.org/sessions/patient-outcomes-preferences-attitudes-poster-iv-covid-19-15891613-2021',\n",
       " 'https://acrabstracts.org/sessions/pediatric-rheumatology-clinical-poster-iii-miscellaneous-rheumatic-disease-16141644-2021',\n",
       " 'https://acrabstracts.org/sessions/ra-diagnosis-manifestations-outcomes-poster-iv-outcomes-trajectory-of-disease-epidemiology-16451673-2021',\n",
       " 'https://acrabstracts.org/sessions/ra-treatments-poster-iii-ra-treatments-their-safety-16741710-2021',\n",
       " 'https://acrabstracts.org/sessions/reproductive-issues-in-rheumatic-disorders-poster-17111731-2021',\n",
       " 'https://acrabstracts.org/sessions/sle-etiology-pathogenesis-poster-14801506-2021',\n",
       " 'https://acrabstracts.org/sessions/sle-treatment-poster-17321772-2021',\n",
       " 'https://acrabstracts.org/sessions/spondyloarthritis-including-psa-diagnosis-manifestations-outcomes-poster-iv-clinical-aspects-of-psa-peripheral-spa-17731800-2021',\n",
       " 'https://acrabstracts.org/sessions/spondyloarthritis-including-psa-treatment-poster-iii-psoriatic-arthritis-ii-18011835-2021',\n",
       " 'https://acrabstracts.org/sessions/systemic-sclerosis-related-disorders-clinical-poster-iii-18361861-2021',\n",
       " 'https://acrabstracts.org/sessions/t-cell-biology-targets-in-autoimmune-inflammatory-disease-poster-15071515-2021',\n",
       " 'https://acrabstracts.org/sessions/vasculitis-non-anca-associated-related-disorders-poster-ii-18621888-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-ra-animal-models-18891892-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-measures-measurement-of-healthcare-quality-18931896-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-metabolic-crystal-arthropathies-basic-clinical-science-18971900-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-orthopedics-low-back-pain-rehabilitation-19011904-2021',\n",
       " 'https://acrabstracts.org/sessions/late-breaking-abstracts-l16-l21-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-b-cell-biology-targets-in-autoimmune-inflammatory-disease-19051908-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-patient-outcomes-preferences-attitudes-19091914-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-ra-diagnosis-manifestations-outcomes-ii-heart-lung-19151918-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-spondyloarthritis-including-psa-diagnosis-manifestations-outcomes-ii-19191922-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-epidemiology-public-health-ii-inflammatory-arthritis-19231926-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-pediatric-rheumatology-basic-science-19271930-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-sle-diagnosis-manifestations-outcomes-ii-predictors-longitudinal-outcomes-19311934-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-genetics-genomics-proteomics-19351938-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-ra-treatments-i-safety-harms-19391942-2021',\n",
       " 'https://acrabstracts.org/sessions/abstracts-spondyloarthritis-including-psa-treatment-ii-biologic-therapies-19431946-2021']"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "links"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "28265ffb",
   "metadata": {},
   "outputs": [],
   "source": [
    "items = links\n",
    "file = open('ACR2021LINKS.txt','w')\n",
    "for item in items:\n",
    "    file.write(item+\"\\n\")\n",
    "file.close()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "0ec22626",
   "metadata": {},
   "outputs": [],
   "source": [
    "# /html/body/div[2]/div/div/div/main/div/div[2]/dl[1]/dd/h5/a\n",
    "# driver.find_element(By.XPATH,'/html/body/div[2]/div/div/div/main/div/div[2]/dl[1]/dd/h5/a').text\n",
    "session_names=[]\n",
    "i=1\n",
    "while(i<=128):\n",
    "    t=driver.find_element(By.XPATH,'/html/body/div[2]/div/div/div/main/div/div[2]/dl['+str(i)+']/dd/h5/a').text\n",
    "    session_names.append(t)\n",
    "    i+=1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "0978d34e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Antiphospholipid Syndrome Poster (0069–0083)',\n",
       " 'B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)',\n",
       " 'Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)',\n",
       " 'Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)',\n",
       " 'Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)',\n",
       " 'Imaging of Rheumatic Diseases Poster (0149–0182)',\n",
       " 'Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)',\n",
       " 'Osteoarthritis – Clinical Poster I (0210–0224)',\n",
       " 'Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)',\n",
       " 'Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)',\n",
       " 'Psychology/Social Sciences Poster (0266–0267)',\n",
       " 'RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)',\n",
       " 'RA – Etiology & Pathogenesis Poster (0011–0045)',\n",
       " \"Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\",\n",
       " 'SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)',\n",
       " 'Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)',\n",
       " 'Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)',\n",
       " 'Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)',\n",
       " 'Vasculitis – ANCA-Associated Poster (0414–0436)',\n",
       " 'Abstracts: Immunological Complications of Therapy (0437–0440)',\n",
       " 'Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)',\n",
       " 'Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)',\n",
       " 'Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)',\n",
       " 'Abstracts: Health Services Research (0462–0465)',\n",
       " 'Abstracts: Imaging of Rheumatic Diseases (0466–0469)',\n",
       " 'Abstracts: RA – Etiology & Pathogenesis (0458–0461)',\n",
       " 'Plenary I (0453–0457)',\n",
       " 'Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)',\n",
       " 'Abstracts: SLE – Animal Models (0470–0473)',\n",
       " 'Abstracts: Osteoarthritis – Clinical (0478–0483)',\n",
       " 'Abstracts: Professional Education (0484–0487)',\n",
       " 'Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)',\n",
       " 'Abstracts: Healthcare Disparities in Rheumatology (0492–0495)',\n",
       " 'Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)',\n",
       " 'Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)',\n",
       " 'Cytokines & Cell Trafficking Poster (0508–0516)',\n",
       " 'Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)',\n",
       " 'Genetics, Genomics & Proteomics Poster (0517–0533)',\n",
       " 'Healthcare Disparities in Rheumatology Poster (0594–0622)',\n",
       " 'Measures & Measurement of Healthcare Quality Poster (0623–0659)',\n",
       " 'Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)',\n",
       " 'Muscle Biology, Myositis & Myopathies Poster (0683–0722)',\n",
       " 'Osteoarthritis – Clinical Poster II (0723–0738)',\n",
       " 'Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)',\n",
       " 'Patient Perspectives Poster (PP01–PP09)',\n",
       " 'Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)',\n",
       " 'RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)',\n",
       " 'RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)',\n",
       " 'Research Methodology Poster (0846–0854)',\n",
       " 'SLE – Animal Models Poster (0534–0540)',\n",
       " 'SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)',\n",
       " 'Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster II: Imaging in Spondyloarthritis (0897–0907)',\n",
       " 'Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)',\n",
       " 'Systemic Sclerosis & Related Disorders – Basic Science Poster (0541–0559)',\n",
       " 'Abstracts: Antiphospholipid Syndrome (0948–0951)',\n",
       " 'Abstracts: Osteoarthritis & Joint Biology – Basic Science (0940–0943)',\n",
       " 'Abstracts: Spondyloarthritis Including PsA – Basic Science (0944–0947)',\n",
       " 'Abstracts: Vasculitis – ANCA-Associated (0952–0955)',\n",
       " 'Abstracts: Infection-related Rheumatic Disease (0962–0965)',\n",
       " 'Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (0966–0969)',\n",
       " 'Plenary II (0956–0961)',\n",
       " 'Abstracts: Pediatric Rheumatology – Clinical (0974–0979)',\n",
       " 'Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: Bugs & Drugs (0980–0983)',\n",
       " 'Abstracts: SLE – Etiology & Pathogenesis (0970–0973)',\n",
       " \"Abstracts: Sjögren's Syndrome – Basic & Clinical Science (0984–0987)\",\n",
       " 'Patient Perspectives (PP10–PP13)',\n",
       " 'Abstracts: Epidemiology & Public Health I: Risk in Rheumatic Diseases (0988–0991)',\n",
       " 'Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)',\n",
       " 'Health Services Research Poster II: Care Models and Innovation (1061–1082)',\n",
       " 'Innate Immunity Poster (0992–1006)',\n",
       " 'Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)',\n",
       " 'Osteoarthritis – Clinical Poster III (1118–1134)',\n",
       " 'Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster (1135–1149)',\n",
       " 'Patient Education/Community Programs Poster (1150–1152)',\n",
       " 'Patient Outcomes, Preferences, & Attitudes Poster III: Patient Preferences (1153–1169)',\n",
       " 'Pediatric Rheumatology – Basic Science Poster (1007–1013)',\n",
       " 'Professional Education Poster (1170–1195)',\n",
       " 'RA – Animal Models Poster (1014–1021)',\n",
       " 'RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)',\n",
       " 'RA – Treatments Poster II: PROs, Biomarkers, & Systemic Inflammation (1223–1256)',\n",
       " 'SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)',\n",
       " 'Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)',\n",
       " 'Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)',\n",
       " 'Systemic Sclerosis & Related Disorders – Clinical Poster II (1364–1390)',\n",
       " 'Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Giant Cell Arteritis & Polymyalgia Rheumatica (1391–1419)',\n",
       " 'Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: COVID-19 Vaccine Experience & Translational Science (1420–1423)',\n",
       " 'Abstracts: Innate Immunity (1430–1433)',\n",
       " 'Abstracts: Systemic Sclerosis & Related Disorders – Basic Science (1434–1437)',\n",
       " 'Plenary III (1424–1429)',\n",
       " 'Abstracts: Clinical Epidemiology (1446–1451)',\n",
       " 'Abstracts: Cytokines & Cell Trafficking (1438–1441)',\n",
       " 'Abstracts: RA – Treatments II: New Findings in Established Therapies (1442–1445)',\n",
       " 'Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases: New Insights into Therapies & Mechanisms of Disease (1452–1457)',\n",
       " 'Abstracts: SLE – Treatment: New Agents, Old Agents (1458–1463)',\n",
       " 'Abstracts: Reproductive Issues in Rheumatic Disorders (1464–1467)',\n",
       " 'Immunological Complications of Therapy Poster (1516–1529)',\n",
       " 'Infection-related Rheumatic Disease Poster (1530–1564)',\n",
       " 'Late-Breaking Posters (L01 - L15)',\n",
       " 'Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II (1565–1583)',\n",
       " 'Orthopedics, Low Back Pain, & Rehabilitation Poster (1584–1588)',\n",
       " 'Osteoarthritis & Joint Biology – Basic Science Poster (1468–1479)',\n",
       " 'Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)',\n",
       " 'Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)',\n",
       " 'RA – Diagnosis, Manifestations, & Outcomes Poster IV: Outcomes, Trajectory of Disease, & Epidemiology (1645–1673)',\n",
       " 'RA – Treatments Poster III: RA Treatments & Their Safety (1674–1710)',\n",
       " 'Reproductive Issues in Rheumatic Disorders Poster (1711–1731)',\n",
       " 'SLE – Etiology & Pathogenesis Poster (1480–1506)',\n",
       " 'SLE – Treatment Poster (1732–1772)',\n",
       " 'Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster IV: Clinical Aspects of PsA & Peripheral SpA (1773–1800)',\n",
       " 'Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)',\n",
       " 'Systemic Sclerosis & Related Disorders – Clinical Poster III (1836–1861)',\n",
       " 'T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (1507–1515)',\n",
       " 'Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)',\n",
       " 'Abstracts: RA – Animal Models (1889–1892)',\n",
       " 'Abstracts: Measures & Measurement of Healthcare Quality (1893–1896)',\n",
       " 'Abstracts: Metabolic & Crystal Arthropathies – Basic & Clinical Science (1897–1900)',\n",
       " 'Abstracts: Orthopedics, Low Back Pain, & Rehabilitation (1901–1904)',\n",
       " 'Late-Breaking Abstracts (L16 - L21)',\n",
       " 'Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (1905–1908)',\n",
       " 'Abstracts: Patient Outcomes, Preferences, & Attitudes (1909–1914)',\n",
       " 'Abstracts: RA – Diagnosis, Manifestations, & Outcomes II: Heart & Lung (1915–1918)',\n",
       " 'Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes II (1919–1922)',\n",
       " 'Abstracts: Epidemiology & Public Health II: Inflammatory Arthritis (1923–1926)',\n",
       " 'Abstracts: Pediatric Rheumatology – Basic Science (1927–1930)',\n",
       " 'Abstracts: SLE – Diagnosis, Manifestations, & Outcomes II: Predictors & Longitudinal Outcomes (1931–1934)',\n",
       " 'Abstracts: Genetics, Genomics & Proteomics (1935–1938)',\n",
       " 'Abstracts: RA – Treatments I: Safety & Harms (1939–1942)',\n",
       " 'Abstracts: Spondyloarthritis Including PsA – Treatment II: Biologic Therapies (1943–1946)']"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "session_names"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "90a101c2",
   "metadata": {},
   "outputs": [],
   "source": [
    "#date\n",
    "# /html/body/div[2]/div/div/div/main/div/div[2]/dl[1]/dt\n",
    "# /html/body/div[2]/div/div/div/main/div/div[2]/dl[2]/dt\n",
    "# /html/body/div[2]/div/div/div/main/div/div[2]/dl[15]/dt\n",
    "# /html/body/div[2]/div/div/div/main/div/div[2]/dl[28]/dt\n",
    "# /html/body/div[2]/div/div/div/main/div/div[2]/dl[107]/dt\n",
    "# /html/body/div[2]/div/div/div/main/div/div[2]/dl[171]/dt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "6e5612aa",
   "metadata": {},
   "outputs": [],
   "source": [
    "timings=[]\n",
    "i=1\n",
    "while(i<=128):\n",
    "    t=driver.find_element(By.XPATH,'/html/body/div[2]/div/div/div/main/div/div[2]/dl['+str(i)+']/dt').text\n",
    "    timings.append(t)\n",
    "    i+=1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "65e54195",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '9:00AM-10:00AM',\n",
       " '9:00AM-10:00AM',\n",
       " '9:30AM-10:30AM',\n",
       " '9:30AM-10:30AM',\n",
       " '10:30AM-11:30AM',\n",
       " '10:30AM-11:30AM',\n",
       " '10:30AM-11:30AM',\n",
       " '10:30AM-12:00PM',\n",
       " '11:00AM-12:00PM',\n",
       " '11:00AM-12:00PM',\n",
       " '2:00PM-3:30PM',\n",
       " '2:00PM-3:00PM',\n",
       " '2:00PM-3:00PM',\n",
       " '3:30PM-4:30PM',\n",
       " '3:30PM-5:00PM',\n",
       " '3:30PM-5:00PM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '9:00AM-10:00AM',\n",
       " '9:00AM-10:00AM',\n",
       " '9:00AM-10:00AM',\n",
       " '9:00AM-10:00AM',\n",
       " '10:30AM-11:30AM',\n",
       " '10:30AM-11:30AM',\n",
       " '10:30AM-12:00PM',\n",
       " '2:00PM-3:30PM',\n",
       " '2:00PM-3:00PM',\n",
       " '2:00PM-3:00PM',\n",
       " '3:30PM-4:30PM',\n",
       " '3:30PM-4:30PM',\n",
       " '4:00PM-5:00PM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '9:00AM-10:00AM',\n",
       " '10:30AM-11:30AM',\n",
       " '10:30AM-11:30AM',\n",
       " '10:30AM-12:00PM',\n",
       " '2:00PM-3:30PM',\n",
       " '2:00PM-3:00PM',\n",
       " '2:00PM-3:00PM',\n",
       " '3:30PM-5:00PM',\n",
       " '3:30PM-5:00PM',\n",
       " '4:00PM-5:00PM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '8:30AM-10:30AM',\n",
       " '9:00AM-10:00AM',\n",
       " '10:30AM-11:30AM',\n",
       " '10:30AM-11:30AM',\n",
       " '10:30AM-11:30AM',\n",
       " '10:30AM-12:00PM',\n",
       " '2:00PM-3:00PM',\n",
       " '2:00PM-3:30PM',\n",
       " '2:00PM-3:30PM',\n",
       " '2:00PM-3:30PM',\n",
       " '3:30PM-4:30PM',\n",
       " '3:30PM-4:30PM',\n",
       " '3:30PM-4:30PM',\n",
       " '4:00PM-5:00PM',\n",
       " '4:00PM-5:00PM',\n",
       " '4:00PM-5:00PM']"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "timings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "e0a97f81",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "128"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# /html/body/div[2]/div/div/div/main/div/div[2]/dl[54]/dt\n",
    "#/html/body/div[2]/div/div/div/main/div/div[2]/dl[107]/dt\n",
    "# /html/body/div[2]/div/div/div/main/div/div[2]/dl[159]/dt\n",
    "# /html/body/div[2]/div/div/div/main/div/div[2]/dl[171]/dt\n",
    "len(timings)\n",
    "# /html/body/div[2]/div/div/div/main/div/div[2]/dl[35]/dd/h5/a\n",
    "# /html/body/div[2]/div/div/div/main/div/div[2]/dl[67]/dd/h5/a\n",
    "# /html/body/div[2]/div/div/div/main/div/div[2]/dl[95]/dd/h5/a"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "067246aa",
   "metadata": {},
   "outputs": [],
   "source": [
    "date=[]\n",
    "for i in range(len(timings)):\n",
    "    if(i<=34):\n",
    "        date.append('Saturday, November 6, 2021')\n",
    "    elif(i>34 and i<=66):\n",
    "        date.append('Sunday, November 7, 2021')\n",
    "    elif(i>66 and i<=94):\n",
    "        date.append('Monday, November 8, 2021')\n",
    "    elif(i>94 and i<=127):\n",
    "        date.append('Tuesday, November 9, 2021')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "61e07018",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Saturday, November 6, 2021      8:30AM-10:30AM\n",
      "Saturday, November 6, 2021      8:30AM-10:30AM\n",
      "Saturday, November 6, 2021      8:30AM-10:30AM\n",
      "Saturday, November 6, 2021      8:30AM-10:30AM\n",
      "Saturday, November 6, 2021      8:30AM-10:30AM\n",
      "Saturday, November 6, 2021      8:30AM-10:30AM\n",
      "Saturday, November 6, 2021      8:30AM-10:30AM\n",
      "Saturday, November 6, 2021      8:30AM-10:30AM\n",
      "Saturday, November 6, 2021      8:30AM-10:30AM\n",
      "Saturday, November 6, 2021      8:30AM-10:30AM\n",
      "Saturday, November 6, 2021      8:30AM-10:30AM\n",
      "Saturday, November 6, 2021      8:30AM-10:30AM\n",
      "Saturday, November 6, 2021      8:30AM-10:30AM\n",
      "Saturday, November 6, 2021      8:30AM-10:30AM\n",
      "Saturday, November 6, 2021      8:30AM-10:30AM\n",
      "Saturday, November 6, 2021      8:30AM-10:30AM\n",
      "Saturday, November 6, 2021      8:30AM-10:30AM\n",
      "Saturday, November 6, 2021      8:30AM-10:30AM\n",
      "Saturday, November 6, 2021      8:30AM-10:30AM\n",
      "Saturday, November 6, 2021      9:00AM-10:00AM\n",
      "Saturday, November 6, 2021      9:00AM-10:00AM\n",
      "Saturday, November 6, 2021      9:30AM-10:30AM\n",
      "Saturday, November 6, 2021      9:30AM-10:30AM\n",
      "Saturday, November 6, 2021      10:30AM-11:30AM\n",
      "Saturday, November 6, 2021      10:30AM-11:30AM\n",
      "Saturday, November 6, 2021      10:30AM-11:30AM\n",
      "Saturday, November 6, 2021      10:30AM-12:00PM\n",
      "Saturday, November 6, 2021      11:00AM-12:00PM\n",
      "Saturday, November 6, 2021      11:00AM-12:00PM\n",
      "Saturday, November 6, 2021      2:00PM-3:30PM\n",
      "Saturday, November 6, 2021      2:00PM-3:00PM\n",
      "Saturday, November 6, 2021      2:00PM-3:00PM\n",
      "Saturday, November 6, 2021      3:30PM-4:30PM\n",
      "Saturday, November 6, 2021      3:30PM-5:00PM\n",
      "Saturday, November 6, 2021      3:30PM-5:00PM\n",
      "Sunday, November 7, 2021      8:30AM-10:30AM\n",
      "Sunday, November 7, 2021      8:30AM-10:30AM\n",
      "Sunday, November 7, 2021      8:30AM-10:30AM\n",
      "Sunday, November 7, 2021      8:30AM-10:30AM\n",
      "Sunday, November 7, 2021      8:30AM-10:30AM\n",
      "Sunday, November 7, 2021      8:30AM-10:30AM\n",
      "Sunday, November 7, 2021      8:30AM-10:30AM\n",
      "Sunday, November 7, 2021      8:30AM-10:30AM\n",
      "Sunday, November 7, 2021      8:30AM-10:30AM\n",
      "Sunday, November 7, 2021      8:30AM-10:30AM\n",
      "Sunday, November 7, 2021      8:30AM-10:30AM\n",
      "Sunday, November 7, 2021      8:30AM-10:30AM\n",
      "Sunday, November 7, 2021      8:30AM-10:30AM\n",
      "Sunday, November 7, 2021      8:30AM-10:30AM\n",
      "Sunday, November 7, 2021      8:30AM-10:30AM\n",
      "Sunday, November 7, 2021      8:30AM-10:30AM\n",
      "Sunday, November 7, 2021      8:30AM-10:30AM\n",
      "Sunday, November 7, 2021      8:30AM-10:30AM\n",
      "Sunday, November 7, 2021      8:30AM-10:30AM\n",
      "Sunday, November 7, 2021      9:00AM-10:00AM\n",
      "Sunday, November 7, 2021      9:00AM-10:00AM\n",
      "Sunday, November 7, 2021      9:00AM-10:00AM\n",
      "Sunday, November 7, 2021      9:00AM-10:00AM\n",
      "Sunday, November 7, 2021      10:30AM-11:30AM\n",
      "Sunday, November 7, 2021      10:30AM-11:30AM\n",
      "Sunday, November 7, 2021      10:30AM-12:00PM\n",
      "Sunday, November 7, 2021      2:00PM-3:30PM\n",
      "Sunday, November 7, 2021      2:00PM-3:00PM\n",
      "Sunday, November 7, 2021      2:00PM-3:00PM\n",
      "Sunday, November 7, 2021      3:30PM-4:30PM\n",
      "Sunday, November 7, 2021      3:30PM-4:30PM\n",
      "Sunday, November 7, 2021      4:00PM-5:00PM\n",
      "Monday, November 8, 2021      8:30AM-10:30AM\n",
      "Monday, November 8, 2021      8:30AM-10:30AM\n",
      "Monday, November 8, 2021      8:30AM-10:30AM\n",
      "Monday, November 8, 2021      8:30AM-10:30AM\n",
      "Monday, November 8, 2021      8:30AM-10:30AM\n",
      "Monday, November 8, 2021      8:30AM-10:30AM\n",
      "Monday, November 8, 2021      8:30AM-10:30AM\n",
      "Monday, November 8, 2021      8:30AM-10:30AM\n",
      "Monday, November 8, 2021      8:30AM-10:30AM\n",
      "Monday, November 8, 2021      8:30AM-10:30AM\n",
      "Monday, November 8, 2021      8:30AM-10:30AM\n",
      "Monday, November 8, 2021      8:30AM-10:30AM\n",
      "Monday, November 8, 2021      8:30AM-10:30AM\n",
      "Monday, November 8, 2021      8:30AM-10:30AM\n",
      "Monday, November 8, 2021      8:30AM-10:30AM\n",
      "Monday, November 8, 2021      8:30AM-10:30AM\n",
      "Monday, November 8, 2021      8:30AM-10:30AM\n",
      "Monday, November 8, 2021      8:30AM-10:30AM\n",
      "Monday, November 8, 2021      9:00AM-10:00AM\n",
      "Monday, November 8, 2021      10:30AM-11:30AM\n",
      "Monday, November 8, 2021      10:30AM-11:30AM\n",
      "Monday, November 8, 2021      10:30AM-12:00PM\n",
      "Monday, November 8, 2021      2:00PM-3:30PM\n",
      "Monday, November 8, 2021      2:00PM-3:00PM\n",
      "Monday, November 8, 2021      2:00PM-3:00PM\n",
      "Monday, November 8, 2021      3:30PM-5:00PM\n",
      "Monday, November 8, 2021      3:30PM-5:00PM\n",
      "Monday, November 8, 2021      4:00PM-5:00PM\n",
      "Tuesday, November 9, 2021      8:30AM-10:30AM\n",
      "Tuesday, November 9, 2021      8:30AM-10:30AM\n",
      "Tuesday, November 9, 2021      8:30AM-10:30AM\n",
      "Tuesday, November 9, 2021      8:30AM-10:30AM\n",
      "Tuesday, November 9, 2021      8:30AM-10:30AM\n",
      "Tuesday, November 9, 2021      8:30AM-10:30AM\n",
      "Tuesday, November 9, 2021      8:30AM-10:30AM\n",
      "Tuesday, November 9, 2021      8:30AM-10:30AM\n",
      "Tuesday, November 9, 2021      8:30AM-10:30AM\n",
      "Tuesday, November 9, 2021      8:30AM-10:30AM\n",
      "Tuesday, November 9, 2021      8:30AM-10:30AM\n",
      "Tuesday, November 9, 2021      8:30AM-10:30AM\n",
      "Tuesday, November 9, 2021      8:30AM-10:30AM\n",
      "Tuesday, November 9, 2021      8:30AM-10:30AM\n",
      "Tuesday, November 9, 2021      8:30AM-10:30AM\n",
      "Tuesday, November 9, 2021      8:30AM-10:30AM\n",
      "Tuesday, November 9, 2021      8:30AM-10:30AM\n",
      "Tuesday, November 9, 2021      8:30AM-10:30AM\n",
      "Tuesday, November 9, 2021      9:00AM-10:00AM\n",
      "Tuesday, November 9, 2021      10:30AM-11:30AM\n",
      "Tuesday, November 9, 2021      10:30AM-11:30AM\n",
      "Tuesday, November 9, 2021      10:30AM-11:30AM\n",
      "Tuesday, November 9, 2021      10:30AM-12:00PM\n",
      "Tuesday, November 9, 2021      2:00PM-3:00PM\n",
      "Tuesday, November 9, 2021      2:00PM-3:30PM\n",
      "Tuesday, November 9, 2021      2:00PM-3:30PM\n",
      "Tuesday, November 9, 2021      2:00PM-3:30PM\n",
      "Tuesday, November 9, 2021      3:30PM-4:30PM\n",
      "Tuesday, November 9, 2021      3:30PM-4:30PM\n",
      "Tuesday, November 9, 2021      3:30PM-4:30PM\n",
      "Tuesday, November 9, 2021      4:00PM-5:00PM\n",
      "Tuesday, November 9, 2021      4:00PM-5:00PM\n",
      "Tuesday, November 9, 2021      4:00PM-5:00PM\n"
     ]
    }
   ],
   "source": [
    "for i in range(len(timings)):\n",
    "    print(date[i]+\"      \"+timings[i])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "52093998",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "128"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(date)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "34c0c96b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "p:  0\n",
      "p:  1\n",
      "p:  2\n",
      "p:  3\n",
      "p:  4\n",
      "p:  5\n",
      "p:  6\n",
      "p:  7\n",
      "p:  8\n",
      "p:  9\n",
      "p:  10\n",
      "p:  11\n",
      "p:  12\n",
      "p:  13\n",
      "p:  14\n",
      "p:  15\n",
      "p:  16\n",
      "p:  17\n",
      "p:  18\n",
      "p:  19\n",
      "p:  20\n",
      "p:  21\n",
      "p:  22\n",
      "p:  23\n",
      "p:  24\n",
      "p:  25\n",
      "p:  26\n",
      "p:  27\n",
      "p:  28\n",
      "p:  29\n",
      "p:  30\n",
      "p:  31\n",
      "p:  32\n",
      "p:  33\n",
      "p:  34\n",
      "p:  35\n",
      "p:  36\n",
      "p:  37\n",
      "p:  38\n",
      "p:  39\n",
      "p:  40\n",
      "p:  41\n",
      "p:  42\n",
      "p:  43\n",
      "p:  44\n",
      "p:  45\n",
      "p:  46\n",
      "p:  47\n",
      "p:  48\n",
      "p:  49\n",
      "p:  50\n",
      "p:  51\n",
      "p:  52\n",
      "p:  53\n",
      "p:  54\n",
      "p:  55\n",
      "p:  56\n",
      "p:  57\n",
      "p:  58\n",
      "p:  59\n",
      "p:  60\n",
      "p:  61\n",
      "p:  62\n",
      "p:  63\n",
      "p:  64\n",
      "p:  65\n",
      "p:  66\n",
      "p:  67\n",
      "p:  68\n",
      "p:  69\n",
      "p:  70\n",
      "p:  71\n",
      "p:  72\n",
      "p:  73\n",
      "p:  74\n",
      "p:  75\n",
      "p:  76\n",
      "p:  77\n",
      "p:  78\n",
      "p:  79\n",
      "p:  80\n",
      "p:  81\n",
      "p:  82\n",
      "p:  83\n",
      "p:  84\n",
      "p:  85\n",
      "p:  86\n",
      "p:  87\n",
      "p:  88\n",
      "p:  89\n",
      "p:  90\n",
      "p:  91\n",
      "p:  92\n",
      "p:  93\n",
      "p:  94\n",
      "p:  95\n",
      "p:  96\n",
      "p:  97\n",
      "p:  98\n",
      "p:  99\n",
      "p:  100\n",
      "p:  101\n",
      "p:  102\n",
      "p:  103\n",
      "p:  104\n",
      "p:  105\n",
      "p:  106\n",
      "p:  107\n",
      "p:  108\n",
      "p:  109\n",
      "p:  110\n",
      "p:  111\n",
      "p:  112\n",
      "p:  113\n",
      "p:  114\n",
      "p:  115\n",
      "p:  116\n",
      "p:  117\n",
      "p:  118\n",
      "p:  119\n",
      "p:  120\n",
      "p:  121\n",
      "p:  122\n",
      "p:  123\n",
      "p:  124\n",
      "p:  125\n",
      "p:  126\n",
      "p:  127\n"
     ]
    }
   ],
   "source": [
    "sub_session_links = [[]*100 for i in range(128)]\n",
    "sub_session_names = [[]*100 for i in range(128)]\n",
    "i=0\n",
    "while(i<128):\n",
    "    driver.get(links[i])\n",
    "    driver.implicitly_wait(2)\n",
    "    j=1\n",
    "    try:\n",
    "        while(j<100):\n",
    "            try:\n",
    "                ss=driver.find_element(By.XPATH,'/html/body/div[2]/div/div/div/main/div/div[2]/dl['+str(j)+']/dd/h5/a')\n",
    "                sub_session_links[i].append(ss.get_attribute('href'))\n",
    "                sub_session_names[i].append(ss.text)\n",
    "            except:\n",
    "                break\n",
    "            j+=1\n",
    "    except:\n",
    "        print(i)\n",
    "    print(\"p: \",i)\n",
    "    i+=1        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "6dd3643b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1980"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "l=0\n",
    "for i in range(len(sub_session_links)):\n",
    "    l+=len(sub_session_links[i])\n",
    "l"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "de4ddee1",
   "metadata": {},
   "outputs": [],
   "source": [
    "subitems = sub_session_links\n",
    "file = open('ACR2021_SUB_LINKS.txt','w')\n",
    "for item in subitems:\n",
    "    file.write(str(item)+\"\\n\")\n",
    "file.close()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "91057154",
   "metadata": {},
   "outputs": [],
   "source": [
    "def Divide(driver):\n",
    "    try:\n",
    "        a=[]\n",
    "        i=1\n",
    "        while(True):\n",
    "            path=\"/html/body/div[2]/div/div/div/main/div/div/div[1]/p[1]/sup[\"+str(i)+\"]\"\n",
    "            my_el=driver.find_element(By.XPATH,path)\n",
    "            a.append(my_el.text)\n",
    "            i+=1\n",
    "    except:\n",
    "        pass \n",
    "    \n",
    "    try:\n",
    "        path=\"/html/body/div[2]/div/div/div/main/div/div/div[1]/p[1]\"\n",
    "        te=driver.find_element(By.XPATH,path)\n",
    "        te=te.text\n",
    "    except:\n",
    "        pass\n",
    "    import re\n",
    "    ss=re.findall(r' and |\\d+|\\D+',te)\n",
    "    \n",
    "    li=[]\n",
    "    for i in ss:\n",
    "        temp=i.strip().strip(\",\").strip()\n",
    "        if(temp==' and ' or temp==',' or temp==\"\" or temp=='and'):\n",
    "            continue\n",
    "        else:\n",
    "            li.append(temp)\n",
    "    x=[]\n",
    "    i=0\n",
    "    j=0\n",
    "    while(i!=len(a) and j !=len(li)):\n",
    "        if(a[i]==li[j]):\n",
    "            x.append(li[j])\n",
    "            i+=1\n",
    "            j+=1\n",
    "        elif(li[j].isnumeric()):\n",
    "            if(li[j][:len(a[i])]==a[i]):\n",
    "                x.append(li[j][:len(a[i])])\n",
    "                x.append(li[j][len(a[i]):]+li[j+1])\n",
    "                j+=2\n",
    "                i+=1\n",
    "            else:\n",
    "                if(li[j-1].isnumeric()):\n",
    "                    x.append(li[j]+\" \"+li[j+1])\n",
    "                else:\n",
    "                    x[len(x)-1]+=(\" \"+li[j]+\" \"+li[j+1])\n",
    "                j+=2 \n",
    "        else:\n",
    "            x.append(li[j])\n",
    "            j+=1\n",
    "    while(j!=len(li)):\n",
    "        if(x[len(x)-1].isnumeric()):\n",
    "            x.append(li[j])\n",
    "        else:\n",
    "            x[len(x)-1]+=li[j]\n",
    "        j+=1\n",
    "    auth=[]\n",
    "    affil=[]\n",
    "    c=0\n",
    "    for i in range(len(x)):\n",
    "        if(x[i-1].isnumeric() and x[i].isnumeric()):\n",
    "            c=1\n",
    "        if(c==0):\n",
    "            auth.append(x[i])\n",
    "        else:\n",
    "            affil.append(x[i])\n",
    "    M_L=[]\n",
    "    k=[]\n",
    "    i=0\n",
    "    while(i!=len(auth)):\n",
    "        l=[]\n",
    "        if(auth[i].isnumeric()):\n",
    "            for j in range(len(affil)):\n",
    "                if(not(affil[j].isnumeric())):\n",
    "                    continue\n",
    "                if(auth[i]==affil[j]):\n",
    "                    l.append(auth[i-1])\n",
    "                    l.append(affil[j+1])\n",
    "            M_L.append(l)\n",
    "        i+=1\n",
    "    return M_L"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "ea046ba2",
   "metadata": {},
   "outputs": [],
   "source": [
    "SESSION=[]\n",
    "SUB_SESSION=[]\n",
    "NAMES=[]\n",
    "AFFILIATION=[]\n",
    "ABSTRACT=[]\n",
    "DISCLOSURE=[]\n",
    "TIME=[]\n",
    "DATE=[]\n",
    "SPEAKER=[]\n",
    "SPEAKER_AFF=[]\n",
    "import re"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d52377e2",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "51 0\n",
      "51 1\n",
      "51 2\n",
      "51 3\n",
      "51 4\n",
      "51 5\n",
      "51 6\n",
      "51 7\n",
      "51 8\n",
      "51 9\n",
      "51 10\n",
      "p 51\n",
      "52 0\n",
      "52 1\n",
      "52 2\n",
      "52 3\n",
      "52 4\n",
      "52 5\n",
      "52 6\n",
      "52 7\n",
      "52 8\n",
      "52 9\n",
      "52 10\n",
      "52 11\n",
      "52 12\n",
      "52 13\n",
      "52 14\n",
      "52 15\n",
      "52 16\n",
      "52 17\n",
      "52 18\n",
      "52 19\n",
      "52 20\n",
      "52 21\n",
      "52 22\n",
      "52 23\n",
      "52 24\n",
      "52 25\n",
      "52 26\n",
      "52 27\n",
      "52 28\n",
      "52 29\n",
      "52 30\n",
      "52 31\n",
      "p 52\n",
      "53 0\n",
      "53 1\n",
      "53 2\n",
      "53 3\n",
      "53 4\n",
      "53 5\n",
      "53 6\n",
      "53 7\n",
      "53 8\n",
      "53 9\n",
      "53 10\n",
      "53 11\n",
      "53 12\n",
      "53 13\n",
      "53 14\n",
      "53 15\n",
      "53 16\n",
      "53 17\n",
      "53 18\n",
      "p 53\n",
      "54 0\n",
      "54 1\n",
      "54 2\n",
      "54 3\n",
      "p 54\n",
      "55 0\n",
      "55 1\n",
      "55 2\n",
      "55 3\n",
      "p 55\n",
      "56 0\n",
      "56 1\n",
      "56 2\n",
      "56 3\n",
      "p 56\n",
      "57 0\n",
      "57 1\n",
      "57 2\n",
      "57 3\n",
      "p 57\n",
      "58 0\n",
      "58 1\n",
      "58 2\n",
      "58 3\n",
      "p 58\n",
      "59 0\n",
      "59 1\n",
      "59 2\n",
      "59 3\n",
      "p 59\n",
      "60 0\n",
      "60 1\n",
      "60 2\n",
      "60 3\n",
      "60 4\n",
      "60 5\n",
      "p 60\n",
      "61 0\n",
      "61 1\n",
      "61 2\n",
      "61 3\n",
      "61 4\n",
      "61 5\n",
      "p 61\n",
      "62 0\n",
      "62 1\n",
      "62 2\n",
      "62 3\n",
      "p 62\n",
      "63 0\n",
      "63 1\n",
      "63 2\n",
      "63 3\n",
      "p 63\n",
      "64 0\n",
      "64 1\n",
      "64 2\n",
      "64 3\n",
      "p 64\n",
      "65 0\n",
      "65 1\n",
      "65 2\n",
      "65 3\n",
      "p 65\n",
      "66 0\n",
      "66 1\n",
      "66 2\n",
      "66 3\n",
      "p 66\n",
      "67 0\n",
      "67 1\n",
      "67 2\n",
      "67 3\n",
      "67 4\n",
      "67 5\n",
      "67 6\n",
      "67 7\n",
      "67 8\n",
      "67 9\n",
      "67 10\n",
      "67 11\n"
     ]
    }
   ],
   "source": [
    "for l in range(51,128):\n",
    "#     len(sub_session_links[l])\n",
    "    temp_speaker=[]\n",
    "    temp_speaker_aff=[]\n",
    "    for m in range(len(sub_session_links[l])):\n",
    "        driver.get(sub_session_links[l][m])\n",
    "        driver.implicitly_wait(2)\n",
    "\n",
    "        #bold_text\n",
    "        try:\n",
    "            tt=driver.find_element(By.CLASS_NAME,'authors-and-affiliation')\n",
    "            M_L=Divide(driver)\n",
    "        except:\n",
    "            M_L=[]\n",
    "        try:\n",
    "            bold_text=tt.find_element(By.TAG_NAME,'b').text\n",
    "        except:\n",
    "            try:\n",
    "                bold_text=tt.find_element(By.TAG_NAME,'strong').text\n",
    "            except:\n",
    "                bold_text=None\n",
    "        \n",
    "            \n",
    "        authors=[]\n",
    "        affiliation=[]\n",
    "        aff_bold=''\n",
    "        \n",
    "        for i in range(len(M_L)):\n",
    "            authors.append(M_L[i][0])\n",
    "            affiliation.append(M_L[i][1])\n",
    "            if(bold_text==None):\n",
    "                aff_bold=None\n",
    "            else:\n",
    "                if(bold_text==M_L[i][0]):\n",
    "                    aff_bold=M_L[i][1]\n",
    "        if(aff_bold==''):\n",
    "            aff_bold=None\n",
    "        try:\n",
    "            background=driver.find_element(By.XPATH,'/html/body/div[2]/div/div/div/main/div/div/p[1]').text\n",
    "        except:\n",
    "            background=None\n",
    "        try:\n",
    "            methods=driver.find_element(By.XPATH,'/html/body/div[2]/div/div/div/main/div/div/p[2]').text\n",
    "        except:\n",
    "            methods=None\n",
    "        try:\n",
    "            results=driver.find_element(By.XPATH,'/html/body/div[2]/div/div/div/main/div/div/p[2]').text\n",
    "        except:\n",
    "            results=None\n",
    "        try:\n",
    "            conclusion=driver.find_element(By.XPATH,'/html/body/div[2]/div/div/div/main/div/div/p[2]').text\n",
    "        except:\n",
    "            conclusion=None\n",
    "        entire=\" \".join([background,methods,results,conclusion])\n",
    "#         print(entire)\n",
    "        try:\n",
    "            dis=driver.find_element(By.CLASS_NAME,'disclosures').text\n",
    "        except:\n",
    "            dis=None\n",
    "#         print('\\n\\n')\n",
    "#         print(dis)\n",
    "\n",
    "        tit=driver.find_element(By.CLASS_NAME,'entry-title').text\n",
    "        sess=session_names[l]\n",
    "        tim=timings[l]\n",
    "        dat=date[l]\n",
    "        times=[]\n",
    "        dates=[]\n",
    "        disclosure=[]\n",
    "        abstract=[]\n",
    "        titles=[]\n",
    "        sess_names=[]\n",
    "        if(authors==[]):\n",
    "            authors.append(None)\n",
    "        if(affiliation==[]):\n",
    "            affiliation.append(None)\n",
    "        for i in range(len(authors)):\n",
    "            disclosure.append(dis)\n",
    "            abstract.append(entire)\n",
    "            titles.append(tit)\n",
    "            sess_names.append(sess)\n",
    "            times.append(tim)\n",
    "            dates.append(dat)\n",
    "                \n",
    "        SUB_SESSION.extend(titles)\n",
    "        NAMES.extend(authors)\n",
    "        AFFILIATION.extend(affiliation)\n",
    "        ABSTRACT.extend(abstract)\n",
    "        DISCLOSURE.extend(disclosure)\n",
    "        SESSION.extend(sess_names)\n",
    "        TIME.extend(times)\n",
    "        DATE.extend(dates)\n",
    "        \n",
    "        temp_speaker.append(bold_text)\n",
    "        temp_speaker_aff.append(aff_bold)\n",
    "        print(l,m)\n",
    "        m+=1\n",
    "        \n",
    "    SPEAKER.append(temp_speaker)\n",
    "    SPEAKER_AFF.append(temp_speaker_aff)    \n",
    "    print(\"p\",l)    \n",
    "    l+=1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "id": "e8b010eb",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "15\n",
      "10\n",
      "34\n",
      "10\n",
      "21\n",
      "34\n",
      "27\n",
      "15\n",
      "16\n",
      "25\n",
      "2\n",
      "28\n",
      "35\n",
      "27\n",
      "34\n",
      "23\n",
      "30\n",
      "27\n",
      "23\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "5\n",
      "4\n",
      "4\n",
      "6\n",
      "4\n",
      "4\n",
      "4\n",
      "6\n",
      "6\n",
      "9\n",
      "34\n",
      "17\n",
      "29\n",
      "37\n",
      "23\n",
      "40\n",
      "16\n",
      "25\n",
      "9\n",
      "22\n",
      "27\n",
      "33\n",
      "9\n",
      "7\n",
      "42\n",
      "11\n",
      "32\n",
      "19\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "6\n",
      "6\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "39\n",
      "22\n",
      "15\n",
      "35\n",
      "17\n",
      "15\n",
      "3\n",
      "17\n",
      "7\n",
      "26\n",
      "8\n",
      "27\n",
      "34\n",
      "47\n",
      "25\n",
      "35\n",
      "27\n",
      "29\n",
      "4\n",
      "4\n",
      "4\n",
      "6\n",
      "6\n",
      "4\n",
      "4\n",
      "6\n",
      "6\n",
      "4\n",
      "14\n",
      "35\n",
      "15\n",
      "19\n",
      "5\n",
      "12\n",
      "25\n",
      "31\n",
      "29\n",
      "37\n",
      "21\n",
      "27\n",
      "41\n",
      "28\n",
      "35\n",
      "26\n",
      "9\n",
      "27\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "6\n",
      "4\n",
      "6\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n",
      "4\n"
     ]
    }
   ],
   "source": [
    "for i in range(len(sub_session_names)):\n",
    "    print(len(sub_session_names[i]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "id": "b348a3f3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "16"
      ]
     },
     "execution_count": 55,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "m"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "61bafc60",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "Antiphospholipid Syndrome Poster (0069–0083)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Fibromyalgia & Other Clinical Pain Syndromes Poster (0118–0127)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Imaging of Rheumatic Diseases Poster (0149–0182)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Osteoarthritis – Clinical Poster I (0210–0224)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)\n",
      "Psychology/Social Sciences Poster (0266–0267)\n",
      "Psychology/Social Sciences Poster (0266–0267)\n",
      "Psychology/Social Sciences Poster (0266–0267)\n",
      "Psychology/Social Sciences Poster (0266–0267)\n",
      "Psychology/Social Sciences Poster (0266–0267)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "RA – Etiology & Pathogenesis Poster (0011–0045)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Vasculitis – ANCA-Associated Poster (0414–0436)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Immunological Complications of Therapy (0437–0440)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (0445–0448)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes I (0449–0452)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Health Services Research (0462–0465)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: Imaging of Rheumatic Diseases (0466–0469)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Abstracts: RA – Etiology & Pathogenesis (0458–0461)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Plenary I (0453–0457)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: SLE – Animal Models (0470–0473)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Osteoarthritis – Clinical (0478–0483)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Professional Education (0484–0487)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Healthcare Disparities in Rheumatology (0492–0495)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Cytokines & Cell Trafficking Poster (0508–0516)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Genetics, Genomics & Proteomics Poster (0517–0533)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Healthcare Disparities in Rheumatology Poster (0594–0622)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Measures & Measurement of Healthcare Quality Poster (0623–0659)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Muscle Biology, Myositis & Myopathies Poster (0683–0722)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Osteoarthritis – Clinical Poster II (0723–0738)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)\n",
      "Patient Perspectives Poster (PP01–PP09)\n",
      "Patient Perspectives Poster (PP01–PP09)\n",
      "Patient Perspectives Poster (PP01–PP09)\n",
      "Patient Perspectives Poster (PP01–PP09)\n",
      "Patient Perspectives Poster (PP01–PP09)\n",
      "Patient Perspectives Poster (PP01–PP09)\n",
      "Patient Perspectives Poster (PP01–PP09)\n",
      "Patient Perspectives Poster (PP01–PP09)\n",
      "Patient Perspectives Poster (PP01–PP09)\n",
      "Patient Perspectives Poster (PP01–PP09)\n",
      "Patient Perspectives Poster (PP01–PP09)\n",
      "Patient Perspectives Poster (PP01–PP09)\n",
      "Patient Perspectives Poster (PP01–PP09)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n",
      "RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)\n"
     ]
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 322,
   "id": "ee6e9449",
   "metadata": {},
   "outputs": [],
   "source": [
    "TEMP_NAMES=NAMES"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "7504c6a1",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "6545"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(SUB_SESSION)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 332,
   "id": "8917ce08",
   "metadata": {},
   "outputs": [],
   "source": [
    "Temp_names=[]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 333,
   "id": "13046d93",
   "metadata": {},
   "outputs": [],
   "source": [
    "for i in range(len(NAMES)):\n",
    "    Temp_names.append(NAMES[i][0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 354,
   "id": "706a23c1",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "24951"
      ]
     },
     "execution_count": 354,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(Temp_names)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 346,
   "id": "2b48ad1d",
   "metadata": {},
   "outputs": [],
   "source": [
    "Total_speaker_names=[]\n",
    "Total_speaker_aff=[]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 347,
   "id": "074e0115",
   "metadata": {},
   "outputs": [],
   "source": [
    "for i in range(len(SPEAKER)):\n",
    "    for j in range(len(SPEAKER[i])):\n",
    "        Total_speaker_names.append(SPEAKER[i][j])\n",
    "        Total_speaker_aff.append(SPEAKER_AFF[i][j])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 376,
   "id": "c54d70ba",
   "metadata": {},
   "outputs": [],
   "source": [
    "Total_sub_sessions=[]\n",
    "Total_sessions=[]\n",
    "for i in range(len(sub_session_names)):\n",
    "    for j in range(len(sub_session_names[i])):\n",
    "        Total_sub_sessions.append(sub_session_names[i][j])\n",
    "        Total_sessions.append(session_names[i])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 377,
   "id": "8ed0fe22",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2961\n",
      "2961\n",
      "2961\n",
      "2961\n"
     ]
    }
   ],
   "source": [
    "print(len(Total_speaker_names))\n",
    "print(len(Total_speaker_aff))\n",
    "print(len(Total_sub_sessions))\n",
    "print(len(Total_sessions))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "48c5a284",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "128"
      ]
     },
     "execution_count": 57,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(links)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 352,
   "id": "c26f7c47",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 388,
   "id": "2223bf37",
   "metadata": {},
   "outputs": [],
   "source": [
    "Data=pd.DataFrame()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 389,
   "id": "a5402441",
   "metadata": {},
   "outputs": [],
   "source": [
    "Data['SESSION_NAMES']=SESSION\n",
    "Data[\"SUB_SESSION\"]=SUB_SESSION\n",
    "Data[\"NAMES\"]=Temp_names\n",
    "Data[\"AFFILIATION\"]=AFFILIATION\n",
    "Data[\"ABSTRACT\"]=ABSTRACT\n",
    "Data[\"DISCLOSURE\"]=DISCLOSURE\n",
    "Data[\"TIME\"]=TIME\n",
    "Data[\"DATE\"]=DATE"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 390,
   "id": "689499ae",
   "metadata": {},
   "outputs": [
    {
     "ename": "IndexError",
     "evalue": "index 8 is out of bounds for axis 0 with size 8",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mIndexError\u001b[0m                                Traceback (most recent call last)",
      "Input \u001b[1;32mIn [390]\u001b[0m, in \u001b[0;36m<cell line: 1>\u001b[1;34m()\u001b[0m\n\u001b[1;32m----> 1\u001b[0m Data\u001b[38;5;241m=\u001b[39mData\u001b[38;5;241m.\u001b[39mdrop(\u001b[43mData\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcolumns\u001b[49m\u001b[43m[\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;241;43m8\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m]\u001b[49m,axis\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m1\u001b[39m)\n",
      "File \u001b[1;32mC:\\ProgramData\\Anaconda3\\lib\\site-packages\\pandas\\core\\indexes\\base.py:5055\u001b[0m, in \u001b[0;36mIndex.__getitem__\u001b[1;34m(self, key)\u001b[0m\n\u001b[0;32m   5048\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m com\u001b[38;5;241m.\u001b[39mis_bool_indexer(key):\n\u001b[0;32m   5049\u001b[0m     \u001b[38;5;66;03m# if we have list[bools, length=1e5] then doing this check+convert\u001b[39;00m\n\u001b[0;32m   5050\u001b[0m     \u001b[38;5;66;03m#  takes 166 µs + 2.1 ms and cuts the ndarray.__getitem__\u001b[39;00m\n\u001b[0;32m   5051\u001b[0m     \u001b[38;5;66;03m#  time below from 3.8 ms to 496 µs\u001b[39;00m\n\u001b[0;32m   5052\u001b[0m     \u001b[38;5;66;03m# if we already have ndarray[bool], the overhead is 1.4 µs or .25%\u001b[39;00m\n\u001b[0;32m   5053\u001b[0m     key \u001b[38;5;241m=\u001b[39m np\u001b[38;5;241m.\u001b[39masarray(key, dtype\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mbool\u001b[39m)\n\u001b[1;32m-> 5055\u001b[0m result \u001b[38;5;241m=\u001b[39m \u001b[43mgetitem\u001b[49m\u001b[43m(\u001b[49m\u001b[43mkey\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m   5056\u001b[0m \u001b[38;5;66;03m# Because we ruled out integer above, we always get an arraylike here\u001b[39;00m\n\u001b[0;32m   5057\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m result\u001b[38;5;241m.\u001b[39mndim \u001b[38;5;241m>\u001b[39m \u001b[38;5;241m1\u001b[39m:\n",
      "\u001b[1;31mIndexError\u001b[0m: index 8 is out of bounds for axis 0 with size 8"
     ]
    }
   ],
   "source": [
    "Data=Data.drop(Data.columns[[8]],axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 392,
   "id": "dec736c2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>SESSION_NAMES</th>\n",
       "      <th>SUB_SESSION</th>\n",
       "      <th>NAMES</th>\n",
       "      <th>AFFILIATION</th>\n",
       "      <th>ABSTRACT</th>\n",
       "      <th>DISCLOSURE</th>\n",
       "      <th>TIME</th>\n",
       "      <th>DATE</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Antiphospholipid Syndrome Poster</td>\n",
       "      <td>Antibodies Targeting Mitochondrial Antigens Ar...</td>\n",
       "      <td>Yann Becker</td>\n",
       "      <td>Département de microbiologie et immunologie, C...</td>\n",
       "      <td>Background/Purpose: Mitochondria are intracell...</td>\n",
       "      <td>None</td>\n",
       "      <td>9:00AM-11:00AM</td>\n",
       "      <td>Sunday, November 10, 2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Antiphospholipid Syndrome Poster</td>\n",
       "      <td>Antibodies Targeting Mitochondrial Antigens Ar...</td>\n",
       "      <td>Anne-Sophie Julien</td>\n",
       "      <td>Service de consultation statistique (SCS). Dép...</td>\n",
       "      <td>Background/Purpose: Mitochondria are intracell...</td>\n",
       "      <td>None</td>\n",
       "      <td>9:00AM-11:00AM</td>\n",
       "      <td>Sunday, November 10, 2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Antiphospholipid Syndrome Poster</td>\n",
       "      <td>Antibodies Targeting Mitochondrial Antigens Ar...</td>\n",
       "      <td>Alexandra Godbout</td>\n",
       "      <td>Axe maladies infectieuses et inflammatoires, C...</td>\n",
       "      <td>Background/Purpose: Mitochondria are intracell...</td>\n",
       "      <td>None</td>\n",
       "      <td>9:00AM-11:00AM</td>\n",
       "      <td>Sunday, November 10, 2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Antiphospholipid Syndrome Poster</td>\n",
       "      <td>Antibodies Targeting Mitochondrial Antigens Ar...</td>\n",
       "      <td>Éric Boilard</td>\n",
       "      <td>Axe maladies infectieuses et inflammatoires, C...</td>\n",
       "      <td>Background/Purpose: Mitochondria are intracell...</td>\n",
       "      <td>None</td>\n",
       "      <td>9:00AM-11:00AM</td>\n",
       "      <td>Sunday, November 10, 2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Antiphospholipid Syndrome Poster</td>\n",
       "      <td>Antibodies Targeting Mitochondrial Antigens Ar...</td>\n",
       "      <td>Paul Fortin</td>\n",
       "      <td>Division de Rhumatologie, Département de Médec...</td>\n",
       "      <td>Background/Purpose: Mitochondria are intracell...</td>\n",
       "      <td>None</td>\n",
       "      <td>9:00AM-11:00AM</td>\n",
       "      <td>Sunday, November 10, 2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24946</th>\n",
       "      <td>6W026: Epidemiology &amp; Public Health (2924–2929)</td>\n",
       "      <td>Cannabis Use Among Patients in a Large US Rheu...</td>\n",
       "      <td>Kristin Wipfler</td>\n",
       "      <td>FORWARD, The National Databank for Rheumatic D...</td>\n",
       "      <td>Background/Purpose: Legalization of cannabis u...</td>\n",
       "      <td>Disclosure: K. Wipfler, Option Care, 3; T. Sim...</td>\n",
       "      <td>11:00AM-12:30PM</td>\n",
       "      <td>Wednesday, November 13, 2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24947</th>\n",
       "      <td>6W026: Epidemiology &amp; Public Health (2924–2929)</td>\n",
       "      <td>Cannabis Use Among Patients in a Large US Rheu...</td>\n",
       "      <td>Teresa Simon</td>\n",
       "      <td>Bristol-Myers Squibb*, Princeton, NJ,</td>\n",
       "      <td>Background/Purpose: Legalization of cannabis u...</td>\n",
       "      <td>Disclosure: K. Wipfler, Option Care, 3; T. Sim...</td>\n",
       "      <td>11:00AM-12:30PM</td>\n",
       "      <td>Wednesday, November 13, 2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24948</th>\n",
       "      <td>6W026: Epidemiology &amp; Public Health (2924–2929)</td>\n",
       "      <td>Cannabis Use Among Patients in a Large US Rheu...</td>\n",
       "      <td>Patricia Katz</td>\n",
       "      <td>University of California, San Francisco, san f...</td>\n",
       "      <td>Background/Purpose: Legalization of cannabis u...</td>\n",
       "      <td>Disclosure: K. Wipfler, Option Care, 3; T. Sim...</td>\n",
       "      <td>11:00AM-12:30PM</td>\n",
       "      <td>Wednesday, November 13, 2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24949</th>\n",
       "      <td>6W026: Epidemiology &amp; Public Health (2924–2929)</td>\n",
       "      <td>Cannabis Use Among Patients in a Large US Rheu...</td>\n",
       "      <td>Frederick Wolfe</td>\n",
       "      <td>FORWARD, The National Databank for Rheumatic D...</td>\n",
       "      <td>Background/Purpose: Legalization of cannabis u...</td>\n",
       "      <td>Disclosure: K. Wipfler, Option Care, 3; T. Sim...</td>\n",
       "      <td>11:00AM-12:30PM</td>\n",
       "      <td>Wednesday, November 13, 2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24950</th>\n",
       "      <td>6W026: Epidemiology &amp; Public Health (2924–2929)</td>\n",
       "      <td>Cannabis Use Among Patients in a Large US Rheu...</td>\n",
       "      <td>Kaleb Michaud</td>\n",
       "      <td>FORWARD, The National Databank for Rheumatic D...</td>\n",
       "      <td>Background/Purpose: Legalization of cannabis u...</td>\n",
       "      <td>Disclosure: K. Wipfler, Option Care, 3; T. Sim...</td>\n",
       "      <td>11:00AM-12:30PM</td>\n",
       "      <td>Wednesday, November 13, 2019</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>24951 rows × 8 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                         SESSION_NAMES  \\\n",
       "0                     Antiphospholipid Syndrome Poster   \n",
       "1                     Antiphospholipid Syndrome Poster   \n",
       "2                     Antiphospholipid Syndrome Poster   \n",
       "3                     Antiphospholipid Syndrome Poster   \n",
       "4                     Antiphospholipid Syndrome Poster   \n",
       "...                                                ...   \n",
       "24946  6W026: Epidemiology & Public Health (2924–2929)   \n",
       "24947  6W026: Epidemiology & Public Health (2924–2929)   \n",
       "24948  6W026: Epidemiology & Public Health (2924–2929)   \n",
       "24949  6W026: Epidemiology & Public Health (2924–2929)   \n",
       "24950  6W026: Epidemiology & Public Health (2924–2929)   \n",
       "\n",
       "                                             SUB_SESSION               NAMES  \\\n",
       "0      Antibodies Targeting Mitochondrial Antigens Ar...         Yann Becker   \n",
       "1      Antibodies Targeting Mitochondrial Antigens Ar...  Anne-Sophie Julien   \n",
       "2      Antibodies Targeting Mitochondrial Antigens Ar...   Alexandra Godbout   \n",
       "3      Antibodies Targeting Mitochondrial Antigens Ar...        Éric Boilard   \n",
       "4      Antibodies Targeting Mitochondrial Antigens Ar...         Paul Fortin   \n",
       "...                                                  ...                 ...   \n",
       "24946  Cannabis Use Among Patients in a Large US Rheu...     Kristin Wipfler   \n",
       "24947  Cannabis Use Among Patients in a Large US Rheu...        Teresa Simon   \n",
       "24948  Cannabis Use Among Patients in a Large US Rheu...       Patricia Katz   \n",
       "24949  Cannabis Use Among Patients in a Large US Rheu...     Frederick Wolfe   \n",
       "24950  Cannabis Use Among Patients in a Large US Rheu...       Kaleb Michaud   \n",
       "\n",
       "                                             AFFILIATION  \\\n",
       "0      Département de microbiologie et immunologie, C...   \n",
       "1      Service de consultation statistique (SCS). Dép...   \n",
       "2      Axe maladies infectieuses et inflammatoires, C...   \n",
       "3      Axe maladies infectieuses et inflammatoires, C...   \n",
       "4      Division de Rhumatologie, Département de Médec...   \n",
       "...                                                  ...   \n",
       "24946  FORWARD, The National Databank for Rheumatic D...   \n",
       "24947              Bristol-Myers Squibb*, Princeton, NJ,   \n",
       "24948  University of California, San Francisco, san f...   \n",
       "24949  FORWARD, The National Databank for Rheumatic D...   \n",
       "24950  FORWARD, The National Databank for Rheumatic D...   \n",
       "\n",
       "                                                ABSTRACT  \\\n",
       "0      Background/Purpose: Mitochondria are intracell...   \n",
       "1      Background/Purpose: Mitochondria are intracell...   \n",
       "2      Background/Purpose: Mitochondria are intracell...   \n",
       "3      Background/Purpose: Mitochondria are intracell...   \n",
       "4      Background/Purpose: Mitochondria are intracell...   \n",
       "...                                                  ...   \n",
       "24946  Background/Purpose: Legalization of cannabis u...   \n",
       "24947  Background/Purpose: Legalization of cannabis u...   \n",
       "24948  Background/Purpose: Legalization of cannabis u...   \n",
       "24949  Background/Purpose: Legalization of cannabis u...   \n",
       "24950  Background/Purpose: Legalization of cannabis u...   \n",
       "\n",
       "                                              DISCLOSURE             TIME  \\\n",
       "0                                                   None   9:00AM-11:00AM   \n",
       "1                                                   None   9:00AM-11:00AM   \n",
       "2                                                   None   9:00AM-11:00AM   \n",
       "3                                                   None   9:00AM-11:00AM   \n",
       "4                                                   None   9:00AM-11:00AM   \n",
       "...                                                  ...              ...   \n",
       "24946  Disclosure: K. Wipfler, Option Care, 3; T. Sim...  11:00AM-12:30PM   \n",
       "24947  Disclosure: K. Wipfler, Option Care, 3; T. Sim...  11:00AM-12:30PM   \n",
       "24948  Disclosure: K. Wipfler, Option Care, 3; T. Sim...  11:00AM-12:30PM   \n",
       "24949  Disclosure: K. Wipfler, Option Care, 3; T. Sim...  11:00AM-12:30PM   \n",
       "24950  Disclosure: K. Wipfler, Option Care, 3; T. Sim...  11:00AM-12:30PM   \n",
       "\n",
       "                               DATE  \n",
       "0         Sunday, November 10, 2019  \n",
       "1         Sunday, November 10, 2019  \n",
       "2         Sunday, November 10, 2019  \n",
       "3         Sunday, November 10, 2019  \n",
       "4         Sunday, November 10, 2019  \n",
       "...                             ...  \n",
       "24946  Wednesday, November 13, 2019  \n",
       "24947  Wednesday, November 13, 2019  \n",
       "24948  Wednesday, November 13, 2019  \n",
       "24949  Wednesday, November 13, 2019  \n",
       "24950  Wednesday, November 13, 2019  \n",
       "\n",
       "[24951 rows x 8 columns]"
      ]
     },
     "execution_count": 392,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 393,
   "id": "9ced2592",
   "metadata": {},
   "outputs": [],
   "source": [
    "Data.to_excel(\"ACR_2019.xlsx\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 380,
   "id": "a55e3c8e",
   "metadata": {},
   "outputs": [],
   "source": [
    "Data2=pd.DataFrame()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 381,
   "id": "fea7d65a",
   "metadata": {},
   "outputs": [],
   "source": [
    "Data2['SESSION_NAMES']=Total_sessions\n",
    "Data2[\"SUB_SESSIONS\"]=Total_sub_sessions\n",
    "Data2[\"SPEAKER\"]=Total_speaker_names\n",
    "Data2[\"AFFILIATION\"]=Total_speaker_aff"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 383,
   "id": "f9aef747",
   "metadata": {},
   "outputs": [
    {
     "ename": "IndexError",
     "evalue": "index 4 is out of bounds for axis 0 with size 4",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mIndexError\u001b[0m                                Traceback (most recent call last)",
      "Input \u001b[1;32mIn [383]\u001b[0m, in \u001b[0;36m<cell line: 1>\u001b[1;34m()\u001b[0m\n\u001b[1;32m----> 1\u001b[0m Data2\u001b[38;5;241m=\u001b[39mData2\u001b[38;5;241m.\u001b[39mdrop(\u001b[43mData2\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcolumns\u001b[49m\u001b[43m[\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;241;43m4\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m]\u001b[49m,axis\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m1\u001b[39m)\n",
      "File \u001b[1;32mC:\\ProgramData\\Anaconda3\\lib\\site-packages\\pandas\\core\\indexes\\base.py:5055\u001b[0m, in \u001b[0;36mIndex.__getitem__\u001b[1;34m(self, key)\u001b[0m\n\u001b[0;32m   5048\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m com\u001b[38;5;241m.\u001b[39mis_bool_indexer(key):\n\u001b[0;32m   5049\u001b[0m     \u001b[38;5;66;03m# if we have list[bools, length=1e5] then doing this check+convert\u001b[39;00m\n\u001b[0;32m   5050\u001b[0m     \u001b[38;5;66;03m#  takes 166 µs + 2.1 ms and cuts the ndarray.__getitem__\u001b[39;00m\n\u001b[0;32m   5051\u001b[0m     \u001b[38;5;66;03m#  time below from 3.8 ms to 496 µs\u001b[39;00m\n\u001b[0;32m   5052\u001b[0m     \u001b[38;5;66;03m# if we already have ndarray[bool], the overhead is 1.4 µs or .25%\u001b[39;00m\n\u001b[0;32m   5053\u001b[0m     key \u001b[38;5;241m=\u001b[39m np\u001b[38;5;241m.\u001b[39masarray(key, dtype\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mbool\u001b[39m)\n\u001b[1;32m-> 5055\u001b[0m result \u001b[38;5;241m=\u001b[39m \u001b[43mgetitem\u001b[49m\u001b[43m(\u001b[49m\u001b[43mkey\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m   5056\u001b[0m \u001b[38;5;66;03m# Because we ruled out integer above, we always get an arraylike here\u001b[39;00m\n\u001b[0;32m   5057\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m result\u001b[38;5;241m.\u001b[39mndim \u001b[38;5;241m>\u001b[39m \u001b[38;5;241m1\u001b[39m:\n",
      "\u001b[1;31mIndexError\u001b[0m: index 4 is out of bounds for axis 0 with size 4"
     ]
    }
   ],
   "source": [
    "Data2=Data2.drop(Data2.columns[[4]],axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 384,
   "id": "8b2b5878",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>SESSION_NAMES</th>\n",
       "      <th>SUB_SESSIONS</th>\n",
       "      <th>SPEAKER</th>\n",
       "      <th>AFFILIATION</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Antiphospholipid Syndrome Poster</td>\n",
       "      <td>Antibodies Targeting Mitochondrial Antigens Ar...</td>\n",
       "      <td>Yann Becker</td>\n",
       "      <td>Département de microbiologie et immunologie, C...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Antiphospholipid Syndrome Poster</td>\n",
       "      <td>Elevated Levels of the Neutrophil Extracellula...</td>\n",
       "      <td>Hui Shi</td>\n",
       "      <td>University of Michigan, Ann Arbor,</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Antiphospholipid Syndrome Poster</td>\n",
       "      <td>Metabolomics Analysis Identifies Biomarkers fo...</td>\n",
       "      <td>Yu Zuo</td>\n",
       "      <td>University of Texas Southwestern, Dallas, TX,</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Antiphospholipid Syndrome Poster</td>\n",
       "      <td>Surface Proteins on Exosomes Derived from Plas...</td>\n",
       "      <td>Polona Žigon</td>\n",
       "      <td>Department of Rheumatology, University Medical...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Antiphospholipid Syndrome Poster</td>\n",
       "      <td>Is There Clinically Relevant Plasma Interferen...</td>\n",
       "      <td>Michael Pham</td>\n",
       "      <td>Mayo Clinic, Rochester, MN,</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2956</th>\n",
       "      <td>6W026: Epidemiology &amp; Public Health (2924–2929)</td>\n",
       "      <td>The Effects of Leisure Time Sitting and Sittin...</td>\n",
       "      <td>Dana Voinier</td>\n",
       "      <td>University of Delaware, Newark,</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2957</th>\n",
       "      <td>6W026: Epidemiology &amp; Public Health (2924–2929)</td>\n",
       "      <td>Knee Injury and Transitions Among States of Kn...</td>\n",
       "      <td>Yvonne Golightly</td>\n",
       "      <td>University of North Carolina at Chapel Hill De...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2958</th>\n",
       "      <td>6W026: Epidemiology &amp; Public Health (2924–2929)</td>\n",
       "      <td>Dietary Patterns and Symptomatic Progression o...</td>\n",
       "      <td>Chang Xu</td>\n",
       "      <td>Brigham and Women's Hospital, Boston, MA,</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2959</th>\n",
       "      <td>6W026: Epidemiology &amp; Public Health (2924–2929)</td>\n",
       "      <td>Associations of Socioeconomic Status with Rheu...</td>\n",
       "      <td>Rebecca Cleveland</td>\n",
       "      <td>Thurston Arthritis Research Center, Chapel Hil...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2960</th>\n",
       "      <td>6W026: Epidemiology &amp; Public Health (2924–2929)</td>\n",
       "      <td>Cannabis Use Among Patients in a Large US Rheu...</td>\n",
       "      <td>Teresa Simon</td>\n",
       "      <td>Bristol-Myers Squibb*, Princeton, NJ,</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2961 rows × 4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        SESSION_NAMES  \\\n",
       "0                    Antiphospholipid Syndrome Poster   \n",
       "1                    Antiphospholipid Syndrome Poster   \n",
       "2                    Antiphospholipid Syndrome Poster   \n",
       "3                    Antiphospholipid Syndrome Poster   \n",
       "4                    Antiphospholipid Syndrome Poster   \n",
       "...                                               ...   \n",
       "2956  6W026: Epidemiology & Public Health (2924–2929)   \n",
       "2957  6W026: Epidemiology & Public Health (2924–2929)   \n",
       "2958  6W026: Epidemiology & Public Health (2924–2929)   \n",
       "2959  6W026: Epidemiology & Public Health (2924–2929)   \n",
       "2960  6W026: Epidemiology & Public Health (2924–2929)   \n",
       "\n",
       "                                           SUB_SESSIONS            SPEAKER  \\\n",
       "0     Antibodies Targeting Mitochondrial Antigens Ar...        Yann Becker   \n",
       "1     Elevated Levels of the Neutrophil Extracellula...            Hui Shi   \n",
       "2     Metabolomics Analysis Identifies Biomarkers fo...             Yu Zuo   \n",
       "3     Surface Proteins on Exosomes Derived from Plas...       Polona Žigon   \n",
       "4     Is There Clinically Relevant Plasma Interferen...       Michael Pham   \n",
       "...                                                 ...                ...   \n",
       "2956  The Effects of Leisure Time Sitting and Sittin...       Dana Voinier   \n",
       "2957  Knee Injury and Transitions Among States of Kn...   Yvonne Golightly   \n",
       "2958  Dietary Patterns and Symptomatic Progression o...           Chang Xu   \n",
       "2959  Associations of Socioeconomic Status with Rheu...  Rebecca Cleveland   \n",
       "2960  Cannabis Use Among Patients in a Large US Rheu...       Teresa Simon   \n",
       "\n",
       "                                            AFFILIATION  \n",
       "0     Département de microbiologie et immunologie, C...  \n",
       "1                    University of Michigan, Ann Arbor,  \n",
       "2         University of Texas Southwestern, Dallas, TX,  \n",
       "3     Department of Rheumatology, University Medical...  \n",
       "4                           Mayo Clinic, Rochester, MN,  \n",
       "...                                                 ...  \n",
       "2956                    University of Delaware, Newark,  \n",
       "2957  University of North Carolina at Chapel Hill De...  \n",
       "2958          Brigham and Women's Hospital, Boston, MA,  \n",
       "2959  Thurston Arthritis Research Center, Chapel Hil...  \n",
       "2960              Bristol-Myers Squibb*, Princeton, NJ,  \n",
       "\n",
       "[2961 rows x 4 columns]"
      ]
     },
     "execution_count": 384,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Data2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 387,
   "id": "b7000132",
   "metadata": {},
   "outputs": [],
   "source": [
    "Data2.to_excel(\"ACR_speakers_2019.xlsx\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "49a29f47",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "5756a4d0",
   "metadata": {},
   "outputs": [],
   "source": [
    "tt = pd.ExcelFile('ACR_speakers_2019.xlsx').parse('Sheet1')\n",
    "sessionxl=tt['SESSION_NAMES']\n",
    "subsessionxl=tt['SUB_SESSIONS']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "827544ad",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "320\n",
      "321\n",
      "322\n",
      "323\n",
      "324\n",
      "325\n",
      "326\n",
      "327\n",
      "328\n",
      "329\n",
      "330\n",
      "331\n",
      "332\n",
      "333\n",
      "334\n",
      "335\n",
      "336\n",
      "337\n",
      "338\n",
      "339\n",
      "340\n",
      "341\n",
      "342\n",
      "343\n",
      "344\n",
      "345\n",
      "346\n",
      "347\n",
      "348\n",
      "349\n",
      "350\n",
      "351\n"
     ]
    }
   ],
   "source": [
    "tx='Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes'\n",
    "for i in range(len(sessionxl)): \n",
    "    if(sessionxl[i].lower() in tx.lower()):\n",
    "        print(i)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "adf19dcf",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Antibodies Targeting Mitochondrial Antigens Are Associated with Reduced Thrombotic Events in APS\n",
      "Elevated Levels of the Neutrophil Extracellular Trap-binding Protein LILRA3 in Primary Antiphospholipid Syndrome\n",
      "Metabolomics Analysis Identifies Biomarkers for APS and Suggests a Potential New Pathway Related to APS Pathogenesis\n",
      "Surface Proteins on Exosomes Derived from Plasma of APS Patients Indicate an Altered Immune, Cell Adhesion and Coagulation Profile\n",
      "Is There Clinically Relevant Plasma Interference with ELISA Detection of APS Antibodies? Reproducibility of Serum and Plasma Testing in a Real-World Clinical Setting\n",
      "Anti-Phosphatidylserine Prothrombin Antibodies as a Predictor of the LAC in an All-Comer Population\n",
      "Anti-phosphatidylserine/prothrombin Antibodies Confer a Distinctive Molecular Profile in Primary Antiphospholipid Syndrome Patients\n",
      "Anti-β2GPI Domain 1 Antibodies Stratify High Risk of Thrombosis and Pregnancy Morbidity in a Large Cohort of Chinese Patients with Antiphospholipid Syndrome\n",
      "‘Non-criteria’ Antiphospholipid Antibodies Add Value to Antiphospholipid Syndrome Diagnoses in a Large Chinese Cohort\n",
      "Added Clinical Utility of Testing for Extra-Criteria Antibodies Specificities Beyond Sapporo and Sydney Criteria Recommendations\n",
      "Identifying Phenotypes of Patients with Antiphospholipid Antibodies: Results from a Cluster Analysis in a Large Cohort of Patients\n",
      "The Clinical and Laboratory Characteristics of Antiphospholipid Antibody Positive Patients Included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)\n",
      "Relationship Between Recurrent Thrombosis and the Antiphospholipid Antibodies Profile in a Cohort of Patients with Antiphospholipid Syndrome\n",
      "Antiphospholipid Syndrome Damage Index (DIAPS): Distinct Long-term Kinetic in Primary Antiphospholipid Syndrome and APS Related to SLE\n",
      "Early Anticoagulation Improves the Long-term Prognosis in Patients with Antiphospholipid Syndrome Associated Portal Vein Thrombosis\n",
      "Pregnancy in Antiphospholipid Syndrome: Outcomes and Risk Factors – Data from a Portuguese Multidisclinary Unit\n",
      "Antiphospholipid Antibodies Prevalence in Women with Late Pregnancy Complication and Low-Risk for Chromosomal Abnormalities\n",
      "Clinical and Genetic Factors Associated with Thrombosis or Pregnancy Morbidity of Antiphospholipid Antibody-Positive Systemic Lupus Erythematosus Patients\n",
      "Antiphospholipid Syndrome-Associated Preeclampsia Is Defined by a Distinct Clinical Phenotype\n",
      "Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase II Results\n",
      "Interleukin-6 Promotes Osteoclast-like Phenotype in Human Rheumatoid Arthritis Synovial Fibroblasts\n",
      "Baseline Cytotoxic Gene Expression Associates with Ustekinumab Response in Systemic Lupus Erythematosus\n",
      "Pannexin-1 KO Mice Are Unresponsive to Tenofovir Induced Bone Loss\n",
      "AMP Deaminase 2 Surface Expression Counteracting CD73-Driven Generation of Anti-Inflammatory Extracellular Adenosine\n",
      "Interferon Kappa Promotes the Development of Psoriasis\n",
      "A Novel Role for Extracellular Sulfatase-2 in Mediating IL-6-induced Adhesion and Migration Molecules in Human Rheumatoid Arthritis Synovial Fibroblasts\n",
      "Citrullination of Interleukin 6 Augments Its Pro-inflammatory Capacity and Signaling Potency Through Interleukin-6 Receptor in Rheumatoid Arthritis\n",
      "CKD-506, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, Regulates Inflammatory Responses Through NF-kB and AP-1 Signaling\n",
      "Chemokine CXCL 10 Gene Expression as a Potential Activity Biomarker of Systemic Lupus Erythematosus\n",
      "Roles of Histone Acetyltransferases CBP/p300 and Transcriptional Factor RORα/REV-ERBα Against TNFα-induced CCL2 Expression in RA-FLSs\n",
      "Biomarker Changes for Patients with Rheumatoid Arthritis Receiving Tofacitinib with Methotrexate or Glucocorticoids vs Tofacitinib Monotherapy\n",
      "Intraarticular and Circulatory Cytokine Responses to Chlamydia Trachomatis: A Clinical Study in Reactive Arthritis/ Undifferentiated Spondyloarthropathy Patients\n",
      "The Effect of Estrogen and Interferon γ on the Immunobiology of Minor Salivary Gland Mesenchymal Stromal Cells\n",
      "Sec16A Abnormalities Affect the Intracellular Trafficking of HLA-B27 in the Pathogenesis of Axial Spondyloarthritis\n",
      "CYR61/TGF-β Axis Promotes Adventitial Fibrosis of Takayasu Arteritis in the IL-17 Mediated Inflammatory Microenvironment\n",
      "Monoclonal ACPA Promote Synovial Fibroblasts Migration Through a Peptidylarginine Deiminases (PAD) Dependent Pathway\n",
      "Transcription Factor Fli-1 Impacts Lupus Nephritis by Orchestrating CXCL10/CXCR3 Axis\n",
      "Undifferentiated Connective Tissue Disease at Risk for SSc: Potential Role of Circulating CXCL-10, CXCL-11 and IL-33 in Predicting Disease Evolution\n",
      "Inhibition of IkB Kinase-IKK Complex of Canonical NF-κB Pathway in Antiphospholipid Antibody-Mediated Endothelial Cell Activation\n",
      "Comparative Efficacy of Beta-2-Glycoprotein I Domain V Structural Analogue Variants in Preventing Antiphospholipid Antibody-Mediated Endothelial Cell Activation\n",
      "Simulated Rheumatology Clinic: Bridging Basic Science and Clinical Application\n",
      "A Qualitative Study of Factors That Influence Interest in a Career in Pediatric Rheumatology\n",
      "The Combat Rheumatologist: Long Term Professional Outcomes of Graduates from a Tri-Service Military Rheumatology Fellowship Program\n",
      "Teaching Rare Diseases Through Role Play: Results of an Experimental Workshop About Raynaud Phenomenon\n",
      "Comparison of Debate vs. Lecture to Teach Medical Students Pediatric Rheumatology\n",
      "Implementation of Recommendations for Prevention of Glucocorticosteroid-Induced Osteoporosis in Hospitalized Patients\n",
      "A Shoulder to Lean On: Differences in Shoulder Examinations Between Rheumatology Educators and Fellows\n",
      "Palliative Care Curriculum in Rheumatology: Teaching Serious Illness Conversations\n",
      "Enhancing Medicine Trainees’ Exposure to Gout Diagnosis and Management Through an Interprofessional Approach in the Primary Care Setting\n",
      "A Prospective, Unblinded, Non-randomized Pilot Study Examining the Effect of a Musculoskeletal Immersion Curriculum for First Year Internal Medicine Residents\n",
      "The Impact of Spaced Education and Reciprocal Peer Teaching on Rheumatology Fellows’ Long-term Recall from Core Curriculum\n",
      "We Can Do Better: Evaluating Inpatient Pediatric Rheumatology Inpatient/Consult Service Performance\n",
      "Addressing the Pediatric Rheumatology Physician Shortage: Does Early Exposure Matter?\n",
      "VA Musculoskeletal “Master Educator” Faculty Development Program for Health Professions Educators: Follow-Up on Changes in Educational Duties and Perceptions of Program Content\n",
      "Evaluation of ACGME Competencies in a Rheumatology Observed Structured Clinical Examination\n",
      "Use of a Systematic Consensus Process to Inform Development of the Veterans Health Affairs Simulation Learning, Education and Research Network (SimLEARN) Musculoskeletal Clinician Course\n",
      "A Shared Mental Model for Teaching and Assessing Examination of the Hand, Wrist, and Elbow in the “Training Rheum” Continuing Professional Development Program\n",
      "Workforce Survey: Career Trends of Combined Adult and Pediatric Rheumatology Fellowship Graduates\n",
      "Learner Practice Gaps in Osteoporosis: Piloting a Metabolic Bone Disease Curriculum Within a Fracture Liaison Service Framework\n",
      "Heterogeneity of Strategies and Methods for Assessment of Competences in Rheumatology Training: Results of a Systematic Literature Review to Inform EULAR Points to Consider\n",
      "An Analysis of Inpatient Rheumatology Consults at an Academic Military Medical Center over 16 Years: Do Consults Requests Accurately Reflect the Curriculum and Prepare Fellows for Board Certification and Future Practice?\n",
      "Bioethics for the Rheumatologist: A Needs-Assessment, Curriculum Development, and Knowledge Assessment of Bioethical Topics for Rheumatology Trainees\n",
      "Development and Usability Testing of Take Charge: An Email Series to Increase Knowledge of Self-Management Skills in People with Lupus\n",
      "Wikipedia as a Source of Health Information for the Public: Systematic Analysis of Quality and Readability of 8 Common Rheumatic Diseases Articles\n",
      "Evaluating an Illustrated Storybook for Children with Juvenile Idiopathic Arthritis\n",
      "Performance of 2010 ACR/EULAR and 1987 ACR Criteria for Classification of Rheumatoid Arthritis in a Population-based Incidence Cohort, 2010-2014\n",
      "Is the Epidemiology of Rheumatoid Arthritis (RA) Changing? Results from a Population-based Incidence Cohort of RA Patients, 2005-2014\n",
      "Statin Use Is Associated with Increased Risk of RA in US Population: Results from a Large Nationwide Study\n",
      "Clinical Presentation and Disease Course Evaluation of Mono- and Bilateral Knee Arthritis: Results from the Leiden Early Arthritis Clinic Cohort\n",
      "Associations Between Circulating Cytokines and Incident Inflammatory Arthritis in an Anti-citrullinated Protein Antibody Positive Population\n",
      "The Epidemiology of Rheumatoid Arthritis in the Czech Republic\n",
      "Early Retirement Attributed to Rheumatoid Arthritis and Its Predictors in Portugal\n",
      "Depression: A Common Comorbidity in Rheumatic Diseases. a Case-Control Study\n",
      "The Burden of Comorbidity in Patients with RA, PSA or SPA in a General Practice Registry\n",
      "Identifying Comorbidities and Seropositivity in Rheumatoid Arthritis Patients Using Single-specialty Electronic Health Record Data\n",
      "Prevalence of Renal Impairment in a US Rheumatoid Arthritis Population\n",
      "Comparing the Generalizability of Cardiovascular Risk in Different Rheumatoid Arthritis Cohorts\n",
      "Exploring Heterogeneity in Rheumatoid Arthritis: Patient Profiling Through Principal Component and Cluster Analysis of the BRASS Registry\n",
      "No Increased Risk of Incidence Diabetes in Patients with Rheumatoid Arthritis Compared to Patients Without RA\n",
      "Accrual of Multimorbidity After Incident Rheumatoid Arthritis and Matched Comparators Using a Large Prospective Cohort with 30 Years of Follow-up\n",
      "Asthma, Chronic Obstructive Pulmonary Disease, and Subsequent Risk for Incident Rheumatoid Arthritis Among Women: A Prospective Cohort Study\n",
      "Epidemiology of JIA-Associated Uveitis: Environmental Factors and Disease Characteristics of a JIA-Associated Uveitis Cohort\n",
      "The Importance of Diagnosis: Clinical Distinctions Between Adult JIA and RA, and a Characterization of Patients with JIA Reclassified as RA in Adulthood\n",
      "Validation of Claims-based Algorithms to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis\n",
      "Accuracy of Administrative Algorithms for Identifying Interstitial Lung Disease in Rheumatoid Arthritis\n",
      "Associations of Self-Reported Inhalant Exposures with Autoantibodies and Disease Severity in U.S. Veterans with Rheumatoid Arthritis\n",
      "A Healthy Plant-Rich Diet and the Risk of Rheumatoid Arthritis in Women\n",
      "Diet as a Risk Factor for Rheumatoid Arthritis\n",
      "Predicting Remission in Rheumatoid Arthritis: External Validation for Tocilizumab Monotherapy Using Corrona Real World Data\n",
      "The Clinical Characteristics of Patients with Inflammatory Arthritis and a Persistently Low Alkaline Phosphatase Level in a Veteran Affairs Rheumatology Clinic\n",
      "Risk of Subsequent Atherosclerotic Cardiovascular Disease After the First Unprovoked Venous Thromboembolism in Patients with Rheumatoid Arthritis\n",
      "The Relationship Between Pain and Patient Demographics, Clinical Features, and Health Outcomes in a Cohort of Rheumatoid Arthritis Patients Recruited and Studied Using a Mobile Application\n",
      "Assessing Care Quality in Rheumatology Services\n",
      "Obesity and Incident Opioid Use in Rheumatoid Arthritis\n",
      "A Validated Text-mining Algorithm to Extract Rheumatoid Arthritis Medication Contained in Format-free Fields of Electronic Medical Records\n",
      "Identification of Patients with Rheumatoid Arthritis Treated with Biologics Using Standardized Vocabularies\n",
      "Risk Factors Associated with Serious Infections Among Users of Biosimilar and Originator Infliximab Therapies\n",
      "Recent Use, Missed Doses and Discontinuation of Infliximab in a Population-Based Cohort: Comparisons of Biosimilar and Originator Exposures\n",
      "Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the US\n",
      "Does a Mandatory Non-medical Switch from Originator to Biosimilar Etanercept Lead to Increase in Healthcare Use and Costs? A Danish Register-based Study of 1620 Patients with Inflammatory Arthritis\n",
      "Efficacy of Etanercept on Radiographic Progression in Adult Patients with Rheumatoid Arthritis or Psoriatic Arthritis: Final Results from a German Non-Interventional, Prospective, Multi-Center Study\n",
      "Effects of Successive Switches to Different Biosimilars Infliximab on Immunogenicity in Chronic Inflammatory Diseases in Daily Clinical Practice\n",
      "Self-Reported Sleep Disturbances in Rheumatoid Arthritis (RA)\n",
      "Joint Overuse in Patients with Rheumatoid Arthritis\n",
      "Associations of Clinical Biomarkers with Radiographic Progression of Rheumatoid Arthritis (RA) in African Americans with Early Disease\n",
      "Effects of Deep Haptic Massage in Fibromyalgia (pilot Study)\n",
      "Utility of Mood Disorders Questionnaire in Fibromyalgia: Data from the Cleveland Clinic Fibromyalgia Registry\n",
      "Relationship Between a History of Abuse and Fibromyalgia Symptoms and Severity: Data from the Cleveland Clinic Fibromyalgia Registry\n",
      "How Well Do Visual Analogue Scales Used in the Fibromyalgia Impact Questionnaire (FIQ) Correlate with Other Measures of Pain, Fatigue, Sleep, Sleep Disturbance, Anxiety and Depression in Patients with Fibromyalgia\n",
      "Opioid Treatment Pattern in a Community Based Rheumatology Clinic\n",
      "Does Fibromyalgia Change the Evaluation of Spondyloarthritis Activity? A Meta-analysis of Observational Studies\n",
      "Fibromyalgia and Multiple Switching of Biologics in Spondylarthritis\n",
      "Effects of Tai Chi versus Aerobic Exercise on Mindfulness in Fibromyalgia\n",
      "A Fibromyalgia Assessment Screening Tool on a Multidimensional Health Assessment Questionnaire (MDHAQ) Which Does Not Include a Self-Report RADAI Painful Joint Count (RADAI), FAST3nJC, Recognizes Fibromyalgia Similarly to Other FAST3 Indices Which Include a RADAI\n",
      "A Positive Response to Nonpharmacological Therapies in Patients with Fibromyalgia\n",
      "Emergency Department Utilization for Fibromyalgia Patients\n",
      "Acupuncture for Chronic Musculoskeletal Pain: A Review of Randomized Controlled Trials\n",
      "Correlation Between Heart Rate Variability Parameters and Circulating Neuropeptides in Fibromyalgia\n",
      "A Functional Exercise Program Improves Pain and Health Related Quality of Life in Patients with Fibromyalgia: A Randomized Controllel Trial\n",
      "Evaluating Fibromyalgia Symptoms in Transgender Patients\n",
      "Hypersensitivity Beyond Pain: Hyperacusis and Hyperalgesia of Patients with Fibromyalgia\n",
      "Metabolomic and Symptom Comparison in Women With/without Fibromyalgia: A Pilot Study\n",
      "Good Pain, Bad Pain: Illness Perception and Physicians Attitude Towards Rheumatoid Arthritis and Fibromyalgia Patients\n",
      "Is Fibromyalgia Associated with Structural or Functional Abnormalities in Skeletal Muscle?\n",
      "Patients with Fibromyalgia Associated with Rheumatoid Arthritis and Patients with Primary Fibromyalgia Differ in Depression, Anxiety, Stress-related Disorders and Events: A Cross-sectional Study\n",
      "Duloxetine for Chronic Pain Management in a Tertiary Care Rheumatology Practice: How Patients Are Doing in the Real World\n",
      "Hand Digital Thermography Findings in Patients with Primary Fibromyalgia\n",
      "Intensive CBT Is Effective in the Treatment of Significant Functional Impairment and Psychological Distress Found in Fibromyalgia: But Can We Improve Depressive Symptoms?\n",
      "Oxytocin Attenuates Tactile Allodynia in Experimental Fibromyalgia Rats\n",
      "Muscle Pressure Correlates with Pain Levels in Fibromyalgia Patients and Muscle Tension May Be the Cause of Their Pain\n",
      "Repeat Muscle Pressures Measured in Fibromyalgia Patients and Compared with Pain Scores\n",
      "Determination of Muscle Pressure in Patients with Fibromyalgia by Two Examiners; The Examiners Get Similar Results\n",
      "Muscle Pressure as Measured by a Manometer Correlates with Dolorimetry in Patients with Fibromyalgia\n",
      "The SELENA SLEDAI Is an Imperfect Measure of Lupus Disease Activity in Patients with Concomitant Fibromyalgia\n",
      "Whom Do Patients with Fibromyalgia Turn to for Emotional Support?\n",
      "Comparing Patients with Fibromyalgia Syndrome with Non-Fibromyalgia Rheumatic Disease Patients Regarding Exercise\n",
      "The Effectiveness of Medications for Fibromyalgia Based on Patient Experiences\n",
      "Concomitant Fibromyalgia in Patients with Other Rheumatic Diseases and Response to Treatment\n",
      "Real-World Evidence Associated with the Treatment of Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review\n",
      "Comorbidities, Health Care Utilization, and Cost of Care in Systematic Lupus Erythematous Increase with Disease Severity During 1 Year Before and After Diagnosis: A Real-World Cohort Study in the United States, 2004–2015\n",
      "Smoking Exposure in Pack-Years Predicts Cutaneous Manifestations of Lupus\n",
      "Health Literacy, Adherence, and Quality of Life of Uveitis Patients\n",
      "Adherence to Biologic Disease-modifying Anti-rheumatic Drugs (DMARDs) —a Comparison of Long-term Adherence Among Patients with Various Inflammatory Conditions by Primary Dispensing Channel\n",
      "Evaluation of Real-World Early-Line Abatacept versus Tumor Necrosis Factor Inhibitors Persistence in Rheumatoid Arthritis Patients with Anti-Citrullinated Protein Antibody or Rheumatoid Factor Positivity\n",
      "Treatment Patterns, Dose Change, and Treatment Discontinuation in RA Patients Switching from First Biologic DMARD to Another Treatment in the US\n",
      "Long-term Financial Impact of Switching from Reference to Biosimilar Etanercept When Considering Short-term Formulary Management Costs in the US\n",
      "Treatment Sequences, Effectiveness, and Costs of Tumor Necrosis Factor Inhibitor Cycling Compared with Swapping to a Novel Disease-modifying Anti-rheumatic Drug in Rheumatoid Arthritis Patients\n",
      "A Systematic Review and Meta-analysis of Observational Studies Reporting on the Use of Checkpoint Inhibitors in Patients with Cancer and Pre-existing Autoimmune Disease\n",
      "Interstitial Lung Disease Associated Health Care Resource Utilization and Cost in Rheumatoid Arthritis Patients in an Insured Population\n",
      "Designing and Testing Treat to Target as a New Care Model in JIA Across a Network of Pediatric Rheumatology Centers\n",
      "Chronic Musculoskeletal Pain and Its Initial Management in Children, Adolescents and Young Adults in the United States\n",
      "Alcohol Use Hospitalizations in People with Gout, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia, and Low Back Pain Are Increasing: A Time-trends Study Using the U.S. National Data\n",
      "Health Services Utilization as Recommended by the American Diabetes Association Among Middle-Aged Patients Disabled with Rheumatoid Arthritis and Diabetes Mellitus\n",
      "Describing Treatment Patterns and Healthcare Costs in Newly Diagnosed Psoriatic Arthritis Patients by Physician Specialty\n",
      "Rheumatoid Arthritis Associated with Longer Hospital Stays in Patients Admitted with Venous Thromboembolism: A Nationwide Analysis 2010-2014\n",
      "Impact of Rheumatoid Arthritis on Outcomes of Atrial Fibrillation: Results for National Inpatient Sample\n",
      "Outpatient Healthcare Utilization Among Incident Cases of Systemic Sclerosis: Results from a Population-based Cohort (1988-2016)\n",
      "Health Professionals Agreed with Recommendations to Evaluate and Optimize Adherence to Disease-modifying Treatments, but Perceived Feasibility Was Lower: A Study of 357 Physicians and Health Professionals in France\n",
      "Gaps in Patient Safety Performance in Patients with Immunosuppressive Therapy: Results of Screening for Infections and Vaccination Status in a Large Real-life Cohort\n",
      "Frequency of Performing Anti dsDNA Antibody in an ANA Negative Patient with Clinical Suspicion of SLE in a Single Centre Trial Before and After the Publication of National Guideline\n",
      "Measuring Advanced/Extended Practice Roles in Arthritis and Musculoskeletal Care in Canada: Stand up and Be Counted Too (2)!\n",
      "Develop Risk Prediction Model and Drug Withdrawl Road Map Through Pattern Extraction and Data Mining: Create a Master Algorithm from the Smart System of Disease Management (SSDM)\n",
      "LARS Study: Latin American Rheumatologist Survey\n",
      "Attitudes and Beliefs About Opioid Medications: Determining Treatment Use in Osteoarthritis\n",
      "Outcomes of a Fracture Liaison Service at an Academic Health Center\n",
      "Who Prescribed Which Osteoporosis Medication to Whom\n",
      "Osteoporosis Management Outcomes in a Southern California County Health System\n",
      "Bone Health in Lupus: Findings from the Southern California Lupus Registry\n",
      "Participation in the Stanford University Chronic Pain Self-Management Program in a Population with a High Prevalence of Arthritis\n",
      "Exercise Is Medicine® in Primary Care Practice: Provider Characteristics and Physical Activity Counseling for Patients with Arthritis, DocStyles, 2018\n",
      "Effectiveness of Screening by Nurse with Predetermined Questionnaire on Infections Before Administration of Intravenous Biologics in Patients with Rheumatoid Arthritis\n",
      "Efficacy of a Counselling Program to Promote Physical Activity in People with Inflammatory Arthritis\n",
      "Improving a SLE-Quality Indicator Tool in an Outpatient Tertiary Care Setting\n",
      "Comparison of Carotid Ultrasound and Coronary Artery Calcium Score in Cardiovascular Risk Stratification of Patients with Inflammatory Rheumatic Diseases\n",
      "Ultrasound versus Conventional Treat-To-Target Strategies in Early Rheumatoid Arthritis: Magnetic Resonance Imaging Outcome Data from a 2-year Randomized Controlled Strategy Trial\n",
      "Frequency of Ultrasound Features of Knee Osteoarthritis and Their Association with Radiographic Features and Symptoms in a Community-Based Cohort\n",
      "Ultrasound Is More Sensitive Compared to Conventional Radiography to Detect Joint Erosions in ACPA-positive Patients with Musculoskeletal Pain\n",
      "Can Synovial Hypertrophy in the Feet Without Doppler Change During Treatment – Results from a Longitudinal Study of Rheumatoid Arthritis Patients Initiating Biological DMARD\n",
      "Impact of Body Mass Index on the Agreement Between Ultrasound- and Clinical Assessments of Disease Activity in Rheumatoid Arthritis : Multicenter and Cross-sectional Study\n",
      "Thermal Imaging in Rheumatoid Arthritis: A Comparative Analysis with Ultrasonography and Clinical Joint Assessment\n",
      "Imaging Neoangiogenesis in Rheumatoid Arthritis (INIRA): Whole-Body Synovial Uptake of a 99mTc-Labelled RGD Peptide Is Highly Correlated with Power Doppler Ultrasound\n",
      "Ultrasound Evaluation of the Achilles Enthesis in Inflammatory and Non-inflammatory Processes: A Systematic Review\n",
      "Evaluating the Performance of a Single-site Musculoskeletal Ultrasound Clinic Associated with an Academic Rheumatology Practice: Diagnostic and Therapeutic Impact on Patient Care and Survey of Patient and Physician Satisfaction\n",
      "Doppler in Entheses: A Potential Useful Outcome in Active Spondyloarthritis and Psoriatic Arthritis\n",
      "In Psoriatic Arthritis Patients Considered in Remission by Their Rheumatologist, Can Discordance in Disease Activity Assessment Between Patient and Rheumatologist Be Explained by Residual Inflammation as Measured by Ultrasonographic Examination?\n",
      "Factors Explaining Patient Perspective in Psoriasis and Psoriatic Arthritis: The Role of Inflammation and Structural Damage Detected by Ultrasound\n",
      "Is Shoulder Involvement an Early Feature of Rheumatoid Arthritis in Clinically Suspect Arthralgia? A Longitudinal Ultrasound Study\n",
      "False Positives in the Ultrasound Diagnosis of Giant Cell Arteritis: Some Diseases Can Also Have Halo Sign\n",
      "Tendons Involvement at Early Onset of Gouty Arthritis, Ultrasonographic Study\n",
      "Assessing the Vascularization of Salivary Glands in Patients with Sjögren’s Syndrome – An OMERACT Ultrasound Group Reliability Exercise\n",
      "Prevalence of Elbow Arthritis in Patients with Rheumatoid Arthritis: A Prospective Ultrasound Study\n",
      "Ultrasound and Magnetic Resonance Imaging Evaluation of the Fingers’ Joints of Psoriatic Arthritis Patients – Interim Analysis\n",
      "In CCP Positive “At Risk of Rheumatoid Arthritis” Individuals, the Presence of Sub-clinical Synovitis in 4-10joints Universally Results in Clinical Synovitis\n",
      "Definition of New Ultrasound Enthesophytes Score: Application in a Consecutive Series of IBD Patients\n",
      "Proliferative Globular Synovitis, an Ultrasound Pattern Associated with Seropositive Rheumatoid Arthritis\n",
      "PANLAR Ultrasound Study Group Recommendations for the Use of Imaging in the Management of Patients with Gout\n",
      "Clinical Impact of a Rheumatology Musculoskeletal Ultrasound Clinic at a U.S. Academic Center\n",
      "Utility of Power Doppler Ultrasound–Detected Synovitis for the Prediction of Flare in Psoriatic Arthritis Patients in Clinical Remission\n",
      "Immuno-Phenotypic Analysis of Peripheral Blood Mononuclear Cells in Rheumatoid Arthritis Patients Treated with E6011, a Humanized Anti-Fractalkine Monoclonal Antibody\n",
      "Beta-2 Glycoprotein I as a DNA- and NET-binding Protein\n",
      "Covalent High Molecular Weight HMGB1 Complexes in Muscle Regeneration: Implications in Inflammatory Myopathy\n",
      "Role of Trained Immunity in the Pathogenesis of Erdheim-Chester Disease\n",
      "Altered Distribution and Enhanced Osteoclastogenesis of Mucosal-associated Invariant T Cells in Gouty Arthritis\n",
      "Increased Sodium Accumulation Detected by 23Na-Magnetic Resonance Imaging in Inflamed Knees of Patients with Autoimmune Joint Disease\n",
      "Altered Inflammatory Response of Macrophages in the Fosl-2 Transgenic Mouse Model of Systemic Sclerosis\n",
      "Novel Ex Vivo Model of Septic Arthritis Identifies Role of Neutrophils in Joint Destruction\n",
      "Therapeutic Anti-TNF Biologic Agents Exhibit Functional Differences in Blocking TNF-induced Effects on Human Monocytes In Vitro\n",
      "Aberrant M1 Polarization of Macrophages in Behcet’s Disease\n",
      "Regulation of Neutrophil Extracellular Traps by Apremilast (phosphodiesterase 4 Inhibition)\n",
      "Aberration of Histone Lysine Methylation in Adult-Onset Still’s Disease Are Novel Biomarker Candidates Associated with the Disease Activity\n",
      "GS-4875, a First-in-Class TPL2 Inhibitor Suppresses MEK-ERK Inflammatory Signaling and Proinflammatory Cytokine Production in Primary Human Monocytes\n",
      "The ACR’s Rheumatology Informatics System for Effectiveness (RISE) Demonstrates Improvements in Many Measures of Quality of Care Between 2015 and 2017\n",
      "Naming Is Everything! the Cost of Inappropriate “Lupus Panel” Testing\n",
      "Infrequent Screening but High Prevalence of Antinuclear Antibodies in Patients with Neuropsychiatric Disorders\n",
      "ANA-lysis: Utility of Repeated Antinuclear Antibody Testing in a Single Center\n",
      "Quality Control of Antinuclear Antibody Detection by Indirect Immunofluorescence and Flow Cytometry-based Recombinant Antigen Assays\n",
      "Increasing Capacity and Reducing Costs of Rituximab Administration\n",
      "Efficacy, Immunogenicity and Cost Analysis of a Systematic Switch from Originator Infliximab to Biossimilar CT-P13 of All Patients with Inflamatory Arthritis from a Single Center\n",
      "Documenting Bone Health for Veterans with Rheumatoid Arthritis in an Outpatient Academic Clinic: A Multiphase Quality Improvement Project\n",
      "Timely Glucocorticoid Tapering in Vasculitis: A Need for Improved Knowledge Translation to Limit Toxicity\n",
      "Screening and Treating Hyperlipidemia in Patient’s on Tofacitinib, Tocilizumab, Sarilumab, and Baricitinib\n",
      "Pre-treatment Screening for Hepatitis B and C Among Users of Biologics or New Synthetic Disease Modifying Drugs: An Analysis Using RISE Data\n",
      "Improving the Rate of Tuberculosis Screening Among High Risk Rheumatoid Arthritis Patients on Biologic Agents Using a Proposed Questionnaire\n",
      "Implementation of Cardiovascular Screening in Hispanic Patient Population with RA, SLE and PsA\n",
      "Improving Adherence to Pregnancy Screening in Patients on Teratogenic Medications Using an Electronic Medical Record Alert System: A Quality Improvement Initiative\n",
      "Improving Safe Prescribing of Hydroxychloroquine in a Safety Net Hospital Rheumatology Clinic\n",
      "A Pragmatic Randomized Trial to Improve Safe Dosing of Hydroxychloroquine\n",
      "Hydroxychloroquine (HCQ) Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution\n",
      "Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus\n",
      "Hydroxychloroquine Retinal Screening and Dosing in an Unique Rheumatologic Patient Population\n",
      "Compliance with Hydroxychloroquine Dosage According to 2016 American Academy of Ophthalmology (AAO) Guidelines: A Study with 6591 Patients\n",
      "Adherence to Guideline Directed Management of Gout Among VA Providers\n",
      "Frailty and Sarcopenia in Inflammatory Rheumatic Disease\n",
      "Cardiac Sarcoidosis Awareness: Are We Underdiagnosing?\n",
      "Presentation Order Bias in Rheumatology Journals: A Content Analysis\n",
      "Adverse Events During Colchicine Use: A Systematic Review and Meta-Analysis of Randomized Controlled Trial Events\n",
      "Excessive Alcohol Intake Is Associated with Tophi Formation in Gout Patients\n",
      "Acute Gout Attacks Among Patients Admitted Due to Heart Failure: Analysis of NIS Database\n",
      "Gout Management in the Medical Community: A Claims-Based Analysis\n",
      "Incident Gout After Renal Transplantation in Gout-naïve Patients: Large Database Analysis\n",
      "Assessing the Relationship Between Gout and Return to Hemodialysis Among U.S. Renal Transplant Patients\n",
      "The Role of a ‘Treat-to-Target’ Approach on Long-term Renal Outcomes in Patients with Gout\n",
      "Renal Transplant Complications in Patients with and Without Gout\n",
      "Treating Gout to Target Entails Renoprotective Effect in Patients with Moderate Chronic Kidney Disease\n",
      "Gout in the US: Significant Association with Cardiovascular and Renal Disease Hospitalizations – A Nationwide Study\n",
      "Effect of Serum Urate Lowering with Allopurinol on Blood Pressure in Young Adults\n",
      "Depressive Symptoms Influence Success of Allopurinol in Reducing Serum Urate\n",
      "Increased Physical Activity in Gout Patients Correlates with Better Prognosis, Decreased Pain, and Suppressed C-Reactive Protein Levels\n",
      "Development of a Multivariable Improvement Measure for Gout\n",
      "Rheumatologist Care Is Associated with Fewer Emergency Room Visits by Persons with Gout\n",
      "Emergency Department Length of Stay in Patients with Acute Gout\n",
      "Factors Associated with the Disappearance of Calcifications Following Ultrasound Guided Percutaneous Lavage of Rotator Cuff Calcific Tendinopathy: A Post Hoc Analysis of a Randomized Controlled Trial\n",
      "Associations of Serum Uric Acid with Cardiovascular Disease Risk: Data from the Korea National Health and Nutrition Examination Survey\n",
      "Subtypes of Gout Based on Comorbidity Patterns Among Black Patients in the US General Population – Cluster Analysis of the National Health and Nutrition Examination Survey 2007-2016\n",
      "Patterns and Clinico-Radiological Correlates of Symptomatic Atlantoaxial Joint Involvement in Patients with Calcium Pyrophosphate Deposition Disease\n",
      "Patterns of Newer Gout Medication Use in a U.S. Electronic Health Record-Based Registry\n",
      "Carotid Atherosclerosis and Sonographic Signs of Urate Crystal Deposits in Patients with Gout: An Association Study\n",
      "Rapid Reduction in Uric Acid Is Associated with Recurrent Cardiovascular Events\n",
      "Risk Factors for Cutaneous Reactions to Allopurinol in Kinh Vietnameses: Results of a Prospective Study in Ho Chi Minh City\n",
      "Primary Hyperparathyroidism Is Associated with a Higher Level of Serum Uric Acid: A Systematic Review and Meta-analysis\n",
      "Allopurinol Use and Type 2 Diabetes Incidence Among Patients with Gout: A VA Cohort Study\n",
      "Evaluation of Opioid Analgesia in Hospitalized Patients with Acute Crystal Induced Arthritis\n",
      "Comparative Risk of Cardiovascular Events in US Veterans with Gout Treated with Febuxostat versus Allopurinol\n",
      "Gout Flares Become Infrequent During a Treat-to-target Strategy over One Year: Data from the NOR-Gout Study\n",
      "Longitudinal Variation in Repeat Serum Urate Levels: Relationship with Hyperuricemia Classification\n",
      "Emergency Department Encounters in a Large US Payer Database: Tophaceous versus Non-tophaceous Gout Patients\n",
      "Impact of Hospital Admissions on Adherence to Allopurinol Therapy After Discharge\n",
      "Colchicine Prophylaxis of Gout Flares When Commencing Allopurinol Is Very Cost Effective: A Health Economic Analysis\n",
      "Frequency of Allopurinol Dose Reduction in Hospitalized Patients with Gout Flares\n",
      "Methods to Efficiently Recruit Minority Patients with Gout for Clinic-Based Registries\n",
      "Efficacy and Outcomes of Telephone-Based Management Program in Patients with Gout\n",
      "Calcium Pyrophosphate Crystal Arthritis During Hospitalizations: A Prospective, Crystal-Proven Case Series\n",
      "Classifying Pseudogout Using Machine Learning Approaches with Electronic Health Record Data\n",
      "Serum Uric Acid Level and Subclinical Coronary Atherosclerosis in Asymptomatic Individuals: An Observational Cohort Study\n",
      "Understanding the Mystery of Sarcoidosis: An Academic Rheumatology Center Experience\n",
      "Practice Patterns in Bone Health and Vitamin D Management in Sarcoidosis: A Survey of Physicians Who Manage Sarcoidosis\n",
      "Methotrexate and Interstitial Lung Disease in Patients with Inflammatory Articular Disease: A Systematic Review\n",
      "Use of Serum Lung Injury Biomarkers for Predicting the Severity of Interstitial Lung Disease in Patients with Connective Tissue Disease Associated Interstitial Lung Disease and Interstitial Pneumonia with Autoimmune Features\n",
      "Role of Alternative Immunosuppressant Therapy in Management of Cardiac Sarcoidosis\n",
      "Periaortitis and Coronary Arteritis in IgG4-Related Disease: Eastern Mediterranean Experience\n",
      "Prognostic Factors and Long-term Outcomes in Cardiac Sarcoidosis\n",
      "The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases\n",
      "Experience with Biologic Agents for the Treatment of Cardiac Sarcoidosis in a U.S. Academic Medical Center\n",
      "Long-term Outcome and Prognostic Factors of Patients with Interstitial Pneumonia with Autoimmune Features: A Single Center Large-scale Observational Cohort Study\n",
      "Novel Approach to the Treatment of Cardiac Sarcoidosis with TNF-alpha Inhibition\n",
      "Systemic and Ocular Sarcoidosis Study of 381 Patients from a Single Universitary Centre in the Last 20 Years\n",
      "Neurosarcoidosis: An Evaluation Based on the Neurosarcoidosis Consortium Consensus Group\n",
      "Seasonal Clustering of Acute Sarcoidosis in South-West Germany and Associations with Particulate Matter Air Pollution\n",
      "Effect of Vitamin D Supplementation on Calcium Levels in Patients with Sarcoidosis: A Retrospective Analysis\n",
      "Neurofilament Light Chain Levels in Cerebrospinal Fluid and Plasma in Neurosarcoidosis\n",
      "Retroperitoneal Fibrosis- a Single Center Experience\n",
      "Prevalence and Predictors of Fibrosis in Rheumatological Patients on Therapy and Risk Factors for Chronic Liver Disease\n",
      "Distinctive Clinical Features and Biomarkers of Connective Tissue Disease Associated Interstitial Lung Disease\n",
      "Idiopathic Granulomatous Mastitis: The Role of Rheumatologists in Treating This Rare Cause of Breast Pain\n",
      "Early Mortality in IgG4-Related Disease\n",
      "Treating Statin-induced Anti-HMGCR Myopathy with Normal Muscle Strength: A New Window of Opportunity\n",
      "ACR/EULAR Criteria for Myositis and Systemic Sclerosis Lack Sensitivity for Scleromyositis\n",
      "Preliminary Response to Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis\n",
      "The Beneficial Effects of Rituximab Treatment in Myositis May Be Due to the Binding of a Non B-Cell Protein, SMPDL3B, in Skeletal Muscle\n",
      "Management of Idiopathic Inflammatory Myopathies Using Intravenous Immunoglobulin Therapy: A Retrospective Cohort Study\n",
      "Surfactant Protein D as a Useful Predictor for Mortality in Myositis-associated Interstitial Lung Disease: A Dimorphic Model Based on anti-MDA5 Antibody\n",
      "Sexual Health in 39 Female Patients with Idiopathic Inflammatory Myopathies\n",
      "Younger Age at Presentation Is a Risk Factor for Failure to Achieve Remission in Adult Dermatomyositis\n",
      "Clinical Manifestations and Comparison of Subtypes of Juvenile Idiopathic Inflamatory Myopathies: Data from the REMICAM Registry\n",
      "Clinical Features of Polymyositis and Dermatomyositis Patients with Severe Dysphagia\n",
      "Seasonal Variation in Idiopathic Inflammatory Myopathies Incidence and Presentation: A Retrospective Study in Beijing and Hong Kong\n",
      "Seasonal and Temporal Analyses of Disease Onset and Diagnosis in Myositis Autoantibody Phenotypes in Juvenile Dermatomyositis (JDM)\n",
      "Performance of the European League Against Rheumatism/American College of Rheumatology Idiopathic Inflammatory Myopathies Classification Criteria in a Myositis Cohort from Argentina\n",
      "Performance of EULAR/ACR Classification Criteria for Idiopathic Inflammatory Myopathies in a Real-life Cohort of Adult Patients\n",
      "Chronic Disease Course and IVIg-dependance in Long-term Follow-up of Anti-HMGCR Immune-mediated Necrotizing Myopathy\n",
      "Single-specificity Anti-SMN Autoantibodies Are Associated with a Novel Scleromyositis Overlap Syndrome\n",
      "Autoantibody Profiles Delineate Three Distinct Subsets of Scleromyositis\n",
      "Anti-MDA5 Dermatomyositis: A Case Series, Systematic Review and Meta-analysis of the Literature\n",
      "Myositis Related Antibodies and Interstitial Lung Disease: Variables Associated with Baseline Lung Function and Functional Improvement: Results from a Multicentric Latin-american Cohort\n",
      "Utility of Anti-SSA/SSB Assay and Anti-Ro 52 Antibody Assay in Routine Clinical Practice for Risk Assessment of Patients with Idiopathic Inflammatory Myositis\n",
      "Frequency of Concomitant Non-aminoacyl-transfer-RNA Synthetase Autoantibodies in Patients with Antisynthetase Syndrome\n",
      "Antisynthetase Syndromes: Correlation of Indirect Immunofluorescence Patterns with Diagnosis Criteria Fulfillment\n",
      "Prevalence of Malignancy in Myositis Patients with Anti-aminoacyl-tRNA Synthetase Antibodies: A Single Center Retrospective Study and Literature Review\n",
      "Frequency and Staining Patterns of Antinuclear Antibodies in Myositis Patients Without Known Myositis-specific Autoantibodies\n",
      "Elevated Serum BAFF Levels in Patients with Dermatomyositis: Association with Interstitial Lung Disease\n",
      "Performance of the Patient Reported Outcomes Measurement Information System 29-item Profile in Comparison to the Clinical Disease Activity Index (CDAI) and Routine Assessment of Patient Index Data 3 (RAPID3) in an Australian Rheumatoid Arthritis Cohort\n",
      "Treat-to-Target Approach in the Management of Elderly Rheumatoid Arthritis Patients\n",
      "Validation of a Satisfaction Measure for Use in Total Joint Replacement Clinical Trials\n",
      "Global Management of Patients with Knee Osteoarthritis Begins with Quality of Life Assessment: A Systematic Review\n",
      "Contribution of Pain Relief to Function, Fatigue, and Quality of Life When Inflammation Is Controlled in Patients with Rheumatoid Arthritis\n",
      "Work Productivity Is Associated with Disease Activity and Functional Ability in Chinese Patients with Axial Spondyloarthritis Using a Smart-Phone Management System: A Prospective Cohort Study\n",
      "Real-World Evidence on the Early Effects of Golimumab on Work Productivity and Activity Impairment in Patients with Spondyloarthritis: Interim Results from a Prospective, Observational Study\n",
      "Assessment of Fatigue in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Qualitative Study to Explore What Patients Feel Should Be Measured in Clinical Trials\n",
      "An Examination of Patient-Reported Outcomes Data from a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis\n",
      "The Impact of Adalimumab vs Placebo on Patient-Reported Outcomes and Utility Measures Among Patients with Moderately to Severely Active Psoriatic Arthritis\n",
      "Patient Reported Outcomes over 2 Years in Psoriatic Arthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Routine Care – Was PRO Remission Achieved? Results from the EuroSpA Collaboration\n",
      "A Novel Patient-Reported Outcome Measure in IgG4-Related Disease: The Symptom Severity Index\n",
      "Differences in Correlation Between Objective Disease Measurements and Patient’s/physician’s Global Assessment in the Large Non-interventional Study SUSTAIN\n",
      "Time to Response for Clinical and Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Tofacitinib, Adalimumab, or Placebo\n",
      "Correlation Between Patient Reported Outcomes Measurement Information System (PROMIS) and RAPID3 in Rheumatoid Arthritis Patients Starting a New Biologic DMARD\n",
      "Assessing Meaningful Changes in Disease Activity as Clinical Trial Efficacy Measures for Cutaneous Lupus Erythematosus\n",
      "Concordance Between Physician and Patient Assessment of Disease Activity in Rheumatoid Arthritis Using Disease Activity Score: Phase II Results\n",
      "Axial Spondyloarthritis Patients Report Important Impairments in Daily Life and Work Ability – a Web Survey in 472 Patients\n",
      "Psychometric Properties of the Pediatric Patient-Reported Outcomes Measurement Information System (PROMIS®) Item Banks in a Dutch Clinical Sample of Children with Juvenile Idiopathic Arthritis\n",
      "Does Improvement in Patient Pain and Fatigue Lag Behind Clinical Remission in Rheumatoid Arthritis Patients? Data from a Rheumatoid Arthritis Registry\n",
      "Comparison of PROMIS Computerized Adaptive Testing-Administered Item Banks versus Fixed Short Forms in Juvenile Myositis\n",
      "Ixekizumab Significantly Improves Patient-reported Overall Health as Measured by SF-36 in Patients with Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Trials\n",
      "Understanding Which Patient-Reported Outcomes Are Important to Rheumatology Patients: Findings from ArthritisPower\n",
      "Poor Concordance Between Remission Judged by Physicians and a Patient-Acceptable Symptom State in Psoriatic Arthritis\n",
      "Is There Any Relationship Between Cardiovascular Comorbidity and a Patient-Acceptable Symptom State in Psoriatic Arthritis?\n",
      "Longitudinal Construct Validity and Responsiveness of MDHAQ and HAQDI in PsA: Can MDHAQ Replace HAQDI?\n",
      "Improved Patient-Reported Outcomes in Patients with Persistently Active Rheumatoid Arthritis Following Treatment with Repository Corticotropin Injection\n",
      "Disease Activity and Quality of Life in Behçet’s Syndrome: The Role of Patient Reported Outcome\n",
      "Multidimensional Health Assessment Questionnaire (MDHAQ) Scores in Spain vs USA: Similar Scores for Clinical Status and Self-report of Depression in Rheumatoid Arthritis (RA) but Poorer Scores for Both in Spondyloarthropathies (SpA) in Spain\n",
      "Multidimensional Health Assessment Questionnaire (MDHAQ) as an Effective Screening Tool to Identify Concomitant Depression in Patients with Rheumatoid Arthritis and Spondyloarthritis in Routine Care\n",
      "Validation of a Risk Perception Questionnaire Developed for Patients with Rheumatoid Arthritis\n",
      "Criterion Validity of the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) Questionnaire and FLARE-RA Cut-offs for Clinical Decision Making: International Collaboration\n",
      "Von Willebrand Factor Is Localized in the Extravascular Tissue of Patients with Juvenile Scleroderma\n",
      "The Study of the Novel G87V Mutation in the TNFRSF1A Gene Identified in a Family with TNF Receptor-Associated Periodic Syndrome (TRAPS)\n",
      "Chondrocytes Influence Fibroblast-like Synoviocytes from Patients with Juvenile Idiopathic Arthritis, Through the Abrogation of TGFβ Signaling, to Delay Cell Differentiation and Maturation\n",
      "Identical T Cell Clones Identified over Time in the Joints of Oligoarticular Juvenile Idiopathic Arthritis Patients\n",
      "Cutaneous Gene Expression Signatures in Juvenile Myositis Reveal a Prominent IFN Signature in Lesional Skin\n",
      "Genetic Signatures Support Inflammation Driven Fibrosis in Localized Scleroderma\n",
      "Interferon Response Gene Expression Differs in Whole Blood, Peripheral Blood Mononuclear Cells, Monocytes, Dendritic Cells, Neutrophils, and Skin Tissue in Patients with the Autoinflammatory Interferonopathies, CANDLE and SAVI\n",
      "Multiple Genetic Diagnoses in a Cohort of Patients with Cryopyrin Associated Periodic Syndrome (CAPS)\n",
      "The Juvenile Idiopathic Arthritis-Associated IL2RA Haplotype Contains an Intronic Enhancer Whose Function Is Diminished by JIA-Associated Genetic Variants\n",
      "Changes in MiR-17-92 Cluster Expression Link Systemic Juvenile Idiopathic Arthritis, Monocyte-to-Macrophage Differentiation, and Interferon Regulation\n",
      "Is down Syndrome Associated Arthritis (DA) a Distinct Disease from Juvenile Idiopathic Arthritis (JIA)?\n",
      "Oligoarticular Juvenile Idiopathic Arthritis Displayed Increased Expression of Co-Inhibitory Receptors Without Signs of T-Cell Exhaustion\n",
      "Differences in Chromatin Architecture in Treatment Naïve Pediatric Lupus Patients\n",
      "Application of Systems Biology-Based In Silico Tools for Optimal Treatment Strategy Identification in Still’s Disease\n",
      "Predictors of Response to Tumour Necrosis Factor – α Inhibitors (TNFi) in Juvenile Idiopathic Arthritis (JIA): A Single-center Experience\n",
      "Distinguishing S100 Proteins and Cytokine Levels Between Active and Inactive Uveitis in Children with Juvenile Idiopathic Arthritis\n",
      "Complement Protein Levels Reflect Disease Activity in Juvenile Idiopathic Arthritis\n",
      "Type I Interferon Score and Interferon Induced Mediators CXCL10 and Neopterin Are Correlated with Disease Activity in Juvenile Dermatomyositis\n",
      "DNASE1L3 Variant in Hypocomplementemic Urticarial Vasculitis Syndrome Identifies a Different Clinical Phenotype\n",
      "Can High ANA Titre Combined with Clinical Features Predict Developing Autoimmune Conditions in Children?\n",
      "Closing the Seronegative Gap in Pediatric Localized Scleroderma and Systemic Sclerosis\n",
      "Speckle Tracking Echocardiography, a Sensitive Tool to Detect Early Cardiac Dysfunctions in Juvenile Systemic Sclerosis\n",
      "Rituximab for Rapidly Progressive Juvenile Systemic Sclerosis: A Proof-of-concept Study in Four Patients\n",
      "Mycophenolate Mofetil for the Treatment of Severe or Methotrexate-refractory Juvenile Localized Scleroderma\n",
      "Is the Presentation and Severity Different of the Juvenile Diffuse and Limited Subtype Systemic Sclerosis? Results of Juvenile Scleroderma Inception Cohort\n",
      "Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests: Results from the Juvenile Scleroderma Inception Cohort\n",
      "Characteristics of Coexisting Localized Scleroderma and Juvenile Idiopathic Arthritis\n",
      "Development of Large Vessel Vasculitis Including Aortitis in a Patient with Deficiency of the IL-1 Receptor Antagonist (DIRA) Points to Converging Roles of IL-1 and TNF in Vascular Pathogenesis Recapitulating Findings from a Murine Model\n",
      "Application of the Autoinflammatory Disease Activity Index (ADDI) to a Cohort of Patients in a Tertiary Hospital\n",
      "Cryopyrin-Associated Periodic Syndrome in Korea: 19 Years of Experience\n",
      "Preliminary Analysis of Hearing Loss in a Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Cohort Followed over a Mean of 10 Years: Normal Hearing at Baseline and Early Treatment with Anakinra Area Associated with Maintenance of Normal Hearing\n",
      "Canakinumab Improves Patient-Reported Outcomes in Patients with Recurrent Fever Syndromes: Results from a Phase 3 Trial\n",
      "Hepatitis a Virus Vaccination in Autoinflammatory Diseases Under Canakinumab and Tocilizumab Treatment\n",
      "STING-associated Vasculopathy with Onset in Infancy (SAVI Syndrome) Can Mimic Juvenile Idiopathic Arthritis\n",
      "What Is the Effect of Statins on the Risk of Rheumatoid Arthritis? Results of a Systematic Review and Meta-Analysis\n",
      "High MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data) Scores in RA Patients Who Have Depression According to a Screening Questionnaire\n",
      "Nail Abnormalities in a Cohort of Rheumatoid Arthritis Patients: Repetitive Trauma-Related Findings in Toenails Are Associated with Radiographic Damage\n",
      "Central Sensitization in Patients with Rheumatoid Arthritis Using the Central Sensitization Inventory\n",
      "The Course of Disability Related to Function of the Upper Extremities in Early Rheumatoid Arthritis over 10 Years of Follow-up\n",
      "ACPA-positive versus ACPA-negative Rheumatoid Arthritis: Two Distinct Erosive Disease Entities on Radiography and Ultrasonography\n",
      "Persistent and Non-Articular Regional and Widespread Pain Are Common in Early Rheumatoid Arthritis, Impacting Remission Rates and Reflected in Patient Global Scores\n",
      "Anti-citrullinated Vimentin Antibodies Are Associated to Early Deterioration of Cortical Bone and Volumetric Bone Mineral Density in Finger Joints in RA-at-risk Patients\n",
      "Including Pain, Fatigue and Functionality Regularly in the Assessment of Patients with Early Rheumatoid Arthritis Separately Adds to the Evaluation of Disease Status\n",
      "Principal Component Analysis Identifies Unique Sub-Populations in Rheumatoid Arthritis Using a Combination of Serological Biomarkers: A Cross Sectional Study\n",
      "Anti-Protein-Arginine Deiminase (PAD) 4 IgA Are Present in the Sera of Rheumatoid Arthritis Patients and Are Associated with Joint Erosion and Biological Treatment Use\n",
      "Vitamin D Is Not Associated with Treatment Responses in Patients with Newly Diagnosed Rheumatoid Arthritis\n",
      "Serum Myostatin in Patients with Rheumatoid Arthritis and Its Correlations with Body Compositions and the Disease Activity\n",
      "The Influence of Mediterranean Diet in Rheumatoid Arthritis: A Monocenter Cross-sectional Study\n",
      "The Effects of Erythrocytes and Platelets on Disease Activity in Patients with RA – ANSWER Longitudinal Cohort Study –\n",
      "Fertility of Women with Rheumatoid Arthritis: Disease Activity Negatively Correlates with Serum AMH Levels\n",
      "Maximal Improvement in Fatigue Lags Behind Achievement of Sustained Remission in Early Rheumatoid Arthritis\n",
      "The Endogenous Plasma Small RNAome of Rheumatoid Arthritis\n",
      "High-titer Rheumatoid Factor Impacts Real-life Management Outcomes of Rheumatoid Arthtitis\n",
      "Continuous Decrease in Serum RF Titer During Anti-TNF Therapy Was Associated with Suppression in Progression of RA Joint Damage\n",
      "Prognostic Factors and Clinical Outcome Modifiers in Patients with Rheumatoid Arthritis: A Review\n",
      "Predicting Risk of Radiographic Progression for Patients with Rheumatoid Arthritis\n",
      "Serum Long-chain n-3 and -6 Fatty Acids Are Associated with Disease Feature at Onset and with 6-month Disease Activity in Early RA: Results from the ESPOIR Cohort\n",
      "Effect of Body Mass Index on the Disease Activity of Patients with Rheumatoid Arthritis in a Gender Specific Manner and Association of Respective Serum C – Reactive Protein Levels with the Body’s Inflammatory Status\n",
      "Location and Size of Affected Joints Are Useful to Predict Prognosis of Patients with Rheumatoid Arthritis\n",
      "Obesity Is a Robust Predictor of Persistent High Fatigue at 1 Year in Women and Men with Early Rheumatoid Arthritis\n",
      "When Will I Get past This Exhaustion? Predictors of Improved Fatigue in the First Year of RA\n",
      "Sleep Quality in Women with Rheumatoid Arthritis Is Associated with Disease Activity and Depressive Symptoms\n",
      "RA Presents in Disease Patterns Impacting Treatment Response\n",
      "Associations of Plasma Extravesicular (EV) MicroRNA Levels in Seropositive and Seronegative Rheumatoid Arthritis (RA)\n",
      "Myopenia in Elderly Female Patients with Rheumatoid Arthritis Is Associated with Severe Joint Damage: A Cross-sectional Study\n",
      "Decreased Muscle Mass, a Novel Predicting Indicator for One-year Radiographic Progression in Rheumatoid Arthritis: A Real-world Cohort Study\n",
      "Inflammation but Also Pain and Function, and Psychological Impact Is Related to Non-Acceptable Status in Patients with Rheumatoid Arthritis: A Factorial Analysis in 643 Patients\n",
      "The Influence of Gender on Composite Disease Activity Indices for Rheumatoid Arthritis\n",
      "Impact of Achieving Early-sustained Remission on Preventing Long-term Functional Loss in Patients with Early Rheumatoid Arthritis\n",
      "Not Achieving Clinical Remission Predicts a Poor Health-Related Quality of Life in Rheumatoid Arthritis Patients: Results of a Latin American Real World Database\n",
      "Production of IL17A in Synovial Tissue Correlates with MRI RAMRIS Scores in ACPA Positive Early Rheumatoid Arthritis\n",
      "Antibody Repertoire Sequencing, Antigen Array Analysis, and Cytokine Profiling of Blood from Individuals at High-risk for RA Reveals Candidate Immunoglobulin V Genes, ACPA, and Cytokines That May Promote the Transition to Arthritis\n",
      "Can a Single Question on Functional Impairments Facilitate the Diagnosis of Early Inflammatory Arthritis? A Cross-Sectional Derivation and Validation Study in Two Early Arthritis Recognition Clinics\n",
      "Effectiveness of Platelet-derived Microparticles for the Diagnosis and Clinical Evaluation of Rheumatoid Arthritis\n",
      "Comparison of Clinical Features, Synovial Histology and Immunohistochemistry in Seropositive Arthralgia, Rheumatoid Arthritis, and Osteoarthritis\n",
      "Evolution of Seropositive Arthralgia over Time: Predictors of Evolution to Rheumatoid Arthritis\n",
      "Third Generation Anti-cyclic Citrullinated Peptide Antibodies Improve Prediction of Clinical Arthritis in Second Generation Anti-cyclic Citrullinated Peptide Positive Subjects at Risk of Rheumatoid Arthritis\n",
      "Citrullinated Antigens with Multiple Citruline Similar Motif Could Be Used for RA Diagnosis\n",
      "S100A11 (calgizzarin) Is Released During Neutrophil Extracellular Traps (NETs) Formation in Rheumatoid Arthritis (RA)\n",
      "Validation of Risk Scores for Predicting Progression in Individuals “At Risk of Rheumatoid Arthritis”\n",
      "Diagnostic Performance of Anti-cyclic Citrullinated Peptide (CCP) 2 and CCP3.1 Assays in Early Rheumatoid Arthritis\n",
      "‘It Felt Like I Was Walking on Rocks” Patients Share First Symptoms of RA\n",
      "Diversity Analysis of Intestinal Flora in Patients with Rheumatoid Arthritis\n",
      "Clinical and Biomarker Factor Associations with Symptoms and Future Development of RA: TIP-RA Collective\n",
      "Pre-Rheumatoid Arthritis Diagnosis Prevalence of Commercial CCP Antibody Positivity Increases over Time with Strong Agreement Between Commercial Assays and Positivity Is Predicative of Developing Rheumatoid Arthritis Within 3 Years\n",
      "Assessment of Anti-Cyclic Citrullinated Protein and Connective Tissue Disease Screening Questionnaire in Healthy Adults from the Oklahoma Immune Cohort\n",
      "Women with Rheumatoid Arthritis Have Higher Lifetime Occupational and Non-occupational Exposure to Silica Dust Compared to French General Population\n",
      "Should There Be Hierarchical Scoring Applied to Serologic Testing in the 2010 ACR/EULAR Classification Criteria?\n",
      "The Generation of Anti-CCP Tests Affects Diagnostic Accuracy in Rheumatoid Arthiritis: A Systematic Literature Review and Meta-Analysis\n",
      "The Dysregulation of NK Cells and Non-Conventional NK-T and γδ-T Cells in Individuals at Risk of Developing Rheumatoid Arthritis\n",
      "EULAR Definition of “Arthralgia Suspicious for Progression to Rheumatoid Arthritis” in a Cohort of Patients Included in a Program for Rapid Diagnosis: Role of Ultrasound and Antibodies\n",
      "Disease Activity Measures at Baseline and 3 Months as Predictors of Rapid Radiographic Progression in Methotrexate Naïve Patients with Early Rheumatoid Arthritis\n",
      "The Role of NFAT5-p65 Complex Enhanceosome in the Inflammatory Responses of Rheumatoid Arthritis Synovial Fibroblasts via TLR4 Signaling\n",
      "Mass Cytometry Identifies Enhanced Histone H3 Citrullination and TNFα Production by CD14 Monocytes in Subjects At-Risk for Future Development of Rheumatoid Arthritis\n",
      "Discovery, Verification and Validation of Rheumatoid Arthritis Activity Monitoring Biomarkers\n",
      "Intestinal Microbiota Dynamics in the Progression of Rheumatoid Arthritis\n",
      "Autophagy Receptor Optineurin in Synovial Fibroblasts Plays a Protective Role Against Joint Destruction in Rheumatoid Arthritis\n",
      "Role of Sialic Acid in the Aggressive Phenotype of RA FLS\n",
      "Inflammation and Neuronal Growth Factors in Rheumatoid Arthritis\n",
      "Liver Dysfunction Associated with Rheumatoid Arthritis: Impact of Obesity and Effects of DMARDs in Hepatic Alterations\n",
      "Subclinical Oral Inflammation Is Common Across the Spectrum of Oral Findings in Rheumatoid Arthritis Patients, Whereas Porphyromonas Gingivalis Antibodies Are Primarily a Marker for Clinical Periodontitis\n",
      "The Impact of Air Pollution on Extracellular Vesicles as a Potential Pro-inflammatory Stimulus in Rheumatoid Arthritis\n",
      "Validation of New Genes Identified in a Molecular Bayesian Network of Rheumatoid Arthritis Synovitis\n",
      "bDMARD-experienced Filgotinib-treated Patient Samples Exhibit a Partial Reversion to the Peripheral Molecular Profile of a Demographically Matched Healthy Population\n",
      "Key Inflammatory Biomarkers at Baseline Are Associated with Filgotinib Response at Week 12 in Rheumatoid Arthritis Patients with Inadequate Response or Intolerance to Biologic DMARDs\n",
      "Autoreactivity to Acetylated Histones Defines a Subset of RA Patients and Is Associated with Acetyl – Citrulline Anti-Modified Protein Autoantibody (AMPA) Cross-Reactivity\n",
      "Phenotype-based Clustering Along with Analysis of Molecular Profile Might Help to Define Precise CV-risk Profiles in RA Patients\n",
      "Towards a Single Cell Portrait of Rheumatoid Arthritis – Development of a Single Cell Multiomics Pipeline for Phase 2 of the Accelerating Medicine Partnership (AMP) – RA Network\n",
      "Circulating 25(OH)D, LL-37 and Antimicrobial Protein and Peptide (APP) Levels Are Altered Prior to Onset of Rheumatoid Arthritis\n",
      "Cigarette Smoking Has Different Impacts on ACPA and RF Production Depending on Shared Epitope Allele Status in Japanese RA Patients; A Study with the Two Independent Japanese Cohorts (IORRA and KURAMA)\n",
      "Autophagy Protein Microtubule-associated Protein 1 Light chain-3B (LC3B) Regulates Joint Inflammation and Destruction in Rheumatoid Arthritis\n",
      "Activation of the Desacetylase Sirtuin-1 Counteracts the Activated and Proangiogenic Profile of Endothelial Cells in Rheumatoid Arthritis and Alleviates Experimental Arthritis\n",
      "A Metagenome-wide Association Study of Gut Microbiome Revealed Novel Etiology of Rheumatoid Arthritis in the Japanese Population\n",
      "A Novel Subclass of Intravascular Non-classical, Tissue Resident Synovial Monocyte Is Critical for Rheumatoid Arthritis Pathogenesis\n",
      "Choline Metabolite Is Associated with Inflammation in Arthritis in the Elderly\n",
      "Endothelial Progenitor Cells in the Pathophysiology of Interstitial Lung Disease Associated with Rheumatoid Arthritis\n",
      "In Rheumatoid Arthritis (RA) Decreases in Conventional Dendritic Cell Lineages Are Associated with Adverse Measures of Myocardial Function and Expansions of Anomalous HLA-DR+ Myeloid Subsets\n",
      "Evaluation of Potential Mechanisms Underlying the Safety Observations of Filgotinib in Clinical Studies in RA\n",
      "mTORC1-phosphorylated CXCR3+memory B Cells and Their Potential as a New Mode of Action of TNF Inhibitors in RA\n",
      "A Pilot Phase 1, Randomized, Double-blind, Two-arm, Parallel Group, Single-dose Study to Evaluate the Safety and Pharmacokinetics of CT-P17 and Humira in Healthy Male Subjects\n",
      "A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis\n",
      "Low-grade Total Rheumatoid Arthritis MRI Scoring System Can Predict Successful Half-dose Reduction of MTX in Patients with RA in Clinical Remission\n",
      "Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results\n",
      "Inhibition of Joint Destruction in Patients with Rheumatoid Arthritis Treated with Peficitinib in Combination with Methotrexate: A Randomized, Double-Blind, Placebo-Controlled Trial in Japan\n",
      "Longer Term Safety and Efficacy of Peficitinib in Patients with Rheumatoid Arthritis After 22.7 Months Mean Treatment Exposure: Interim Data from a Long-Term, Open-Label Extension Study in Japan, Korea and Taiwan\n",
      "Safety Profile of Upadacitinib in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase 3 Clinical Program\n",
      "Treatment with Upadacitinib Is Associated with Improvements in Reverse Cholesterol Transport in Patients with Rheumatoid Arthritis: Correlation with Changes in Inflammation and HDL Levels\n",
      "A Comparative Analysis of Upadacitinib Monotherapy and Upadacitinib Combination Therapy for the Treatment of Rheumatoid Arthritis from Two Phase 3 Trials\n",
      "Efficacy and Safety of Upadacitinib Monotherapy in MTX-naïve Patients with Early Active RA Receiving Treatment Within 3 Months of Diagnosis: A Post-hoc Analysis of the SELECT-EARLY\n",
      "Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis: Results at 48 Weeks\n",
      "A Pooled Analysis of 1-year Clinical Outcomes Among 6-month Responders and Non-responders from Three Randomized Controlled Studies of TNF Inhibitor Biosimilars in Patients with Rheumatoid Arthritis\n",
      "Clinical Responses in Patients with Inadequate Response to bDMARDs upon Treatment with Upadacitinib\n",
      "Impact of Baseline Demographics and Disease Activity on Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib\n",
      "A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs\n",
      "Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 Weeks\n",
      "Efficacy of Biosimilar Candidate ABP 710 in a Phase 3 Study in Subjects with Moderate to Severe RA: Additional Analysis Focusing on the ACR Individual Components\n",
      "Efficacy and Safety Results from a Phase 3 Study of Biosimilar Candidate ABP 710 in Subjects with Moderate to Severe RA\n",
      "Discontinuation of Disease Modifying Drugs Due to Inefficacy in Patients with Incident Rheumatoid Arthritis\n",
      "Treatment with Upadacitinib Results in the Normalization of Key Pathobiologic Pathways in Patients with Rheumatoid Arthritis\n",
      "The Impact of Upadacitinib versus Methotrexate or Adalimumab on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis\n",
      "A Comparison of Upadacitinib Plus Methotrexate and Upadacitinib Plus Other CsDMARDs in Patients with Rheumatoid Arthritis: An Analysis of Two Phase 3 Studies\n",
      "Factors Associated with Persistent Drug-free Remission in Patients with Rheumatoid Arthritis\n",
      "Factors Influencing Discontinuation in Long-term RA Treatment\n",
      "Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 48 Weeks\n",
      "Assessment of Bone and Cartilage Turnover Markers Following Treatment with Repository Corticotropin Injection in Patients with Persistently Active Rheumatoid Arthritis\n",
      "Characterization of Remission in Patients with Rheumatoid Arthritis Treated with Upadacitinib or Comparators\n",
      "Phase I Evaluation of the PDE4 Inhibitor LY2775240: Head to Head Comparison with Apremilast Using an Ex Vivo Pharmacodynamic Assay\n",
      "Efficacy and Safety of Gonadotropin-Releasing Hormone Antagonism in Severe Biologic Refractory Rheumatoid Arthritis\n",
      "A Phase 2 Study of E6011, an Anti-Fractalkine Monoclonal Antibody, ㏌ Patients with Rheumatoid Arthritis Inadequately Responding to Biologics\n",
      "Impact of Formulary Change on TNFi Treatment Patterns and Healthcare Utilization Costs in RA Patients\n",
      "CXCL13 Serum Levels and Circulating Follicular Helper T-Cells Decrease After Co-stimulation Blockade with Abatacept in Rheumatoid Arthritis\n",
      "Exploratory Analysis of a Phase 2b Study Confirms Substantial Pain Improvement with Anti-GM-CSF Monoclonal Antibody Otilimab (GSK3196165) in Patients (Pts) with Active RA\n",
      "PERFUSE: A French Prospective/Retrospective Non-interventional Cohort Study of Infliximab-naïve and Transitioned Patients Receiving Infliximab Biosimilar SB2; An Interim Analysis\n",
      "Efficacy and Safety Results from a Randomized Double-Blind Study That Compared the Proposed Biosimilar ABP 798 with Rituximab in Subjects with Moderate to Severe RA\n",
      "Long-Term Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to CsDMARDs: Results at 60 Weeks\n",
      "A Randomized Double-Blind Study Comparing Pharmacokinetics (PK) and Pharmacodynamics (PD) of ABP 798 with Rituximab in Subjects with Moderate to Severe RA\n",
      "Comparing Real-world Retention Rates in a Matched Cohort of Rheumatoid Arthritis Patients Who Either Remained on the Etanercept Originator or Switched to a Biosimilar\n",
      "Multicenter, Evaluator-blinded, Randomized, Non-inferiority Study, to Assess the Efficacy, Safety and Immunogenicity of Etanercept Biosimilar (EtaBS) vs. Reference Etanercept (EtaRef) in Combination with Methotrexate for the Treatment of Patients with Rheumatoid Arthritis\n",
      "‘BENEFIT’ Pan-European Observational Study to Evaluate the Real-world Effectiveness of SB4 Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis or Axial Spondyloarthritis: A Switch Success Story\n",
      "Cytokine Signaling Pathways Inhibited by Different Biologics in Rheumatoid Arthritis Patients\n",
      "Tolerance, Survival, and Adherence to Methotrexate Treatment in Patients with Rheumatoid Arthritis\n",
      "Molecular Analysis of the Mode of Action of Upadacitinib in Rheumatoid Arthritis Patients: Whole Blood RNA Expression Data from the SELECT-NEXT Study\n",
      "Change in Rheumatoid Arthritis (RA)-Related Autoantibody Profile and Risk of Disease Flare After Withdrawal of Therapy in Patients with Early RA Treated with Abatacept and MTX\n",
      "Inhibition of Structural Joint Damage with Upadacitinib as Monotherapy or in Combination with Methotrexate in Patients with Rheumatoid Arthritis\n",
      "Efficacy and Safety of a Novel Subcutaneous Formulation of CT-P13 over the 1-year Treatment Period and After Switching from Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis: Results from Part 2 of Phase I/III Randomized Controlled Trial\n",
      "US Rheumatologists’ Beliefs and Knowledge About Biosimilars – an Ongoing Survey\n",
      "Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study\n",
      "Upadacitinib Treatment and the Routine Assessment of Patient Index Data 3 (RAPID3) Among Patients with Rheumatoid Arthritis\n",
      "In the Real World Clinical Setting Etanercept Biosimilar SB4(BENEPAIL®) Demonstrates Equivalent Safety and Effectiveness in Biological Naïve as Well as with ENBREL® Pretreated RA,SPA, and PSA Patients\n",
      "Etanercept Biosimilar GP 2015 (Erelzi®) in Rheumatic Diseases: Interim Analysis of Real-World Data from COMPACT: A Multicentric, Prospective, Observational Cohort Study\n",
      "Evidence to Guide Glucocorticoid Tapering Is Lacking in RA\n",
      "Lyn-Deficient Murine Lupus Is Exacerbated by Glucocorticoid-Induced Leucine Zipper (GILZ) Deficiency\n",
      "Human Gingiva-derived Mesenchymal Stem Cells Are Therapeutic in Lupus Nephritis Through Targeting of CD39-CD73 Signaling Pathway\n",
      "The Role of the Intestinal Microbiota in Lupus Nephritis\n",
      "Rab4A Controls mTOR Pathway Activation, Pro-inflammatory Lineage Development, and Disease Pathogenesis in Lupus-prone Mice\n",
      "CD6 Modulation Ameliorates Skin and Kidney Disease in a Spontaneous Murine Model of SLE\n",
      "Amelioration of Immune Complex-Mediated Glomerulonephritis by CD6 Modulation\n",
      "Dermal Lymphatic Dysfunction Is Associated with Disease Activity in the MRL/lpr Lupus Model\n",
      "Inactivation of Transaldolase and HRES-1/Rab4 Predisposes to Hepatitis in a Mouse Model of Systemic Lupus Erythematosus\n",
      "Treatment of Lupus-prone MRL-lpr Mice with the Mitochondrial Antioxidant MitoQ\n",
      "Angiotensin Receptor Blockers Prevent Loss of Dendritic Complexity in a Lupus Mouse Model of Cognitive Impairment\n",
      "Inhibition of Nuclear Pore Export Ameliorates Lupus via Modulation of Plasma Cell Generation and Survival\n",
      "The Single-cell Transcriptomic Landscape of NZB/W Murine Lupus at Early and Late Stages of Disease\n",
      "Potent Anti-neutrophil Properties of the Natural Compound 6-Gingerol in Models of Lupus and Antiphospholipid Syndrome\n",
      "LILRA3 Promotes Lupus-like Chronic Graft-versus-Host Disease by Expansion of Follicular Helper T Cells and Anti-dsDNA Autoantibodies\n",
      "Microglia-Specific Transcriptional Signatures Correlate with Behavioral Deficits in ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’\n",
      "Effect of Ifnα and Costimulatory Blockade on Brain Infiltration in a Model of ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’\n",
      "Flux Analysis Reveals Influence of Rab4 Expression on Mitochondrial and Pentose Phosphate Pathway Metabolism of Lupus T Cells\n",
      "Ultraviolet Light Induces Increased T Cell Activation in Lupus-Prone Mice via Type I Interferon-Dependent Inhibition of T Regulatory Cells\n",
      "Unique Primed Status of Microglia Under the Systemic Autoimmune Condition of Lupus-Prone Mice\n",
      "The Role of Adopter Protein SH3BP2 in a Murine Systemic Lupus Erythematosus Model\n",
      "UV Light Stimulates a Systemic Neutrophil Response Associated with Transient Kidney Injury\n",
      "Rab4A Increases Mitochondrial Oxidative Stress and Glutathione Disulfide Accumulation That Underlie Neurobehavioral Changes in Lupus-Prone Mice\n",
      "Dysfunction of TRIM21 Promotes Aberrant Plasmablast Differentiation in Systemic Lupus Erythematosus Due to the Reduction of TRIM21-mediated Ubiquitylation of IRF5\n",
      "Cenerimod, a Potent and Selective Sphingosine-1-Phosphate Receptor 1 Modulator, Controls Systemic Autoimmunity and Organ Pathology in Mouse Models of Systemic Lupus Erythematosus and Sjögren’s Syndrome\n",
      "Selective Inhibition of the Immunoproteasome with KZR-616 Blocks Multiple Cell Signaling Pathways, Plasma Cell Signatures and Myeloid Cell Associated Damage in the NZB/W Lupus Nephritis Model\n",
      "Validation and Transcultural Adaptation of the Spanish Version of Brief Index of Lupus Damage (BILD) Questionnaire\n",
      "How Often Should SLE Patients Be Tested for Lupus Anticoagulant?\n",
      "Longitudinal Trends for Estimated Glomerular Filtration Rate and Predictors of Change in Patients with Systemic Lupus Erythematosus\n",
      "African-American Risk of Proteinuria After SLE Diagnosis Increases Throughout Thirty Years of Followup\n",
      "Elevated Serum Interleukin-23 Level in Patients with Systemic Lupus Erythematosus Is Associated with Disease Activity, Clinical and Immunological Markers\n",
      "A Novel Method to Analyze Circulating Immune Complexes Predicts Disease Activity and Severity in Systemic Lupus Erythematosus and Rheumatoid Arthritis\n",
      "Complement Deposition C4d on Platelets Is Associated with Vascular Events in Systemic Lupus Erythematosus\n",
      "Association Between Neutrophil to Lymphocyte, Monocyte to Lymphocyte, and Platelet to Lymphocyte Ratios and Lupus Disease Activity and Lupus Nephritis\n",
      "Decreased HVEM Expression in Lupus Patients and Impact of HVEM Knockout Mouse Model of Lupus Suggest a Role for BTLA Signaling in Disease Pathogenesis\n",
      "Association of Co-positivity for Anti-dsDNA, -Nucleosome, and -Histone Antibodies and Disease Activity in Patients with Lupus Nephritis: Results from the KORNET Registry\n",
      "A Meta-Analysis of Anti-Ribosomal P Autoantibodies in Systemic Lupus Erythematosus: A Misunderstood Autoantibody\n",
      "Is ANA-status at Disease Inception Associated with Long-term Damage Accrual and Direct and Indirect Health Care Costs in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort?\n",
      "Patients of African Descent Score Higher on Quality of Life Indices Despite Their Known Disease Severity\n",
      "Potentially Reversible Associations with Fatigue in SLE Patients – Results from a Single-centre Study\n",
      "Performance of the Proposed American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Lupus Erythematosus in Korean Patients\n",
      "Predictors of Renal Damage in Systemic Lupus Erythematosus Patients from Latin America\n",
      "Clinical Relevance According to Staining Patterns and Titers of Antinuclear Antibody\n",
      "Newly Diagnosed Lupus Nephritis in Elderly Predicts Good Renal Outcome: A Distinct Disease Subset from Young-onset Lupus Nephritis\n",
      "Applying Systemic Lupus International Collaborating Clinics (SLICC) and Provisional ACR/EULAR Systemic Lupus Erythematosus Classification Criteria in a Cohort of Patients with Undifferentiated Connective Tissue Disease\n",
      "Assessing Perceptions, Barriers, and Preferences to Exercise in Patients with Systemic Lupus Erythematosus\n",
      "Serum Albumin as a Long-term Predictor of Renal Evolution in Lupus Nephritis\n",
      "Performance of the “Do You Know What I Mean” Questionnaire in the Assessment of Disease Knowledge in Patients with Systemic Lupus Erythematosus\n",
      "Disentangling Connective Tissue Diseases: Overlaps and Disparities in Clinical Diagnosis, Classification Criteria and Autoantibodies – Results from the Lupus Extended Autoimmune Phenotype Study\n",
      "Diminished Memory B-cells in Systemic Lupus Erythematosus Patients with Low Disease Activity\n",
      "Antiphospholipid Syndrome (APS) in Systemic Lupus Erythematosus (SLE) Leads to a More Severe Disease\n",
      "Association of Serum and Urine Levels of TWEAK, MCP-1 and NGAL with Disease Activity in Systemic Lupus Erythematosus\n",
      "Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus\n",
      "Peripheral Blood Toll Like Receptor 7 Expression and Serum Interferon Lambda 1 Levels in Systemic Lupus Erythematosus and Their Relation to Disease Activity and Lupus Nephritis\n",
      "Myxovirus Resistance Protein a Is a Useful Additional Histological Marker for Cutaneous Lupus Erythematosus\n",
      "Utility of Repeat Renal Biopsies in Patients with Lupus Nephritis in Western Australia\n",
      "Sensitivity to Change of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort\n",
      "The PROMIS-29 as a Measure of Type 1 and 2 SLE Activity\n",
      "Lack of Uptake of Prophylactic Human Papilloma Virus (HPV) Vaccination Among Women with Systemic Lupus Erythematosus (SLE) in the Detroit, MI Area, a High Risk Population\n",
      "Complement Activation in Probable Systemic Lupus Erythematosus (pSLE) May Predict Progression to SLE Defined by Fulfillment of ACR Classification Criteria\n",
      "Association Between Ambient Air Pollutant Exposures and Childhood-Onset Systemic Lupus Erythematosus: A 12-Year Population-Based Cohort Study in Taiwan\n",
      "Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study\n",
      "Mouse SLE Studies Do Not Describe Human SLE\n",
      "Clinical Characteristics of Lymphadenopathy in Systemic Lupus Erythematous: A Case Control Study from a Tertiary Care Center\n",
      "Affordability Concerns Prevalent Among Patients with Systemic Lupus Erythematosus (SLE)\n",
      "Clinical and Serological Lupus Activity Before and After Developing End Stage Renal Disease\n",
      "Cluster Profiling of Patients in a Real-World Data Set with Systemic Lupus Erythematosus and Their Associated Treatments\n",
      "Performance of Montreal Cognitive Assessment (MoCA) in Screening for Cognitive Impairment in Patients with Lupus Compared to the Neuropsychological Battery\n",
      "Performance of the EULAR/ACR 2019 Classification Criteria for Systemic Lupus Erythematosus in Men, Diverse Ethnicities, and Early Disease\n",
      "Longitudinal Changes in Manifestations of SLE\n",
      "Patients Who Do Not Fulfill the 2018 EULAR/ACR Criteria for Systemic Lupus Erythematosus Accrue Less Damage: Data from a Multicenter, Multiethnic US Cohort\n",
      "Evaluation of the Lupus Foundation of America – Rapid Evaluation of Activity in Lupus (LFA-REAL) Clinician Reported Outcome (ClinRO) and Patient Reported Outcome (PRO) in a Primarily Mestizo Population\n",
      "Correlation Between the Lupus Foundation of America – Rapid Evaluation of Activity in Lupus (LFA-REAL) Patient Reported Outcome (PRO) and Health-Related Quality of Life (HRQoL) and Other PROs in a Primarily Mestizo Population\n",
      "Biologic Differences Between Type 1 and 2 Lupus\n",
      "Clinical Biomarkers at Renal Flare Are Associated with Histologic Changes in Repeat Renal Biopsy in Patients with Biopsy-proven Lupus Nephritis\n",
      "Neutrophil Lymphocyte Ratio as a Marker for Immune Complex-Driven Inflammation in Patients with Systemic Lupus Erythematosus\n",
      "Association Between the Soluble Terminal Complement Complex C5b-9 (sC5b-9) and Signs of Active Kidney Disease in a Swiss SLE Cohort\n",
      "CCP Autoantibody Positive SLE Patients Show Unique Enrichments in SLE Criteria and Autoantibody Biomarkers That Vary by Race\n",
      "Comparison of the Physicians’ Clinical Diagnosis and the EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Multiethnic Cohort\n",
      "Patterns of High Disease Activity Status and Outcomes in Systemic Lupus Erythematosus\n",
      "Urinary MRP8/14, an Endogenous Toll-Like Receptor 4 Ligand, Reflects Renal Disease Activity in Lupus Nephritis: A Cross-Sectional and Longitudinal Assessment\n",
      "Adjusted GAPSS in Systemic Lupus Erythematosus Patients in Argentina\n",
      "Correlation of Urinary Soluble CD163 Levels with Clinicopathological Features in Lupus Nephritis: Its Role as a Potential Biomarker\n",
      "Hair Chemicals and Systemic Lupus Erythematosus: A Case-Control Study\n",
      "Body Mass Index at Time of Diagnosis Is Predictive of Future Disease Activity in SLE\n",
      "Environmental and Atmospheric Factors in Systemic Lupus Erythematosus: A Regression Analysis\n",
      "The Performance of a Renal Activity Index in Lupus Nephritis in Induction Therapy\n",
      "Differing Opinions on Clinical Research Between Healthcare Providers and Lupus Patients\n",
      "Measurement of Type I IFNα Production at the mRNA Level and Its Potential Use as a Biomarker in Systemic Lupus Erythematosus\n",
      "Revising the SLEDAI-2K to Include Additional Constitutional Symptoms to More Accurately Assess Lupus Disease Activity\n",
      "Sleep Quality Among Patients with Systemic Lupus Erythematosus\n",
      "Association of Cumulative Urinary Podocyte Number and Urinary Podocalyxin with Long-term Renal Prognosis in Lupus Nephritis\n",
      "Seasonality of Cutaneous and Systemic Flares in Adults and Children in the Einstein Lupus Cohort\n",
      "Prior Knowledge Feature Reduction Improves Performance in a Machine Learning Model of Systemic Lupus Erythematosus Flare Status Using Serum Proteomics\n",
      "Improving Patient-Centered Care by Utilizing Lupus Wellness Program\n",
      "A Tale of Three Cohorts: SLE Criteria in Developed vs Developing Countries\n",
      "Neuronal BC RNAs: Systemic Lupus Erythematosus Autoantibodies Cause Dendritic Transport Impairments\n",
      "Oncostatin M Receptor (OSMR) Underexpression in Patients with Ankylosing Spondylitis\n",
      "The Correlation of Bone Bridge and Low Bone Mineral Density Measured by Quantitative Computed Tomography in Patients with Ankylosing Spondylitis\n",
      "Comparing Symptoms, Treatments Patterns, and Quality of Life of Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Patients: Findings from a US Survey\n",
      "Frequency and Characteristics of Inflammatory Bowel Disease in Spondyloarthritis with Biological Therapy: Study of 270 Patients from the Same Center\n",
      "Diagnostic Utility of Individual Inflammatory Back Pain Parameters in Patients with Axial Spondyloarthritis\n",
      "Dactylitis Occurrence in Early Spondyloarthritis: Five Years Data from a French National Prospective Cohort\n",
      "Analysing Impairments in Physical Performance as Assessed by the as Performance Index (ASPI) in Patients with Axial Spondyloarthritis (axSpA)\n",
      "Development of a Set of ASAS Quality Standards for Adults with Axial Spondyloarthritis\n",
      "The Impact of Sex and Disease Classification on Patient-reported Outcome Measures in Axial Spondyloarthritis: A Descriptive Prospective Cross-sectional Study\n",
      "ASDAS Is More Important Than BASDAI in Advanced Ankylosing Spondylitis\n",
      "Evidence-Based Recommendations for the Management of Enteropathic Arthritis: A Rheumatology – Gastroenterology Collaborative Initiative\n",
      "Temporal Relationship Between Enteropathic Spondylitis Symptoms/diagnosis and Inflammatory Bowel Diseases Diagnosis: HUR-BIO Real Life Results\n",
      "Worse Outcomes for Female Patients with Axial Spondyloarthropathy\n",
      "Understanding mNY Radiograph Score Discordance in Axial Spondyloarthritis Clinical Trials Using Imaging Criteria for Subject Eligibility\n",
      "Sarcopenia, Segmental Muscle Strength and Body Composition in Young Axial Spondylarthritis Patients: Results from MyoSpA Study\n",
      "Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for Follow-up of Ankylosing Spondylitis (AS) Patients with a Rheumatologist-patient Interactive Smart System of Disease Management (SSDM): A Cohort Study from China\n",
      "Effect of Long-term Treatment with TNF-α Inhibitor on Lipid Profile in Spondyloarthritis: Data from Nationwide Korean College of Rheumatology Biologics (KOBIO) Registry\n",
      "Early Recognition of Patients with Axial Spondyloarthritis by Using a Practical Referral System – Evaluation of the Recently Proposed 2-step Strategy\n",
      "Identification of Factors Associated with Magnetic Resonance Images Changes Suggestive of Axial Spondyloarthritis in the Axial Skeleton of Individuals < 45 Years – Evaluation of Data from a Large Community Study\n",
      "Localization and Morphology of Magnetic Resonance Imaging Features of Pathologic Changes in the Sacroiliac Joints Suggestive of Axial Spondyloarthritis – a Systematic Comparison of Patients and Controls with Chronic Back Pain\n",
      "Facet Joint Ankylosis on Whole Spine Low-Dose CT in Radiographic Axial Spondyloarthritis\n",
      "Spinal Bone Formation as Assessed by Low-Dose CT Scan in Patients with Radiographic Axial Spondyloarthritis – Comparison of the Progression Observed in Vertebrae and Facet Joints\n",
      "Gender Contrasts in Patient Reported Outcomes Don’t Alter the Disease Activity Score in Axial Spondyloarthritis Patients\n",
      "Restricted Work Participation Relates to High Disease Activity in Spondyloarthritis Patients\n",
      "Is There an Impact of Uveitis, Psoriasis and Inflammatory Bowel Disease on Musculoskeletal Disease Activity and Function in Axial Spondyloarthritis?\n",
      "Association of Comorbidities with Disease Activity and Functional Impairment in Axial Spondyloarthritis: Results from a Nationwide Population-Based Study\n",
      "Allograft Inflammatory factor-1 Drives Th17 Like Pathologic Signature and Predict Poor Response to TNF Inhibitor in Ankylosing Spondylitis\n",
      "Rheumacheck – Spondyloarthritis: Comprehensive Fast-track Diagnosis Program. What Benefits Does It Offer in a Developing Country?\n",
      "A Biomarker of Type VI Collagen Degradation (C6M) Is Associated with Changes in ASDAS MRI Measures of Inflammation in Patients with Axial Spondyloarthritis During TNF Inhibitor Therapy\n",
      "Radiographic Association of Hip and SI Joints in Ankylosing Spondylitis Patients\n",
      "Effect of Testosterone on Spinal Ankylosis in Ankylosing Spondylitis : in Vivo and in Vitro\n",
      "Drug Concentrations and Anti-drug Antibodies Influence in Response to Adalimumab: Results from the BioEfficacySpA Clinical Trial\n",
      "Increased Prevalence of Cardiac Disorders in Dutch Ankylosing Spondylitis Patients: The CARDAS Study\n",
      "The Gut Enthesis Axis Coming into Focus with the Description of Enriched Entheseal Resident Mucosal Associated Invariant T-cells (MAITs) Capable of IL17A and TNF Production\n",
      "Smoking, Alcohol Intake and Body Mass Index in Prediction of Disease Activity over Time in Early Axial Spondyloarthritis – Results from the SPondyloArthritis Caught Early (SPACE) Cohort\n",
      "What Is the Impact of MRI on the Performance of the ASAS Classification Criteria in Patients Presenting with Undiagnosed Back Pain?\n",
      "Longitudinal Assessment of MRI of the Sacroiliac Joints in the ASAS Classification Cohort: Evolution of Diagnostic Features and Predictive Utility for Axial Spondyloarthritis\n",
      "Replacement of Radiographic Sacroilitis by MRI Structural Lesions: What Is the Impact on Classification of Axial Spondyloarthritis in the ASAS Classification Cohort?\n",
      "Performance of the ASAS Classification Criteria Presenting with Undiagnosed Back Pain: Data from the Screening in Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Cohort\n",
      "Enhanced Performance of the ASAS Classification Criteria by Deletion of Non-Discriminatory Clinical Items: Data from the Screening in Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Cohort\n",
      "What Is the Impact of Discrepancy Between Central and Local Readers in Evaluation of MRI Scans on the Classification of Axial Spondyloarthritis? Data from the ASAS Classification Cohort Study\n",
      "Prostaglandin Receptor EP4 Drives Pathogenic Th17 Cell Development in Ankylosing Spondylitis and Is a New Marker of Disease Activity\n",
      "High Prevalence of Sacroiliac Bone Marrow Edema on MRI in Post Partum Women: A Temporary Phenomenom\n",
      "Identification of Potential Risk Factors for Spinal Structural Damage in Chinese Patients with Ankylosing Spondylitis\n",
      "Muscle Physical Properties in Young Adult Axial Spondyloarthritis Patients, the MyoSpA Study\n",
      "Frequency of Disease Flares Under Long-Term Anti-TNF Therapy in Patients with Early Axial Spondyloarthritis: Results from the Etanercept versus Sulfasalazine in Early Axial Spondyloarthritis Trial (ESTHER)\n",
      "Development of an Optimized Online Self-Referral Tool for Early Recognition of Patients with Axial Spondyloarthritis – Data from the OptiRef Study\n",
      "Comparison of Men and Women with Axial Spondyloarthritis in the US-Based Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry\n",
      "Are the Modified New York and ASAS Criteria Interchangeable in the Classification of Patients with Spondyloarthritis with Radiographic Sacroiliitis?\n",
      "Do Illness Perceptions and Coping Change over Time in Patients Recently Diagnosed with Axial Spondyloarthritis? A 2-Year Follow-Up Study in the SPACE Cohort\n",
      "Macrophage Migration Inhibitory Factor Is a Critical Regulator in a Mouse Model of Spondyloarthritis\n",
      "Effectiveness of TNFi After a First Switch in Patients with Early Axial Spondyloarthritis: A Longitudinal Analysis of the DESIR Cohort\n",
      "Expansion of Peripheral Cytotoxic T Cells in Co-morbid Inflammatory Bowel Disease and Spondyloarthritis\n",
      "Prevalence of Radiographic Entheseal Lesions at the Hip and Pelvic Region in Patients with Ankylosing Spondylitis versus Controls\n",
      "Baseline Characteristics and Natural History of Radiographic versus Non-radiographic Axial Spondyloarthritis: 5 Years Follow-up of the Desir Cohort\n",
      "Ankylosing Spondylitis-associated Killer Immunoglobin-like Receptors Are Strongly Expressed on γδ T Cells\n",
      "Retina of Ankylosing Spondylitis Patients Shows Early Signs of Atherosclerotic Disease in Comparison with Healthy Controls\n",
      "Objective Ankylosing Spondylitis Physical Performance Index (ASPI) Is Highly Reliable and Feasible in Chilean Patients\n",
      "Can Fecal Calprotectin Predict Future Development of Inflammatory Bowel Disease in Axial Spondyloarthritis Patients? – TReasure Real-Life Preliminary Data\n",
      "Tapering of Tumor Necrosis Factor Inhibitor and Healthcare Cost Differences in Patients with Ankylosing Spondylitis: A Retrospective Analysis of Korean National Health Insurance Data\n",
      "Effects of NSAIDs and TNF Inhibitors on Cardiovascular Events in Ankylosing Spondylitis: A Systematic Review and Meta-Analysis\n",
      "Association of Clinical and Radiographic Phenotype of Axial Spondyloarthritis and Skin Psoriasis: Results from the German Spondyloarthritis Inception Cohort\n",
      "Peripheral Involvement Is Associated with Less Radiographic Spinal Progression in Patients with Early Axial Spondyloarthritis: Results from the German Spondyloarthritis Inception Cohort\n",
      "Factors Associated with Complete Spinal Fusion in Patients with Ankylosing Spondylitis\n",
      "Relation of Therapies for Ankylosing Spondylitis to Risk of Total Hip and Knee Arthroplasty\n",
      "Arterial Elasticity by 2 Dimensional Circumferential Strain and Beta Stiffness Index in Patients with Ankylosing Spondylitis\n",
      "The Use of Microbial Flow Cytometry to Analyze the Intestinal and Oral Microbiota\n",
      "Ten-year Atherosclerotic Cardiovascular Disease Risk Scores in Axial Spondyloarthritis versus the General Population: A Cross-sectional Study\n",
      "Evaluation of the Early Cervical Structural Changes in Patients with Non-Radiographic Axial Spondyloarthropathy\n",
      "Axial Spondyloarthritis: Knowledge, Screening and Referral Practices Amongst Primary Care Providers\n",
      "Associations of Work-Related Abilities with Disability in Ankylosing Spondylitis\n",
      "Are There Really Differences Between Non-radiographic and Radiographic Axial Spondyloarthritis? Data from the Spanish Atlas\n",
      "Metabolomics Screening in Axial Spondyloarthritis: Identifying Potential Biomarkers\n",
      "Pain Perception and Opiate Use Among Patients with Inflammatory Arthritis\n",
      "Gender Differences in Comorbidities and Treatment Utilization Among Ankylosing Spondylitis Patients Initiating a Biologic in a Real-World Setting\n",
      "Assessing the Humanistic and Economic Burden of Enthesitis Among Patients with Peripheral and Axial Spondyloarthritis: Results from a Multi-National Real World Survey Database\n",
      "Recognition of Inflammatory Back Pain by US Healthcare Providers and Barriers to Specialist Referral\n",
      "An Observational Analysis of the Co-existence of Brugada Syndrome in Patients with Spondyloarthritis; A Potentially Important Link\n",
      "Diagnostic Delay in Spondyloarthritis\n",
      "Targeted 1H NMR Based Metabolomics Analysis Revealed Significantly Higher Synovial Phe/Tyr Ratio in Reactive Arthritis and Undifferentiated Spondyloarthropathy\n",
      "Association Between Radiographic Progression and Cardiovascular Risk in Spondyloarthritis: Data from CoSpaR REGISTRY\n",
      "Severity and Evolution over Time of Gastro-Intestinal Involvement in Patients with Systemic Sclerosis in Two Large and Independent Cohorts\n",
      "Improvement and Stabilization of Lung Function in Patients with SSc-ILD Treated with Nintedanib vs Placebo in a Randomized, Placebo-Controlled Phase III Trial: Proportions of Patients with FVC Changes Using Cutoffs Previously Proposed to Define Minimally Clinically Important Differences\n",
      "Structural Abnormalities of the Optic Nerve Head and Retinal Nerve Fiber Layer Using Optical Coherence Tomography in Patients with Systemic Sclerosis\n",
      "Relationship Between High-Resolution Computer Tomography and FVC% Predicted for Classification of Pulmonary Hypertension in Systemic Sclerosis\n",
      "Ultrasound Evaluation of the Hands in Patients with Systemic Sclerosis: Osteophytosis Is a Major Contributor to Tender Joints\n",
      "Safety and Tolerability of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis Based on Demographic Characteristics\n",
      "NEMO Score in Nailfold Videocapillaroscopy Is a Good Tool to Assess Both Steady State Levels and Overtime Changes of Disease Activity in Patients with Systemic Sclerosis: A Comparison with Both the Composite EScSG and EUSTAR Indices for This Disease Status Entity\n",
      "Characteristics of Patients with Systemic Sclerosis in the Rheumatology Informatics System for Effectiveness (RISE) Registry\n",
      "Imaging Technique (R)evolution to Measure the Digital Microcirculatory Flow in Systemic Sclerosis: A Systematic Review\n",
      "Looking for a “Very Early” Nailfold Capillaroscopic Pattern: Specific Alterations of Nailfold Capillaries May Precede the Validated Scleroderma-Patterns in Systemic Sclerosis Patients\n",
      "Dental Health in Systemic Sclerosis Patients Risk Factors and Comorbidities\n",
      "Diagnosing Pulmonary Hypertension Using the Proposed 6th World Symposium on Pulmonary Hypertensions New Definitions\n",
      "Distinct Characteristics of the Gut Microbiome of Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth\n",
      "Baseline Subject Demographics and Disease Characteristics in a Phase 3 Study of Safety and Efficacy of Lenabasum in Diffuse Cutaneous Systemic Sclerosis\n",
      "Ultrasound Measurement of the Nail Bed Matrix Thickness as a Useful Marker for Scleroderma-Related Interstitial Lung Disease\n",
      "The Lymphangiogenetic Factor VEGF-C and Its Receptor VEGFR-3 Are Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis\n",
      "Diagnosis of Systemic Sclerosis: How and When\n",
      "Biomechanical Properties of Skin for Assessment of Scleroderma: A Systemic Review\n",
      "Amniotic Membrane Dressings Provide an Effective Treatment for Systemic Sclerosis Digital Ulcers\n",
      "Digital Blood Perfusion Differences Between Black Africans and Caucasians with Systemic Sclerosis\n",
      "Mortality and Morbidity in Scleroderma Renal Crisis: A Systematic Literature Review\n",
      "Nailfold Videocapillaroscopy Patterns and Digital Occlusive Arterial Disease on Laser Doppler Flowmetry Strongly Predicts the Diagnosis of Systemic Sclerosis and Other Connective Tissue Diseases\n",
      "Modelled Patient Level Skin Score Trajectory Predicts Risk of Death or Major Organ-Based Complications in Diffuse Cutaneous Systemic Sclerosis\n",
      "Energy Levels: An Overlooked Element in Patient Assessment in Scleroderma\n",
      "A Systemic Review of Factors Associated with Systemic Sclerosis-associated Pulmonary Arterial Hypertension (SSc-PAH)\n",
      "Risk of Heart Valve Disease in Systemic Sclerosis\n",
      "Vonoprazan, a Novel Potassium-competitive Acid Blocker, for Treatment of Proton Pump Inhibitor-resistant Reflux Esophagitis in Patients with Systemic Sclerosis\n",
      "Risk Assessment in Connective Tissue Disease Associated Pulmonary Arterial Hypertension\n",
      "The Relationship Between Gastrointestinal Symptoms and Severity and Whole Gut Transit in Patients with Systemic Sclerosis\n",
      "Reduced Circulating Levels of Inorganic Pyrophosphate Are Associated with Ectopic Calcification in Scleroderma Spectrum Disorders\n",
      "The MUC5B Promoter Variant Does Not Predict Outcomes in Systemic Sclerosis-related Interstitial Lung Disease\n",
      "Systemic Sclerosis Myocarditis Has Unique Clinical, Histological and Prognostic Features: Comparative Analysis Between Patients with Endomyocardial Biopsy-proven Myocarditis\n",
      "Does Digital Thermal Monitoring Correlate to Specific Nailfold Videocapillaroscopy Abnormalities?\n",
      "Rituximab Rescue Therapy in Patients with Systemic Sclerosis or Other Connective Tissue Diseases and Refractory Interstitial Lung Disease\n",
      "THOR-809: An IL-2 Engineered from an Expanded Genetic Alphabet for the Potential Treatment of Autoimmune Disorders\n",
      "KINE-101, a Novel Synthetic Peptide with Potent Regulatory T Cells Activation to Treat Rheumatoid Arthritis\n",
      "Type I Interferon Signature Activation in Antiphospholipid Syndrome: Gene Expression Heterogeneity Among Disease Subsets\n",
      "Difference of Induced CD4+ and Natural Regulatory T Cells in Targeting Inflamed Synovial Tissues in Autoimmune Arthritis\n",
      "SLAMF6 Clustering Is Required to Augment Autoimmune T Cell Activation\n",
      "Histonedeacetylase 1 (HDAC1): A Key Mediator of T Cells for the Pathogenesis of Rheumatoid Arthritis\n",
      "Negative Immune Checkpoint Molecules on T Regulator Cells Distinguish RA, SLE and Healthy Controls\n",
      "Interferon Pathway Activation in T Follicular Helper (Tfh) Cell Subsets in Human Myositis\n",
      "Tumor Necrosis Factor Receptor 2 Signaling Potentiates Proliferation and Suppressive Activities of Follicular Regulatory T Cells\n",
      "IL-21-mediated Suppression of STAT5 Phosphorylation Underlies Treg Depletion and Dysfunction in SLE\n",
      "Characterizing the Brain T Cell Receptor Repertoire in Neuropsychiatric Lupus\n",
      "Low Frequency of Circulating T Follicular Helper 1 Cells Is Associated to Adequate Response to Adalimumab Therapy in Rheumatoid Arthritis\n",
      "Selective Induction of Functional Regulatory T-Cells in Healthy Volunteers by NKTR-358, a Novel IL-2 Conjugate Treg Stimulator, in Development for the Treatment of Autoimmune Diseases\n",
      "Mass Cytometry Immunophenotyping of Synovial Fluid from Checkpoint Inhibitor Related Arthritis\n",
      "Targeting ITK Signaling Ameliorates Collagen-Induced Arthritis via Shifting the Balance Between Th17 and Regulatory Th17 Cells\n",
      "CD126 Negative CD4+Foxp3+ Cell Represents a Superior Treg Subset in Treating Autoimmune Diseases\n",
      "Serine Arginine-Rich Splicing Factor 1 (SRSF1) Restrains IFN-γ and IL-17 Inflammatory Cytokine Production and Its Selective Deficiency in T Cells Exacerbates Experimental Autoimmune Encephalomyelitis (EAE) and Nephrotoxic Nephritis (NTN)\n",
      "Serine Arginine-rich Splicing Factor 1 (SRSF1) Is Indispensable for Homeostasis and Function of Regulatory T Cells\n",
      "Novel, Selective, Orally Active PAD4 Inhibitors for the Treatment of Autoimmune Disorders\n",
      "The DLEU2/miR-15a/16-1 Cluster Inhibit Foxp3+ Treg Cells in Salivary Glands of pSS via Targeting Foxp3\n",
      "Increased T Cell Polyreactivity with Marked Accumulation of TNF-α DP (CD4+CD8+) in the Synovial Tissue of pre-RA, Arthralgia Subjects\n",
      "Expanded Peripheral T Helper Cells Characterize the Early Rheumatoid Arthritis Synovium\n",
      "Mucosal Associated Invariant T Cells in Giant Cell Arteritis\n",
      "Targeting CD6 Expression Attenuates T Cell Activity in Murine Collagen Induced Arthritis\n",
      "Bioinformatics Analysis of Transcriptomics Data Reveals That SRSF1 Is a Novel Molecular Brake for the T Cell Activation Program and Controls Key Cytokine Signaling Genes Implicated in Systemic Lupus Erythematosus\n",
      "The Transcription Factor STAT3 Regulates Pathogenic Th17 Responses in Autoimmune Disease via Noncanonical Roles\n",
      "Impact of Interleukin-9 on the Immune Suppressive Functions of Regulatory T Cells in Rheumatoid Arthritis\n",
      "In Vitro Characterization of the Effect of Cenerimod, a Potent and Selective Sphingosine 1-Phosphate Receptor 1 (S1P1) Modulator, on S1P1 Receptor Expression, Receptor Internalization, and Migration of Primary Human T Cells in the Presence or Absence of Glucocorticoids\n",
      "Persistent Synovial Resident Memory T Cells Mediate Arthritis Flares\n",
      "CD8+ Cytotoxic T Lymphocytes Are Clonally-expanded in IgG4-related Disease and Home to Affected Tissues\n",
      "Defective EZH2 Expression Attenuates Treg Differentiation in Rheumatoid Arthritis\n",
      "The Indole Derivative NecroX Blocks Th17 Cell Differentiation and Fibroblast-like Synoviocytes-mediated Th1/Th17 Responses in Rheumatoid Arthritis\n",
      "Polymorphonuclear Neutrophils and Regulatory T Lymphocytes (Treg) Cooperate to Sustain Treg Activity but This Interaction Is Altered in Rheumatoid Arthritis Patients\n",
      "Mitochondrial Transplantation Suppressed Muscle Inflammation and Improved the Mitochondrial Dysfunction in C Protein-induced Myositis Model\n",
      "Administration of a CD45 Antibody Drug Conjugate as a Novel, Targeted Approach to Achieve Immune System Reset: A Single Dose of CD45-targeted ADC Safely Conditions for Autologous Transplant and Ameliorates Disease in Multiple Models of Autoimmune Disease\n",
      "In Vitro Human Enthesitis Model with Induced IL-17A and TNFα from CD4+ and CD8+ T Cells and Effect of Pharmacological Antagonism with Janus Kinase and Retinoic Acid Receptor-related Orphan Receptor γ Inhibition\n",
      "Inhibition of Necroptosis Suppresses Muscle Cell Death and Inflammatory Infiltrate, and Improves Muscle Strength in Experimental Polymyositis\n",
      "Blockade of Antigen-specific T Cell Activation by a Non-Depleting Anti-HLA-DR Monoclonal Antibody with a Unique Binding Epitope\n",
      "Treatment with Abatacept but Not with TNF Blockers, Is Associated with a Reduction of Constitutively Elevated Circulating Follicular Helper T Cells in Rheumatoid Arthritis\n",
      "Elevated Proliferative Capacity of CD8+ T Cells in Giant Cell Arteritis\n",
      "Vascular Damage Is Less Present in an Early Inception Cohort in Takayasu’s Arteritis\n",
      "Polymyalgia Rheumatica: New Therapeutic Strategy Based on Low Dose Metrotexate Plus Local Infiltration with Corticosteroids\n",
      "Association Between Acute-phase Reactants, interleukin-6(IL6), Tumor Necrosis Factor-a(TNFa) and Disease Activity in Takayasu’s Arteritis During Follow-up with Repeated Evaluation of Vascular Imaging Manifestations\n",
      "Are Hematologic Indexes Helpful in the Diagnosis and Prognosis of Polymyalgia Rheumatica?\n",
      "Cardiac Involvements Are Related to Poor Prognosis in Patients with Takayasu’s Arteritis in China\n",
      "Childhood-Onset Takayasu’s Arteritis (TAK) Is Clinically More Active, However Has Similar Cumulative Damage Compared to Adult-Onset TAK\n",
      "Detrimental Factors Affecting the First-year Clinical Response in Korean Patients with Polymyalgia Rheumatica\n",
      "Takayasu Arteritis and Sacroiliitis: A Case Control Study in 28 Patients of a Single Italian Center\n",
      "Childhood Takayasu Arteritis: Characteristics and Outcomes of a Mexican Cohort\n",
      "Extravascular Inflammatory Manifestations of Takayasu Arteritis in a Monocentric Cohort\n",
      "Pregnancy Outcome in Patients with Takayasu Arteritis: The Results of Turkish Takayasu Study Group\n",
      "Drug Retention and Discontinuation Reasons Between Seven Biologics in Patients with Takayasu Arteritis\n",
      "Initial Clinical Presentation Is Associated with Outcome in Takayasu’s Arteritis\n",
      "Dynamic Distribution and Phenotype Shift from M1 to M2 of Macrophages in Vascular Lesions of Naïve and Treated Patients with Takayasu Arteritis\n",
      "A Novel Diagnostic Algorithm for Polymyalgia Rheumatica Using Three Musculoskeletal Sites on Whole Body PET/CT\n",
      "A Volar Pattern of 18F-Fluorodeoxyglucose Uptake at the Hand on Whole Body PET/CT Predicts Glucocorticoid-Responsive Disease in Polymyalgia Rheumatica\n",
      "Long-term Clinical Course and Outcomes of 2013 Patients with Takayasu Arteritis\n",
      "Interleukin-6 May Predict Disease Relapse During Long-term Follow-up in Takayasu’s Arteritis in a Han Chinese Population\n",
      "Polymyalgia Rheumatica Patients with and Without Elevated Baseline Acute Phase Reactants: Distinct Subgroups of Polymyalgia Rheumatica?\n",
      "Prescribing Methotrexate in Polymyalgia Rheumatica: A Missed Opportunity?\n",
      "Polymyalgia Rheumatica: Winter Is Coming\n",
      "Are There Any Identifiable Triggers in Polymyalgia Rheumatica? A Matched-Control Study\n",
      "Treatment Efficacy Evaluation of Leflunomide by Regulating Macrophages in Takayasu Arteritis\n",
      "The Clinical and Angiographic Features of Chinese Takayasu’s Arteritis Patients: A Cohort Study of 591 Patients in 6 Years\n",
      "Application of Different Sets of Classification/diagnostic Criteria for Polymyalgia Rheumatica: Single Center Study of 100 Patients\n",
      "Predictors of Long-term Therapy with Glucocorticoid in Polymyalgia Rheumatica\n",
      "Outcome Measures in Large-Vessel Vasculitis: Relationships Between Patient, Physician, Imaging, and Laboratory-Based Domains\n",
      "Angiographic Patterns and Changes in Arterial Lesions in Patients with Behcet’s Disease\n",
      "Damage in Takayasu‘s Arteritis Is Associated with Age at Symptom-onset, Disease-duration and Corticosteroid Dose but Not Relapse in Routine Follow-up\n",
      "Involvement of Iliofemoral and Axillary Arteries in PET-CT May Be Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis\n",
      "Risk of Cardiovascular Disease in SLE Is Significant Early and Highlights Racial Disparities\n",
      "A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease\n",
      "Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naïve or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study\n",
      "Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial\n",
      "TNF-α Drives Progressive Obliterative Pulmonary Vascular Disease and Represents a Novel Model of Connective-Tissue Disease Associated Pulmonary Arterial Hypertension (CTD-PAH)\n",
      "From Diagnosis to the Establishment of the Labalaba Foundation: My Journey from Surviving to Thriving\n",
      "Living and Adjusting to a Diagnosis of Rheumatoid Arthritis (RA) with an Interdisciplinary Team\n",
      "Bridging the Gap: Leveraging Social Media to Improve Patient Support; Build a Path to Collaborative Medicine\n",
      "Reclaiming Medical Autonomy Through Healthcare Advocacy\n",
      "Race for Relapsing Polychondritis Drives Awareness, Accelerates Research, and Improves the Quality of My Life: How Motorsports Help Me Overcome the Hopelessness of an Incurable, Rare Disease\n",
      "Art for Arthritis: A New Approach\n",
      "Coming to Terms with Lupus: How Learning to Listen to My Body and Letting it Tell Me What to Do Improved My Quality of Life\n",
      "Framework for Enhancing Patient-Physician Communication in the Context of Rare Disease\n",
      "Journeying Towards Hope: Making a Difference in The Lives of Lupus Patients in Mauritius\n",
      "The Practice of Reiki and Meditation in Maintaining Medical Compliance and Decreased Anxiety in an Adult with Juvenile Rheumatoid Arthritis\n",
      "Trends in Incidence and Prevalence of Osteoarthritis in the United Kingdom: Findings from the Clinical Practice Research Datalink (CPRD)\n",
      "Cigarette Smoking Is a Risk Factor for ANCA-Associated Vasculitis\n",
      "The Risk of Venous Thromboembolism in Patients with Psoriatic Disease and Rheumatoid Arthritis, a Population-based Study\n",
      "Results from a Randomized Controlled Trial of the Safety of the Live Varicella Vaccine in TNF-Treated Patients\n",
      "Systemic Sclerosis Deaths at Younger Ages Have Decreased over the past Five Decades\n",
      "Immune-Mediated Inflammatory Diseases (IMID) Collectively Rank Among the Leading Causes of Death\n",
      "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia (FM): Evidence for a Broad Spectrum of Activity on the FM Syndrome\n",
      "A Path Model Analysis of the Cognitive Determinants of Physical Activity Among Patients with Fibromyalgia (FM)\n",
      "Dietary Intake Does Not Explain Microbiome Alterations or Symptom Severity in Fibromyalgia\n",
      "The Efficacy of Non-Pharmacological Interventions for Fibromyalgia: A Systematic Review with Meta-Analysis\n",
      "Maintaining Musculoskeletal Health: A Randomized Controlled Prevention Trial Amongst People at High Risk of Developing Chronic Widespread Pain\n",
      "Diagnosis of Fibromyalgia: Comparison of AAPT and ACR Criteria\n",
      "Effect of a Mobile App to Monitor Patient Reported Outcomes in Rheumatoid Arthritis: A Randomized Controlled Trial\n",
      "Implementing Patient-Reported Outcome Measures in Clinical Care: Rheumatologist Perspectives on Opportunities and Challenges\n",
      "High Baseline Patient’s Compared with Evaluator’s Global Assessment Is Associated with Lower Retention and Remission Rates of First TNF Inhibitor in Psoriatic Arthritis Patients – Data from the EuroSpA Research Collaboration Network\n",
      "Patient-Reported Outcomes from a Randomised, Open-Label, Parallel-Group Study Evaluating Ixekizumab versus Adalimumab in Patients with PsA Who Are Biologic DMARD Naïve: 24-Week Results\n",
      "Does Discordance Between Baseline Patient’s and Evaluator’s Global Assessment of Disease Activity Impact Retention and Remission Rates of a First TNF Inhibitor in Patients with Axial Spondyloarthritis? Data from the EuroSpA Research Collaboration Network\n",
      "Are PROMIS Measures Associated with Minimal Disease Activity in Psoriatic Arthritis?\n",
      "Small Vessel Vasculitis Syndrome with Autoinflammation Caused by De Novo Mutations in LYN Kinase\n",
      "Monomethyl Fumarate as a Novel Therapy for Macrophage Activation Syndrome: Mechanism of Action in an Animal Model\n",
      "Sex Differences in Autoimmunity and Cardiovascular Risk Could Be Associated with Altered Treg Phenotype and Lipoprotein Metabolism\n",
      "Monocyte and Macrophage Transcriptional Phenotypes in Systemic Juvenile Idiopathic Arthritis Reveal TRIM8 as a Mediator of IFNγ Hyperresponsiveness and Risk for Macrophage Activation Syndrome\n",
      "Interferon Signature and Cytokine Patterns Define Novel Autoinflammatory Diseases\n",
      "Disease Activity, Cytokine Profiles, and the Risk of Incident Diabetes in Rheumatoid Arthritis\n",
      "Trajectory of Multimorbidity in Rheumatoid Arthritis in a U.S. Commercial Insurance Claims Database from 2006-2015\n",
      "Elevation of Anti-Citrullinated Protein Antibodies Prior to Rheumatoid Arthritis Onset and Risks for Developing Chronic Obstructive Pulmonary Disease or Asthma\n",
      "Mortality Ratio and Risk Factors in CT Confirmed Rheumatoid Arthritis Related Lung Disease: UIP, Pleural Effusion and the Time of Diagnosis of Rheumatoid Arthritis – Lung Disease\n",
      "High Lung Attenuation Measured with Quantitative Densitometry as a Surrogate Marker for Interstitial Lung Disease in RA: Association with Anti-CCP, Smoking, and Absence of Shared Epitope\n",
      "Impact of Glucocorticoid Tapering on Markers of Bone Metabolism in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab: Exploratory Analysis from a Randomized Controlled Trial\n",
      "Expression Profiling of Genes in Rheumatoid Fibroblast‑like Synoviocytes Regulated by Fas Ligand Using cDNA Microarray Analysis\n",
      "The Long Non-coding RNA HOTAIR Regulates BMP2 and Wnt Pathways in Synovial Fibroblasts\n",
      "Enhanced Expression of mRNA for TAK1 in CD34+ Cells of the Bone Marrow in Rheumatoid Arthritis\n",
      "Semaphorins: From Angiogenesis to Inflammation in Rheumatoid Arthritis\n",
      "The Long Noncoding RNA HOTTIP Regulates Cell Cycle and Inflammatory Response in Hand Synovial Fibroblasts\n",
      "Diurnal Stability of Transcriptional Profiles in Rheumatoid Arthritis\n",
      "Comparison of Rituximab-Associated Hypogammaglobulinemia Rates in Patients with Systemic Rheumatologic Conditions\n",
      "MACE and VTE Across Multiple Upadacitinib Studies in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase 3 Clinical Program\n",
      "Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 7 Years: An Updated Integrated Safety Analysis\n",
      "Risk of Serious Infection with Long-Term Use of Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis\n",
      "Risk of Malignancies Associated with Biologics in Rheumatoid Arthritis: Analysis of a National Claim Database\n",
      "Safety of Synthetic and Biological DMARDs: A Systematic Literature Review Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis\n",
      "Mesenchymal Stem Cell Therapy Induces FLT3L and CD1c+ Dendritic Cells in Systemic Lupus Erythematosus Patients\n",
      "Adverse Events of Special Interest, SLE Medication Utilization, Hospitalizations, and Organ Damage: Results from a Phase 4, Randomized, Double-Blind, Placebo-Controlled, 52-week Study of Belimumab in Adults with Active, Autoantibody-Positive SLE\n",
      "Long-term Outcome of a Randomized Controlled Trial Comparing Tacrolimus with Mycophenolate Mofetil as Induction Therapy of Severe Lupus Nephritis\n",
      "Efficacy of Belimumab in Patients of Black Race with Systemic Lupus Erythematosus and High Disease Activity or Renal Manifestations\n",
      "Cutaneous Lupus Erythematosus Disease Area & Severity Index (CLASI) Demonstrates Thresholds for Detection of Treatment Response in a Phase-2, Placebo-Controlled Trial of Ustekinumab in SLE\n",
      "First Use of Cenerimod, a Selective sphingosine-1-phosphate 1 (S1P1) Receptor Modulator, for the Treatment of Systemic Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase II, Proof-of-Concept Study\n",
      "Association Between Bone Marrow Edema and Structural Progression in the Same Quadrant in Axial Spondyloarthritis – 5-year Data from the DESIR Cohort\n",
      "Ileal but Not Colonic Inflammation Is Linked to Fatty Lesions on MRI of the Sacroiliac Joints in Spondyloarthritis Patients\n",
      "Two-Year Progression of Facet Joint Ankylosis on Whole Spine Low-Dose CT in Patients with Radiographic Axial Spondyloarthritis\n",
      "Do Smoking and Socio-economic Factors Independently Influence Imaging Outcomes in Axial Spondyloarthritis? Five-year Data from the DESIR Cohort\n",
      "Which Magnetic Resonance Imaging Lesions of the Sacroiliac Joints Are of Diagnostic Value for Axial Spondyloarthritis?\n",
      "MRI of the Sacroiliac Joints in Athletes: Do Semi-axial Slices Added to Standard Semi-coronal Scans Facilitate Recognition of Non-specific Bone Marrow Edema?\n",
      "Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis— Results of Phase I/II Investigator-Initiated, Double-Blind Randomized Placebo-Controlled Trial\n",
      "Change in Scleroderma Skin Histology Correlates with the Combined Response Index in Systemic Sclerosis (CRISS) in Patients with Early, Diffuse Cutaneous Systemic Sclerosis\n",
      "Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects\n",
      "Evaluation of the Highly Selective Endothelin a Receptor Antagonist Zibotentan in Systemic Sclerosis Associated Chronic Kidney Disease\n",
      "Safety and Efficacy of B-cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension in a Multi-center NIH Clinical Trial\n",
      "The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud Phenomenon in Early Diffuse Scleroderma: Results of the “Tamer”‘ Study\n",
      "Clinical Manifestations of Patients with Eosinophilic Granulomatosis with Polyangiitis in a Large North American Cohort\n",
      "Off-Label Use of Biotherapies to Treat Relapsing And/or Refractory Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)\n",
      "ANCA-Associated Vasculitis Management in the United States: Data from the RISE Registry\n",
      "Granulomatosis with Polyangiitis Sustained Remission Off-Therapy: Data from the French Vasculitis Study Group Registry\n",
      "Survival After Lung Transplantation in Adults with Primary Systemic Vasculitides: Analysis of the United Network of Organ Sharing (UNOS) Database\n",
      "Comparative Analysis Between ANCA-associated Interstitial Lung Disease and Interstitial Pneumonitis with Autoimmune Features\n",
      "Effect of the Dr. Bart Application on Healthcare Use and Clinical Outcomes in People with Osteoarthritis of the Knee And/or Hip in the Netherlands; A Randomized Controlled Trial\n",
      "“When You Read This, You Really Feel Old!” Perspectives of Young People with Inflammatory Arthritis on Patient Reported Outcome Measures from a European Qualitative Study\n",
      "Rheumatoid Arthritis Patients’ Perspectives on Tapering of Biologics: A Qualitative Study\n",
      "The Association of Serum Magnesium with Chondrocalcinosis and Osteoarthritis\n",
      "Evaluation of Marijuana and Cannabidiol Use in the Rheumatologic Population from a Patient and Clinician Perspective: A Survey-Based Study\n",
      "Avoidable Acute Care Use for Vaccine-Preventable Illnesses Among Medicaid Beneficiaries with Lupus: Demographic and Healthcare Utilization Differences\n",
      "Rate of Thirty-Day Readmissions in Systemic Lupus Erythematosus Rivals Congestive Heart Failure and Exceeds the General Medicare Population\n",
      "Treatment Patterns and Persistency Following the First Biologic DMARD in Patients with Rheumatoid Arthritis: Real-World Analysis of 2012–2016 US Medicare Data\n",
      "Physical Therapy and Opioid Use in Knee Osteoarthritis\n",
      "Adherence to Statin Therapy in Rheumatoid Arthritis Patients: A Population-Based Cohort Study\n",
      "The Impact of Psychiatric Comorbidity on Health Care Utilization and Preventive Health Care in Rheumatoid Arthritis: A Population Based Study\n",
      "Diseased Lupus Nephritis Kidneys Serve as a Primary Site of Systemic Autoimmune Development\n",
      "Auto-antibodies Targeting Components of Sarcolemma Repair: A Pathogenic Mechanism in Human Inflammatory Myopathies\n",
      "Serum Anti-Vimentin Autoantibodies May Uniquely Predict Response to Therapy in Lupus Nephritis\n",
      "B Cell-specific MyD88 Regulates Pathology After Disease Onset in Murine Lupus\n",
      "Interferon-Alpha Disrupts Multiple B Cell Tolerance Mechanisms in 3H9 Mice\n",
      "TLR9 Signaling in HCV-Associated Atypical Memory B Cells Triggers Th1 and Rheumatoid Factor Autoantibody Responses\n",
      "Adverse Childhood Experiences Are Associated with Systemic Lupus Erythematosus in a Clinical Population from Bronx, New York\n",
      "The Presence of Extractable Nuclear Antigens (ENA) Antibodies in a Large Population-based Cohort from the Netherlands and Their Association with Known Risk Factors for Systemic Lupus Erythematosus and Primary Sjögren Syndrome\n",
      "Frequency, Severity and Costs of Flares Increase with Disease Severity in Newly Diagnosed Systematic Lupus Erythematous: A Real-World Cohort Study, United States, 2004–2015\n",
      "A Spatial-temporal Analysis of Organ-specific Lupus Flares in Relation to Fine Particulate Matter Pollution and Temperature\n",
      "Hydroxychloroquine Use and Cardiovascular Events Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis\n",
      "Mortality Rates After Coronary Revascularization Procedures Among Systemic Lupus Erythematosus Compared to Diabetes Mellitus and General Population Medicaid Patients\n",
      "Ultrasound Demonstrates Rapid Reduction of Crystal Depositions During a Treat-to-target Approach in Gout Patients: Two-year Results from a Longitudinal, Observational Study (NOR-GOUT)\n",
      "Lack of Effect of Tart Cherry Concentrate Dose on Serum Urate in People with Gout\n",
      "Serum Urate Lowering with Allopurinol Improves Endothelial Function in Young Adults\n",
      "Sensitivity of Dual-Energy CT, Ultrasound, and X-Ray for Pseudogout: A Pilot Study\n",
      "The Effects of a Low-Fat, Mediterranean, or Low-Carbohydrate Diet on Serum Urate\n",
      "Prevalence of Atopic Features in Classic Autoinflammatory Diseases\n",
      "Bone Manifestations in Gaucher Disease: A Monocentric Study of 128 Patients\n",
      "A Third of Relapsing Polychondritis Patients with Ear Involvement at Presentation Had Airway Involvement at the Last Follow-up with a High Mortality Rate\n",
      "Sarcoidosis as a Systemic Disease. Clinical and Epidemiological Characterization of Systemic Phenotype in 1521 Patients\n",
      "Musculoskeletal Sarcoidosis: Characterization and Clinical Expression of 129 Patients with Granulomatous Infiltration of Bones And/or Muscles\n",
      "Epidemiology and Presentation of Sarcoidosis with and Without HIV Infection\n",
      "Mesenchymal Stem Cell Senescence Alleviates Their Chondrogenic and Seno-Suppressive Properties, Contributing to Osteoarthritis Development\n",
      "Critical Role of the Cholinergic System Involvement in Osteoarthritis\n",
      "Mitochondrial DNA Impact on Joint Degeneration Process Using DMM OA and Spontaneous Aging Conplastic Mice Models\n",
      "Identification of Genetic Variants Associated with Erosive Hand Osteoarthritis Using Pedigrees from a State-Wide Population-Based Cohort\n",
      "Adenosine A2A Receptor Signaling Activates FoxO1 and FoxO3 and Promotes Cartilage Autophagy\n",
      "Lorecivivint (SM04690), a Potential Disease-Modifying Osteoarthritis Drug, Inhibits CLK2 and DYRK1A, Novel Molecular Regulators of Wnt Signaling, Chondrogenesis, and Inflammation\n",
      "Is Long-term High-intensity Strength Training Beneficial or Harmful for Knee Osteoarthritis Patients? The Strength Training and Arthritis Trial (START)\n",
      "Is There Any Role for Opioids in the Management of OA?\n",
      "Perfusion in Bone Marrow Lesions Assessed on Dynamic Contrast-enhanced MRI and Its Association with Pain in Knee Osteoarthritis: A Cross-sectional Study\n",
      "Co-morbidities Associated with Discordance Between Structural Severity and Pain in Osteoarthritis: Implications for Clinical Trial Design in OA – a Post-Hoc Analysis of Data from Two Randomized Controlled Trials\n",
      "Depression as a Moderator of Analgesic Effectiveness in Knee Osteoarthritis\n",
      "The Effects of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Chronic Knee Pain in Older U.S. Adults\n",
      "Development and Initial Validation of the Systemic JADAS, a New Composite Disease Activity Score for Systemic Juvenile Idiopathic Arthritis\n",
      "Development and Initial Validation of the MS Score for Diagnosis of Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis\n",
      "Systemic Juvenile Idiopathic Arthritis-Lung Disease: Characterization and Risk Factors\n",
      "Multiplex Serum Analysis Identifies Potential Biomarkers of Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome, and Associated Pulmonary Alveolar Proteinosis: Evidence for Independently-regulated Hyperinflammatory and Eosinophilic Inflammation\n",
      "Free Interlukin-18: A New Promising Biomarker for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome\n",
      "Adenosine Deaminase 2 as a Circulating Biomarker of Macrophage Activation Syndrome\n",
      "Indicators of Actionable Levels of Atherosclerosis in RA Patients Who Appear to Have Low or Intermediate Atherosclerotic Cardiovascular Risk Based on Standard Risk Algorithms\n",
      "Improved Incidence of Cardiovascular Disease in Patients with Incident Rheumatoid Arthritis in 2000s: A Population-Based Cohort Study\n",
      "First Cardiovascular Event in Rheumatoid Arthritis: Do Patients with Venous Thromboembolism Have a Different Risk Profile Than Patients with Atherosclerotic Cardiovascular Disease?\n",
      "Highly-sensitive Cardiac Troponin-I and Beta-2-Glycoprotein-I IgA Antibodies Inform the Utility of Screening and Follow-up Non-invasive Coronary Atherosclerosis Evaluation and Optimize Cardiovascular Risk Assessment in Rheumatoid Arthritis\n",
      "Incidence of Dementia and Association with Cardiovascular Disease and Risk Factors in Rheumatoid Arthritis – Analysis of a National Claims Database\n",
      "Methotrexate Is Associated with Reduced Cardiovascular Risk in Rheumatoid Arthritis Independent of Disease Activity Modification\n",
      "Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis Naïve to Methotrexate Therapy: FINCH3 Primary Outcome Results\n",
      "Monotherapy with Upadacitinib in MTX-naïve Patients with Rheumatoid Arthritis: Results at 48 Weeks\n",
      "Efficacy and Safety of Fenebrutinib, a BTK Inhibitor, Compared to Placebo in Rheumatoid Arthritis Patients with Active Disease Despite TNF Inhibitor Treatment: Randomized, Double Blind, Phase 2 Study\n",
      "Neurostimulation for Treatment of Drug Refractory Rheumatoid Arthritis: A First-in-Human Study Using a Novel Vagus Nerve Stimulator\n",
      "Ultra-Low Doses of Rituximab for Retreatment of RA: A Randomized Controlled Non-Inferiority Trial\n",
      "Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in MTX-IR Patients with Rheumatoid Arthritis\n",
      "A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obinutuzumab or Placebo in Combination with Mycophenolate Mofetil in Patients with Active Class III or IV Lupus Nephritis\n",
      "Response to Placebo in Randomized Clinical Trials with Biologics in Non-renal, Non-neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review and Pooled Analysis\n",
      "Treatment of Lupus Nephritis with anti-CD20 Followed by Anti-BAFF: Impact on B Cell Reconstitution, B Cell Subsets, and Autoreactivity\n",
      "A Randomized Prospective Trial to Assess the Clinical Utility of Multianalyte Assay with Complement Activation Products in Diagnosing Systemic Lupus Erythematosus\n",
      "A Phase 1b/2a Trial of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus\n",
      "Efficacy and Safety of Dapirolizumab Pegol in Patients with Moderately to Severely Active Systemic Lupus Erythematosus: A Randomized, Placebo-Controlled Study\n",
      "Tumor Necrosis Factor Inhibitors Slow Radiologic Progression in Patients with Ankylosing Spondylitis: 18-year Longitudinal Cohort Study\n",
      "Predictors of Survival of Secukinumab Treatment in a Multicenter Cohort of 556 Spondylarthritis\n",
      "Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis Following 1 Year of Treatment with Certolizumab Pegol: 48-Week Interim Results from a 96-Week Open-Label Study\n",
      "Earlier Treatment of Non-Radiographic Axial Spondyloarthritis with Certolizumab Pegol Results in Improved Clinical and Patient-Reported Outcomes\n",
      "Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study\n",
      "TNF Inhibitors Reduce Spinal Radiographic Progression in Axial Spondyloarthritis by Mechanisms Associated with but Also Independent of Disease Activity\n",
      "Comparison of Clinical Manifestations in IgG4 Related Disease Patients with/without Aortitis/Periaortitis and Periarteritis: A Prospective Cohort Study of 587 Patients with IgG4-RD Disease\n",
      "Improvements in Disease Activity and Quality of Life for up to 64 Weeks in Patients with Behçet’s Syndrome: Results from a Phase III Study\n",
      "TNF Inhibitor Treatment and Dramatic Stroke Risk Reduction in Patients with Deficiency of Adenosine Deaminase 2\n",
      "Relapsing Cryoglobulinemic Vasculitis Following Successful HCV Eradication by Interferon-Free Direct Acting Antivirals, an International Multicenter Study\n",
      "Assessment of Femoral Vein Wall Thickness with Doppler Ultrasound Can Be a Diagnostic Tool for Behcet’s Disease\n",
      "Low-Dose IL-2 Effectively Restored Decreased Regulatory T Cells in Patients with Behcet’s Disease\n",
      "Alterations in Cholesterol Homeostasis Regulate Autoimmunity/Age-associated B Cells\n",
      "Identification of IFN-γ-producing Effector B Cells in Humans: Their Relevance to the Pathogenesis of Systemic Lupus Erythematosus\n",
      "A Novel Image Analysis Program, “CytoSkaler”, Demonstrates That Anti-Vimentin Antibody Affinity Maturation in Lupus Tubulointerstitial Nephritis Also Results in More Selective Antigen Targeting\n",
      "Autoantibodies in Rheumatoid Arthritis Target Citrulline-Containing and Native Epitopes from Conformationally Disordered Regions of Proteins\n",
      "Microenvironment in Systemic Sclerosis Provides a Protective Niche for Tissue-resident B Cells During B Cell Depletion Therapy with Anti-CD20 Antibody\n",
      "The Presence of Circulating CD19+CD21lo cells Predicts the Presence of Interstitial Lung Disease in Patients with Systemic Sclerosis\n",
      "Alterations of Memory and Naive B Cell Subsets Associate with Reduced IFNα and TNFRII in ANA+ Healthy Individuals\n",
      "Identifying Jo-1-Specific B Cells in the Primary Immune Repertoire in Idiopathic Inflammatory Myopathies\n",
      "Discovery of DWP212525, a Potent JAK3 and BTK Dual Target Inhibitor for the Treatment of Autoimmune Diseases\n",
      "Minimal Residual Autoimmunity After Rituximab in ANCA-associated Vasculitis Patients\n",
      "Bruton’s Tyrosine Kinase (BTK) Pathway Is Active in Synovium at Various Stages of Rheumatoid Arthritis Disease Progression\n",
      "Circulating PR3-Specific B Cells in Patients with Active ANCA-Associated Vasculitis\n",
      "ß-adrenergic Receptor Activation: A Way to Enhance CD4 T Cell Suppression by Improving Regulatory B Cell Function\n",
      "New-onset ANCA-associated Vasculitis Is Associated with Significant Phenotypic B Cell Dysfunction\n",
      "B Cell ROCK1 Promotes Germinal Center Responses and Is Required for Optimal Humoral Immunity\n",
      "Disease Severity Is Linked to an Increase in Autoantibody Diversity in IgG4-related Disease\n",
      "Serum IgG4 Concentrations Differ According to Race and Sex\n",
      "Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Disease: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures\n",
      "Functional Impairment of Mitf and the MiT Transcription Factor Family Dysregulates B Cell Activation and Function\n",
      "Identification of Novel Genes Associated with Dysregulation of B Cells in Patients with Primary Sjögren’s Syndrome\n",
      "The Impact of Race on Birth Outcomes Among Women with Autoimmune Rheumatic Diseases\n",
      "Incidence of Non-serious Infections Among Live Born Infants Born to Mothers Who Used Biologic Medications During Pregnancy for the Treatment of Autoimmune Diseases\n",
      "Mediation of Adverse Pregnancy Outcomes in Autoimmune Conditions by Pregnancy Complications\n",
      "Cardiovascular Risk Awareness in Patients with Rheumatic Diseases: A Case-Control Study\n",
      "Assessing Psoriatic Arthritis Treatment Trends and Patient Journeys Between 2012 and 2018\n",
      "Biosimilar Etanercept Use in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis: The RHUMADATA® Registry Experience\n",
      "Characteristics of Patients with Seropositive or Seronegative Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from the US-Based Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries\n",
      "Cancer Risk in Patients with Ankylosing Spondylitis: A Nationwide Population-based Dynamic Cohort Study from Korea\n",
      "Patient Reported Outcomes over Time in 25,988 Axial Spondyloarthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Clinical Practice – Is PRO Remission Achieved? Results from the EuroSpA Collaboration\n",
      "Predicting ASDAS Inactive Disease After 6 Months of TNFi Treatment in Bio-Naive Axial Spondyloarthritis Patients Treated in Clinical Practice – Results from the EuroSpA Collaboration\n",
      "Probiotic Use and Psoriatic Arthritis Disease Activity\n",
      "Psoriatic Arthritis – Epidemiology, Incidence Rate in Psoriasis Patients, Comorbidity Profiles and Risk Factor Analysis\n",
      "Golimumab Improves Work Productivity and Activity and Quality of Life in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Final Results from a Non-Interventional Study in Germany (GO-ART)\n",
      "Does Drug Effectiveness of 2nd and 3rd TNF Inhibitors in Patients with Psoriatic Arthritis Depend on the Reason for Withdrawal from the Previous Treatment? – Results from the EuroSpA Research Collaboration\n",
      "Causes of Death in ANCA-Associated Vasculitis According to ANCA Type\n",
      "Identification of a Distinct Intestinal Behçet’s Disease Cluster in Japan: A Nationwide Retrospective Observational Study\n",
      "Risk of Preterm Birth by Timing of Lupus Diagnosis Among Women in the Georgia Lupus Registry\n",
      "Efficacy and Safety of Dose Adjustment Based on Patients’ Body Size in Low Dose Intravenous CYC Treatment for Rheumatic Diseases\n",
      "The US Prevalence of Inflammatory Bowel Disease and Associated Axial Pain: Data from the National Health & Nutrition Examination Survey (NHANES)\n",
      "EULAR Points to Consider for the Development, Evaluation and Implementation of Mobile Health Applications for Self-management in Patients with Rheumatic and Musculoskeletal Diseases\n",
      "The Role of Immunosuppressive Therapy in the Development of Atherosclerotic Cardiovascular Disease in Patients with Psoriatic Arthritis\n",
      "Learning the Relationships Between Psoriatic Arthritis and a Patient’s History of Musculoskeletal Symptoms from Electronic Health Records Using Bayesian Networks\n",
      "Trends in NSAIDs and Opioids Among Patients with SLE: A Population-based Study\n",
      "Epidemiology and Mortality of SLE (Systemic Lupus Erythematosus) in Hungary Based on a Nationwide Retrospective Claims Database Study\n",
      "The Safety of Pulse Therapy- Systematic Review and Meta-analysis\n",
      "Opioid Overdose Hospitalizations in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis\n",
      "Development of an Algorithm to Identify Sjögren’s Syndrome Patients in the French National Healthcare Claims Database\n",
      "Estimate of Prevalence of Secondary Distal Renal Tubular Acidosis Among Patients with Sjogren’s Syndrome and Systemic Lupus Erythematosus in a US Population with Employer-Sponsored Health Insurance\n",
      "Prevalence of Diagnosed Systemic Lupus Erythematosus (SLE), Patient Healthcare Utilization and Characteristics by Major Health Insurance Types in the US\n",
      "Heritability and Familial Risk of Systemic Lupus Erythematosus in Sweden: A Population-based Case-control Study\n",
      "Relationships Among Cognitive Emotion Regulation, Body Image, Family and Marital Function and Quality of Life in Chinese Female Patients with Systemic Lupus Erythematosus\n",
      "Systemic Lupus Erythematosus and Sjögren’s Syndrome in the Agricultural Health Study: Lower Risk Associated with Childhood Farm Residence and Raising Livestock\n",
      "Are Rheumatologists Correctly Identifying and Controlling Traditional Cardiovascular Risk Factors?\n",
      "Mobile Apps in Rheumatology: Review and Analysis Using the Mobile App Rating Scale (MARS)\n",
      "Development of Smart-phone Spondyloarthritis Management System and Real-world Study of Chinese Patients with Ankylosing Spondylitis\n",
      "Expanding Access to Research Using Tele-Health: Lupus and Informatics Feasibility Study\n",
      "Lupus Teledematology: A Pilot Project to Evaluate the Plausibility of a Rapid Access Dermatology Service for Lupus Patients\n",
      "Rheumatologists’ Opinions and Use of Telemedicine in the Southwestern U.S\n",
      "Improving Healthcare Quality and Reducing Cost via Online Interaction for Chinese Patients with Rheumatic Diseases Based on Smart System of Disease Management (SSDM) Mobile Tool\n",
      "Survival and Cost of Biologic DMARDs in a Military Medical Center: A Quality Improvement Initiative\n",
      "Switching Patterns Among Patients with Chronic Inflammatory Diseases Switching to an Infliximab Biosimilar or Remaining on Originator Infliximab (REMICADE)\n",
      "Non-medical Switching from Reference to Biosimilar Etanercept – No Evidence for Nocebo Effect – a Retrospective Analysis of Real-life Data\n",
      "Government Subsidization of Biologic Therapy for Inflammatory Arthritis in a Co-Funded Healthcare Model: A Singapore Experience\n",
      "US Community Rheumatologists’ Knowledge and Perceptions of Biosimilar Expanded Indication Approval by Extrapolation\n",
      "Patterns of Medication Use for Patients with Sarcoidosis: Data from the ACR’s RISE Registry\n",
      "Prevalence of Burnout in Rheumatology Professionals\n",
      "The Association Between Physician Sex and Faculty Rank Among Academic Rheumatologists in the United States\n",
      "Factors Impacting Referral of Juvenile Idiopathic Arthritis Patients to a Tertiary Level Pediatric Rheumatology Center in North India\n",
      "Healthcare Factors More Predictive of Smoking Cessation in Patients with Rheumatoid Arthritis Than Patient Characteristics\n",
      "The Direct and Indirect Costs of Illness Associated with Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review\n",
      "Health Care Resource Utilization and Costs in Patients with Juvenile Idiopathic Arthritis Treated with Abatacept and Other Targeted Disease Modifying Anti-rheumatic Drugs\n",
      "A Medical Assistant Driven Quality Improvement Intervention Increases Rates of DEXA Screening Among RA Patients\n",
      "Interventions to Improve Time to Appointment and Outcome Variables in the Pediatric to Adult Transition of Care in Rheumatology\n",
      "Physician-Patient Interaction and Medication Adherence in Lupus Nephritis\n",
      "Direct Medical and Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States\n",
      "The Risk of Toxic Retinopathy Among Patients on Hydroxychloroquine\n",
      "Loss to Follow-up in Registries of Rheumatic Patients Treated with Biologics: A Potentially Valuable Hidden Real-world Data That Is Being Overlooked?\n",
      "Facility-Level Variation in Biologic Disease Modifying Agents for Medicare Enrollees with Rheumatoid Arthritis\n",
      "Medicare Spending (2012-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis\n",
      "Medicaid Spending (2013-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis\n",
      "Optimizing the Management of Flares in Patients with Rheumatoid Arthritis with the Help of Non-Physician Providers: Results of a Randomized Controlled Trial\n",
      "Improving Access in an Academic Rheumatology Department by Reducing the No Show Rate\n",
      "Predictors of Health-Related Quality of Life in Patients with Musculoskeletal Diseases: A Longitudinal Analysis from an Electronic Health Record Database\n",
      "Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices\n",
      "Lifetime Direct Medical and Indirect Cost of Knee Osteoarthritis: Impact of Pain and Structural Severity\n",
      "The Socioeconomic, Gender, Urban-rural, and Regional Disparities in the Risk of Acute Myocardial Infarction Among RA Patients\n",
      "Racial Disparities in Lupus Medication Adherence\n",
      "Barriers and Facilitators of Medication Adherence Among Minority SLE Patients: A Qualitative Study\n",
      "Racial Disparities in Factors Associated with SLICC Damage Score Among Patients with SLE\n",
      "Understanding Clinical Trials Participation Among Individuals of African Descent with Lupus Through the Lens of Critical Race Theory: A Qualitative Analysis\n",
      "The Representation of Skin Tones in Images of Patients with Lupus Erythematosus\n",
      "Therapy of Lupus Nephritis with Mycophenolate Mofetil in Routine Clinical Practice: Response Rates and Role of Ethnicity\n",
      "Poverty and Systemic Lupus International Collaborating Clinics Damage Index (SDI) Are Significant Risk Factors for Hospitalization in SLE Patients\n",
      "Examining Five Year Lupus Retention in Care in an Academic Cohort\n",
      "Are There Country Differences in Disease Activity and Life Impact of Psoriatic Arthritis? An Analysis of 436 Patients from 14 Countries\n",
      "Factors Associated with Participation in Rheumatic Disease-Related Research Among Underrepresented Populations: A Systematic Review\n",
      "The Impact of Gender on Time to Rheumatoid Arthritis Classification\n",
      "Low Rates of Bone Mineral Density Testing by Rheumatologists in Patients with Systemic Lupus Erythematosus and Glucocorticoid Therapy\n",
      "Double Trouble: Utility of Serial TB Screening in a Rheumatology Clinic Serving a Foreign-Born Population\n",
      "Hispanic Patients with Rheumatoid Arthritis Have Greater Discordance Between Patient and Physician Global Estimates Than Other Ethnic Groups, Explained Largely by Fibromyalgia (FM) According to a FM Assessment Screening Tool 3 (FAST3)\n",
      "The Status of Latin-American Women in Rheumatology\n",
      "Differences in Clinical Outcomes According to the Healthcare Regime in Colombian Patients with Rheumatoid Arthritis\n",
      "#WomeninRheumatology: Is There a Speaker Gender Gap at ACR Meetings?\n",
      "Investigating Health Literacy and Numeracy in an Academic Center Lupus Cohort\n",
      "Deep Learning Social Media Analysis Demonstrated Gender-Specific Disparity in Side Effects from Rheumatoid Medications\n",
      "Clinical Trials in Rheumatoid Arthritis Have Inadequate Racial/Ethnic, Gender and Age Diversity: A Systematic Review\n",
      "Gadolinium-Enhanced Magnetic Resonance Imaging in Shoulders Contributes Accurate Diagnosis and Predicting Recurrence to Patients with Polymyalgia Rheumatica\n",
      "Changes in Novel Composite Scores of Disease Activity and Cumulative Damage Are Prognostic of Accelerated Knee Osteoarthritis: Data from the Osteoarthritis Initiative\n",
      "Erosions Are the Most Often Reported Structural Lesion on MRI of the Sacroiliac Joints in axSpA Patients with IBP\n",
      "Novel Computer Assisted Methodology for Quantitative Assessment of MRI Treatment Responses to Apremilast in Patients with Psoriatic Arthritis\n",
      "Utility of Coronary Calcium Scoring (CCS) in the Spectrum of Connective Tissue Disorders (CTDs) for the Evaluation of Subclinical Coronary Atherosclerosis – a Systematic Review\n",
      "A New Risk Factor for Predicting the Long-term Outcome of Pulmonary Arterial Hypertension Associated with Connective Tissue Disease: Pulmonary Artery Size Measured by Chest Computed Tomography\n",
      "To Evaluate Spine Ankylosis, Vertebral Fractures and Bone Fragility on a Single Imaging Exam in Patients with Ankylosing Spondylitis: Myth or Reality?\n",
      "Frequently Encountered Artifacts in Novel Application of Dual-Energy CT to Vascular Imaging: A Pilot Study\n",
      "Influence of Steroid Treatment on 18F-FDG PET/CT Accuracy to Detect Vascular and Musculoeskeletal Involvement in Patients with Polymyalgia Reumatica\n",
      "Cortical Bone Erosion in the 2nd Metacarpal Bone Head: Association with Its Bone Mineral Density by HR-pQCT in Rheumatoid Arthritis Patients\n",
      "Evidence of Subclinical Joint Inflammation of Hands by Magnetic Resonance Imaging in Patients with Psoriatic Arthritis in Minimal Disease Activity – Interim Analysis\n",
      "The Relationship Between Subclinical Inflammation and Bone Damage in Patients with Rheumatoid Arthritis Using Multimodality Imaging\n",
      "Magnetic Resonance Imaging in Patients in Clinical Remission: Tenosynovitis and Osteitis Are Independent Predictors of Radiographic and MRI Damage Progression\n",
      "Prevalence of Subclinical Sacroiliitis in Young Patients with Inflammatory Bowel Disease Revealed by Entero-MRI\n",
      "Periarticular Inflammation and Bone Marrow Oedema Are Important in the Evaluation of Enthesitis on MRI in Patients with Peripheral and Axial SpA\n",
      "Development and Validation of a Preliminary MRI Sacroiliac Joint Composite Structural Damage Score in a 5-year Longitudinal Study of Patients with Axial Spondyloarthritis\n",
      "Near Infrared Indocyanine Green Imaging Reveals Altered Anatomy and Diminished Function in Lymphatic Vessels in the Hands of Rheumatoid Arthritis Patients During Flare\n",
      "Clinical Utility of DECT in the Diagnosis of Gout at Mayo Clinic in Florida\n",
      "Resting-State Functional Connectivity of Pain Processing Brain Region Associated with Therapeutic Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis\n",
      "Confirmation of Manual Cartilage Segmentation Findings by Automated Segmentation: Retrospective Analysis of MRI Images from a Sprifermin Phase II Study\n",
      "Tocilizumab in Aortitis: A Multicenter Study of 79 Patients\n",
      "Fluorescence Optical Imaging in the Diagnosis of Individuals Suspected of Arthritis Development – a Probabilistic Approach\n",
      "Gout and Serum Urate Levels Are Associated with Lumbar Spine Monosodium Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study\n",
      "Rheumatoid Arthritis Activity Assessment with Cellphone Thermal Camera Imaging Compared to Clinical and Ultrasound Assessments\n",
      "New Imaging Modality to Evaluate Arthritis in Lupus Based on Frequency-domain Optical Transmission\n",
      "How Accurate Is Physical Joint Inflammation of the MTP-joints and What Can We Learn from Additional MRI on Forefoot Involvement in Early Arthritis?\n",
      "Delayed Gadolinium-enhanced MR Imaging of Cartilage – A Pilot Study to Measure the Effect of Adalimumab Plus MTX versus Placebo Plus MTX on Cartilage in Early RA Patients (CAR-ERA-Study)\n",
      "Novel PET-Coronary Flow Reserve Imaging to Assess for Coronary Microvascular Dysfunction in Systemic Lupus Erythematosus Compared to Subjects with Diabetes Mellitus and Controls\n",
      "Baylor Rheumatology Initiative: Developing and Guiding Engagement (BRIDGE) Transition Pathway Creation and Implementation\n",
      "A Quality Improvement Project to Increase Documentation Efficiency in an Academic Rheumatology Practice\n",
      "Application of the Systemic Lupus Erythematosus (SLE) Quality Indicators in Patients Attending a Young Adult Transition Program\n",
      "Effect of a Clinical Decision Support System on a Quality Indicator of Glucocorticoid-induced Osteoporosis and Trends of Drug Treatment in a Japanese Hospital\n",
      "EMR-integrated Disease Activity Calculators Improve Treatment to Target in Rheumatoid Arthritis\n",
      "Can an MDHAQ (Multidimensional Health Assessment Questionnaire) 60-Symptom Checklist to Monitor Early Medication Outcomes (MDHAQ/MEMO60) Detect Adverse Events of High-Risk Medications?\n",
      "Quantitative Physician Global Assessment of Damage And/or Distress, in Addition to Inflammation, at Routine Rheumatology Care: Documenting the Complexity of Rheumatology Patient Encounters as a Rationale for Possible Higher Reimbursement?\n",
      "Patient Preference for an Electronic MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/ Routine Assessment of Patient Index Data), Which Gives Similar Results Compared to a Paper Version\n",
      "Factors Associated with Clinical Disease Activity Index Adoption at an Academic Rheumatology Practice\n",
      "Practice Based Education Program to Increase Vaccination Rate in Patients on Immunotherapeutic Agents\n",
      "Improving Rates of Cervical Cancer Screening and HPV Vaccination in Patients with Lupus\n",
      "Influenza Vaccination Rates Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis on Immunosuppressive Therapy: Findings from a Large Public Hospital\n",
      "Are We Meeting Benchmarks for Wait Times to Pediatric Rheumatology Care for Juvenile Idiopathic Arthritis (JIA)?\n",
      "Testing Rheumatoid Arthritis Performance Measures to Optimize Treat to Target Strategies\n",
      "Psychometric Properities of the Patient Related Outcome Measure FACIT-Fatigue in Rheumatic Arthritis and Psoriatic Arthritis: A Literature Review\n",
      "Improvements in Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody: 1-Year Results of a Phase III Trial\n",
      "Real-World Remission Outcomes in the First Year Following RA Diagnosis Vary Considerably with the Disease Activity Index Used and a Sizable Proportion Have Persistent Active Disease Across All Measures: Results from the Canadian Early Arthritis Cohort (CATCH)\n",
      "Performance of the Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29) Item Profile in a Cohort of Australians with RA, OA and Other Inflammatory Arthritic Conditions\n",
      "A Quality Improvement Intervention to Reduce 30-Day Hospital Readmission Rates Among Patients with Systemic Lupus Erythematosus\n",
      "Outpatient Readmission in Rheumatology: A Machine Learning Predictive Model of Patient’s Return to the Clinic\n",
      "Patient-reported Outcome Measures in Systemic Lupus Erythematosus: Use in Clinical Practice – Preliminary Results from the Integrate Project\n",
      "Utilization of a Multispecialty Team for the Diagnosis of Giant Cell Arteritis Reduces Patient Morbidity\n",
      "Improving Exercise Counselling of Patients with Inflammatory Arthritis: A Quality Improvement Project\n",
      "Psychological Profile in Patients with Rheumatic Diseases in China: A Study of HADS Self-assessment with Smart System of Disease Management (SSDM)\n",
      "A Retrospective Review and Prospective Intervention for Outpatient Follow-Up of Hospitalized Patients in Rheumatology\n",
      "The Effects of Pegloticase on Mean Arterial Blood Pressure: An Age Modulated Relationship?\n",
      "A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-Ranging Study to Evaluate Efficacy and Tolerability of SHR4640 in Patients with Hyperuricemia\n",
      "Pilot, Randomized, Double-Blinded, Placebo Controlled Efficacy AndSafety Study of a Transdermal Alkalinizing and Pain Relieving Treatment ForAcute Gout Flare\n",
      "Phase 2 Dose-ranging Study of SEL-212 in Symptomatic Gout Patients: Selection of Doses for Further Clinical Development\n",
      "Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Enables Sustained Reduction of Acute Gout Flares in Symptomatic Gout Patients\n",
      "Uric Acid Level as a Predictor of Long Term Mortality in Advanced Age Population\n",
      "How Are Flares Reported in Long-term Gout Clinical Trials? A Content Analysis of Randomized Controlled Trials\n",
      "Impact of Psoriasis Disease Activity and Other Risk Factors on Serum-urate Levels in Patients with Psoriasis and Psoriatic Arthritis – A Post-hoc Analysis of Pooled Data from Three Phase 3-trials with Secukinumab\n",
      "Relationships Between Allopurinol Dose, Oxypurinol Levels and Serum Urate – in Search of an Oxypurinol Therapeutic Concentration\n",
      "Enteral Administration of ALLN-346, a Recombinant Urate-degrading Enzyme, Decreases Serum Urate in a Pig Model of Hyperuricemia\n",
      "AR882, a Potent and Selective URAT1 Inhibitor with a Favorable Pharmacological, Pharmacokinetic and Toxicity Profile\n",
      "Limits of Detection of Monosodium Urate Crystals in Synovial Fluid by Ultrasound\n",
      "Neutrophil Activation Identifies Patients with Active Polyarticular Gout – a Role for Neutrophil Biomarkers in Monitoring Gout Disease Activity and Severity\n",
      "A Neutrophil Signature Is Strongly Associated with Cardiovascular Risk in Gout\n",
      "Soluble Triggering Receptor Expressed on Myeloid cells-1 (sTREM-1) Ameliorates Monosodium Urate Crystals (MSUC)-induced Inflammation in a Mouse Air-pouch Model of Gout\n",
      "AR882, a Potent and Selective Uric Acid Lowering Agent Acting Through Inhibition of Uric Acid Reuptake, Shows Excellent Pharmacokinetics and Pharmacodynamics in a Phase 1 Clinical Trial\n",
      "Do Serum Urate-Associated Genetic Variants Influence Gout Risk in People on Diuretics? Analysis of the UK Biobank\n",
      "Improvement in Hepatic Fibrosis Estimated by Fibrosis-4 (FIB-4) Index in Subjects with Chronic Refractory Gout Treated with Pegloticase\n",
      "Whole Blood RNA Sequencing Study of Gout Cases and Controls Demonstrates Transcriptomic Differences with Relevance to Inflammatory Cell Activation\n",
      "Identification and Characterization of a Novel Dysfunction Variant p.I242T in ABCG2 Transporter in a Family with Early-onset Hyperuricamia and Gout\n",
      "Inconsistency in Uric Acid Reference Ranges Among 20 Top United States Hospitals: What Is “Normal”?\n",
      "Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Mitigates Formation of Anti-Drug Antibodies Resulting in Sustained Uricase Activity in Symptomatic Gout Patients\n",
      "Subcutaneous or Oral Methotrexate Exposure and Response to Pegloticase in Uncontrolled Gout Patients in a Community Rheumatology Practice\n",
      "Treatment with OLT1177™, an Oral NLRP3 Inflammasome Inhibitor, Reduces Systemic Inflammation During Gout Flares in Humans\n",
      "Monosodium Urate and Calcium Pyrophosphatecrystal-induced Interleukin 1 Production Depends on Glucose Uptake Through Glut1 Transporter\n",
      "The Association Between Urate and CSF Markers of Alzheimer’s Disease in a Population-Based Sample of 70-Year-Olds\n",
      "A Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Anakinra in Difficult-To-Treat Acute Gouty Arthritis: The anaGO Study\n",
      "Further Characterizing Morphea Subsets Using a Multi-center, Prospective, Cross-sectional Analysis of Morphea in Adults and Children\n",
      "Impact of Smoking Status on Remission in Hidradenitis Suppurativa\n",
      "Anakinra Treatment in Recurrent Pericarditis: Single Center Experience\n",
      "Tocilizumab – An Effective Rescue Therapy for Refractory Unclassified Autoinflammatory Diseases in Children\n",
      "Efficacy of Canakinumab Treatment in Adult-onset Still’s Disease\n",
      "Using PROMIS Data to Assess Activity of Inflammatory Eye Disease\n",
      "Adult-Onset Still’s Disease and Spondyloarthritis: Overlapping Syndrome or Incidental Association? A Series of 5 Cases\n",
      "Clinical Manifestations and Management of US Patients with SAPHO (Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis) Syndrome, a Retrospective Study\n",
      "Pelvic Congestion Syndrome, an Uncommon Cause of Osteoarticular Pain\n",
      "Can Patient-Reported Outcomes and Disease Activity Scores Predict Patient Acceptable Symptom State in Adult-Onset Still’s Disease?\n",
      "The Impact of Aging on Familial Mediterranean Fever Patients\n",
      "Pattern of Arthropathy in Patients with Cystic Fibrosis\n",
      "Novel Nonsense Variant and Entire Deletion of TNFAIP3 Cause Haploinsufficiency of A20 Clinically Distinct from Behçet’s Disease\n",
      "A Retrospective Medical Chart Review of Patients with Periodic Fever Syndromes Initiating Canakinumab in the United States\n",
      "Is Exon 2 Associated with FMF or a New Disease?\n",
      "Comparison of FMF Patients with Age of Onset Before 20 versus 40 Years and Over\n",
      "Recommendation on Colchicine Dosing and Definition of Colchicine Resistance/Intolerance in the Management of Familial Mediterranean Fever\n",
      "Effects of Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody, on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 1-Year Results of a Phase III Trial\n",
      "Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO): A Case Series\n",
      "The Study of Peripheral Blood Lymphocyte Subsets and CD4+T Subsets in Recurrent Polychondritis\n",
      "The Time Lag – the Race in Diagnosis and Management of Hemophagocytic Lymphohistiocytosis\n",
      "Clinical Features of Elderly-onset Adult Still’s Disease\n",
      "The Prevalence and Patterns of Celiac Disease Associated Arthropathy and Coexistence of Celiac Disease with Rheumatic Disorders in a Single Tertiary Medical Center\n",
      "Quality of Life in Patients with SAPHO Syndrome: A Single-center Survey of 588 Patients\n",
      "Mandibular Involvement in SAPHO Syndrome: A Single-center Retrospective Study of 26 Patients\n",
      "AGBL3 as a Novel Gene Associated with Hereditary Hypocomplementemic Urticarial Vasculitis and Favorable Response to Rituximab\n",
      "Epidemology, Clinical Features and Relationship to Biological Therapy of Uveitis in Axial Spondyloarthritis: Single Center University Study\n",
      "Different Colchicine Preparations for Familial Mediterranean Fever: Are They the Same?\n",
      "Effective Treatment of TNFα Inhibitors in Chinese Patients with Blau Syndrome\n",
      "Effectiveness and Safety of Off-label Use of Tocilizumab in Refractory Autoimmune Diseases: A Multicenter Study\n",
      "Adult-Onset Still’s Disease Prognosis Score: Clinical Patterns, Complications and Biologic Treatment\n",
      "Biological Therapy in Non Ischaemic Optic Neuritis Associated to Immune-mediated Inflammatory Diseases: Multicenter Study\n",
      "Certolizumab Therapy in Patients with Uveitis During Pregnancy: Multicenter Study\n",
      "New Aspects of Clinical and Immunological Characteristics in Patients with Anti-KS Antibody\n",
      "Spectrum of Organ Involvement in Idiopathic Inflammatory Myopathies, Frequency of Comorbidities, and Relationship to Anti-SSA/SSB Positivity\n",
      "Myositis Specific Antibodies and Clinical Features in Patients from Argentina\n",
      "Damage and Comorbidities in a Cohort of Patients with Idiopathic Inflammatory Myopathy\n",
      "Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States\n",
      "Response Rate and Sustained Remission in Idiopathic Inflammatory Myopathies Receiving Conventional Immunosuppressive Stepwise Management\n",
      "JAK Inhibitors: A Promising Molecular-targeted Therapy in Dermatomyositis\n",
      "Maintenance Therapy for anti-MDA5-Positive Dermatomyositis Patients with Interstitial Lung Disease: Can They Achieve Drug-Free Remission?\n",
      "Female Sex Is a Risk Factor for Failure to Achieve Remission in Polymyositis\n",
      "Risk Factors of Cancer-Associated Inflammatory Myopathies: A Multicenter Study\n",
      "Idiopathic Inflammatory Myopathies: Are Muscle Biopsies Still Needed?\n",
      "Changes in Nail-fold Capillary Abnormalities, and Serum FGF and VEGF Levels in Dermatomyositis Patients with anti-MDA5 Antibody During the Clinical Course\n",
      "Patients with Anti-tRNA Synthetase Syndrome Are More Likely to Present to Pulmonary Clinic and Have a Higher Prevalence and Severity of Lung Disease Than Patients with Other Types of Myositis or Systemic Sclerosis\n",
      "Anti-mitochondrial Autoantibodies in Idiopathic Inflammatory Myopathies\n",
      "Line Blot Immunoassay in Inflammatory Myopathies: Diagnostic Accuracy and Factors Predicting Positive Results in Routine Clinical Practice\n",
      "Antigen Bead Array versus ELISA to Detect anti-cN1A Antibodies in Patients with Sporadic Inclusion Body Myositis and Correlation with Clinical, Serological and Histological Features\n",
      "Identification of Distinctive Interferon Gene Signatures in Different Types of Inflammatory Myopathy\n",
      "Semi-Quantitative and Quantitative Evaluation of Magnetic Resonance Imaging in Patients with Idiopathic Inflammatory Myopathies – a Subanalysis of the Prometheus Study\n",
      "Abnormal High Density Lipoprotein Particle Size and Number in Idiopathic Inflammatory Myopathies\n",
      "Multiple Subpopulations of Lymphocytes Were Absolutely Decreased in Dermatomyositis/polymyositis Patients and Restored by Low-dose IL-2\n",
      "Alterations in Activin A-Myostatin-Follistatin System Associate with Disease Activity in Inflammatory Myopathies\n",
      "Otoferlin Is Increased in Muscle and PBMCs from Untreated Children with Juvenile Dermatomyositis: Possible Association with Decreased Circulating Natural Killer Cells\n",
      "Increased MxA Protein Expression and Dendritic Cells in Spongiotic Dermatitis Differentiates Dermatomyositis from Eczema\n",
      "Increased Hsp90 in Plasma and Muscle Tissue Associates with Disease Activity and Skeletal Muscle Involvement in Idiopathic Inflammatory Myopathies\n",
      "A Randomised Clinical Trial of Curcuma Longa Extract for Treating Symptoms and Effusion-Synovitis of Knee Osteoarthritis\n",
      "Clinical Significance of Magnetic Resonance Imaging Derived Femur Bone Shape in Young Adults\n",
      "Predictor of Placebo Response in Hand Osteoarthritis: A Post Hoc Analysis of Two Randomized Controlled Trials\n",
      "Rates of Incident Radiographic Knee Osteoarthritis and Knee Replacement by Sex and Race, Across Three Large, Diverse Cohorts\n",
      "Subcutaneous Tanezumab vs NSAID for the Treatment of Osteoarthritis: Efficacy and General Safety Results from a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study\n",
      "Intra-Articular TPX-100 Significantly Delays Pathological Bone Shape Change at 6 and 12 Months in Moderate to Severe Tibiofemoral OA\n",
      "Efficacy and Safety of Hylan G-F 20 versus Intra-Articular Corticosteroids in Patients with Knee Osteoarthritis: A Systematic Literature Review, Meta-Analysis, and Network Meta-analysis\n",
      "Quality Improvement in Diagnostic and Therapeutic Arthrocentesis in the Flexed Knee Using Pneumatic Compression of the Suprapatellar Bursa\n",
      "Risk Factors for Pain After Total Joint Replacement in Osteoarthritis: Different Pain Measures, Distinct Predictors?\n",
      "A Prospective, Multi-center, Randomized, Clinical Trial Comparing the Effectiveness and Safety of Cooled Radiofrequency Ablation versus a Single Injection of Hyaluronic Acid in the Management of OA Knee Pain\n",
      "Subject Enrichment Criteria for Phase 3 Studies of Lorecivivint (SM04690), a Potential Disease-Modifying Knee Osteoarthritis Drug: A Post Hoc Study on the Effects of Baseline Comorbid Pain and Joint Space Width on Patient-Reported Outcomes\n",
      "Concordance of Baseline Pain Measures (Across Two Reporting Instruments) Influences Treatment Effect: Post Hoc Analysis of a Phase 3 Randomized Controlled Trial of Triamcinolone Acetonide Extended-Release in Patients with Knee Osteoarthritis\n",
      "Osteoarthritis: What’s in a Name?\n",
      "Prevalence of Symptomatic Axial Osteoarthritis and Poliarticular Phenotypes in Spain: EPISER 2016 Study\n",
      "Knee Morphology Associates with Tibio-Femoral and Patello-Femoral Osteoarthritis: A Case-Control Study\n",
      "Readmissions After Staged vs Simultaneous Bilateral Total Knee Replacements (TKR)\n",
      "Patient-Specific Reference Values for Objective Physical Function Tests: Cross-Sectional Analysis Using Data from the Osteoarthritis Initiative\n",
      "Relation of MRI-detected Structural Damage in the Patellofemoral Joint to Pain and Performance Based Function: The MOST Study\n",
      "Frail Patients Have Less Pain After Total Hip Replacement\n",
      "Frail Patients Have Worse Function After Total Knee Replacement\n",
      "In an International, Multicentre, Double-blind, Randomised Study in Knee Osteoarthritis Patients, Diacerein Was Found as Effective as Celecoxib in Reducing Pain and Disease Symptoms\n",
      "Impact of ACL Injury Management on the Development of Knee Osteoarthritis: A Meta-analysis\n",
      "Individual Socio-economic Status and Symptomatic Hip and Knee Osteoarthritis: A Longitudinal Study, Results from the KHOALA Cohort\n",
      "What Is the Relationship Between the 3 Knee Bones in Osteoarthritis? Baseline and Longitudinal Associations Using a Latent Growth Modelling Approach on 37,583 MR Images from the Osteoarthritis Initiative\n",
      "Evaluation of Intra-articular CNTX-4975 in Subjects with Painful Bilateral Knee Osteoarthritis: Effects on Pain with Walking and Patient Impression of Change in Pain\n",
      "Autologous Conditioned Serum and Plasma Rich in Growth Factors Show Stronger Evidence of Efficacy Than Other Kinds of Platelet-Rich Plasma\n",
      "Visceral Fat Deposition Associated with Pain in Osteoarthritis\n",
      "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Japanese Subjects of the ADAMTS-5 Inhibitor S201086/GLPG1972, a Potential New Treatment in OA\n",
      "Safety Profile to Date of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis\n",
      "The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial\n",
      "Disease Manifestations and Impact on Quality of Life in Subjects with Pre-Pubertal Onset Systemic Lupus Erythematosus\n",
      "Disease Activity in Childhood-Onset Systemic Lupus Erythematosus: Initial Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry\n",
      "Disease Activity and Health Care Utilization Among Young Adults with Childhood-onset Lupus Transitioning to Adult Care: Follow-Up Data from the Pediatric Lupus Outcomes Study\n",
      "Worsening Disease Activity and Inability to Taper Corticosteroids in an Ethnically Diverse Cohort of Pediatric-Onset Lupus Patients After Transition to Adult Care\n",
      "Persistent Disease Activity Is Associated with Avascular Necrosis Development in Juvenile Systemic Lupus Erythematosus\n",
      "Infections and Mortality in 230 Childhood Lupus Patients: A Single Center Experience from North India\n",
      "Impact of Preceding and Co-existing Autoimmune Cytopenias on Severity of Childhood-onset Systemic Lupus Erythematosus: A Single-Center Retrospective Cohort Study\n",
      "Validation of the 2017 Weighted Criteria in Pediatric Systemic Lupus Erythematosus (SLE)\n",
      "Evaluating the New 2018 ACR/EULAR SLE Classification in Pediatric Patients\n",
      "Long-term Renal Survival of Pediatric Onset Lupus Patients in a Population-Based Cohort\n",
      "Low Bone Mineral Density Was Associated with Lupus Nephritis Irrespective of Duration on Steroid Treatment in a Large Observational Study of Juvenile Systemic Lupus Erythematosus Patients\n",
      "Clinical Variables Influencing Prednisone Dosing Towards the Development of Corticosteroid Treatment Algorithms in Pediatric Proliferative Lupus Nephritis\n",
      "Cognitive Impairment in Childhood-Onset Systemic Lupus Erythematosus: Early Detection with MRI Spectroscopy and Its Association with MOG Antibodies\n",
      "Systemic Vascular Involvement in Kawasaki Disease: A Single Center Cohort\n",
      "Tracking Whole-Brain Volumetric Trends in Childhood-onset Systemic Lupus Erythematosus Patients in the Clinical Setting by Magnetic Resonance Imaging\n",
      "Kawasaki Disease Shock Syndrome – More Common Than We Think: Our Experience at Chandigarh, North India\n",
      "Orange Brown Chromonychia in Kawasaki Disease: A Clinical Sign That Merits Greater Attention\n",
      "Depression and Anxiety Symptoms in Childhood-Onset Systemic Lupus Erythematosus\n",
      "Ethnicity and Neonatal Lupus Erythematosus Manifestations Risk in a Large Multi-Ethnic Cohort\n",
      "Kawasaki Disease: Is Intravenous Immunoglobulin Alone Adequate for the Child with Kawasaki Disease and Coronary Artery Lesions? A Retrospective Study of 65 Children with Kawasaki Disease from a Single North Indian Centre\n",
      "Serum Sickness Following Rituximab Treatment of Childhood-Onset SLE: A Single Center Experience\n",
      "Exercise Improves Arterial Inflammation in Childhood-onset Takayasu Arteritis: A Randomized Controlled Trial\n",
      "Identifying Additional Risk Factors for Arterial and Venous Thrombosis Among Pediatric Antiphospholipid Antibodies Carriers\n",
      "Practice Variations in Treatment of Pediatric Anti-neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis (AAV) with Renal Disease\n",
      "Incidence of Retinopathy in Individuals Who Initiated Hydroxychloroquine Therapy During Childhood\n",
      "Improving Eye Screening Among Pediatric Rheumatology Patients Receiving Hydroxychloroquine: Experience of a Quaternary Care Center\n",
      "Pediatric Sjögren Syndrome: A Single-Center Experience\n",
      "A Systematic Literature Review of Efficacy and Safety of Biologic Agents for the Treatment of Juvenile Dermatomyositis\n",
      "Is Early Standardized Rituximab Therapy Sufficient for Toddlers with NMDAR Encephalitis?\n",
      "Are Patterns of Early Disease Severity Predictive of Grade 12 Academic Achievement in Patients with Childhood-onset Chronic Rheumatic Diseases?\n",
      "Comorbidities and Treatments in United States Youth with Chronic Musculoskeletal Pain\n",
      "Improving Adolescent Health Care Transition: Piloting the Transition Readiness Assessment Questionnaire\n",
      "Health­-related Social Media Use by Parents of Children with Rheumatic Diseases\n",
      "Review of Effectiveness of an Intensive Rehabilitation Programme in Managing Strength, Pain and Function in 123 Young People with Rheumatological Conditions\n",
      "Conditional Deletion of MKL1 Inhibits Osteoclast Formation and Bone Erosions in Collagen Induced Arthritis Mice\n",
      "Light Mediated Therapeutics in Arthritis\n",
      "Platelet Derived Growth Factor Receptor Alpha (PDGFRα) Blockade Inhibits Arthritis in Mice\n",
      "Sema3B Expression Is Reduced in Rheumatoid Arthritis Patients and Has a Protective Role in a Murine Model of Arthritis\n",
      "Adipocytokines and Obesity in the Context of Rheumatoid and Osteoarthritis Mouse Models\n",
      "A Novel Role for Nod2 in Controlling Autoantibody Production and Arthritis in SKG Mice\n",
      "Fecal Transfer from Mice on High or Low Magnesium Diets Confers Arthritis Protection\n",
      "Important Role of CD11c+ Cells in Inflammatory Arthritis\n",
      "Inhibition of Calcium/calmodulin-dependent Protein Kinase IV in Rheumatoid Arthritis: Dual Effect on Th17 Cell Activation and Osteoclastogenesis\n",
      "Tofacitinib Enhanced Cerebral Brain-derived Neurotrophic Factor Levelsin a Rat Model of Rheumatoid Arthritis\n",
      "Anti-citrullinated Protein Antibodies Induce Subclinical Inflammation, Bone Loss and Pain in Mice\n",
      "Translational Imaging of Treatment Effects for a Novel Anti-TNF-Steroid Antibody Drug Conjugate in a Rat Model of Rheumatoid Arthritis\n",
      "Lineage Tracing of Murine Lymphatic Smooth Muscle Cells to Determine the Role of the Lymphatic System in Inflammatory Arthritis\n",
      "Development of a Novel Anti TNF-Steroid Antibody Drug Conjugate That Shows Promising Efficacy at Doses That Avoid Steroid Side Effects in a Mouse Model of Rheumatoid Arthritis\n",
      "Identification of Citrullinated Peptide Specific T-cells in Humanized Mice Immunized with Citrullinated Peptides\n",
      "Identification of CJ-15314, a Novel Highly Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis\n",
      "pH-Sensitive Nanoformulated Triptolide as a Targeted Therapeutic Strategy for Rheumatoid Arthritis\n",
      "Increased Antibody and T-cell Responses Following Treatment of Collagen-Induced Arthritis in C57Bl/6 Mice with Organic Dust Inhalants\n",
      "Inhibition of Endoplasmic Reticulum Stress Using 4-phenylbutyric Acid Ameliorates the Severity of Collagen-induced Arthritis in Mice via Attenuation of Proliferation and Inflammatory Responses of Synovial Fibroblasts\n",
      "The Role of Flip in Differentiation and Survival of Synovial Tissue Resident Macrophages\n",
      "Stromal Cell-derived DCSTAMP Coordinates Cell Migration and Osteoclast Activation in TNF-driven Murine Arthritis\n",
      "Stimulation of Splenic Neurovascular Bundle Protect Mice from Developing Collagen-induced Arthritis\n",
      "Targeted Drug Delivery Using a Novel Joint-homing Peptide for Arthritis Therapy\n",
      "RKIP, as an Upstream Regulator of Intracellular Signaling, Exerts Anti-arthritic Effect in Fibroblast-like Synoviocyte and Collagen-induced Arthritis\n",
      "Oral Collagen Type V Supplementation Inhibits Cartilage Degeneration in Experimental Arthritis\n",
      "The Patient’s Perspective on a Disease Flare During Tapering of DMARDs in Rheumatoid Arthritis\n",
      "Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis\n",
      "No Difference in Treatment Continuation of Different Biologics in Elderly Patients > 70 Years Compared to Younger Patients ≤ 65 Years\n",
      "No Confirmation of Increased Risk of Idiopathic Facial Nerve Palsy Under Tocilizumab\n",
      "United States Rheumatology Practice-Based Real-World Evidence of Infusion Reactions in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab or Infliximab: Impact of Prior Biologic Exposure and Methotrexate Utilization\n",
      "The Comparative Risk of Osteoporotic Fractures Among Patients with Rheumatoid Arthritis Receiving TNF Inhibitors versus Other Biologics: A Nation-wide Cohort Study in Korea\n",
      "Patterns of Fatigue in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs\n",
      "Tumor Necrosis Factor Alpha Inhibitor (TNF-α Inhibitor) Exposure and Risk of Hip Fracture in Veterans with Rheumatoid Arthritis: A Nested Case Control Study\n",
      "Systematic Literature Review and Meta-Analysis of DAS28 Clinical Response Rates Among Advanced Therapies in Biologic-Naïve Patients with Rheumatoid Arthritis\n",
      "Fatigue Levels Are Not Associated with Inflammatory Activity, but with Subjective Outcomes: Results from a Longitudinal Study of Patients with Rheumatoid Arthritis Initiating bDMARD Therapy\n",
      "Joint-specific Responses to Tofacitinib and Methotrexate in Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Start\n",
      "Risk of Immunotherapy Related Toxicity in Patients with Rheumatoid Arthritis\n",
      "Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort\n",
      "Impact of Tocilizumab on Anxiety and Depression in Patients with Rheumatoid Arthritis\n",
      "Identification of Heterogenous Treatment Response Trajectories to anti-IL6 Receptor Treatment in Rheumatoid Arthritis\n",
      "Pop a Pill or Give Myself a Shot? Patient Perspectives of Disease-modifying Anti-rheumatic Drug (DMARD) Choice for Rheumatoid Arthritis (RA)\n",
      "Increased High Molecular Weight Adiponectin and Lean Mass During Tocilizumab Treatment in Patients with Rheumatoid Arthritis: A 12 Month Multicenter Study\n",
      "Are There Differences in Efficacy and Safety of Biological Disease-modifying Antirheumatic Drugs Between Elderly-onset and Young-onset Rheumatoid Arthritis?\n",
      "Post-Traumatic Stress Disorder, Depression, Anxiety and Persistence of Methotrexate and TNF Inhibitors in Patients with Rheumatoid Arthritis\n",
      "Achievement of Remission in Two Early Rheumatoid Arthritis Cohorts Implementing Different Treat-To-Target Strategies\n",
      "Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials\n",
      "Earlier Biologic Initiation over Two Decades of Real World Observational Data from the RAPPORT Biologics Registry of Northern Alberta, Canada\n",
      "Patient Disease Trajectories in Baricitinib-2 Mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs\n",
      "Mortality of Rheumatoid Arthritis Patients, Treated to Target at Low Disease Activity: 17-years Follow-up of the BeSt Cohort\n",
      "Effects of Upadacitinib on Patient-Reported Outcomes After 24 Weeks in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs: Results from SELECT-NEXT and SELECT-BEYOND Phase 3 Studies\n",
      "Impact of Smartphone Application Based Management in Rheumatoid Arthritis: SMART- RA Study\n",
      "A Comparison of Convergent Validity and Sensitivity to Change of the Conventional Scoring Method to Alternative Scoring Methods of the Health Assessment Questionnaire in Rheumatoid Arthritis\n",
      "A Comparison of Clinical Improvement Following a Major Therapeutic Change Utilizing Updated Treatment Thresholds Defined by Three Different Disease Activity Measures\n",
      "DAS28-CRP Cut-offs for High Disease Activity Assessment Is Lower Than DAS28-ESR in Rheumatoid Arthritis\n",
      "Leptin-adjustment of the Multi-biomarker Disease Activity (MBDA) Score Reduces the Influence of Adiposity\n",
      "Defining Minimal Clinically Important Changes for the Patient Activity Scale-II\n",
      "Correlation of Ultrasound Guided Synovial Biopsies and Surgical Synovial Biopsies in Patients with Inflammatory Arthritis\n",
      "Ultrasound Guided Synovial Biopsies Safely Aid in the Assessment of Inflammatory Arthritis\n",
      "Utility of Rheumatoid Arthritis Impact of Disease (RAID) in Routine Care; Identification of Patients Achieving DAS28 Remission or Low Disease Activity, and Burden of Unmet Patient Reported Outcomes\n",
      "Relationship Between Waking Functions and Disease Activity in Rheumatoid Arthritis Patients Analyzed by Wearable Device\n",
      "Longitudinal Work Transitions in Early Inflammatory Arthritis Patients: Are There Targets for Intervention to Improve Employment?\n",
      "Affect of Obesity on Multi-Biomarker Disease Activity (MBDA) Measurements in Rheumatoid Arthritis (RA) Patients\n",
      "Construct Validation of PROMIS Short Form and Profile-29 T-Scores with SF-36 in Rheumatoid Arthritis Patients Treated for 1 Year: Results from a Real World Evidence-Based Study in the United States\n",
      "Self-joint Counts by People with Rheumatoid Arthritis: Does a Video Increase Accuracy and Does It Matter?\n",
      "An Engineered Glove for the Computerised Quantification of Hand Disability in Rheumatoid Arthritis\n",
      "One Size Fits All : Replacing ESR by γGT in DAS28 Calculation Permits a Dual Evaluation of Joint Activity Together with Cardiovascular Risk\n",
      "Angiogenic Factors for Assessing Rheumatoid Arthritis in the Era of Sonographic Diagnosis and Biologic Therapy\n",
      "Not All Joints Are Equal: Challenge DAS28 System and Identify Factors Leading to a Mismatch Between T2T and HAQ Among RA Patients Through Data Mining from Smart System of Disease Management (SSDM)\n",
      "Create an Algorithm of Outcome Forecasting and Decision Making for RA Treatment: Data Mining and Machine Learning via the Smart System of Disease Management (SSDM)\n",
      "Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US\n",
      "Patient-Reported Outcomes of Upadacitinib versus Adalimumab Use in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate: 26-Week Analysis of a Phase 3 Study\n",
      "Impact of 24- or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials\n",
      "Adherence to Treatment with Intravenous Biological Agents in Patients with Rheumatoid Arthritis\n",
      "Performance of CQR5 vs CQR19 in the Evaluation of Adherence to Tofacitinib in Daily Clinical Practice\n",
      "MTX Withdrawal in Patients with RA Who Achieve Low Disease Activity with Tofacitinib Modified-Release 11 Mg Once Daily + MTX: An Assessment of the Impact on the Short Form-36 Patient-Reported Outcome\n",
      "High Baseline Serum IL-6 Predicts Increased Sarilumab Treatment Response for Patient Reported Symptoms and Health-Related Quality of Life Among Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate\n",
      "Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study\n",
      "Patient Characteristics, Treatment Patterns, and Treatment Persistency in Biologic DMARD-Experienced Rheumatoid Arthritis Patients in a US RA Registry\n",
      "High Serum IgA and High Proportion of Activated Th17 and Activated Treg Cells Are Predictive Biomarkers for Remission Achievement with Abatacept in Patients with Early, Seropositive Rheumatoid Arthritis\n",
      "The Efficacy of Low Dose Prednisone for Remission Induction in Newly Diagnosed Rheumatoid Arthritis Patients\n",
      "Glucocorticoid Tapering in Monthly 1-mg Decrements Does Not Result in Clinically Manifest Adrenal Insufficiency in Patients with Rheumatoid Arthritis: Learnings from a Phase 3/4 Study\n",
      "Duration of Oral Corticosteroid Therapy Does Not Change with the Addition of a Parenteral Injection: Results from a Real-World Canadian Early RA Cohort\n",
      "Discontinuation of Oral Glucocorticoid After Initiation of Biological DMARDs Due to a Higher Dose of Methotrexate; A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study\n",
      "Association Between Baseline Anti-citrullinated Protein Antibody Status and Response to Abatacept or Non-TNF Inhibitor Therapy in Patients with RA: Results from a US National Observational Study\n",
      "Low Probability of Clinical Worsening Following Switching Biologic DMARD in Patients with RA and Partial Response to Adalimumab\n",
      "The Association Between Treatment of Abatacept or Other Target Disease-Modifying Anti-rheumatic Drugs and Type 2 Diabetes Mellitus (T2DM)-Related Healthcare Resource Utilization and Costs in Commercially Insured Rheumatoid Arthritis Patients with T2DM\n",
      "Treatment Response to Biologic DMARDs in Patients with RA: A Retrospective Analysis of the RISE Registry\n",
      "Prediction of Clinical Response to Abatacept in Rheumatoid Arthritis Patients Through the Determination of Anti-Carbamylated Proteins Antibodies Levels\n",
      "Connective Tissue Remodeling Is Differently Modulated by Tocilizumab versus Methotrexate Monotherapy in Patients with Early RA: The AMBITION Study\n",
      "The Relationship Between Abatacept Exposure and CD86 Receptor Occupancy in Rheumatoid Arthritis Patients Following Subcutaneous Administration and Its Association to Patient Outcomes\n",
      "Impact of Sarilumab on Unacceptable Pain and Inflammation Control in Moderately-to-Severely Active Rheumatoid Arthritis (RA) Patients in 3 Phase 3 Studies\n",
      "Association Between Baseline Anti-CCP2 Antibody Concentration and Clinical Response After 6 Months of Treatment with Abatacept or a TNF Inhibitor in Biologic-Experienced Patients with RA: Results from a US National Observational Study\n",
      "Risk of Immunization to Rituximab in Systemic Autoimmune Diseases and Rheumatoid Arthritis: Frequency and Risk Factors. Analysis of the Efficacy of an Alternative Treatment by Ofatumumab\n",
      "Persistence of Tocilizumab Therapy Among Patients with Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry\n",
      "Comparative Effectiveness of Tocilizumab in Combination with Methotrexate versus Tumor Necrosis Factor Inhibitors (TNFis) in Combination with Methotrexate in Patients with Rheumatoid Arthritis with Prior Exposure to TNFis\n",
      "Sarilumab and Tocilizumab Receptor Occupancy (RO), and Effects on C-Reactive Protein (CRP) Levels, in Patients with Rheumatoid Arthritis (RA)\n",
      "Evaluation of Effectiveness and Usage Patterns of Tofacitinib in Treatment of Rheumatoid Arthritis in Australia: An Analysis from the OPAL-QUMI Real World Dataset\n",
      "Real Life Retention of Tofacitinib in Patients with Rheumatoid Arthritis\n",
      "Australian Rheumatoid Arthritis (RA) Biologic Treatment Pathways: An Australian Rheumatology Association Database (ARAD) Analysis\n",
      "Efficacy, Safety and Continuation Rate of Abatacept and Tocilizumab in Patients with Rheumatoid Arthritis : The Comparative Observational Study\n",
      "CDAI Analysis of Dose Escalation in a Trial of Infliximab for Rheumatoid Arthritis\n",
      "Treatments Patterns Among Patients with Rheumatoid Arthritis Treated with a Biologic Disease-modifying Anti-rheumatic Drug: A Nation-wide Study in Korea\n",
      "Expression of Uncoupling Protein-1 in Subcutaneous Fat Is Increased by Tocilizumab\n",
      "Impact on Costs and Quality of Life over 5 Years of Treat-to-target Treatment Strategies Initiating Tocilizumab, Methotrexate or Their Combination in Early Rheumatoid Arthritis: Economic Evaluation of the U-Act-Early Trial\n",
      "Baricitinib Provides Better Pain Relief Across All Disease Activity Levels Compared with Placebo and Adalimumab in Rheumatoid Arthritis\n",
      "Efficacy of Pharmacological Treatment in Rheumatoid Arthritis: A Systematic Literature Review Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis\n",
      "Comparison of Healthcare Resource Utilization and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Initiated Treatment with Abatacept versus Other Targeted Disease-Modifying Anti-Rheumatic Drugs\n",
      "Cycling of Tumor Necrosis Factor-α (TNF-α) Inhibitors versus Switching to Different Μechanism of Αction in Rheumatoid Arthritis Patients with Inadequate Response to TNF-α Inhibitor: A Bayesian Network Meta-analysis\n",
      "Positivity of Anti-Ro/SSA Antibody Confer Poor Response and Persistence with Abatacept Therapy\n",
      "Efficacy and Safety of Tofacitinib Modified-Release 11 Mg Once Daily + MTX in RA Patients with an Inadequate Response to MTX: Open-Label Phase Results from a Global Phase 3b/4 MTX Withdrawal Study\n",
      "Efficacy of Tofacitinib Monotherapy, Tofacitinib with Methotrexate and Adalimumab with Methotrexate in Patients with Early ( ≤ 2 Years) vs Established ( > 2 Years) Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Strategy\n",
      "Improvement of Mental Health and Quality of Life During Therapy with Tocilizumab\n",
      "Effect of Tofacitinib on the Qualitative Profile of High Density Lipoproteins Molecules in Patients with Rheumatoid Arthritis\n",
      "B Cell Profile for Early Identification of Optimal Responders to TNF-inhibitors in Rheumatoid Arthritis\n",
      "Long-Term Effectiveness and Safety of Infliximab, Golimumab and Golimumab-IV in Rheumatoid Arthritis Patients from a Prospective Observational Registry\n",
      "Predictors of Response, Adverse Events and Treatment Retention in RA Patients Treated with Either Subcutaneous- or Intravenous- Golimumab in a Prospective, Observational Registry\n",
      "Cost-per-Responder Analysis of Sarilumab for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis (RA)\n",
      "Heterogeneity in the Pattern of Use of JAK-inhibitors Between Countries Participating in an International Collaboration of Registers of Rheumatoid Arthritis Patients (the JAK-pot Study)\n",
      "Effect of Tocilizumab on HDL and LDL Characteristics in Patients with Rheumatoid Arthritis: Preliminary Results\n",
      "Reduction in CD4 TEMRA Cells and Its Association with DAS28 (CRP) < 2.6 Treatment Response with Abatacept in Patients with Early, ACPA+, DMARD-Naïve RA\n",
      "Patient-Reported Outcomes of Abatacept in Combination with MTX in Early, MTX-Naïve, ACPA Positive Patients with RA: 1-Year Results from a Phase IIIb Study\n",
      "The Effect of HLA-DRB1 Risk Alleles (Shared Epitope) on Changes in Immune Cell Subsets and Disease Activity Following Treatment with Abatacept versus Adalimumab in Seropositive Biologic-Naïve Patients with Early, Moderate-to-Severe RA: Data from a Head-to-Head Single-Blinded Trial\n",
      "Effect of ACPA IgM Serostatus on Efficacy Outcomes Following Treatment with Abatacept or Adalimumab: A Post Hoc Analysis of a Phase III Head-to-Head Trial\n",
      "Impact of TNF Inhibitor Cycling with Adalimumab and Etanercept vs Switching to Tofacitinib\n",
      "Comparison of Real-World Persistence of Subcutaneously Administered Biologic Disease-Modifying Antirheumatic Drug Therapies Among Patients with Rheumatoid Arthritis Switching from Another Biologic\n",
      "Time to Discontinuation of Tofacitinib in Rheumatoid Arthritis Patients with and Without Methotrexate: Results from a Rheumatoid Arthritis Cohort\n",
      "Results at 6 Months of Abatacept vs TNF-α Blockers in Patients with Severe, Long-standing, DMARDs Resistant Rheumatoid Arthritis\n",
      "Predictors of Response to Etanercept-Methotrexate Treatment: Post-hoc Analysis of a Randomized, Open-label Study in Latin American Patients with Rheumatoid Arthritis\n",
      "Real-Life Golimumab Persistence in Patients with Chronic Inflammatory Rheumatic Disease: Results of the GO PRACTICE Study\n",
      "Tapering and Discontinuing Prednisolone Without Deteriorated Disease Control by Optimizing Methotrexate in Patients with Rheumatoid Arthritis Under Stable Treatment – 2-year Results in the Real-world Clinical Practice –\n",
      "Association Between Seropositivity and Discontinuation of Tumor Necrosis Factor Inhibitors Due to Insufficient Response in Rheumatoid Arthritis\n",
      "Improvement in Matrix metalloproteinase-3 Levels at 12 Weeks Independently Predicts Achievement of Low Disease Activity at 52 Weeks in Bio-switch Patients with Rheumatoid Arthritis Treated with Abatacept\n",
      "Acute Effects of IL-6 Blockade, TNFα Inhibitor or Glucocorticoids on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis\n",
      "Analysis of Adverse Events of Methotrexate (MTX), bDMARDs and Tofacitinib (TOFA) Reported to Pharmaceuticals and Medical Devices Agency (PMDA), Japan\n",
      "Comparison of the Efficacy and Safety of Abatacept in Rheumatoid Arthritis Patients with and Without Interstitial Lung Disease\n",
      "Discontinuation of Concomitant Methotrexate in Japanese Patients with Rheumatoid Arthritis Treated with Tocilizumab: An Interventional Study\n",
      "Effect of Baricitinib on Functional Impairment in RA Patients with Moderate Disease Activity and an Inadequate Response to Conventional DMARDs\n",
      "Relationship Between Adalimumab Concentrations, Plasma Cytokines, Anti-drug Antibodies and Disease Activity in Rheumatoid Arthritis\n",
      "Is Background Methotrexate Still Advantageous in Extending TNF Drug Survival in the Elderly: An Analysis of the British Society for Rheumatology Biologics Register – Rheumatoid Arthritis\n",
      "Comparison of Sustained Clinical Remission And/or Low Disease Activity Rate Between Rapidly and Gradually De-escalation of Abatacept in Rheumatoid Arthritis\n",
      "Real World Switching Patterns of Etanercept Original and Biosilmilar in Germany\n",
      "Tofacitinib in Patients with Rheumatoid Arthritis and Indicative of Depression And/or Anxiety: A Post Hoc Analysis of Phase 3 and Phase 3b/4 Clinical Trials\n",
      "Pre-Biologic Use of Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis in the United States\n",
      "Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interventional Study in Germany\n",
      "Comparison of Ultra High‐resolution Ultrasound (UHFUS) of Labial Salivary Glands and Conventional Salivary Gland Ultrasonography in Primary Sjögren’s Syndrome Assessment\n",
      "Ultrasonography of Major Salivary Glands in Primary Sjögren’s Syndrome: Identification of Distinct Evolving Patterns in the Long-Term Follow-up\n",
      "Clinical Phenotyping of Patients with Primary Sjögren’s Syndrome Using Salivary Gland Ultrasonograhpy\n",
      "Salivary Gland Hypofunction in a Mouse Model for Sjögren’s Syndrome Is Strongly Associated with Hyperglycemia\n",
      "Histological Characteristics in SICCA Syndrome – Clinical and Serological Association\n",
      "Comparison of Clinical Phenotype, Serological Characteristics and Histologic Features Between Males and Females Patients with Primary Sjögren’s Syndrome (pSS)\n",
      "Baseline EULAR Sjögren’s Syndrome Patient-Reported Index Has a Significant Impact on the Longitudinal Course of Sjögren’s Syndrome\n",
      "Sjӧgren’s Syndrome Foundation National Survey: The Impact and Burden of Oral Symptoms\n",
      "B and T Cell Immunologic Features Associated with Higher Disease Activity Score and Focus Score in Primary Sjögren Syndrome\n",
      "The Increased Ratio of Blood CD56bright to CD56dim NK Cells Is a Distinguishing Feature of Primary Sjögren’s Syndrome\n",
      "Neurological Involvement in a Cohort of Primary Sjogren’s Syndrome Patients: Results of a Multicenter Italian Study\n",
      "Dual Analysis with Nerve Ultrasound and Skin Biopsy in Painful Neuropathy Associated with Sjögren’s Syndrome\n",
      "Systemic Manifestations of Primary Sjögren Syndrome out of the ESSDAI Classification: Prevalence and Clinical Relevance in a Large International, Multi-ethnic Cohort of Patients\n",
      "Minor Salivary Gland Biopsy and Dry Ocular Tests to Detect Occult Sjögren Syndrome in Patients with Interstitial Pneumonia with Autoimmune Features\n",
      "Pulmonary Cysts: Very Common Finding on Computed Tomography of the Chest of Asymptomatic Patients with Primary Sjögren’s Syndrome\n",
      "Pathogenesis of Vaginal Dryness in Primary Sjögren’s Syndrome: A Histopathological Case-control Study\n",
      "Positive Rate of Small Intestinal Bacterial Overgrowth Test (SIBO) Was Significant Correlations to Disease Activity of Primary Sjogren’s Syndrome (pSS)\n",
      "The Oral Microbiome as a Risk Factor for Benign or Pathologic Autoimmunity Associated with Anti-SSA/Ro Positivity and Mimicry for Von Willebrand Factor Type a Domain Protein (vWFA) of L. Mirabilis\n",
      "Diversity Analysis of Intestinal Flora in Patients with Sjogren’s Syndrome\n",
      "Evaluation of Changes in Oral Health-Related Quality of Life over Time in Patients with Sjögren’s Syndrome\n",
      "Clinical Characteristics of Primary Sjögren’s Syndrome in Adult Patients Diagnosed at Age Less Than or Equal to 35 Years versus Those over 35 Years of Age\n",
      "Effects of Resistive Exercise on Fatigue and Disease Activity in Women with Primary Sjogren’s Syndrome\n",
      "New 2019 SLE EULAR/ACR Classification Criteria for SLE Are Valuable for Distinguishing Patients with SLE from Patients with pSS in Daily Practice\n",
      "Health-Related Quality of Life in Primary Sjogren’s Syndrome: Insights from Using PROMIS and Comparison to ESSPRI\n",
      "Polyautoimmunity and Major Organ Involvement Prevalence in Sjögren´s Syndrome: Thyroid, Liver, Lung and Kidney as Targets. a Single Center Cross Sectional Study\n",
      "Primary Sjögren’s Syndrome and Development of Another Connective Tissue Disease During Follow-up\n",
      "Syndecan-1 Is a Potential Biomarker for Salivary Glandular Function and Disease Activity in Patients with Sjögren’s Syndrome\n",
      "Factors Influencing the ESSPRI Index in Primary Sjögren’s Syndrome\n",
      "Should Lupus Podocytopathy Be a Subclass in Class I and Class II Lupus Nephritis?\n",
      "Routine Clinical Pathology Measurements Are Predictive of the Risk of Organ Damage Accrual in SLE\n",
      "Imbalance Between Th17 and Regulatory T Cells in Patients with Systemic Lupus Erythematosus Combined EBV/CMV Viremia\n",
      "Decreased Nocturnal Blood Pressure Dipping in Patients with Systemic Lupus Erythematosus: Association with Markers of Inflammation\n",
      "The Association of Body Weight Fluctuation and All-Cause Mortality in Patients with Systemic Lupus Erythematosus\n",
      "Interstitial Lung Disease in Patients with Systemic Lupus Erythematosus: Who Should We Screen?\n",
      "Renal Arteriosclerosis Predicts Cardiovascular Disease in Lupus Nephritis\n",
      "Assessment of the QRISK2, QRISK3, SLE Cardiovascular Risk Equation, Framingham and Modified Framingham Risk Calculators as Predictors of Cardiovascular Disease Events in Systemic Lupus Erythematosus\n",
      "HER2 as a Biomarker of Proliferative Lupus Nephritis in Children\n",
      "Cachexia in Systemic Lupus Erythematosus\n",
      "High Risk Low Attenuation Non-Calcified Coronary Plaque in Lupus vs. Controls\n",
      "Poor Long-term Renal Outcome in Systemic Lupus Erythematosus Without Abnormal Urinalysis: A Possible Link with Silent Lupus Nephritis\n",
      "Can the Montreal Cognitive Assessment (MoCA) Improve the Automated Neuropsychological Assessment Metrics (ANAM) Performance in Screening for Cognitive Impairment in Lupus Patients?\n",
      "Validity Evidence Supports the Use of Automated Neuropsychological Assessment Metrics (ANAM) as a Screening Tool for Cognitive Impairment in Patients with Systemic Lupus Erythematosus\n",
      "Persistent Cognitive Impairment in Lupus Patients over 1 Year and Associated Factors\n",
      "Incidence and Predictors of Atherosclerotic Vascular Events in a Multicentre Inception SLE Cohort\n",
      "Causes of Death in SLE: Analysis of Inpatient Death from 2000-2018 in a Tertiary Care Hospital in India\n",
      "Lymphocyturia Is a Good and Cheap Biomarker for Active Lupus Nephritis and Is Sensitive to Change\n",
      "Prevalence and Outcome of Thrombocytopenia in Systemic Lupus Erythematosus – Single Centre Cohort Analysis\n",
      "The Impact of the New American College of Cardiology/American Heart Association Definition of Hypertension on Cardiovascular Events in Systemic Lupus Erythematosus\n",
      "Factors Implicated in the Development of Early Osteonecrosis in Systemic Lupus Erythematosus\n",
      "Presence of Antiphospholipid Antibodies in Patients with SLE and Venous Thromboembolic Events of African American and Caucasian Race\n",
      "Development of Comorbidity in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus\n",
      "Impact of Diabetes on Risk of End Stage Renal Disease in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus\n",
      "The Association of Lupus Nephritis Histopathologic Classification with Venous Thromboembolism Is Modified by Age at Biopsy\n",
      "Prognostic Value of Urinary Biomarkers for the Developing of End Stage Renal Disease in Patients with Systemic Lupus Erythematosus\n",
      "Factors Associated with Accrual of Damage over Time in Patients with SLE: Results from a Multinational Latin American Cohort\n",
      "Endothelial Dysfunction and Arterial Stiffness in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis\n",
      "All-cause Hospitalizations and Mortality in Systemic Lupus Erythematosus in the US- results from a National Inpatient Database\n",
      "Oxidized Human Serum Albumin Is Increased in Systemic Lupus Erythematosus, but Not in Rheumatoid Arthritis\n",
      "Disease Activity and Dysregulated Iron Metabolism: A Potentially Overlooked Mechanism for Anaemia in Patients with Systemic Lupus Erythematosus?\n",
      "Prevalence of Cognitive Impairment in an Inception Lupus Cohort as Assessed by a Comprehensive Neuropsychological Battery\n",
      "Clinical and Sociodemographic Associates of Depression and Anxiety in Systemic Lupus Erythematosus\n",
      "Anti-ovarian Antibodies Are Not Associated with Premature Menopause in SLE Treated with Cyclophophosphamide\n",
      "Defining the SLE-Associated Pulmonary Arterial Hypertension Phenotype\n",
      "Heart Rate Visit-to-Visit Variability in Patients with Systemic Lupus Erythematosus Is Associated with Increased Mortality\n",
      "High Expression of CD38 on CD8 T Cells Predicts Increased Burden of Infections in Patients with SLE\n",
      "Role of Aerobic Exercise in Modulating Fatigue in Women with Systemic Lupus Erythematosus\n",
      "Assessing the Validity of QRISK3 at Predicting Cardiovascular Events in Systemic Lupus Erythematosus Patients\n",
      "Assessing Long-term Poor Outcomes in Systemic Lupus Erythematosus Patients with Acute Coronary Syndromes\n",
      "Disability Among Subtypes of SLE\n",
      "The Impact of Body Mass Index Variability in Systemic Lupus Erythematosus\n",
      "Frailty and Sarcopenia in Women with Systemic Lupus Erythematosus\n",
      "Prevalence of Peripheral Neuropathy and Its Electrophysiological Types in Patients with Systemic Lupus Erythematosus\n",
      "Persistency in Platelet C4d and Thrombosis Risk Score Associate with Thrombosis in Systemic Lupus Erythematosus\n",
      "Stroke Clusters in SLE by Lupus Autoantibodies\n",
      "The Systemic Lupus Erythematosus Cardiovascular Risk Equation\n",
      "Homocysteinemia Predicts Renal Insufficiency in Systemic Lupus Erythematosus\n",
      "Association of African- American Ethnicity and Smoking Status and Total and Individual Damage Index in Systemic Lupus Erythematosus\n",
      "Risk Factors for Avascular Necrosis in SLE: A Multivariate Model\n",
      "Effect of the Metabolic Syndrome on Renal Function Decline in Four Rheumatic Diseases: An 8-year Longitudinal Analysis\n",
      "Organ Damage Free Survival in Southern Chinese Patients with Active Lupus Nephritis\n",
      "Prediction of Organ Damage Accrual in Systemic Lupus Erythematosus Using a Frailty Index\n",
      "Systemic Lupus Erythematosus Registries: Are the Measures Captured in the Real World Similar to Those in Clinical Trials?\n",
      "Disease Activity and Cognitive Function in Systemic Lupus Erythematosus\n",
      "LDL-cholesterol as a Risk Factor of Progression to ESRD in Patients with Lupus Nephritis\n",
      "Factors Associated with Peripheral Neuropathies in Patients with Systemic Lupus Erythematosus: A Single Center Experience\n",
      "The Effects of Anti-glutamate Receptor Subunit Antiantibodies on Systemic Lupus Erythematosus Without Neuropsychiatric Involvement\n",
      "Do All Antiphospholipid Antibodies Confer the Same Risk for Major Organ Involvement in Systemic Lupus Erythematosus Patients?\n",
      "Platelet Bound Complement Split Product (PC4d) May Be a Marker of Platelet Activation and Cardiovascular Events in Systemic Lupus Erythematosus\n",
      "Factors Associated with Damage Accrual in SLE Patients with No Clinical or Serological Disease Activity\n",
      "Early Vascular Ageing as a Predictor of Future Cardiovascular Events and Mortality in Systemic Lupus Erythematosus Patients: A Prospective Cohort Study\n",
      "T-cell Exhaustion in Prolonged Remission SLE Patients\n",
      "The Impact of Disease Activity and Related Factors on Cognitive Dysfunction in SLE\n",
      "Cognitive Impairments in SLE Negatively Related to Participation and Quality of Life: A Systematic Review\n",
      "Mortality in a SLE Inception Cohort of Hispanic Patients\n",
      "Progression and Factors Associated with Damage Accrual in a SLE Inception Cohort of Hispanic Patients\n",
      "Severe Infection Prior to Diagnosis of Systemic Lupus Erythematosus (SLE) Is Associated with Disease-Specific Attributes and Long-Term Comorbidities\n",
      "Baseline Serum Osteopontin (OPN) Level Is Associated with Early Coronary Artery-calcification and Its Progression in Patients with Systemic Lupus Erythematosus\n",
      "Bronchoalveolar Lavage Fluid Analysis and Mortality Risk in Systemic Lupus Erythematosus Patients with Pneumonia and Respiratory Failure\n",
      "Evidence for Substantial Immune Activation in Asymptomatic ANA Positive Individuals\n",
      "Identification of Differentially Expressed Genes and Signaling Pathways in Systemic Lupus Erythematosus by Integrated Bioinformatics Analysis\n",
      "The Integration of Genetic Data, Molecular Pathway Analysis and Differential Expression to Delineate the Impact of Ancestral Differences on Lupus\n",
      "Renal Single Cell Genomics Links Type II Interferon and Lupus Nephritis in African-Americans\n",
      "Type I Interferon Levels Vary with Regional Ancestry in European-derived SLE Cohorts\n",
      "NLRP12 Regulates Interferon-α Expression and Is a Biomarker for Disease Activity of Systemic Lupus Erythematosus\n",
      "Anti-IFNAR Treatment Does Not Reverse Neuropsychiatric Disease in MRL/lpr Lupus Mice\n",
      "Single Cell Transcriptome Analysis of Circulating Plasmacytoid Dendritic Cells and Switched Memory B-cells in SLE Patients Reveals Transcriptional Subsets Within the Classical Cell Lineages\n",
      "Neutrophils Are an Important Source of Microparticles in Lupus and Asymptomatic ANA+ Individuals\n",
      "Lysosome Defects in SLE Promote the Accumulation of Nuclear Antigens on the Surface of Hematopoietic Cells\n",
      "Dynamic Changes During SLE Flare Implicate Age-Associated B Cells and Altered T Follicular and Peripheral Helper Cell Responses in Disease Activity\n",
      "Interferon Lambda Promotes Age-Associated B Cells\n",
      "Characterization of Antibody Secreting Cells in Patients with Active Systemic Lupus Erythematosus\n",
      "Lupus Auto-antibodies Act as Positive Allosteric Modulators at GluN2A-containing NMDA Receptors to Induce Excitotoxicity and Spatial Memory Deficits\n",
      "Epstein-Barr Virus Interleukin 10 in SLE Pathogenesis\n",
      "DNA Methylation Changes Are Associated with Particulate Matter 2.5 Exposure in SLE Patients\n",
      "Expanded Circulating Peripheral Helper T Cells Are Associated with B Cell Differentiation in Systemic Lupus Erythematosus\n",
      "Lipocalin-2 Exacerbates Lupus Nephritis by Promoting Th1 Cell Differentiation\n",
      "Mass Cytometric Immunophenotyping Highlights a Dysregulated T cell-B Cell Axis in Patients with New-onset Lupus\n",
      "Circulating MicroRNAs as Potential Biomarkers for Monitoring the Response to In Vivo Treatment with Rituximab in Systemic Lupus Erythematosus\n",
      "Examining the Transcriptional Impact of Liganded ERα in the Inflammatory Milieu of Systemic Lupus Erythematosus\n",
      "RNA Sequencing of PBMCs Reveals Estrogen-Mediated Upregulation of Micro-RNA Processing Machinery\n",
      "Urinary C3d Is a Good Marker for Monitoring Treatment Response After 3 Months of Induction Treatment in Patients with Biopsy Proven Lupus Nephritis\n",
      "Distinct Cell-bound Complement Activation Signatures Are Observed in Patients with Systemic Lupus Erythematosus\n",
      "Molecular Profiling Identifies Immunologic Subgroups and Informs Mechanism of Action of Baricitinib in SLE\n",
      "Beneficial Effect of Angiotensin Receptor Blocker in a Spondyloarthritis Animal Model\n",
      "TNF Inhibitors Improves Arterial Stiffness with Cs DMARDs-resistant Active Psoriatic Arthritis: A Cohort Extended Study\n",
      "Genetic Ablation of γδTCR Inhibits IL-23-induced Neutrophilia and Attenuates Epidermal Hyperplasia, Synovitis, Onycholysis and Enthesitis Associated with Psoriatic Arthritis\n",
      "Tendon T-cell Interactions as Drivers of Chronicity in Spondyloarthritis\n",
      "Vaspin rs35262691 Is Associated with Atherosclerotic Disease in Axial Spondyloarthritis Patients\n",
      "Memory ex-Th17 Cells Contribute to Synovial Inflammation in Spondyloarthritis\n",
      "C-X-C Motif Chemokine 10 (CXCL10) as a Transcriptomic Biomarker of Psoriatic Arthritis Susceptibility\n",
      "PDE4 Inhibition Could Improve Endothelial and Adipose Tissue Dysfunction Associated with Psoriatic Arthritis, Key Processes in Cardiovascular Disease\n",
      "IL-17A Induces Distinct Functional Differences Between Two Novel Mesenchymal Stem Cell Populations Identified at the Human Enthesis\n",
      "Single Cell RNA Sequencing of Patients with Psoriatic Disease\n",
      "Apremilast Inhibits Immune Cells Support of Inflammatory Osteoclastogenesis\n",
      "Effects of Anti-TNF on MiR Expression in Monocytes and CD4+ T-Lymphocytes in Spondyloarthritis\n",
      "Regulatory Role of IL-23 and Its Receptor System in Spondyloarthritis and Its Therapeutic Relevance in anti-IL-17 Failure Patients\n",
      "Comparison of Different Remission Indices in Patients with Psoriatic Arthritis: A Post Hoc Analysis of Data from Phase 3 Tofacitinib Studies\n",
      "Impact of Alternate Mechanism of Action Biologics and Tofacitinib on TNF-α Inhibitor Prescribing in Psoriatic Arthritis: Results from Annual National Patient Chart Audits\n",
      "Golimumab Improves Direct Costs of Healthcare Utilization and Indirect Costs Within Patients with RA, PsA, and as – Analysis of a Non-Interventional Study in Germany\n",
      "Systematic Literature Review and Network Meta-Analysis Comparing Incidence of Uveitis and IBD in Axial Spondyloarthritis Patients Treated with Anti-TNF versus Anti-IL17A in Placebo Controlled Randomized Trials\n",
      "Multi-Symptom Impact on the EQ5D Index in Bio-naïve Active Psoriatic Arthritis Patients: An Analysis Through Week 24 of the GO-VIBRANT Study\n",
      "Clinical Characteristics and Treatment Profiles of Patients with Ankylosing Spondylitis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry\n",
      "Real-World Use of Apremilast in Combination with Biologic Therapy in Patients with Psoriatic Arthritis: Findings from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry\n",
      "Secukinumab Provides Sustained Improvement of Enthesitis in Ankylosing Spondylitis Patients: A Pooled Analysis of Four Pivotal Phase 3 Trials\n",
      "Effect of Phosphodiesterase 4 Inhibition with Apremilast on Cardiometabolic Outcomes in Psoriatic Arthritis – Initial Results from the Immune Metabolic Associations in Psoriatic Arthritis (IMAPA) Study\n",
      "The Impact of Time Since First Diagnosis on the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis\n",
      "Secukinumab Provides Improvement in Nail Psoriasis and Inhibition of Radiographic Progression in Psoriatic Arthritis Patients with Nail Phenotype: 52-Week Results from a Phase III Study\n",
      "Infliximab Serum Trough Levels Predict Non-clinical Response in Patients with Axial Spondyloarthritis\n",
      "Impact of TNF-α Inhibitor on Lipid Profile and Atherogenic Index of Plasma in Axial Spondyloarthritis: Two-year Follow-up Data from the Catholic Axial Spondyloarthritis COhort (CASCO)\n",
      "Ixekizumab Demonstrates Improvement Comparable to Adalimumab Across ACR Components in Biologic-Naïve Patients with Psoriatic Arthritis\n",
      "Impact of Apremilast on PsA Impact of Disease Core Components in Patients with a Limited Number of Active Joints: Results from a Real-World Study\n",
      "Blockage of TNFα and IL-12/23 Improves Depressive Symptoms in Patients with Psoriatic Arthritis – Analysis of Clinical Trial Data\n",
      "Long-term Clinical Outcome of Anti-TNF Treatment in Patients with Early Axial Spondyloarthritis: 10-year Data of the Etanercept vs. Sulfasalazin in Early Axial Spondyloarthritis Trial\n",
      "Exposure-Response Analyses for Upadacitinib Efficacy and Safety in Ankylosing Spondylitis – Analyses of the SELECT-AXIS I Study\n",
      "Improvement in the Signs and Symptoms of Psoriatic Arthritis with Ixekizumab Compared to Adalimumab in Patient Subgroups Defined by Baseline Disease Characteristics\n",
      "Guselkumab Was More Effective Than Secukinumab in Patients with Plaque Psoriasis and the Subset of Patients with Self-Reported Psoriatic Arthritis in a Randomized, Double-blind, Head-to-head Comparison Study over 1 Year\n",
      "Real Life 12 Year Retention Rate of Subcutaneous Anti-TNF in Spondyloarthritis. Results from a Multicenter Cohort of 1170 Patients\n",
      "Comparative Effectiveness of Ustekinumab and TNF Inhibitors in Patients with Psoriatic Arthritis in a Real-world, Multicenter Study\n",
      "Efficacy of Secukinumab in a US Patient Population with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies\n",
      "A Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Secukinumab in US Biologic-Naive Patients with Active Psoriatic Arthritis and Psoriatic Skin Lesions\n",
      "Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study\n",
      "Effectiveness of Switching Between TNF Inhibitors in Patients with Axial Spondyloarthritis: Is the Reason to Switch Relevant?\n",
      "Ixekizumab: 52-Week Efficacy and Safety in Radiographic Axial Spondyloarthritis Patients with Prior Inadequate Response/Intolerance to Tumor Necrosis Factor Inhibitors\n",
      "The Effect of Tofacitinib on Residual Pain in Patients with Psoriatic Arthritis\n",
      "Safety Profile of Ixekizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Integrated Analysis of 18 Clinical Trials\n",
      "Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years\n",
      "Persistence with Etanercept in Patients with Ankylosing Spondylitis or Psoriatic Arthritis in Germany: A Real-World Analysis\n",
      "Long‑Term Certolizumab Pegol Treatment of Axial Spondyloarthritis Is Associated with Rapid and Sustained Reduction of Active Inflammation and Minimal Structural Changes in the Spine: 4‑Year MRI Results\n",
      "Certolizumab Pegol Improves Work and Household Productivity and Social Participation over 1 Year of Treatment in Patients with Non-Radiographic Axial Spondyloarthritis\n",
      "Certolizumab Pegol-Treated Patients with Non-Radiographic Axial Spondyloarthritis Demonstrate Improvements in Sleep Quality and Other Patient Reported Outcomes\n",
      "Impact of Age and Disease Duration on the Response to IL-17A Inhibitor (Secukinumab) Treatment in Ankylosing Spondylitis: Pooled Results from the Phase 3 MEASURE Studies\n",
      "Ixekizumab Improves Fatigue, Pain, and Sleep up to 52 Weeks in Patients with Radiographic Axial Spondyloarthritis\n",
      "Drug Survival of Ustekinumab in Psoriatic Arthritis: A Real-World Multicentric Cohort of 252 Patients\n",
      "Retention Rates and Response of Anti-TNF Treatments in the Enteropathic Spondylitis: HUR-BIO Real Life Results\n",
      "Impact of Baseline Body Mass Index on the Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis\n",
      "Inadequate Response Within a Year of Biologic and Oral Synthetic DMARD Treatment Initiation Among Psoriatic Arthritis Patients in the USA Real-World Setting\n",
      "Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials\n",
      "Achievement of RAPID3 and cDAPSA Treatment Targets Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in Subjects Treated with Apremilast\n",
      "Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis\n",
      "Tumour Necrosis Factor Inhibitor Monotherapy versus Combination Therapy with Conventional Synthetic Disease-modifying Anti-rheumatic Drugs for the Treatment of Psoriatic Arthritis: A Combined Analysis of European Biologics Databases\n",
      "Predicting Response to Biologic Therapy in Patients with Axial Spondyloarthritis (axSpA)\n",
      "Long-Term Treatment Patterns of Biologics and Apremilast Among Patients with Moderate-to-Severe Plaque Psoriasis by Psoriatic Arthritis Status\n",
      "Ixekizumab Is Effective in the Treatment of Radiographic Axial Spondyloarthritis Regardless of the Level of C-Reactive Protein or Magnetic Resonance Imaging Scores\n",
      "Inflammatory Bowel Disease and Anterior Uveitis in Patients Treated with Ixekizumab for Radiographic Axial Spondyloarthritis: Results from Two Phase 3 Studies Through 52 Weeks\n",
      "Impact of Body Weight on Efficacy of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis\n",
      "Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis—An Analysis from a Phase 2 Study\n",
      "Safety of Tildrakizumab in Psoriatic Arthritis: An Interim Analysis from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial\n",
      "Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in a Phase 3 Study\n",
      "Limited Changes in Hematological Parameters During Tildrakizumab Treatment: Post Hoc Analysis of Data from the Tildrakizumab Psoriasis Clinical Program\n",
      "Resolution of Enthesitis and Dactylitis Is Maintained over Two Years of Ixekizumab Treatment in Patients with Psoriatic Arthritis\n",
      "The Efficacy and Safety of Anti-TNFα Treatment in Ankylosing Spondylitis Patients with Late Onset Compared to Those with Adult Onset; The Data from TURKBIO Registry\n",
      "Real World Effectiveness of Secukinumab in Patients with Ankylosing Spondylitis: Findings from a Recent Cross Sectional Survey of Rheumatologists and Patients in Europe\n",
      "ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Underlying Rheumatoid and Psoriatic Arthritis\n",
      "Withdrawal of Ixekizumab Results in Loss of Efficacy in Multiple Clinical Domains in Patients with Psoriatic Arthritis Who Had Achieved Minimal Disease Activity: Results from the SPIRIT-P3 Study\n",
      "The Performance Characteristics of Composite Measures Used in a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis\n",
      "Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study\n",
      "Achievement of Very Low Disease Activity and Remission Treatment Targets Is Associated with Reduced Radiographic Progression in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol\n",
      "A Novel MK2 Inhibitor for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases\n",
      "Concomitant Treatment with Methotrexate Does Not Increase the Efficacy of Ustekinumab or TNF Inhibitors in Psoriatic Arthritis: Results from a Real-world, Multicenter Study\n",
      "The Effects of Apremilast Therapy on Deployability in Active Duty U.S. Army Soldiers with Plaque Psoriasis and Psoriatic Arthritis\n",
      "Ustekinumab and TNF Inhibitors Similarly Improve Patient-perceived Impact of Psoriatic Arthritis but Differentially Affect the Scale Subdomains: Results from a European Observational Cohort Study\n",
      "Biologic Use and Reasons for Switching Biologic Therapy in Patients with Non-radiographic Axial Spondyloarthritis in the United States:Findings from a US Survey\n",
      "Early Treatment Failure with Apremilast Among Biologic-naïve Patients with Psoriatic Arthritis\n",
      "Long-Term Effectiveness and Safety of Infliximab and Golimumab in Ankylosing Spondylitis Patients from a Prospective Observational Registry\n",
      "Long-Term Effectiveness and Safety of Infliximab, Golimumab and Ustekinumab in Psoriatic Arthritis Patients from a Prospective Observational Registry\n",
      "Predictors of Response, Adverse Events and Treatment Retention in Ankylosing Spondylitis Patients Treated with Golimumab in a Prospective, Observational Registry\n",
      "Ixekizumab Significantly Improves Self-reported Overall Health as Measured by Short-Form-36 in Patients with Active Non-radiographic Axial Spondyloarthritis: 16- and 52-Week Results of a Phase 3 Randomized Trial (COAST-X)\n",
      "Effectiveness and Retention Rate of Secukinumab for Psoriatic Arthritis and Axial Spondyloarthritis: Real-life Data from the Italian LORHEN Registry\n",
      "Ixekizumab Improves Self-reported Overall Functioning and Health as Measured by the Assessment of SpondyloArthritis International Society Health Index in Patients with Active Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Randomized Trials\n",
      "Drug Survival of Secukinumab for Axial Spondyloarthritis in a Real-World Setting Possible Response Factors\n",
      "Primary 1-Year Data of Ixekizumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Patients with Radiographic Axial Spondyloarthritis Including Data in Patients Rerandomized from Adalimumab to Ixekizumab\n",
      "Ixekizumab Demonstrates Consistent Improvement up to Week 108 in Psoriatic Arthritis Across Individual ACR Components for Patients Naïve to Biologic DMARDs or with Previous Inadequate Response to TNF Inhibitors\n",
      "Does Retention and Remission Rates to 2nd and 3rd TNF Inhibitors in Patients with Axial Spondyloarthritis Depend on the Reason from Withdrawal to the Previous Treatment? – Real World Data from 12 European Countries in the EuroSpA Research Collaboration\n",
      "Clinically Meaningful Improvement in Skin and Nail Psoriasis in Bio-naïve Active Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Results Through Week 52 from a Phase-3 Study\n",
      "Impact of Peripheral Swollen and Tender Joints at Baseline on Response to Treatment with Secukinumab in Ankylosing Spondylitis\n",
      "Effect of Secukinumab on Radiographic Progression Through 2 Years in Patients with Active Psoriatic Arthritis: End-of-study Results from a Phase III Study\n",
      "Drug Survival and Safety of Biosimilar CT-P13 versus Reference Infliximab in Patients with Ankylosing Spondylitis: Data from the Korean College of Rheumatology Biologics Registry\n",
      "Exposure–Response Modeling of an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, BMS-986165, for Pain Visual Analog Scale Score, in Patients with Psoriasis and Musculoskeletal Symptoms\n",
      "Secukinumab Effectiveness in 1134 Patients with Psoriatic Arthritis Treated in Routine Clinical Practice in 11 European Countries in the EuroSpA Research Collaboration Network\n",
      "Proposition of a Novel Animal Model of Systemic Sclerosis Induced by Type V Collagen in C57BL/6 Mice Reproducing Fibrosis, Vasculopathy and Autoimmunity\n",
      "Computational Methods for Drug Repositioning of Systemic Sclerosis Using Gene Fold-Change and Network Analyses\n",
      "Thy-1 (CD90) as a Novel Marker for Tracking in Vivo Skin Fibrosis\n",
      "The Metabolic Intermediate Alpha-Ketoglutarate Suppresses the TGFβ-driven Profibrotic Responses of Dermal Fibroblasts\n",
      "TGF-β Isoforms Modulate the RNA Cargo of Extracellular Vesicles (Exosomes) Isolated from Cultured Normal Human Lung Microvascular Endothelial Cells: A Mechanistic Link Between Endothelial Cell Dysfunction and the Establishment of a Profibrotic Phenotype in SSc?\n",
      "Myocardial Involvement in SSc: Key Role of Lin-gp38+ Stromal Cells in the Onset of Fibrosis and Defects of the Conduction System\n",
      "The Effect of Nintedanib versus Mycopheolate Mofetil in the FRA2 Mouse Model of Systemic Sclerosis Associated Interstitial Lung Disease\n",
      "CXCL4-L1 Levels Are Elevated in Systemic Sclerosis Patients and Correlate with Pulmonary Arterial Hypertension and Capillaroscopic Indices of Vascular Damage\n",
      "Clonally Expanded CD4+ Cytotoxic T Cells, Endothelial Cell Apoptosis and the Pathogenesis of Early Systemic Sclerosis\n",
      "Induction of a Profibrotic Phenotype in Normal Dermal Fibroblasts by Expression of PIM1 Kinase and Demonstration of Antifibrotic Effects of Inhibition of PIM Kinases in Systemic Sclerosis Dermal Fibroblasts\n",
      "Genome-Wide DNA Methylation Signatures in Classical Monocytes from African Ancestry Patients with Systemic Sclerosis\n",
      "Identification of Differential Chromatin Accessibility Using ATAC-seq in a Novel 3D Tissue Culture System of Systemic Sclerosis\n",
      "The PPAR Agonist Lanifibranor Protects Against Right Ventricular Hypertrophy in a Mouse Model of Systemic Sclerosis Associated Pulmonary Hypertension\n",
      "Parallel Analysis of Systemic Sclerosis and Keloidal Morphea Skin Biopsies Delineates the Hallmark Profibrotic Gene Expression Profile for Scleroderma in Vivo\n",
      "Analysis of Serum Markers Across the Scleroderma Spectrum Shows Subset and Stage Specific Profiles of Fibrogenesis\n",
      "Proteomic and Transcriptomic Analysis of Human Eosinophilic Fasciitis Fibroblasts\n",
      "Profibrotic Macrophage Activation in Systemic Sclerosis Is Dependent on the Mechanosensing MRTF-A Pathway\n",
      "Dissecting the Cellular Mechanism of Prostacyclin Analog Iloprost in Reversing Vascular Dysfunction in Scleroderma\n",
      "Inhibition of Histone Readers Bromodomain and Extraterminal Domain Proteins Alleviates Scleroderma Fibrosis\n",
      "BDCA2 Targeting of Human Plasmacytoid Dendritic Cells via CBS004 Reverts Dependent IFN Activation and Tissue Fibrosis in vitro and in vivo\n",
      "The Diversity and Community Metrics of the Esophageal Microbiome of SSc Patients\n",
      "PI3K-Akt Pathway Plays a Crucial Role in Production of Collagen in Fli1 Deficient Condition and Its Inhibitor Has the Therapeutic Potential in Treating Fibrosis\n",
      "Lymphocyte Subset Abnormalities in Early Diffuse Cutaneous Systemic Sclerosis\n",
      "Effects of Abatacept on T Regulatory Cells in Early Diffuse Systemic Sclerosis\n",
      "CD123+ Plasmacytoid Dendritic Cells from Systemic Sclerosis Patients Are Susceptible to the Cytotoxic Activity of Tagraxofusp, a CD123-Targeted Therapy\n",
      "Aberrant Expression Levels of Soluble Co-inhibitory Receptors Linked to Disease Activity in Systemic Sclerosis\n",
      "Dysregulated IL-6 Dependent Dermal Adenosine Signaling via Adenosine A2A Receptor May Drive Fibrosis in Systemic Sclerosis\n",
      "Identification of miRNAs in Systemic Sclerosis Based on Activity and Network Analysis­­­\n",
      "Classical Monocytes from African Ancestry Patients with Systemic Sclerosis Show Transcription and Energy Regulation Gene Expression Signatures\n",
      "CD4+ T Helper Cell Populations with High PD-1 Expression Are Expanded in Systemic Sclerosis\n",
      "Cytokine Signatures Differentiate Systemic Sclerosis Patients at High versus Low Risk for Pulmonary Arterial Hypertension\n",
      "A Common Transcriptional Signature Is Present in Circulating Classical Monocytes and Skin Macrophages in Systemic Sclerosis\n",
      "CCR2+ Circulating Monocytes Contribute to the Survival of ADSC in Bleomycin-Induced Skin Fibrosis\n",
      "Identification of Distinct Pro-Fibrotic Monocyte and Macrophage Subsets in Systemic Sclerosis\n",
      "Epigenetic Regulation-Mediated Reduction in the Expression of Prostacyclin Receptor and Prostacyclin Synthase in Scleroderma Skin, Vascular Smooth Muscle Cells, and Microvascular Endothelial Cells\n",
      "Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom\n",
      "Significance of Abnormal Nailfold Videocapillarscopy Among Patients with Raynaud’s Phenomenon And/or Suspected Connective Tissue Disease: A Cross-Sectional Single-Center US Experience\n",
      "Contribution of Chest Wall Muscle Atrophy to Decline of Forced Vital Capacity in Patients with Systemic Sclerosis-associated Interstitial Lung Disease\n",
      "Assessment of the Repeatability and Convergent Validity with Dermal Collagen of High Frequency Ultrasound in Systemic Sclerosis\n",
      "Evidence-based Consensus Statements for the Identification and Management of Interstitial Lung Disease in Systemic Sclerosis\n",
      "Relationship Between YKL-40, VEGF, and IL-5 in Borderline mPAP and Pulmonary Hypertension in Systemic Sclerosis\n",
      "Comparison of Different Pulmonary Hypertension Screening Algorithms in Patients with Systemic Sclerosis\n",
      "Correlation Between Raynaud’s Condition Score, Nailfold Videocapillaroscopy and Laser Speckle Contrast Analysis in Secondary Raynaud’s Phenomenon Due to Systemic Sclerosis\n",
      "Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial\n",
      "The Clinical Features of Anti-RNA Polymerase III Antibodypositive Systemic Sclerosis with and Without Malignancy\n",
      "Sexual Health in 60 Female Patients with Systemic Sclerosis\n",
      "Endoscopic Findings in a Scleroderma Cohort with and Without Interstitial Lung Disease\n",
      "Cutaneous and Musculoskeletal Clinical Characterization of a Cohort of Patients with Chronic Graft-versus-host Disease\n",
      "Change in Calcinosis over 1 Year Using the SCTC Radiologic Scoring System for Calcinosis of the Hands in Patients with Systemic Sclerosis\n",
      "Automated Nailfold Capillary Counting System (AUTOCAPI) in Systemic Sclerosis Patients with Different Capillaroscopic Patterns\n",
      "Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use\n",
      "Effects of Nintedanib in Patients with Diffuse and Limited Cutaneous Systemic Sclerosis and Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial\n",
      "Comparison of Automated Capture and Analysis System of Sublingual Microvessels and Nailfold Videocapillarscopy for Microvascular Assessment in Systemic Sclerosis\n",
      "Incidence Rate and Prevalence of Valvular Heart Disease in Systemic Sclerosis: A Retrospective Cohort Study from a Single Institution\n",
      "The Collaborative National Quality and Efficacy Registry for Scleroderma: Data Completion Outcomes from a Multicenter United States Cohort Using Guideline-Based Registry Practices\n",
      "Systemic Sclerosis Auto-antibody Profiles Predict Interstitial Lung Disease Onset but Not Progression\n",
      "Mycophenolate Mofetil and Cyclophosphamide Improve Health-Related Quality of Life in Patients with Systemic Sclerosis Who Participated in SLS II\n",
      "Baseline Skin Score, Older Age and CD34-selection Influence the Outcome of Autologous Stem Cell Transplantation for Systemic Sclerosis – Results of a Prospective Non-interventional Study from the European Society for Blood & Marrow Transplantation (EBMT)\n",
      "Multicenter Double-Blind, Proof-of-Concept, Randomized Placebo-Controlled Trial of Riociguat in Systemic Sclerosis-associated Digital Ulcers\n",
      "Anticentromere Antibody Levels and Isotypes Associate with Disease Severity in Systemic Sclerosis\n",
      "Efficacy and Safety of Romilkimab in Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-Blind, Placebo-Controlled, 24-week, Proof of Concept Study\n",
      "Esophageal Dilation and Other Clinical Factors Associated with Pulmonary Function Decline in Patients with Systemic Sclerosis\n",
      "Histologic Features Correlate with the Modified Rodnan Skin Score, Serum Inflammatory Markers, and Patient Reported Outcomes in Patients with Early, Diffuse Cutaneous Systemic Sclerosis\n",
      "Health-Related Quality of Life in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Impact of Lung Function on Patient-Reported Outcomes in a Randomized Phase III Trial\n",
      "Sarcopenia in Systemic Sclerosis\n",
      "Impact of Visceral Involvement in the Characterization and Prognosis of Patients Without Skin Involvement Classified as Systemic Sclerosis (SSc) According to 2013 ACR/EULAR Criteria in a Large Single Cohort\n",
      "Linaclotide for the Treatment of Gastrointestinal Symptoms in Systemic Sclerosis\n",
      "Serial Sublingual Videomicroscopy in Systemic Sclerosis Clinic: Are the Microcirculation Measurements Correlated with Gastrointestinal Symptoms?\n",
      "Circulating Cell Free DNA Released from Eosinophils Is a Practical Biomarker in Patients with Eosinophilic Granulomatosis with Polyangiitis\n",
      "Does PR3-ANCA+ Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)Really Exist?\n",
      "Assessments of Quality of Life in Patients with Eosinophilic Granulomatosis with Polyangiitis\n",
      "Reducing the Number of Rituximab Infusions at Onset of Maintenance Therapy for ANCA-associated Vasculitides: Results of a Post Hoc Analysis from a Randomized–controlled Trial\n",
      "Glucocorticoids in Incident ANCA-Associated Vasculitis (AAV) Patients – A Study of Routine Clinical Practice in the EU Demonstrates Prolonged Use and Temporal Relationship to Adverse Events and Infections\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Maintenance Treatment in ANCA Associated Vasculitis in Real World Clinical Practice – Burden of Disease, Use of Glucocorticoids and Impact on Patient Functional Status Remain Major Problems\n",
      "Long Term Outcome of Hydralazine-Associated Vasculitis\n",
      "Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Registry\n",
      "Comparison of Mizoribine with Azathioprine in Efficacy and Safety for ANCA-Associated Vasculitis\n",
      "Evaluation of Subclinical Coronary Atherosclerosis in ANCA-associated Small Vessel Vasculitides (AAVs) Compared to Matched Controls Through Visual Assessment of Coronary Arterial Calcium (CAC) Score Using Non-Gated Chest Computed Tomography (CT)\n",
      "Hospital Admissions and Mortality in Patients with ANCA-associated Vasculitis\n",
      "Use of Rituximab for the Treatment of ANCA-Associated Vasculitis in Canada, 2010-2018\n",
      "Factors Associated with Overall and First-Year Mortality in Turkish Patients with ANCA-Associated Vasculitides: Retrospective, Multicentre Trial\n",
      "Survival in ANCA-Associated Vasculitis in a Latin-American Center: 28 Years of Experience\n",
      "A Retrospective Cohort Study Using Clinical Notes and Latent Topic Modeling to Characterize the Natural History of ANCA-Associated Vasculitis\n",
      "Does Pneumocystis Jiroveci Pneumonia (PJP) Prophylaxis Prevent Hospitalizations for Other Infections in Vasculitis Patients?\n",
      "Management of Severe Renal Disease in Anti-Neutrophil-Cytoplasmic-Antibodies Associated Vasculitis: Role of Rituximab and Plasma Exchange?\n",
      "Interstitial Lung Disease in ANCA Associated Vasculitis: A Single Center Retrospective Analysis\n",
      "Adaptive Study Design of a Randomized, Multicenter, 2-Part Phase 2 Trial of Replacement of Glucocorticoids by IFX-1, a C5a Inhibitor, in Active Granulomatosis with Polyangiitis and Microscopic Polyangiitis\n",
      "Design of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of 2 Different Dose Regimens of IFX-1, a C5a Inhibitor, as an Add-On Therapy for Granulomatosis with Polyangiitis or Microscopic Polyangiitis\n",
      "The Association of Reduced Low-Density Lipoprotein (LDL) Cholesterol Levels with ANCA-Associated Vasculitis (AAV)\n",
      "Inpatient Epidemiology of Granulomatosis with Polyangiitis in the United States\n",
      "Cardiac Involvement of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss): Initial Manifestations and Outcomes Based on Data from a Monocenter Patient Cohort\n",
      "Remission and Low Disease Activity State in Patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual\n",
      "Inpatient Burden, Expenditures and Comorbidities of Polyarteritis Nodosa: National Inpatient Sample 2014\n",
      "Risk of Vasculitis Associated with Inflammatory Bowel Diseases: Evidence for a Role of TNF-α Blockers\n",
      "Dramatic but Suspensive Effect of interleukin-1 Inhibitors on Persistent Urticarial Vasculitis\n",
      "Glucocorticoids Plus Rituximab versus Glucocorticoids Plus Placebo in Non-infectious Active Mixed Cryoglobulinemia Vasculitis: Results of a Placebo-Controlled Randomized Trial\n",
      "Off-Label Use of Biotherapies to Treat Relapsing And/or Refractory Polyarteritis Nodosa\n",
      "The Long-term Outcome of Patients with Arthritis of Behçet’s Disease\n",
      "Efficacy of TNF α Inhibitors for Refractory Vascular Behcet’s Disease: A Multicenter Observational Study of 27 Patients\n",
      "Long-Term Follow-Up of Anti-IL6-Receptor Tocilizumab in Refractory Uveitis in Patients with Behçet Disease: Multicenter Study of 14 Patients in Clinical Practice\n",
      "Biological Therapy in Neurobehçet: Multicenter Study of 31 Patients\n",
      "Pharmacogenetics and Pharmacodynamics of Response to Apremilast in a Phase 3 Clinical Study in Subjects with Active Behçet’s Disease\n",
      "Apremilast in Combination vs Monotherapy for Refractory Oral And/or Genital Ulcers in Behçet’s Disease: National Multicenter Study of 51 Cases\n",
      "Is the Risk of Tuberculosis Increased in Behçet’s Disease Compared to Other Rheumatological Disorders After Anti-TNF-α Treatment?\n",
      "Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 64 Weeks: Long-term Results from the Japanese Subgroup in a Phase III Study\n",
      "Development of Machine Learning Models (Artificial Neural Networks) for Prediction of Vision Threatening Behçet’s Disease\n",
      "Disease Course of Behçet’s Syndrome Patients Not Fulfilling International Study Group Criteria at Presentation\n",
      "Clinical Characteristics and the Level Disease Activity of Behcet´s Disease in China: A Study Based on Smart System of Disease Management (SSDM)\n",
      "Amyloidosis in Behcet’s Disease: Experience of a Vasculitis Centre at Silk Road\n",
      "Target Organ Associations in Polyarteritis Nodosa (PAN): Results of a Worldwide Collaboration Study\n",
      "Increased Levels of IL-2 and IL-4 Promote Th17/Treg Immune Imbalance in Patients with Behcet’s Disease\n",
      "Efficacy of Leflunomide for Treatment of Vasculitis\n",
      "Cyclophosphamide Therapy for the Neurologic Involvement of Behçet’s Disease – Is It Superior to Azathioprine in Preventing Relapses?\n",
      "HLA-B*51 and Its Subtypes in Brazilian Patients with Behçet’s Disease\n",
      "IL-6 Promotes IgG4-related Disease by Inducing Fibroblast-dependent Tfh Cell and B Cell Differentiation Factors\n",
      "Azathioprine and Glucocorticoid Combination Might Be a Good Treatment Option to Achieve Remission in Patients with IgG4-related Disease\n",
      "Juvenile-Onset IgG4-Related Disease: A Systematic Review\n",
      "Chemokine and Cytokine Tear Profile of Patients with IgG4-Related Disease\n",
      "Distinctive Imaging Features Between IgG4-Related Ophthalmic Disease and Graves’ Orbitopathy: A Comparative Study\n",
      "Head and Neck Involvement of IgA Vasculitis: A Case-Control Study\n",
      "Drug-induced IgA Vasculitis: Data from the French Pharmacovigilance Network and the WHO VigiBase\n",
      "Can We Predict Early Relapses in Adult IgA Vasculitis?\n",
      "Predictors of Gastrointestinal and Renal Involvement in Adult IgA Vasculitis\n",
      "Poor-Prognosis Factors of Systemic Vasculitides with Gastrointestinal Involvement: Data from a Large Retrospective Study\n",
      "Identifying Patterns of Histopathologic Presentation in CNS Vasculitis\n",
      "Geographic Disparities in Mortality Rates of Vasculitis in the United States: 1999 to 2017\n",
      "Clinical Phenotypes in Relapsing Polychondritis in a Prospective Cohort\n",
      "Pentoxifylline Gel for Oral Ulcers in Patients with Behçet’s Syndrome\n",
      "Adult Primary Central Nervous System Vasculitis Treatment and Course: A Long-term Follow-up Study\n",
      "Mixed Cryoglobulin Immune Complex Proteomics: Analysis by Mass Spectroscopy\n",
      "Mixed Cryoglobulinaemia Since the Advent of New Direct-acting Antivirals for Hepatitis C Infection: Clinical Characteristics, Etiologies and Biological Features in 679 Patients\n",
      "Development of Ultrasound Detectable Arthritis Among ACPA Positive Subjects with Musculoskeletal Symptoms: The Risk RA Prospective Study\n",
      "Methotrexate in Patients with Hand Erosive Osteoarthritis Refractory to Usual Treatments: A Randomized, Double-blind, Placebo-controlled Trial\n",
      "Six-week Treatment with Low-dose Prednisolone in Patients with Painful Hand Osteoarthritis (HOPE): Results from a Randomised Double-blind Placebo-controlled Trial\n",
      "The Prospective Open Label Preventive Approach to Congenital Heart Block with Hydroxychloroquine (PATCH) Study Demonstrates a Reduction in the Recurrence Rate of Advanced Block\n",
      "UV Light Induces Acute Type I Interferon Production in the Skin and Blood Which Is cGAS Dependent\n",
      "A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus\n",
      "Perceived Stress Independently Associates with Worse Type 2 Symptoms in Systemic Lupus Erythematosus\n",
      "Comparison of the Thrombosis Risk Score with Triple Positivity in SLE Thrombosis\n",
      "Describing Intra-Individual Cognitive Function Course over Time in Lupus Patients: Persistent and Fluctuating Cognitive Impairment, Affected Cognitive Domains, and Severity\n",
      "Clinical Implications of Neutrophil Extracellular Traps in Systemic Lupus Erythematosus\n",
      "Avascular Necrosis Is Associated with APOL1 Variants in African Americans with Systemic Lupus Erythematosus\n",
      "Ability of Inflammatory and Regulatory Soluble Mediators to Forecast Impending Clinical Disease Flare and Inform a Refined Lupus Flare Prediction Index in a Confirmatory Cohort of SLE Patients\n",
      "Anti-neutrophil Extracellular Trap (NET) Autoantibodies in Primary Antiphospholipid Syndrome\n",
      "Defibrotide Inhibits Antiphospholipid Antibody-Mediated NET Release and Endothelial Cell Activation\n",
      "The Epidemiology of the Antiphospholipid Syndrome in the UK, 1990 – 2016\n",
      "Antiphospholipid Antibody Profile Stability over Time: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)\n",
      "Cognitive Dysfunction (CD) and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Primary Antiphospholipid Syndrome (PAPS)\n",
      "Descriptive Analysis of Biopsy-proven Antiphospholipid Antibody-associated Nephropathy Patients Included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)\n",
      "CCL25, a Novel Fibroblast and Macrophage Chemoattractant That Potentiates RA Bone Erosion\n",
      "Interferon-gamma Supports Transcriptional Activity of BIRC5 in CD4+ T Cells in Established Rheumatoid Arthritis\n",
      "GM-CSF Is a Pro-Inflammatory Cytokine in Experimental Vasculitis of Medium and Large Arteries\n",
      "Biomarker Profiling Reveals Novel Mechanistic Insights into Ustekinumab Therapeutic Responses in Systemic Lupus Erythematosus\n",
      "A First-in-class Selective and Potent IRAK4 Degrader Demonstrates Robust in Vitro and in Vivo Inhibition of TLR/IL-1R Activation and Inflammation\n",
      "Myosin Regulation of TNF Receptor 2 Signaling May Contribute to Anti-TNF Therapy Response\n",
      "An Evaluation of Burnout Among U.S. Rheumatology Fellows: A National Survey\n",
      "Education of Rheumatology Faculty: Evaluation of an Interactive Team Based Approach versus Traditional Didactic Teaching\n",
      "Identifying Educational Themes and Knowledge Gaps Through Analysis of Electronic Consultation (eConsult) Communication Between Primary Care Physicians and Rheumatologists\n",
      "Rheumatology Mechanism Madness: A Pilot Collaborative Learning Activity for Rheumatology Trainees\n",
      "Time to Bridge the Gap in Rheumatology Education: Interactive Team Based Learning Is Most Effective in Increasing Internal Medicine Residents’ Knowledge\n",
      "Wellness and Resiliency Among Recent Rheumatology Fellowship Graduates: A Qualitative Study\n",
      "Safety and Humoral Immunogenicity to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis (interim Analysis)\n",
      "Comparison of Infection-Related Hospitalization Risk and Cost in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis Treated with Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs\n",
      "Utility of Repeat Latent Tuberculosis Testing in Patients Taking Biologics\n",
      "Performance of the RABBIT Infection Score in a Prospective Multicenter Cohort of Rheumatoid Arthritis Patients from Argentina\n",
      "Safety of the Zoster Vaccine Recombinant, Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center’s Experience with 400 Patients\n",
      "Perioperative Anti-rheumatic Medications Are Not Associated with 30-day Odds of Infection in Rheumatoid Arthritis Patients Undergoing Surgery: A Retrospective Cohort Study\n",
      "Inflammatory Arthritis Induced by Immune Checkpoint Inhibitor Therapy: A Distinct Clinical Entity and Immunologic Phenotype\n",
      "Teprotumumab, a Novel Biologic for Active Thyroid Eye Disease\n",
      "Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists After Immunotherapy Cessation\n",
      "A Quarter of Patients Treated with Checkpoint Inhibitors Develop Immune-Related Adverse Events: A University Center Experience\n",
      "Rheumatic Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Retrospective, Pharmacovigilance Study\n",
      "Commonly Used Drugs in Rheumatology May Alter Anti-Tumoral Response to Immune Checkpoint Inhibitors\n",
      "Delineating Early Response Trajectories to Biologics in Polyarticular Course Juvenile Idiopathic Arthritis\n",
      "New Medications Are Needed for Children with Juvenile Idiopathic Arthritis\n",
      "Long-term Outcome of Juvenile Idiopathic Arthritis: From the Methotrexate to the Biologic Era\n",
      "Subcutaneous or Intravenous Abatacept Monotherapy in Pediatric Patients with Polyarticular-Course JIA: Results from Two Phase III Trials\n",
      "Psoriasis Associated with Anti-Tumor Necrosis Factor-Alpha Therapies in Children with Inflammatory Bowel Disease, Juvenile Idiopathic Arthritis, and Chronic Noninfectious Osteomyelitis\n",
      "Arthropathy of Down Syndrome: An Under-diagnosed Inflammatory Joint Disease That Warrants a Name Change\n",
      "Experimental Rheumatoid Joint Ameliorated by CRISPR Interference Targeting Long Non-coding RNA H19 Through Wnt Signaling Inactivation\n",
      "MyD88 S209R Enhances Inflammation in Mouse Models of Arthritis\n",
      "Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice\n",
      "The Card9-Neutrophil Signaling Axis Is Critical to Induction of Th17-Mediated Arthritis in SKG Mice\n",
      "Potential Involvement of OX40 Expressing Tfh Cells on Regulation of Autoantibody Sialylation in Experimental and Rheumatoid Arthritis\n",
      "Cholesterol Sequestering in Macrophages Contributes to the Lipid Paradox in Chronic Arthritis\n",
      "A Human SLE Variant NCF1-R90H Drives Lupus-like Kidney Disease in a Pristane-induced Murine Lupus Model\n",
      "Reversible Dysregulation of Renal Circadian Rhythm in Lupus Nephritis\n",
      "Single Cell Analysis of Renal Myeloid Cells from NZB/WF1 Mice with Lupus Nephritis Reveals Multiple Subsets with Altered Functions\n",
      "The Pathogenic Potential of Choroid Plexus T Cells in Neuropsychiatric Lupus\n",
      "Surrogate Pathways of Complement Activation in Novel Polygenic SLE-like Models of Kidney Injury\n",
      "The Glucocorticoid-Induced Protein GILZ Represent a Checkpoint in the IFN Program in SLE\n",
      "Causal Effect of TNF-α, IL-12p70, IL-17 Levels on the Risk of Psoriatic Arthritis: A Mendelian Randomization Study\n",
      "The Deubiquitinase TRABID Is a Potential Therapeutic Target in Spondyloarthritis\n",
      "Entheseal CD90+ SOX9+ Cartilage-like Cells Initiate Spinal Ankylosis in Ankylosing Spondylitis\n",
      "CLEC5A/MDL-1 Is Critical for Inflammatory Arthritis and Skin Inflammation\n",
      "Microbiome in Offspring of Ankylosing Spondylitis Patients\n",
      "Cytokine Dependence of Enthesis-resident Lymphocytes in Murine Spondyloarthritis\n",
      "Continuing versus Withdrawing Ixekizumab in Patients with Psoriatic Arthritis Who Achieved Sustained Minimal Disease Activity: Results from the SPIRIT-P3 Study\n",
      "The Ankylosing Spondylitis Disease Activity Score Reflects and Predicts Response to Biologic Treatment in Axial Spondyloarthritis Patients with Coexistent Fibromyalgia Compared to the Bath Ankylosing Spondylitis Disease Activity Index\n",
      "Clinically Relevant Deficits in Performance Tests in Patients with Axial Spondyloarthritis(axSpA) – Collecting Questionnaires Is Insufficient\n",
      "Tildrakizumab Efficacy for Psoriatic Arthritis: 24-week Analysis of Swollen and Tender Joint Counts and Pain\n",
      "6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA Research Collaboration Network\n",
      "Magnetic Resonance Enterography as a Screening Tool to Detect Sacroiliitis in Crohn’s Disease: Association with Clinical and Endoscopic Markers of Crohn’s Disease Activity\n",
      "Short- and Long-term Morbidity and Mortality Outcomes of African American Patients with Systemic Sclerosis-Related Interstitial Lung Disease\n",
      "Subtypes of Scleroderma Lung Involvement Associated with Burden of Disease and Outcomes\n",
      "Reliability of Traditional Cardiovascular Risk Calculators in Predicting Risk of Cardiovascular Disease in Systemic Sclerosis\n",
      "Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial\n",
      "Serum Interferon Chemokine Score Predicts Better Response to Immunosuppression in Systemic Sclerosis Related Interstitial Lung Disease\n",
      "Frequency and Predictors of Meaningful Decline in Forced Vital Capacity During Follow up оf a Large Cohort of Systemic Sclerosis Associated Pulmonary Fibrosis Patients\n",
      "Clinical Outcomes of Patients with Giant Cell Arteritis with Polymyalgia Symptoms Only vs Cranial Symptoms Only Treated with Tocilizumab or Placebo in a Randomized Clinical Trial\n",
      "Ustekinumab for the Treatment of Giant Cell Arteritis\n",
      "Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial\n",
      "Different Patterns and Specific Outcomes of Large-Vessel Involvements in Giant Cell Arteritis\n",
      "Risk Factors for Treatment Failure in Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone versus Prednisone Alone\n",
      "Resolution of Vascular Inflammation in Patients with Giant Cell Arteritis Receiving Glucocorticoids, Methotrexate or Tocilizumab Treatment: Data from the Italian/German RIGA Study\n",
      "Patients and Relatives Coping with Inflammatory Arthritis: Impact of Communication, Social Support and Relatives Burden on Patients Perceived Health\n",
      "Predictors of Mortality Among Black Women with Systemic Lupus Erythematosus: The Black Women’s Experiences Living with Lupus (BeWELL) Study\n",
      "The Contribution of Disease Activity, Depression, and Anxiety to Health-Related and Non-Health-Related Quality of Life in US and Filipino Patients with SLE\n",
      "Physical Inactivity Is a Risk Factor for Incident Depression in Systemic Lupus Erythematosus\n",
      "Does Cartilage Loss Cause Pain in Osteoarthritis?\n",
      "A National Needs Assessment of Males with SLE: Assessing Medical, Psychosocial, Support & Coping Needs\n",
      "Racial Disparities in Septic and Aseptic Total Knee Replacement Revision Risk: A Study Using Four State-wide Inpatient Databases\n",
      "Cost-related Prescription Non-adherence Is Associated with Patient-reported Outcomes of Systemic Lupus Erythematosus Activity and Damage: The Michigan Lupus Epidemiology & Surveillance (MILES) Cohort\n",
      "Needs Assessment of Rheumatology Fellowship Program Directors on the Need for a Health Disparities Curriculum for Our Fellowship Programs\n",
      "The Association of Discrimination and Stress on Cardiovascular Disease in a Population-Based Cohort with Systemic Lupus Erythematosus\n",
      "Community-level Deprivation Index: Impact on Discharge Destination After Elective Hip Replacement\n",
      "Racial Differences in Highly Effective Contraceptive Use Among Medicaid Beneficiaries with SLE\n",
      "The Utility of Fat Lesions in Close Relation to Other Structural MRI Lesions in the Sacroiliac Joints for Diagnosing Patients with Axial Spondyloarthritis\n",
      "Evaluating the OMERACT Definitions of Ultrasound Gout Structural Lesions in the Diagnosis of Gout\n",
      "Tenosynovial Aspiration by Ultrasound Guidance: Correlation and Diagnostic Implications of Tenosynovial Analysis and Ultrasound Doppler Signal\n",
      "High-resolution MRI Assessment of Flexor Tendon Pulleys in Psoriatic Arthritis for Disease Monitoring and Differentiation from Rheumatoid Arthritis Using a 16-channel Hand Coil\n",
      "Beta-2-Glycoprotein-I IgA Antibodies Predict Coronary Plaque Burden, Progression and Moderate the Effect of Inflammation on Atherosclerosis in Rheumatoid Arthritis\n",
      "Joint Tenderness and Ultrasound Inflammation in DMARD-naïve Early Rheumatoid Arthritis Patients\n",
      "Using Electronic Visits (E-Visits) to Achieve Goal Serum Urate Levels in Patients with Gout in a Rheumatology Practice: A Pilot Study\n",
      "Use of a Novel Electronic Auto-notification Process to Manage Transitions of Care in Rheumatic Patients on DMARD Therapy\n",
      "Treat to Target Opportunities – Design, Testing, and Adoption of a Novel EHR-Integrated Electronic System to Engage Rheumatologists and Capture Decision Making\n",
      "Improving Pneumococcal Vaccination Rates in High Risk Rheumatology Patients\n",
      "Gaps in Care for Patients with SLE: Data from the ACR’s RISE Registry\n",
      "Improving Lupus Care Index Documentation in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)\n",
      "Gene Expression Meta-Analysis Reveals Commonalities in Gene Activation and Enrichment of Immune Pathways and Cell Types in Dermatomyositis Target Tissues\n",
      "Body Composition in Myositis Patients Is Negatively Changed Compared to Healthy Controls and the Changes Are Associated with Disease Activity and Duration, Skeletal Muscle Involvement and Physical Activity and Nutritional Status\n",
      "Clinical Correlations of Autoantibodies Against Heat Shock Cognate 71 kDa Protein in Patients with Juvenile Dermatomyositis\n",
      "Myeloid Dendritic Cells (mDCs) Are Major Producers of Interferon-β in Dermatomyositis and Higher Numbers of mDCs Are Found in Hydroxychloroquine Nonresponders\n",
      "NMR-Based Serum, Urine and Muscle Metabolomics in Inflammatory Myositis for Diagnosis and Activity Assessment: Serum Metabolomics Can Differentiate Active from Inactive Myositis\n",
      "Myositis-Specific Antibodies and Muscle Histopathology in Juvenile Dermatomyositis: New Insights into the Mechanism of Injury\n",
      "Worsening Trends in Osteoporosis Management in the Medicare Population: 2010-2014\n",
      "Geisinger HiROC Performance 2017-2018: Continuing to Narrow the Post-Fracture Treatment Gap\n",
      "Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results from the FRAME Clinical Trial\n",
      "Subject Characteristics and Changes in Bone Mineral Density After Transitioning from Denosumab to Alendronate in the Denosumab Adherence Preference Satisfaction (DAPS) Study\n",
      "Effect of Discontinuation of Denosumab in Subjects with Rheumatoid Arthritis Treated with Glucocorticoids\n",
      "Romosozumab Improves Lumbar Spine Bone Mineral Density and Bone Strength Greater Than Alendronate as Assessed by Quantitative Computed Tomography and Finite Element Analysis in the ARCH Trial\n",
      "Quantifying the Placebo Effect After Intra-Articular Injections: Implications for Trials and Practice\n",
      "The Relation of Pain Sensitization and Conditioned Pain Modulation to Pain Patterns in Knee Osteoarthritis: The Multicenter Osteoarthritis Study\n",
      "Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials\n",
      "Association of Pain Centralization with DMARD Response in Active RA\n",
      "Anti-CCP Antibody and Pain Sensitization in Rheumatoid Arthritis\n",
      "Elucidating Pain Mechanisms in Polyarticular Juvenile Idiopathic Arthritis Patients\n",
      "Autoantibodies to Malondialdehyde-acetaldehyde Preceding the Diagnosis of Rheumatoid Arthritis\n",
      "A Search to the Target Tissue in Which RA-specific Inflammation Starts: A Detailed MRI Study to Improve Identification of RA-specific Features in the Phase of Clinically Suspect Arthralgia\n",
      "Antibody Systems Targeting Citrullinated, Carbamylated, and Peptidyl Arginine Deaminase Autoantigens Distinguish Rheumatoid Arthritis in Combination with Rheumatoid Factors\n",
      "Anti-Mitochondrial Antibodies Predict Severe Erosive Disease in Rheumatoid Arthritis\n",
      "Serum Calprotectin Is a Prognostic Marker for Drug-Free Remission in RA\n",
      "Biomarkers of Clinical Relapse and Radiological Progression in Patients with Rheumatoid Arthritis in Remission: Observational Study of 5 Years of Follow-up\n",
      "Methotrexate Adverse Events in a Randomized Double-Blind Placebo-Controlled Trial:Results from the Cardiovascular Inflammation Reduction Trial (CIRT)\n",
      "Hydroxychloroquine Use Is Associated with a Lower Risk of Major Adverse Cardiovascular Events in Medicare Recipients with Rheumatoid Arthritis\n",
      "Association Between Rheumatoid Arthritis Treatment and the Risk of Death or Readmission After Major Surgery\n",
      "Statin Exposure Moderates the Effects of Chronic Inflammation on Coronary Atherosclerosis Progression and Cardiovascular Events in Rheumatoid Arthritis\n",
      "Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Initiating Biologic and Non-biologic DMARDs, a Population-based Study\n",
      "Biologics Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Non-calcified Coronary Plaque Progression and Stabilizing Vulnerable Plaques\n",
      "Breastfeeding in Women with Rheumatic Diseases\n",
      "Sexual Function and Health-related Quality of Life in Male Patients with Systemic Lupus Erythematosus, the Untold Story\n",
      "Rheumatoid Arthritis in Pregnancy and Offspring School Performance. a Danish Nationwide Register-Based Study\n",
      "sFlt-1, PlGF and VEGF in the Differential Diagnosis Between Active SLE Nephritis During Pregnancy and Preeclampsia\n",
      "Assessing Commercial Titers of anti-Ro60 and Ro52 Antibodies to Risk Stratify Surveillance of Anti-Ro/SSA Antibody Positive Pregnancies\n",
      "Serious Infections in Offspring Exposed in Utero to Non-TNFi Biologics and Tofacitinib\n",
      "Systems Biology in 874 Patients with Primary Sjögren’s Syndrome Indicates the Predominant Role of Interferon Alpha Compared to Interferon Gamma, Its Association with Systemic Complications, and a New Aspect of the Genetic Contribution of HLA\n",
      "BTK Overexpression Is Associated with the Risk of Lymphoma in Primary Sjögren’s Syndrome: Data from Whole Blood Transcriptome of 346 Patients Followed-up Prospectively for 10 Years\n",
      "IL-6 Receptor Inhibition in Primary Sjögren Syndrome : Results from a Randomized Multicenter Academic Double Blind Placebo-controlled Trial of Tocilizumab in 110 Patients\n",
      "Sicca/Sjögren Syndrome Triggered by PD-1/PD-L1 Checkpoint Inhibitors: Data from the International ImmunoCancer Registry (ICIR)\n",
      "Using Multi-modal Ultrasound to Assess Disease Activity Within the Salivary Glands of Patients with Primary Sjögren’s Syndrome Treated with Ianalumab (VAY736)\n",
      "Abatacept Reduces Serum CXCL13 and Disease-Relevant Immune Cell Phenotypes in a Double-Blind, Placebo-Controlled Primary Sjögren’s Syndrome Clinical Trial\n",
      "Increased Risk of Progression to Lupus Nephritis for Lupus Patients with Elevated Interferon Signature\n",
      "Validation of a Serologic Antibody Biomarker Against a Candidate Gut Pathobiont for the Diagnosis of Lupus Nephritis\n",
      "Reduced DNASE1L3 Activity in Sporadic SLE Is Linked to Increased DNA Load of Microparticles, Reactivity to DNASE1L3-sensitive Antigens, and Lupus Nephritis\n",
      "Tubulointerstitial Inflammation Predicts Outcomes in Lupus Nephritis\n",
      "Urine CD163 Significantly Discriminates Active Lupus Nephritis and Strongly Correlates with Proliferative Glomerulonephritis\n",
      "Development of a Multi-Modality Imaging Approach to Evaluate Lupus Nephritis\n",
      "Preliminary Identification of Arthritis-Associated Microbiota in Experimental Spondyloarthritis\n",
      "miR-21-5p Expression as a Marker of Treatment Response in Psoriatic Arthritis Patients\n",
      "Inflammatory Processes in Experimental Spondyloarthritis Are Accompanied by Formation of Ectopic Lymphoid Structures and B Cell Lineage Alterations in the Bone Marrow\n",
      "Targeting the Oxidative Stress Pathway in Experimental Spondyloarthritis Reduces Pro-inflammatory Response in Rat Macrophages and Modulates Their Metabolic Requirements\n",
      "High Dimensional Flowcytometric Profiling Distinguishes Psoriasis and Psoriatic Arthritis\n",
      "Associations of HLA-B Alleles, Enthesitis and Peripheral Arthritis in Ankylosing Spondylitis\n",
      "School Nurse Education for Juvenile Idiopathic Arthritis\n",
      "Parent-Reported Medication Side-Effects and Their Impact on Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry\n",
      "Improvement in Hepatitis B Screening Prior to Initiation of Biologic Therapy in the Pediatric Rheumatology Clinic\n",
      "Disability and Health-Related Quality of Life Outcomes in Patients with Systemic or Polyarticular Juvenile Idiopathic Arthritis Treated with Tocilizumab in Randomized Controlled Phase 3 Trials\n",
      "Assessing Psychosocial Needs in Juvenile Dermatomyositis Patients Across the United Kingdom\n",
      "Discriminant and Predictive Ability of the Parent Version of the Juvenile Arthritis Disease Activity Score in Two Large Multination Cohorts of Patients with Juvenile Idiopathic Arthritis\n",
      "Time-trends in Opioid Use Hospitalizations in Common Musculoskeletal Conditions: Gout, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia, and Low Back Pain\n",
      "Opioid Prescription Use Among Patients with Rheumatic Disease: A Population Based Cohort Study\n",
      "National Estimates of Pain Medication Use in Patients with Osteoarthritis\n",
      "Association of Gout with Vitamin D: A Population-Based Study\n",
      "Factors in Achieving Serum Uric Acid Target and the Occurrence of Gouty Arthritis: A Cross-sectional Study Based on Japanese Health Insurance Claim Data\n",
      "Association of Traumatic Knee Injury with Knee Function, Symptoms, and Radiographic Osteoarthritis in Military Officers\n",
      "Risk of Non-vertebral Fracture in Gout Compared to Rheumatoid Arthritis\n",
      "Epidemiology of Gout in South Korea with the National Health Insurance Corporation Database\n",
      "High Dietary Sodium Intake May Be Associated with Symptomatic Knee Osteoarthritis in a Korean Population: Korean National Health and Nutrition Examination Survey, 2010-2011\n",
      "Opioids Use Among Medicare Beneficiaries with Knee Osteoarthritis: Prevalence and Correlates of Chronic Use\n",
      "Cross-sectional Associations of Multiple Joint Osteoarthritis in the Osteoarthritis Initiative\n",
      "Pharmacoepidemiology of Gout Treatment in Office-based Outpatient Care from 2009- 2016\n",
      "Usage of Predicting Out-of-Office Blood Pressure Calculator in Hispanic Patients with Rheumatic Diseases\n",
      "The Current State of Big Data Use and Artificial Intelligence in RMDs: A Systematic Literature Review Informing EULAR Recommendations\n",
      "Association of Periodontitis with Rheumatological Disorders: NHANES III Analysis\n",
      "Arthritis, Physical Function, and Disability Among Older Mexican Americans over 20-Years of Follow-up\n",
      "Arthritis, Upper-Lower Extremity Functional Limitations, and Disability in American Older Adults: Findings from the National Health and Aging Trends Study (NHATS)\n",
      "Evaluation of Methods to Account for Differential Follow-up When Comparing Clinical Trial Data to Observational Data\n",
      "Association Between Anemia and Hyperuricemia: Korean National Health and Nutrition Survey 2016-2017\n",
      "Clinical, Serologic and Morphologic Features of Interstitial Pneumonia with Autoimmune Features (IPAF): A Single Center Experience\n",
      "Comparison of Medication New User Definitions in Multi-Specialty EMR Data\n",
      "Body Mass Index and Systemic Corticosteroid Use as Indicators of Disease Burden and Their Influence on the Safety Profile of Certolizumab Pegol Across Indications\n",
      "Alcohol Consumption Is Not an Independent Predictor of Fatigue Severity over Time\n",
      "Co-morbidities in Patients with OA and RA: Results from a Large US Rheumatic Disease Registry\n",
      "The Prevalence of 78 Autoimmune Diseases in Catalonia (MASCAT-PADRIS Big Data Project)\n",
      "Prevalence of Thyroid Dysfunction with Therapeutic Indication in Patients with Rheumatological Diseases\n",
      "The Association of Serum Uric Acid Levels and the Risk of Lower Urinary Tract Symptoms in Korean Healthy Adults\n",
      "Automated Diagnosis Extraction from Electronic Medical Records with Machine Learning Classifiers\n",
      "Cross-sectional Study and Mendelian Randomization Analysis of Diet in Six Prevalent Autoimmune Diseases\n",
      "The Opioid Epidemic: The Rheumatology Response to Management of Chronic Pain\n",
      "Population Impact Attributable to Modifiable Risk Factors for Hyperuricemia and the Fallacy of the Variance Explained\n",
      "Transitions in Lumbar Spine Osteoarthritis: The Johnston County Osteoarthritis Project\n",
      "Impact of Eliminating the Bouted Minutes Requirement in the New 2018 Physical Activity Guidelines for Americans on Gender Disparity in Guideline Attainment for Persons with or at High Risk of Knee Osteoarthritis\n",
      "It Starts at Work: The Relationship Between Workplace Supports and Presenteeism Among Young Adults with Rheumatic Disease\n",
      "The Health-promoting Potential of Everyday Activities: Preliminary Results from an Exploratory Study of Adults with and Without Inflammatory Arthritis\n",
      "Activity in Work and Life: The Association Between Physical Activity and Employment Status with Future Slow Walking in Knee Osteoarthritis\n",
      "Understanding Knee Function and Symptom Management in Individuals with Risk Factors for Knee Osteoarthritis\n",
      "Why so Fast? A Focus on Reasons for an Increase in Arthritis-Attributable Activity Limitation Trends, 2002-2017\n",
      "Too Soon to Say: Promising Results from a Community-Delivered RCT Examining Work-Related Outcomes of the Chronic Disease Self-Management Program\n",
      "Arthritis-Attributable Work Limitation Variation by U.S. County Classifications and Selected Characteristics, 2017\n",
      "Prevalence of Corticosteroid Use in Incidental Vertebral or Hip Fractures\n",
      "When It Just Won’t Stop: Chronic Pain and High Impact Chronic Pain Among U.S. Adults with Arthritis\n",
      "Restricting Activity to Evade Knee Symptoms Is Associated with Worse Physical Function and Radiographic Osteoarthritis\n",
      "Differences in Stepping and Standing Based on Self-reported Exercise Identity in Persons Following Total Knee Replacement\n",
      "Characterization of DOCK8 as a Novel Gene Associated with Macrophage Activation Syndrome\n",
      "Role of Mitochondrial DNA from OA Patients in Cellular Apoptosis, Senescence and Autophagy\n",
      "Identification of Immunological Processes Associated with the Response to Abatacept in Rheumatoid Arthritis Using Longitudinal Blood RNA-seq Analysis\n",
      "Identification and Validation of Transcriptional Genes Associated with Osteoporotic Vertebral Fractures by Microarray Study, in Community Elderly Women\n",
      "Analysis of Lupus Nephritis Gene Expression Reveals Dysregulation of Pathogenic Pathways Activated Within Infiltrating Cells\n",
      "Comprehensive Characterization of the Immune Infiltrate of Skin Biopsies from Cutaneous Lupus Erythematosus Patients Using Single Cell RNAseq\n",
      "Genetic Evidence for Recent Positive Selection of the HLA-B*51:01 Allele in the Turkish Population, a Population with a High Prevalence of HLA-B*51-Associated Behçet’s Disease\n",
      "Tumorigenesis Related Gene Identification in Dermatomyositis Using Meta-Analysis\n",
      "Tripartite Motif (TRIM) Gene Family Expression in Dermatomyositis\n",
      "Multi-Organ System Meta-Analytic Approach to Investigating Sarcoidosis\n",
      "The Expression of the Interferon Inducible Gene SERPING1 Is Reduced by Rituximab and Correlates with Clinical Response in Systemic Lupus Erythematosus\n",
      "Mononuclear Leukocyte DNA Methylome Imprinting of Networked Signaling and Immunity Regulatory Pathways in Gout\n",
      "The Pre-pregnancy Rheumatoid Arthritis Gene Expression Signature Correlates with Improvement or Worsening of Disease Activity During Pregnancy: A Pilot Study\n",
      "Analysis of Discoid Lupus Erythematosus (DLE) Gene Expression Reveals Dysregulation of Pathogenic Pathways Associated with Infiltrating Immune/Inflammatory Cells\n",
      "Investigating the Post-Partum Flare in Rheumatoid Arthritis Using Transcriptome Analysis\n",
      "Interactions Between Genome-Wide Genetic Factors and Current Smoking in Determining SLE Risk\n",
      "Genome-wide Association Study in a Japanese Population Revealed Novel Candidate Genes for Antineutrophil Cytoplasmic Antibody-associated Vasculitis\n",
      "The Emerging Regulatory Function of microRNA146a in Bone Biology and Osteoporosis\n",
      "Two Biomarkers with Predictive Capacity to Diagnosis Pre-Radiographic Knee Osteoarthritis: Data from the Osteoarthritis Initiative\n",
      "Polymorphisms in Genes Involved in Methotrexate Pathway: Predictor of Response to Methotrexate Therapy in Indian Rheumatoid Arthritis Patients\n",
      "Metabolic Regulation in Cybrids Obtained from Healthy and Osteoarthritic (OA) Patients: Impaired Metabolic Flexibility in OA Process\n",
      "Integrating Genetic Risk Scores and Pre-Diagnostic Metabolomics to Infer Dysregulated Mechanisms in Rheumatoid Arthritis in Women\n",
      "The Mechanism of DC-STAMP-Mediated Signaling in Cell-Cell Fusion and Osteoclast Maturation\n",
      "The p.R321C Mutation in P62 Associated with Paget’s Disease of Bone Leads to a Change of Localization of the Protein in Human Osteoclasts\n",
      "Apolipoprotein L1 Variant-Carrying Monocytes Exhibit Mitochondrial Respiration Defects\n",
      "Transcriptomic Responses in CD4+ T Cells During Successful Therapy for Juvenile Idiopathic Arthritis\n",
      "Genes Associated with Nucleotide Oligomerization Domain-Like Receptor Signaling Pathway Are Upregulated in Discoid Lupus Erythematosus\n",
      "Estimating the Infiltration of Immune Cells in Synovium of Rheumatoid Arthritis Compared to Osteoarthritis and Healthy Control Using Transcriptomic Profiling\n",
      "Association of Functional (GA)n Microsatellite Polymorphism in the FLI1 Gene with Susceptibility to Human Systemic Sclerosis\n",
      "Association of TERT and DSP Polymorphisms with Susceptibility to Myeloperoxidase-ANCA-Associated Vasculitis\n",
      "Characterizing Arthritis Related to Immune Checkpoint Inhibitors Using Synovial Fluid and Matched Blood\n",
      "Aggregation of Functional Variants in NOTCH4 Gene Increases SSc Risk\n",
      "Contribution of MOCS on Xanthinuria Type III and Its Clinical Significance for Screening\n",
      "Pleiotropy of Systemic Lupus Erythematosus (SLE) Risk Alleles: Association with Increased Risk for Type 1 Diabetes (T1D) Complications Through a PTPN22 Polymorphism\n",
      "Pleiotropy of Genetic Predisposition to Rheumatoid Arthritis Increases the Risk for Autoimmune Disease\n",
      "Mitochondrial DNA Sub-haplogroup H1 Influences the Risk of Rapidly Progressive Osteoarthritis of the Knee: Data from the Osteoarthritis Initiative\n",
      "Whole Transcriptome Analysis Maps Proinflammatory and Procoagulant Pathways in aPL Treated HUVECs\n",
      "Combining Clinical and Candidate Gene Data into a Risk Score for Azathioprine-Associated Leukopenia in Routine Clinical Practice\n",
      "A Role for Microbiota in the Pathophysiology of Takayasu Arteritis (TAK) and Giant Cell Arteritis (GCA)\n",
      "Determining a Polygenic Risk Score in Pediatric Systemic Lupus Erythematosus\n",
      "A Genome-Wide Association Study of Copy Number Variations Identifies the Deletion Associated with Efficacy of TNF-Alpha Blocker Therapy in Korean Patients with Rheumatoid Arthritis\n",
      "The High Dose Influenza Vaccine Increases Immune Protection in Both Adults and Elderly Seropositive RA Patients\n",
      "Efficacy and Safety of the Adjuvanted Recombinant Zoster Vaccine in Adults with Pre-existing Potential Immune Mediated Diseases: A Pooled Post-hoc Analysis on Two Parallel Randomized Trials\n",
      "Safety of Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su, Shingrix) Among Patients with Autoimmune Inflammatory Diseases\n",
      "Evaluation of Influenza and Pneumococcal Vaccination Rate in Patients with Rheumatoid Arthritis and Spondyloarthritis, and the Attitudes of Rheumatologists About Vaccination\n",
      "A Quality Improvement Intervention to Improve Influenza and Pneumococcal Vaccination Rates in Immunosuppressed Inflammatory Arthritis Outpatients\n",
      "An Intervention Bundle Increases Uptake of Influenza Vaccine by Rheumatoid Arthritis Patients\n",
      "Tuberculin Skin Test and Quantiferon®-TB Gold In-Tube Test for Latent Tuberculosis Before Biologic Treatments: Lower Agreement Rate in Spondyloarthropathies Compared to Rheumatoid Arthritis\n",
      "Distinctive Pattern of LTBI Screening Parameters in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) in Endemic Areas\n",
      "Comparison of Single and Dual Latent Tuberculosis Screening Strategies Before the Initiation of Biologic and Targeted Therapy in Rheumatological Patients in Hong Kong\n",
      "Screening for Hepatitis B Surface Antigen and Core Antibody Prior to Administration of Rituximab in Rheumatology Patients\n",
      "Hepatitis C Affects More Than Just the Liver: A Retrospective Chart Review on the Prevalence of Connective Tissue Diseases and Autoantibodies in Hepatitis C Virus Infections in an Academic Rheumatology Clinic\n",
      "First-line Antiretroviral Therapy with Tenofovir Produces Deleterious Effects on Bone and an Increase in Proinflammatory Cytokines Expression After 12 Months of Treatment in Naïve HIV Patients\n",
      "Anti-TNF Therapy in Patients with HIV Infection\n",
      "Vasculitis in HIV-Infected Individuals: Making the Case for an Antigen Driven Process\n",
      "The Comparative Efficacy of Pneumocystis Pneumonia Prophylactic Regimens in Patients with Connective Tissue Diseases Receiving Prolonged High-dose Glucocorticoids\n",
      "Features of Pneumocystis Jirovecii Pneumonia in Juvenile Idiopathic Inflammatory Myopathy\n",
      "Comparison of the Management and Prognosis of Pneumonia in Patients with and Those Without Rheumatoid Arthritis Using the Japanese Diagnosis Procedure Combination Database\n",
      "Risk Factors for Pulmonary Nontuberculous Mycobacterial Disease in Rheumatoid Arthritis Patients\n",
      "Are Immunosuppressants a Risk Factor Associated with Mycobacterium Tuberculosis Infection in Colombian Patients with Systemic Lupus Erythematosus? A Case-control Study\n",
      "Invasive Aspergillosis in Rheumatologic Patients in Tertiary Care Hospital in Mexico\n",
      "Symptomatic Coccidioidomycosis Infections in Patients on Biologic Therapies\n",
      "Real Life Serious Infections in Patients with Chronic Inflammatory Arthritis on Treatment with TNF Inhibitors\n",
      "Biological Therapy Is Associated with Faster Recovery and Lower Frequency of Switch Treatment in Patients with Chikungunya Fever\n",
      "Risk Factors for Cytomegalovirus Infection in Patients with Autoimmune Diseases\n",
      "BK Polyomavirus Viremia and Viruria in Patients with Autoimmune Connective Tissue Diseases: Impact of Immunosuppressants\n",
      "Serious Infection in Patients with Systemic Lupus Erythematosus, Lupus Nephritis and Rheumatoid Arthritis Compared to the General Population: Incidence Rates Using Real-World Claims Data\n",
      "Impact of Tapering Targeted Therapies (bDMARDs or Jakinibs) on the Risk of Adverse Events of Special Interest in Patients with Rheumatoid Arthritis or Spondyloarthritis: A Systematic Analysis of the Literature and Meta-analysis\n",
      "Efficacy and Safety of Tocilizumab Treatment for Anti–human T Lymphotropic Virus Type I Antibody–positive Rheumatoid Arthritis\n",
      "Impact of Day of Admission and Time to Diagnostic Arthrocentesis on Mortality and Other Outcomes in Septic Arthritis: A Nationwide Analysis\n",
      "No Evidence of an Increased Risk of Serious Infections Among 3 Classes of Biologics for Psoriasis or Psoriatic Arthritis: A Retrospective Real-World Cohort Study\n",
      "Hospitalization Trends for Bacterial Septic Arthritis in the United States from 1997 to 2014\n",
      "Outcomes and Risk Factors in Septic Arthritis with Underlying Rheumatic Conditions\n",
      "Clinical Features of Prosthetic Joint Infections in Patients with Rheumatic Diseases vs Osteoarthritis\n",
      "Screening and Follow-up of Patients with Rheumatic Diseases and Rheumatological Treatments Infected with Trypanosoma Cruzi (American Trypanosomiasis or Chagas’ Disease). Is It Possible a Reactivation?\n",
      "Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up\n",
      "Combined Detection of Cytokines and Biomarkers Improve the Diagnostic Performance of Bacteria Infection in Rheumatoid Arthritis\n",
      "Diagnosis of Inflammatory Rheumatic Diseases: Preliminary Approach by Urine Metabolomics\n",
      "Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study\n",
      "Multiple Industrial Air Pollutants and Anti-Citrullinated Protein Antibody Positivity\n",
      "NYX-2925 Impacts Functional and Chemical Neuroimaging Biomarkers and Patient-reported Outcomes of Pain in Patients with Fibromyalgia\n",
      "Cardiovascular Disease Risk in Calcium Pyrophosphate Deposition Disease\n",
      "Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA\n",
      "Interferon-gamma (IFN-γ) Neutralization with Emapalumab and Time to Response in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (s-JIA) who failed High-Dose Glucocorticoids\n",
      "A Serum Proteomic Signature Defines Transition from the Preclinical State to Rheumatoid Arthritis\n",
      "Tapering of Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis Patients in Sustained Remission: Results from a Randomized Controlled Trial\n",
      "A Multicenter Randomized Study in Early Rheumatoid Arthritis to Compare Active Conventional Therapy versus Three Biological Treatments: 24 Week Efficacy and Safety Results of the NORD-STAR Trial\n",
      "Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis\n",
      "Maintenance of Remission Following Dose De-Escalation of Abatacept in Early, MTX-Naïve, ACPA-Positive Patients with RA: Results from a Randomized Phase IIIb Study\n",
      "Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study\n",
      "Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study\n",
      "Tofacitinib as Monotherapy Following Methotrexate Withdrawal in Patients with Psoriatic Arthritis Previously Treated with Open-label Tofacitinib + Methotrexate: A Randomized, Placebo-controlled Sub-study of OPAL Balance\n",
      "Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial\n",
      "GLCCI1 Polymorphism Is Associated with Prednisone Response in Giant Cell Arteritis: A Multicenter Prospective Study\n",
      "Anti–MDA5 Antibody Positive Dermatomyositis Is Not Always Associated with Recalcitrant Lung Disease or Mortality\n",
      "Thyroperoxidase Antibodies in Patients with Positive ANA\n",
      "Enrichment of IL-17-producing CD4+ T Cells in Synovial Fluid from Patients with Arthritis After anti-CTLA-4 and anti-PD-1 Combination Therapy\n",
      "Rituximab Safety and Persistence in Patients with Systemic Autoimmune Diseases\n",
      "Complement Component 3 as Biomarker of Cardiometabolic Risk in Rheumatic Diseases: Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Systemic Lupus Erythematosus\n",
      "Acute Myocardial Infarction in Rheumatoid Arthritis, Gout, and Osteoarthritis: A Retrospective Study Using the National Inpatient Sample from 2002-2016\n",
      "Extracellular Adenosine Increases IL-6 Production by Aging Tenocytes and May Contribute to the Age-related Pattern of Polymyalgia Rheumatica\n",
      "Therapeutic Strategies and Survival in Patients with Interstitial Pneumonia with Autoimmune Features\n",
      "Cardiovascular Risk Evaluation in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Results from the “Cardiovascular Obesity and Rheumatic DISease (CORDIS)” Study Group of the Italian Society of Rheumatology\n",
      "Overall Survival in Patients with PD-1 Inhibitor-related Inflammatory Arthritis and Metastatic Melanoma\n",
      "Rheumatic Immune-related Adverse Effects from Checkpoint Inhibitor Immunotherapy in Patients with Solid Tumors in a Latin American Population\n",
      "Rheumatic Immune-Related Adverse Events Associated with Treatment with Immune Checkpoint Inhibitors: A Multicenter Study of 38 Cases\n",
      "Preexisting Autoimmune Disease and Rheumatic Immune-Related Adverse Events Associated with Cancer Immunotherapy: A Case Series from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)\n",
      "Rituximab Therapy for Interstitial Pneumonia with Autoimmune Features (IPAF): A Case Series of Nineteen Patients\n",
      "Frailty in Systemic Rheumatic Diseases: A Systematic Review\n",
      "Neuromyelitis Optica Overlaps Frequently with Systemic Rheumatic Diseases in African-Americans: Experience at a Large US Academic Medical Center\n",
      "Musculoskeletal Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy: Single Center Experience\n",
      "Long-term Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Incidence of Severe Infections Through 3 Years (148 Weeks) from 2 Phase 3 Trials\n",
      "Complications of Immune Checkpoint Inhibitor Therapy in Patients with and Without Pre-existing Rheumatologic Disease\n",
      "Musculoskeletal Ultrasound Enhances the Evaluation of Checkpoint Inhibitor Associated Musculoskeletal Immune Related Adverse Events\n",
      "Muscle Involvement Revealed by 18F-PET-CT in Polymyalgia Rheumatica\n",
      "Principal Components Analysis as a Tool to Identify Lesional Skin Patterns in Cutaneous Lupus Erythematosus\n",
      "Frequency of Polyautoimmunity in a Tertiary Hospital\n",
      "Patient Reported Outcomes and Factors Predicting Clinical Disease Activity in Patients with Immune-Checkpoint Inhibitor Inflammatory Arthritis\n",
      "Safety of Immune Checkpoint Inhibitors in Patients Treated for Cancer with Pre-existing Autoimmune Diseases\n",
      "Ocular Scleral Pathology and Relationship with Autoimmune Diseases: Study of 101 Patients from a Single Universitary Centre\n",
      "Role of Insulin Resistance and Inflammation on Resting Energy Expenditure in Patients with Rheumatoid Arthritis\n",
      "The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3-Year-Prospective Study from a Referral Center of Lung Transplantation\n",
      "Expanding the Phenotypic and Genotypic Spectrum in Yao Syndrome\n",
      "Checkpoint Inhibitor-Associated Arthritis: Phenotype, Steroid Dose, Serology and Survival\n",
      "Rheumatic Immune Related Adverse Events Associated with Cancer Immunotherapy: A Nationwide Multi-centre Canadian Cohort from the Canadian Research Group of Rheumatology in Immuno-oncology (CanRIO)\n",
      "Pachymeningitis in Rheumatic Disease\n",
      "Myopenia Is an Independent Risk Factor for Rotator Cuff Tear and Shoulder Dysfunction in Elderly People : Data from NAMGARAM Cohort\n",
      "Perioperative Glucocorticoid Management in Patients with Rheumatologic Diseases Undergoing Elective Joint Surgeries\n",
      "Characteristics of Patients with Rheumatoid Arthritis Undergoing Primary Total Joint Replacement: A 14-year Trend Analysis (2004-2017)\n",
      "Prevalence of Postoperative Anemia in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Undergoing Total Knee Arthroplasty: A Study of National Inpatient Sample 2010-2014\n",
      "Lumbar Spinal Stenosis in Patients with Wild-type Transthyretin Cardiac Amyloidosis\n",
      "Stakeholder Feedback on Novel Behavioral Intervention Targeting Comorbid Chronic Back Pain and Depression in Older Adults\n",
      "Multimodal Edema Management After Total Knee Arthroplasty: A Pilot Study\n",
      "A Randomised Controlled Clinical Trial Comparing the Effectiveness of 6 and 12 Weeks of a Shoulder Specific Exercise Programme for Patients with Rotator Cuff Related Shoulder Pain\n",
      "Early Start of Outpatient Physical Therapy After Knee Replacement Is Associated with More Objectively-measured Steps and Time Spent Upright\n",
      "Reporting of Adverse Events in Randomized Controlled Trials of Therapeutic Exercise for Knee Osteoarthritis: A Systematic Review\n",
      "Risk Factors for Poor Outcomes After Hip Fracture Patients in the Robust Elderly: Are Patient Reported Outcomes Important?\n",
      "Functional Exercise for Adults with Chronic Nonspecific Low Back Pain\n",
      "Depression of Vitamin D Levels After Adult Primary Posterior Spinal Fusion: Are We Adding Insult to Injury?\n",
      "Descriptive Analysis of Patient-Reported Home Exercise and Physical Activity and Their Associations with Patient Baseline Characteristics Following Total Knee Replacement\n",
      "Test-Retest Reliability and Validity of a Mobile Health Application to Automate the 30 Seconds Chair Stand Test – Preliminary Data to Create a Contemporary Instrument for Randomized Clinical Trials\n",
      "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of the Anti-ADAMTS-5 Nanobody®, M6495, in Healthy Male Subjects: A Phase I, Placebo-Controlled, First-in-Human Study\n",
      "A Novel Composite Score Reflecting Disease Activity Predicts Future Knee Replacements: Data from the Osteoarthritis Initiative\n",
      "Sarcopenia and the Likelihood of Incident Knee Osteoarthritis and Knee Pain Among Older Adults in the Health ABC Study\n",
      "Associations Between Baseline and Longitudinal Quantitative Joint Space Width and Incident Hip Osteoarthritis: The Johnston County Osteoarthritis Project\n",
      "Erosive Hand Osteoarthritis, Metabolic Syndrome and Knee Osteoarthritis: A Cross-sectional Study Using Data from the PROCOAC Cohort\n",
      "High Molecular Weight Intraarticular Hyaluronic Acid for the Treatment of Knee Osteoarthritis: A Network Meta-Analysis\n",
      "Natural Disease Progression in Hand Osteoarthritis: Results from a Belgian Ten-years Prospective Cohort Study\n",
      "Relation of MRI-detected Structural Damage in the Knee to Anterior Knee Pain: The MOST Study\n",
      "Relation of Intra-Articular Knee Mineralization on CT to Knee Pain in People with or at Risk of Knee Osteoarthritis\n",
      "A Flexion Contracture Is a Risk Factor for Radiographic Progression and Earlier Need for Arthroplasty in Knee Osteoarthritis: Data from the Osteoarthritis Initiative\n",
      "MRI-detected Abnormalities in Prediction Models of Incident Radiographic Knee Osteoarthritis over 10 Years of Follow-up\n",
      "What Is an Important Difference in Gait Speed in Adults with Knee Osteoarthritis?\n",
      "A Low Cartilage Formation & Repair Endotype Predicts Radiographic Progression in Symptomatic Knee Osteoarthritis Patients and Identifies Optimal Responders to a Potential OA Treatment\n",
      "The Association of Plasma Fatty Acids Levels with Hand and Knee Osteoarthritis\n",
      "Reference Curves for the Knee Injury and Osteoarthritis Outcome Score in the Middle-aged Dutch Population\n",
      "Multi-vendor Multi-site T1ρ and T2 Quantification of Knee Cartilage\n",
      "Construct Validity of OMERACT Ultrasound Knee Scores with Pain, Other Symptoms, Radiographic and MRI Findings\n",
      "Stabilization of Patellar Bone-Shape Correlates Significantly with Reduced Knee Pain Frequency After IA TPX-100 in Subjects with Bilateral Patellofemoral OA\n",
      "“If It Was Unicorn Dust I’d Have It Again.” Patient Experiences of Hip Osteoarthritis and Treatments in the Hip Injection Trial\n",
      "Surgical and Medical Weight Loss Threshold Dictates Decreases in Knee Osteoarthritis Pain but Not Reductions in Inflammatory Biomarkers\n",
      "BMI Has Minimal Effect on Reduction of Symptoms in Patients with Osteoarthritis of the Knee Treated with Diclofenac 1% Gel\n",
      "Machine Learning Defines the Relationship Between Structural Knee Osteoarthritis and Patient-Important Outcomes: An 8-year Study of 47,858 Knee MRIs from the Osteoarthritis Initiative (OAI)\n",
      "Clinically Relevant Improvements in Knee Osteoarthritis Pain with Diclofenac Sodium Gel 1%\n",
      "Severe Acute Localized Reactions Following Intra-Articular Hyaluronic Acid Injections in Knee Osteoarthritis\n",
      "Is There an Association of Serum LDL, HDL and Total Cholesterol with the Development of Knee Osteoarthritis?\n",
      "Magnetic Resonance Imaging of Knee Joint Protection Following an Intra-Articular Injection of Lipid-Based Dexamethasone Sodium Phosphate Sustained Release Formulation on Subjects with Knee Osteoarthritis\n",
      "Developing a Comprehensive Patient-Specific Disease Progression Prediction Model for Knee Osteoarthritis Using Machine/Deep Learning Methods\n",
      "Trends in Prescribing of NSAIDs and Opioids Among Osteoarthritis Patients in British Columbia, Canada, 1998-2014\n",
      "Impact of Hypothetical Changes in the Use of Analgesics on the Burden of Osteoarthritis: A Population-based Microsimulation Study\n",
      "Adenosine A2A Receptor Signals Through AMPK and SIRT1 to Increase Chondrocyte Homeostasis\n",
      "A Drug Repurposing Story: New Therapeutic Tools Ready to Block Innate Immune Responses in Osteoarthritis\n",
      "FOXO1 Is Required for Human Osteoclast Differentiation\n",
      "Mechanism of Chondroprotective Effects of 4-Methylumbelliferone and 2-Deoxyglucose\n",
      "CD39 Produced from Human Gingiva-Derived Mesenchymal Stem Cells Regulates the Balance of Osteoclasts and Osteoblasts Through Wnt / β-catenin Pathway in Osteoporosis\n",
      "Identification of Distinct Lipidomic Profiles in Synovial Membranes from Inflammatory Arthritis by Mass Spectrometry Imaging\n",
      "Protective Effects of Intra-Articular Formulated Liraglutide in Osteoarthritis: Preclinical Studies\n",
      "The Rat Homolog to FX201, a Gene Therapy in Development for the Treatment of Osteoarthritis, Demonstrates Dose-Dependent Decreases in the Severity of Cartilage and Bone Lesions Following Anterior Cruciate Ligament Transection\n",
      "Fibrates as Drugs with Senolytic and Autophagic Activity for Osteoarthritis Treatment\n",
      "Regulation of Interleukin-1β (IL-1β)-induced COX-2 Expression and IL-6 and MMP-1 Production in Human OA Synovial Fibroblasts by Guanylate Binding Protein 5\n",
      "The Synthesis of Hydrogen Sulfide Is Impaired in Osteoarthritic Chondrocytes from Diabetic Patients and in Vitro in Cells Under High Glucose Environment\n",
      "HSP90AA1, a Chaperone-mediated Autophagy Mediator, Is a Biomarker of Joint Damage in Osteoarthritis\n",
      "What Is the Pathogenic Meaning of Chondrocyte Hypertrophy in Osteoarthritis? Effect of Evc Deletion Through Hedgehog Signaling\n",
      "Disorganization of Chondrocyte Columns in the Growth Plate During Experimental Osteoarthritis in Mice\n",
      "Functional Differences Between Osteoclasts and Osteoclast-like Cells Differentiated from Peripheral Blood Mononuclear Cells in Patients with Rheumatoid Arthritis\n",
      "Senescent Synoviocytes in Knee Osteoarthritis Correlate with Disease Biomarkers, Synovitis, and Knee Pain\n",
      "Preclinical Evaluation of Targeting TGF-beta Signaling and Senescence in ex Vivo Models of Human Knee and Spine Osteoarthritis\n",
      "Alendronate-CGS21680 Conjugates Prevent Bone Erosion in a Murine Osteolysis Model but Not in A2A KO Mice\n",
      "Divergent Mononuclear Cell Participation and Cytokine Release Profiles Define Hip and Knee Osteoarthritis\n",
      "Insights into Osteoarthritis Progression by Gene Expression and miRNA Profiling of Mesenchymal Stromal Cells from Medial and Lateral Femoral Condyles\n",
      "CCN3 Regulates Macrophage Function in MSU-induced Inflammation\n",
      "Establishing an in Vitro Model of Hand Osteoarthritis by Generating Induced Pluripotent Stem Cells (iPSc) That Carry Single Nucleotide Polymorphisms Associated with Hand Osteoarthritis Risk\n",
      "Netrin-1 and Its Receptor Unc5B Mediates Tenofovir Induced Bone Loss and Dipyridamole, an Agent That Blocks Adenosine Transporter, Is Able to Modulate the Signal\n",
      "Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor\n",
      "Inhibition of CD44 Intracellular Domain Production Suppresses Bovine Articular Chondrocyte De-differentiation Induced by Excessive Mechanical Stress Loading\n",
      "Adenosine A2A Receptor (A2AR) Stimulation Mitigates Mitochondrial Inflammaging, Enhances Mitochondrial Metabolism and Reduces Reactive Oxygen Species-Mediated Mitochondrial Injury In Vitro and In Vivo in Osteoarthritis\n",
      "Inhibition of Choline Kinase Alpha Improves Synovitis and Cartilage Damage in Animal Models of Osteoarthritis\n",
      "Fragility Fractures in a Community Setting: Clinical Characteristics, Care Gaps, and Outcomes\n",
      "Dual Femur Bone Density Measurements with Novel Sonographic Approach – Radiofrequency Echographic Multi Spectrometry\n",
      "MRI-based Textural Analysis of Trabecular Bone: A Novel Method for the Opportunistic Screening of Bone Quality\n",
      "Bone Mineral Density and Microarchitecture Among Chinese Patients with Rheumatoid Arthritis\n",
      "Mediators of Bone Metabolism (DKK1, OPG, Sclerostin and RANKL) in a Cohort of Patients with Elderly-onset Arthritis\n",
      "Study of Vertebral Fracture Prevalence and Scanographic Bone Attenuation Coefficient of the First Lumbar Vertebra (SBAC-L1) in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis vs. Controls\n",
      "Relationship Between Structural Spine Involvement and the Scanographic Bone Attenuation Coefficient of L1 in a Population of 73 Patients with Ankylosing Spondylitis\n",
      "What Are the Consequences of Spinal Ankylosis on the Bone Trabecular Fragility Assessed on CT- scan in Patients with Ankylosing Spondylitis?\n",
      "Patients with Axial Spondyloarthritis Have Abnormal Microarchitecture Despite Normal Areal Bone Mineral Density and Trabecular Bone Score by DXA\n",
      "Evaluation of Factors Associated with Bone Structure in an SLE Cohort Measured by Clinical 3T MRI and DEXA\n",
      "Assessment of Bone Quality by Trabecular Bone Score (TBS) in Systemic Lupus Erythematosus Patients\n",
      "Modeling-Based Bone Formation Persists in the Femoral Neck Despite Remodeling Inhibition in Subjects Treated with Denosumab\n",
      "Bone Mineral Density of the Spine, Hip, and Distal Radius in Patients with Postmenopausal Osteoporosis\n",
      "DEXA Does Not Accurately Reflect FRAX Score in Patients with Autoimmune Disease on Corticosteroids\n",
      "1,25D3 Promotes Mineralization of Osteoblasts by Activating C/EBPβ-DKK1 Axis\n",
      "Randomized Control Study in Glucocorticoid-Induced Osteoporosis Treated with Bisphosphonate or Denosumab (GOBID)\n",
      "Abaloparatide Followed by Alendronate on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis\n",
      "Bone Metabolism Impairment in Heart Transplant: Results from a Prospective Cohort Study\n",
      "Bone Health: An Independent Predictor of Coronary Artery Disease\n",
      "Attenuated Association Between Proton Pump Inhibitor Use and Fracture Risk After Consideration of Chronic Comorbidities\n",
      "Parkinson’s Disease and Risk of Fractures : A Meta Analysis of Cohort Studies\n",
      "Systematic Osteoporosis Screening in Chronic Obtructive Pulmonary Disease (Study of Correlation Between Pulmonary Functions Tests and Bone Parameters): Emphysematous Status Is Linked to Low Bone Density and Osteoporosis\n",
      "Factors Contributing to Fracture in Pernicious Anemia Patients Presenting with Symptomatic Subacute Vertebral Compression Fractures\n",
      "Can We Predict Hypophosphatasia-Mutation Result Based on Alkaline Phosphatase Serum Levels?\n",
      "Rheumatoid Arthritis Disease Activity Is Associated with Low Femoral Neck Bone Mineral Density in a Diverse Cohort of Patients\n",
      "Differences in Fracture Risk Assessment (FRAX) and Osteoporosis Treatment Cutoffs with and Without Bone Mineral Density Are Greater in Anti-Cyclic Citrullinated Peptide Positive Rheumatoid Arthritis\n",
      "Applicability of FRAX in Clinical Practice: 10-year Results\n",
      "Improving Compliance with Screening for Osteoporosis in Elderly Women\n",
      "Results of the Implementation of a Bone Health Program in Patients with Rheumatoid Arthritis to Improve the Evaluation of Osteoporosis\n",
      "Hip Fracture Incidence in a Teaching Hospital: Intervention for the Prevention of Second Hip Fracture\n",
      "Osteoporosis Screening in a Resident-Driven Clinic of a Large Academic Hospital\n",
      "Osteoporosis Screening in African American Patients of Rheumatoid Arthritis Patients: Are We Doing Enough?\n",
      "Strength Training for People with Rheumatoid Arthritis: Barriers, Facilitators, and Tailoring Considerations\n",
      "Gathering Patients’ and Physicians’ Perceptions to Improve Outcomes in Systemic Autoimmune Myopathies\n",
      "Role of Clinical Impact, Disease-specific Knowledge and Beliefs About Medication on Therapeutic Adherence in Rheumatoid Arthritis: An Integrative Structural Equation Modeling Approach\n",
      "Reproductive Health Awareness and Needs: Assessment of Parents, Female Adolescents, and Young Adults with Pediatric Rheumatic Diseases\n",
      "Mining Social Media Data to Investigate Patient Perceptions Regarding DMARD Pharmacotherapy for Rheumatoid Arthritis\n",
      "Parent Perspectives on Addressing Emotional Health for Youth with Juvenile Myositis: A Qualitative Focus Group Study\n",
      "Evaluating Important Change in Cutaneous Disease Activity as an Efficacy Measure for Clinical Trials in Dermatomyositis\n",
      "Knowledge, Needs and Expectations Among Systemic Lupus Erythematosus: Preliminary Results from the INTEGRATE Pilot Project\n",
      "What Are the Prescribing Trends and Satisfaction Levels with Analgesics for Osteoarthritis as Reported by US Rheumatogists, Orthopaedic Surgeons, and Primary Care Physicians?\n",
      "Polymyositis (PM) and Dermatomyositis (DM) Symptom Flares and Associated Impact from the Patient Perspective\n",
      "Symptoms and Impacts in Psoriatic Arthritis: Findings from Qualitative Patient Interviews\n",
      "Patient Factors Associated with Willingness to Change Rheumatoid Arthritis Medications\n",
      "Legal Matters: Attitudes Regarding Marijuana for Medical Use Among Patients with Rheumatic and Musculoskeletal Disease\n",
      "Evaluation of Rheumatoid Arthritis Patients’ Preferences Using Discrete Choice Experiment\n",
      "Contribution of Personality Traits, Psychological Factors and Health Related Quality of Life on Medication Adherence in Patients with RA\n",
      "Understanding Vulnerabilities in Diagnosis and Care of Childhood and Adult-Onset Lupus: A Qualitative Study\n",
      "The #Worldlupusday 2019 Across Twitter: An Explorative Analysis of Spreading Concepts and Sentiment Perceptions on Social Media\n",
      "Comparing Patient and Provider Perspectives on Long Term Biologic Use and Tapering in Stable, Well-Controlled Rheumatoid Arthritis\n",
      "The Urge for Mobile Apps in Rheumatology – a German Patient Perspective\n",
      "Adherence to Subcutaneous Anti-tnf Therapies in Chronic Inflammatory Rheumatism and Therapeutic Education\n",
      "Patient Beliefs and Perceptions of Methotrexate for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis\n",
      "Patient and Clinical Characteristics Associated with Increased Willingness to Adopt RA Treatment After an Educational Intervention: An Analysis of the Confident Treatment Decisions for Living with Rheumatoid Arthritis (CONTROL-RA) Trial\n",
      "Causes of Influenza Vaccine Hesitancy in Rheumatoid Arthritis and Adults with Juvenile Idiopathic Arthritis\n",
      "Physical Challenges in RA: A Qualitative Study of an Online Patient Support Group\n",
      "Patients’ Journeys Through Giant Cell Arteritis: A Qualitative Study\n",
      "Post Traumatic Stress Disorder in Patients with Rheumatoid Arthritis\n",
      "Evaluation of Illness Perception in Systemic Sclerosis Patients with Pulmonary Involvement\n",
      "A Qualitative Study Evaluating Near-Patient Tools Including a Mobile Application for Earlier RA Referral; Potential to Reduce Chronic Disease Burden\n",
      "Prescribing Exercise: Facilitators and Barriers to the Successful Implementation of Physical Activity Guidelines in Inflammatory Arthritis\n",
      "The Effects of Message Framing on Patients’ Perceptions and Willingness to Switch to a Biosimilar\n",
      "Treatment Preferences in Patients with Axial Spondyloarthritis\n",
      "Increasing Use of Biologics over Time in the First Year After Diagnosis of Systemic JIA Among Patients Enrolled in the Childhood Arthritis & Rheumatology Research Alliance (CARRA) Registry\n",
      "Inpatient Treatment Variation in New-Onset Systemic Juvenile Idiopathic Arthritis\n",
      "Early Treatment with Anakinra in Systemic Juvenile Idiopathic Arthritis\n",
      "Long-Term Efficacy and Safety of Сanakinumab in Children with Systemic Juvenile Idiopathic Arthritis\n",
      "Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis\n",
      "Reasons for Initiation of Canakinumab of Patients with Systemic Juvenile Idiopathic Arthritis: A Retrospective Medical Chart Review from the United States\n",
      "Systemic Therapy in Children with Juvenile Idiopathic Arthritis-Associated Uveitis Immediately Following Failure of Methotrexate, Adalimumab and Infliximab\n",
      "Adalimumab Alone Is Superior to Adalimumab Plus Methotrexate in Juvenile Idiopathic Arthritis Associated Uveitis: Data from the ORCHIDEA Registry\n",
      "Frequency of Juvenile Idiopathic Arthritis (JIA) Subgroups and JIA-associated Uveitis Among JIA Patients Admitted to Referral Pediatric Rheumatology Clinics In TurkEy: A Retrospective Study, JUPITER\n",
      "Patients’ and Parents’ Perception of Disease and Its Impact on Life in Juvenile Idiopathic Arthritis: Results from Multinational Virtual Focus Groups by the OMERACT JIA Working Group\n",
      "The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Patient Characteristics, Patient Reported Outcomes and Consensus Treatment Plan Choices\n",
      "Injection Fear in Juvenile Idiopathic Arthritis Patients Using Injectable Medications\n",
      "Profiling Behavioral and Psychological Symptoms in Children with Spondyloarthritis and Polyarthritis\n",
      "Association of Body Mass Index with Juvenile Idiopathic Arthritis Disease Activity: A Portuguese and Brazilian Collaborative Analysis with Data from Reuma.pt Registry\n",
      "Improvement in Patient-Reported Outcomes in Patients Aged 2–5 Years with Polyarticular-Course JIA Treated with Subcutaneous Abatacept: 2-Year Results from a Phase III International Study\n",
      "Effect of Immunogenicity on Efficacy and Safety of Subcutaneous or Intravenous Abatacept in Pediatric Patients with Polyarticular-Course JIA: Findings from Two Phase III Trials\n",
      "Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment According the Juvenile Spondyloarthritis Disease Activity Index\n",
      "Sarilumab, a Human Monoclonal Antibody to the Interleukin-6 Receptor, in Polyarticular-course Juvenile Idiopathic Arthritis: A 12-week, Multinational, Open-label, Dose-finding Study\n",
      "Utilization of Biologic Treatments in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis\n",
      "Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry\n",
      "Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis\n",
      "Investigation of Inactive Disease Activity States Among JIA Patients in the CARRA Registry\n",
      "Incidence of Juvenile Idiopathic Arthritis in the United Kingdom: Estimates from a National Primary Care Dataset\n",
      "Long Term Outcomes of Childhood Onset Rheumatoid Arthritis\n",
      "Long-term Outcome of Juvenile-onset Psoriatic Arthritis\n",
      "A Retrospective Study Comparing Refractoriness to Biologic Disease Modifying Anti-Rheumatic Drugs in Adults with Juvenile Idiopathic Arthritis as Compared to Those with Rheumatoid Arthritis\n",
      "Predictors of Health Care Transition Practices Among North American Pediatric Rheumatology Providers\n",
      "Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution\n",
      "Subjective and Objective Dyscognition in Adolescents with Juvenile Fibromyalgia Syndrome\n",
      "The down Syndrome Arthropathy Cohort in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics, Treatment and Outcomes\n",
      "Alagille Syndrome and Chronic Arthritis: An International Case Series\n",
      "Farber Disease (Acid Ceramidase Deficiency): The First Natural History Study of This Rare Disease Involving Symptoms Which Can Mimic JIA\n",
      "Clinical Factors Distinguishing Between Pediatric Tumors with Arthritis at Onset and JIA: Preliminary Analysis of the ONCOREUM Study\n",
      "Baseline Characteristics and Quality of Life Metrics in Non-Infectious Uveitis\n",
      "The Association Between Non-restorative Sleep and Diurnal Patterns of Cognitive Function and Fatigue in People with Fibromyalgia and Matched Controls\n",
      "Preferences and Insights for Rheumatoid Arthritis Clinical Prevention Trial Participation\n",
      "Major Stressors in the Year Prior to Diagnosis Affects RA Characteristics at Presentation and 1 Year\n",
      "A Pilot Study of the Psychosocial Impact of Undifferentiated Connective Tissue Disease\n",
      "Sexual Health, Intimacy and Rheumatology Practices\n",
      "Self-reported Anxiety, Depression and Levels of Physical Activity in Patients with Adult Idiopathic Inflammatory Myopathies\n",
      "Interstitial Lung Disease Is Associated with Distinct Fine Specificities of Anti-Carbamylated Peptide/Protein Antibodies in Rheumatoid Arthritis\n",
      "The Course of Disability in Early Rheumatoid Arthritis over 10 Years of Follow-up in Women and Men – Comparison with the General Population\n",
      "Risk Factors for Transfusion and Use of Tranexemic Acid in Patients with Rheumatoid Arthritis Undergoing Total Hip Arthroplasty and Total Knee Arthroplasty\n",
      "Profile of Renal Function in Patient Suffering from Rheumatoid Arthritis\n",
      "Comparison Between Fibromyalgia and Neuropathic Pain in Patients with Established Rheumatoid Arthritis\n",
      "Emotional and Social Determinants of Health Increase Office Communication for Patients with Rheumatoid Arthritis\n",
      "Bone Microstructure of Patients with Rheumatoid Arthritis: A HR-pQCT Study\n",
      "Multimorbidity May Worsen Fatigue in Patients with Rheumatoid Arthritis\n",
      "Prevalent and Incident Multimorbidity in Rheumatoid Arthritis: A Population-Based Cohort Study\n",
      "Intermetatarsal Bursitis Is Prevalent in Patients with Established Rheumatoid Arthritis and Is Associated with Anti-CCP and RF\n",
      "The Interaction Between Human Leukocyte Antigen Class II Alleles and Seroprotection to Seasonal Influenza Vaccination in Patients with Rheumatoid Arthritis: A post-hoc Analysis\n",
      "Clinical Study of Peripheral Blood Lymphocyte Subsets in Patients with Rheumatoid Arthritis Complicated with Osteoporosis\n",
      "Determinants of Cognitive Function in Rheumatoid Arthritis (RA) Patients\n",
      "Association of Sexual Dysfunction and Depression in Rheumatoid Arthritis Female Patients\n",
      "Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis: Results from Japanese Multi-institutional Study Using Research Electronic Data Capture\n",
      "Patients with Rheumatoid Arthritis Have a Higher Risk of Bipolar Disorder: A Systematic Review and Meta-analysis\n",
      "Improved Anxiety, Depression, and Emotional Distress for Rheumatoid Arthritis Patients Following the Completion of an Online Mental Health Intervention\n",
      "Association of Rheumatic Autoimmune Disease, Including Rheumatoid Arthritis, with Post-Traumatic Stress Disorder but Not Traumatic Brain Injury in Veterans\n",
      "National Trends in Hospitalizations and Mortality for Acute Myocardial Infarction in Patients with Rheumatoid Arthritis: Data from National Inpatient Sample 2010-2014\n",
      "Gut Dysbiosis Is Associated with Measures of Early Vascular Dysfunction in Patients with Rheumatoid Arthritis\n",
      "Elevated Pro-inflammatory Lipid Mediators Associate with Low Paraoxonase 1 Activity in Patients with Rheumatoid Arthritis and Arthritic K/BxN Mice\n",
      "Are Vitamin D Metabolite Levels at Time of Diagnosis Associated with Long-term Severe Cardiovascular Events in Early Diagnosed Rheumatoid Arthritis Patients, Aggressively Treated During 10 Year Follow Up? Post-hoc Analyses of Observational Data from the CIMESTRA Cohort\n",
      "Knowledge of Cardiovascular Disease Risk Among Patients with Rheumatoid Arthritis\n",
      "Subclinical Myocardial Dysfunction Assessed by Strain Imaging in Patients with Rheumatoid Arthritis and Spondyloarthritis\n",
      "Toward Cardiovascular Risk Stratification in Rheumatoid Arthritis: Use of Regression Tree Analyses to Evaluate Impact of Serum Biomarkers and Cardiovascular Risk Factors on Carotid Intima Media Thickness\n",
      "The Association Between Disease Activity with Coronary Microvascular Dysfunction in Rheumatoid Arthritis\n",
      "Metabolic Syndrome and Early Arthritis: Frequency, Association with Antibodies Profile and Disease Activity\n",
      "High Intensity Interval Training Improves Rheumatoid Arthritis Cardiorespiratory Fitness and Systemic Inflammation in Association with Alterations in Skeletal Muscle Metabolomic Profiles\n",
      "Prognostic Markers for Preclinical Cardiovascular Disease in Rheumatoid Arthritis and Correlation with Disease Activity\n",
      "Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors and the Role of Auto-antibodies\n",
      "In Rheumatoid Arthritis, New-onset Prednisone Use Is Associated with a Daily Dose, Cumulative Dose, and Duration-dependent Risk for Cardiovascular Events at 6 Months and 1 Year of Use\n",
      "Do Myocardial Inflammation and Microvascular Dysfunction in RA Lead to Adverse Changes in Left Ventricular Structure and Function over Time? A Longitudinal Analysis of Participants from Rheumatoid Arthritis: Study of the Myocardium\n",
      "Factors Associated with Differing Types of Heart Failure in Patients with Rheumatoid Arthritis\n",
      "Association of Rheumatoid Arthritis-related Autoantibodies with Pulmonary Function Test Abnormalities in a Prospective Rheumatoid Arthritis Registry\n",
      "Cardiovascular Risk Factors in Rheumatoid Arthritis: Prevalence, Comparison of Risk Calculators and Subclinical Atherosclerosis in Indian Patients\n",
      "Risk of Incident Myocardial Infarction Among Disabled Patients with Rheumatoid Arthritis Who Were Beneficiaries of the Social Security Disability Insurance\n",
      "Is Cardiovascular Risk and Mortality in Rheumatoid Arthritis Compared to Diabetes Mellitus and the General Population Overestimated?\n",
      "Prediction of Myocardial Fibrosis in Rheumatoid Arthritis Assessed by Cardiac Magnetic Resonance Imaging Using Artificial Neural Networks Models\n",
      "Levels of Proinflammatory Cytokines in Rheumatoid Arthritis Patients with Carotid Plaque: A Case-Control Study\n",
      "Treat to Target Is Not Linked to Best Myocardial Strain Indices: Is There Really a Myocardial Dysfunction Directly Associated with Disease Activity?\n",
      "Validation of a Claims Algorithm to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis\n",
      "Exposure to Avian and Fungal Antigens in Patients with Rheumatoid Arthritis-AssociatedInterstitial Lung Disease: Something to Keep in Mind\n",
      "Treatment of Interstitial Lung Disease and Airway Disease Complicated with Rheumatoid Arthritis\n",
      "Findings of Pulmonary Abnormalities on High Resolution Computed Tomography in a Cohort of Rheumatoid Arthritis Patients Without Known Lung Disease\n",
      "Association of Serum KL-6 Level and Change of Pulmonary Function in Interstitial Lung Disease of Rheumatoid Arthritis – Data from Prospective KOrean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) Study\n",
      "Treatment with Biologic DMARDs Does Not Increase Risk of Severe Pulmonary Events in Patients with Rheumatoid Arthritis and Pre-existing Lung Disease\n",
      "Efficacy of Mycophenolate Mofetil in the Treatment of Rheumatoid Arthritis Associated Interstitial Lung Disease\n",
      "Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Retrospective Multicenter Study of 263 Patients\n",
      "Interstitial Lung Abnormalities in Rheumatoid Arthritis Patients: Identifying Associated Risk Factors\n",
      "Long-term Survival in Lung Transplantation and Allograft Rejection in Patients with Interstitial Lung Disease Related with Rheumatoid Arthritis: Study from a Single Referral Center\n",
      "KL-6 Is a Useful Marker to Monitor the Progression of RA-ILD, but Not to Diagnose or Predict the Development of ILD\n",
      "Epidemiology, Risk/Prognostic Factors, and Treatment Landscape in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Literature Review\n",
      "Derivation and Validation of a Biomarker-Based Cardiovascular Risk Prediction Score in Rheumatoid Arthritis\n",
      "Helicobacter Pylori Infection Among Korean Patients with Rheumatoid Arthritis and Its Interaction with Shared Epitope\n",
      "Gingival-Derived Mesenchymal Stem Cells Alleviate Cartilage Damage in Collagen-Induced Arthritis via Suppressing Activities of Inflamed Synovial Fibroblast\n",
      "Bromodomain Inhibitor, I-BET762 Inhibits Production of Pro-inflammatory in Rheumatoid Arthritis Fibroblast-like Synoviocytes and Differentiation of Osteoclast\n",
      "Histologic and Clinical Correlates of Ultrasound Measures of Joint Inflammation: Analysis of RA Tissue Obtained by Ultrasound Guided Biopsy in Phase 2 of the Accelerating Medicines Partnership RA Network\n",
      "Major Histocompatibility Antigen HLA-DQB1*0601 Is Associated with Rheumatoid Arthritis Among Indians in a Replication Study: Evidence of Gene-Environment Interaction with LPG Stove Use\n",
      "NADPH Oxidase 4 Regulates the Migration and Invasion of Synoviocytes in Rheumatoid Arthritis Through Pro-angiogenic Factor Secretion\n",
      "Anti-inflammatory Effect of Novel Spleen Tyrosine Kinase Inhibitor, SKI-O-592, on Fibroblast-like Synoviocyte in Rheumatoid Arthritis and THP-1 Cell\n",
      "Survivin Controls the Transcriptional Activity by Changing the Pattern of Histone H3 Marks on Chromatin\n",
      "Presence of the MerTK Receptor on Human Synovial Tissue Macrophages Lowers Inflammatory Cytokine Production and Activation of the MerTK+CD206+ Subpopulation Limits the Inflammatory Response of Synovial Fibroblasts\n",
      "Anti-Polygalacturonic Acid Antibody (PGA-Ab) Induced Bone Destruction in Rheumatoid Arthritis by Promoting Osteoclastogenesis via Integrin Beta 5\n",
      "Protein Profiling and Network Enrichment Analysis in Individuals Before and After the Onset of Rheumatoid Arthritis\n",
      "Circulating Mitochondrial Danger-Associated Molecular Patterns as Novel Biomarkers of Disease Activity and Inflammation in Rheumatoid Arthritis\n",
      "Pyruvate Kinase M2 May Contribute to the Inflammation and Joint Destruction in Rheumatoid Arthritis\n",
      "Periodontal Pockets as a Potential Source of Circulating TREM-1 and Its Ligand PGLYRP1 in Patients with Rheumatoid Arthritis\n",
      "Histone Lysine Methyltransferase MLL1 Regulates the Expression of Cytokines and Chemokines in Rheumatoid Arthritis Synovial Fibroblasts\n",
      "Biomarkers Identified by Serum Inflammatory Profile Analysis to Predict Biologic Treatment Response in Rheumatoid Arthritis Patients\n",
      "Individual Functions of Histone-acetyltransferases CBP and p300 in Regulating Autophagy and Proteasomal Degradation in Synovial Fibroblasts\n",
      "Novel Somatic Mutations Identified by Whole Genome Sequencing of Rheumatoid Arthritis (RA) Fibroblast-Like Synoviocytes (FLS)\n",
      "A Composite IFN-Based Signature Is Associated with a Filgotinib-Specific Clinical Response in bDMARD-Experienced Rheumatoid Arthritis Patients\n",
      "Increased Accumulation of Malondialdehyde-Acetaldehyde Modified HDL in Macrophage Without Decreased Cholesterol Efflux\n",
      "Loss-of-function of the DNA Repair Nuclease MRE11A Induces Mitochondrial Failure and Tissue Inflammation in Rheumatoid Arthritis\n",
      "Methotrexate Treatment Is Associated with Reduction of Neutrophil Reactive Oxygen Species and CD177 in RA Patients\n",
      "Expression of Peptidyl-arginine Deiminases in Peripheral Blood Neutrophils and Its Association with Single Nucleotide Variants in Patients with Rheumatoid Arthritis\n",
      "Beyond Genes—a Multi-omic Analysis of Monozygotic Twins Discordant for Rheumatoid Arthritis\n",
      "Elevated Serum Levels of Tie-1 in Patients with Rheumatoid Arthritis\n",
      "Tenosynovitis at the Metatarsophalangeal Joints, a Novel Feature of RA: Results from an Anatomical and Large Magnetic Resonance Imaging Study of Tendon Sheaths of the Forefoot\n",
      "Metabolic Changes Induced by Anti-Malondialdehyde Antibodies Promote Osteoclast Development\n",
      "Withdrawal of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Sarilumab Open-Label EXTEND Study: Efficacy and Safety Analysis\n",
      "Real-World Distribution of Anti-Cyclic Citrullinated Peptide Concentrations and Impact on Treatment Patterns of Patients with Rheumatoid Arthritis\n",
      "ACPA Testing and Resultant Treatment Patterns in Patients with Rheumatoid Arthritis: Findings from US Community Rheumatology Practices\n",
      "Replication of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis\n",
      "Antirheumatic Therapy Is Associated with Reduced Complement Activation in Rheumatoid Arthritis\n",
      "Antirheumatic Therapy Is Not Associated with Changes in Circulating N-terminal Pro-brain Natriuretic Peptide Levels in Patients with Active Rheumatoid Arthritis\n",
      "Methotrexate Liver Toxicity in a Large Randomized Controlled Trial\n",
      "Short-term Risk of Major Adverse Cardiovascular Events or Venous Thrombo-embolic Events in Patients with Rheumatoid Arthritis Initiating a Janus Kinase Inhibitor: A Meta-analysis of Randomised Controlled Trials\n",
      "High Body Mass Index Shortens Retention of Tumor Necrosis Factor-α Blocker Treatment in Rheumatoid Arthritis\n",
      "Safety of Biological DMARD in Patients with Interstitial Lung Disease from a Chilean Cohort of Patients with Rheumatoid Arthritis\n",
      "Early Treatment of Rheumatoid Arthritis with Disease-Modifying Anti-Rheumatic Drugs at < 3 versus 3-6 Months from Onset of Symptoms: Results from a Cohort of Hispanics from Puerto Rico\n",
      "Associations of Disease-Modifying Anti-Rheumatic Drug (DMARD) Adherence with Time to First Biologic and Cycle Time on DMARDs, and Healthcare Utilization/Cost in a New RA Patient Cohort\n",
      "Influence of the Clinical Characteristics and Different Genetic Polymorphisms Related to MTX, on the Efficacy and Safety in Patients with RA Treated with MTX in Monotherapy\n",
      "Multi-center Analyses on 518 Cases with Rheumatoid Arthritis Developing Lymphoproliferative Disorders (RA-LPD): The Prognostic Factors and the Influence of Anti-rheumatic Drugs on LPD Development\n",
      "Risk of Diabetes Treatment Switching or Intensification Associated with Use of Abatacept versus Other Biologic Drugs in Patients with Rheumatoid Arthritis and Diabetes Mellitus\n",
      "Comparison of Healthcare Resource Utilization (HCRU) and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Switch to Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs\n",
      "The Effect of DMARDs on Cardiovascular Outcomes in Rheumatoid Arthritis: A Systematic Literature Review\n",
      "Risk of Diverticulitis and Gastro-Intestinal Perforation in Rheumatoid Arthritis Treated with Tocilizumab Compared to Rituximab and Abatacept: A Prospective Propensity-matched Cohort Study\n",
      "Treatment Patterns with Disease Modifying Anti-rheumatic Drugs in United States Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis\n",
      "Discontinuation of Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis\n",
      "Risk of Malignancies Across Biologic Classes in Rheumatoid Arthritis: Analysis of a National Claim Database\n",
      "Post-Approval Comparative Safety Study of Tofacitinib and Biologic DMARDs: Five‑Year Results from a US-based Rheumatoid Arthritis Registry\n",
      "Two Decades of Changes in RA Treatment and Disease Outcomes from the United States\n",
      "MRI of the Wrist in Early Rheumatoid Arthritis After 1-year Treat-to-target Strategy\n",
      "Safety of Baricitinib Under Clinical Settings in Patients with Rheumatoid Arthritis, Using Data from All-Case Post-marketing Surveillance and Spontaneous Reports\n",
      "Modifiable Factors Associated with Response to Treatment in Early Rheumatoid Arthritis\n",
      "Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry\n",
      "Comparative Analysis of Clinical, Laboratory and Therapeutic Strategies Among Blacks with Rhupus, SLE and RA\n",
      "High Initial Methotrexate Dose Is Not Associated with an Increased Risk of Liver Toxicity in Korean Patients with Rheumatoid Arthritis\n",
      "Improving Depression by Joint Surgery in Established Rheumatoid Arthritis; Results from Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Patient’s Reported Outcome\n",
      "Baseline Characteristics Associated with Sustained SDAI Remission Following Treatment with Abatacept in Combination with MTX Compared with Abatacept Placebo in Combination with MTX in ACPA Positive Patients with Early RA\n",
      "Relationships Between DAS28 Response and Clinical, Functional and Radiographic Outcomes in Year 2 of the COMET Study of Etanercept in Patients with Rheumatoid Arthritis\n",
      "Treatment for Rheumatoid Arthritis After Methotrexate-associated Lymphoproliferative Disorder Developed\n",
      "Yoga Improves Fatigue and Mental Health in Rheumatoid Arthritis: Preliminary Results of a Randomized Controlled Trial\n",
      "Efficacy and Safety of Chinese Herbal Medicine Biqi Capsule Combined with Methotrexate in Patients with Rheumatoid Arthritis: A Pilot Study\n",
      "Consensus Statement and Recommendations on Methotrexate Use in Combined Therapy with Biological or Targeted Synthetic Disease Modifying Drugs in Patients with Rheumatoid Arthritis\n",
      "Management of Patients with Incident Rheumatoid Arthritis in Rheumatology Clinical Practice\n",
      "Patient Characteristics Associated with Long Term Glucocorticoid Use in a Commercially Insured Incident RA Cohort\n",
      "Treat to Target by Specific Cytokine Interdiction: Multiple Biomarker Disease Activity Test Deconstructed\n",
      "Prediction of Disease Relapses by Multi-biomarker Disease Activity Score and Autoantibody Status in RA Patients Tapering DMARD Treatment in Stable Remission\n",
      "Effect of Biologics on the Hemoglobin A1c in a Population of Rheumatoid Arthritis Patients\n",
      "The Effectiveness of anti-IL-6 Therapy to Elderly-onset Rheumatoid Arthritis\n",
      "Risk of Thromboembolism with Janus Kinase Inhibitors: A Systematic Review and Meta-Analysis of Randomized Placebo Controlled Trials\n",
      "Use and Influence of Biologic/Janus Kinase Monotherapy Among Recently Switched Rheumatoid Arthritis Patients: Results from an Annual National Patient Chart Audit\n",
      "DMARD-naïve Rheumatoid Arthritis (RA) Patients Have Greater RAPID3 Improvement over 6 Months After 1st Visit Than Patients Who Were Treated Previously Treated with DMARDs, Although Baseline RAPID3 Was Similar: The Importance of Early Treatment\n",
      "DNA Methylation of the Dual Specificity Phosphatase 22 (DUSP22) Gene Promoter in Plasma and Medication Use in Rheumatoid Arthritis (RA)\n",
      "Skin Lesions as a Side Effect of anti-IL6 Therapy: Transcriptome Analysis of Peripheral Blood Shows a Risk of Paradoxical Neutrophil Activation and Exacerbation of Skin Ulcer\n",
      "Prevalence of Anxiety and Depression in a Cohort of Patients with Rheumatic Diseases on Biological Infusions\n",
      "Changes in the Initial Usage Pattern of Biologic Disease-modifying Antirheumatic Drugs in Rheumatic Diseases During the past Twelve Years: A Real-world Setting Analysis\n",
      "The Effect of Co-medication with Methotrexate and Other Conventional Synthetic Disease Modifying Anti-rheumatic Drugs on First Tumor Necrosis Inhibitor Drug Survival in Patients with Rheumatoid Arthritis: Results Form a Nationwide Registry\n",
      "Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate\n",
      "Which Factors Influence Achievement of Treatment Satisfaction in Rheumatoid Arthritis?\n",
      "Adverse Events of Special Interest in Patients with Rheumatoid Arthritis Treated with Peficitinib in Asian Population: Pooled Safety Findings\n",
      "Does Combined Therapy Affects Adherence in Rheumatoid Arthritis?\n",
      "Protein Biomarkers Predicting the Response to IFX+MTX+LEF Treatment in Patients with Rheumatoid Arthritis\n",
      "Hepatobiliary Events in >5000 Patients with Inflammatory Arthritis Treated with Biosimilar or Originator Etanercept in Routine Care, Results from the Danish Nationwide DANBIO Registry\n",
      "The Safety Profile of Upadacitinib in Japanese Patients with Rheumatoid Arthritis\n",
      "A Prospective Analysis of Factors Impacting Medication Decision-Making in Patients with Rheumatoid Arthritis\n",
      "Risk of Serious Infections in Offspring According to TNFi Subtypes\n",
      "Targeted Education Improves Awareness of Reproductive Health Issues Among Women with Rheumatologic Diseases\n",
      "Effect of Race and Lupus Nephritis on Pregnancy Outcomes in Systemic Lupus Erythematosus: An Individual Participant Meta-analysis\n",
      "Impact of the Healthy Outcomes in Pregnancy with SLE Through Education of Providers (HOP-STEP) Program: A Mixed Methods Approach\n",
      "Perspectives of Female Patients with Rheumatic Diseases Regarding Pregnancy Planning with Rheumatologists\n",
      "Perspectives About Contraception Among Reproductive-Aged Women with Rheumatic Diseases\n",
      "Pregnancy in Rheumatoid Arthritis: Continue, Reduce or Stop TNF Inhibitors? A Prospective Observational Study\n",
      "Reproductive Health Intention Screening in Women with Systemic Rheumatic Diseases: Low Uptake and Gender-Specific Provider Patterns Following a Standardized Intervention\n",
      "The Vasculitis Pregnancy Registry (V-PREG): Information from the First 3 Years\n",
      "Reproductive Counseling Documentation Practices for Women Receiving Teratogenic Medications in an Academic Rheumatology Clinic Serving a Medicaid/Medicare Patient Population\n",
      "Improving Lactation Knowledge Among Providers Caring for Rheumatology Patients\n",
      "The Titer of Anti-Double Stranded DNA Antibody Could Affect the Apgar Score of Newborns, Which Is Considered as the Predictive Clinical Index for Neurological or Physical Development\n",
      "Higher Than Expected Rates of Adverse Pregnancy Outcomes in Patients with Systemic Lupus Erythematosus from Three Tertiary Care Centers\n",
      "Mobile Responsive App – Useful Additional Tool for Data Collection in the German Pregnancy Register Rhekiss?\n",
      "Combined First-Trimester Serum BAFF and sFlt-1 Levels as an Early Biomarker of Spontaneous Abortion\n",
      "Pregnancy Outcomes in Women Exposed to Golimumab\n",
      "Progesterone Decreases Gut Permeability Through Upregulating Occludin Expression in Primary Human Gut Tissues and Caco-2 Cells\n",
      "A Multicentre Study of 244 Pregnancies in Women with Undifferentiated Connective Tissue Disease: Foetal/Perinatal and Maternal Outcomes and Disease Evolution Towards a Definite Connective Tissue Disease\n",
      "Optimal Hydroxychloroquine Drug Levels in Pregnant Women with Systemic Lupus Erythematosus\n",
      "Disease Flares of Rheumatoid Arthritis During Pregnancy: What Is the Impact of Stopping bDMARDs at the Beginning of Pregnancy?\n",
      "Pregnancy in Patients with Systemic Lupus Erythematosus After Cyclophosphamide Therapy\n",
      "Contraception Documentation Rates in Women with Rheumatic Diseases on Teratogenic Medications in an Academic Rheumatology Clinic\n",
      "Burden of Systemic Lupus Erythematosus Among Korean Women in Childbearing Years Based on the National Health Insurance Service Data\n",
      "Assisted Reproductive Technology in Patients with Inflammatory and Autoimmune Rheumatic Disease\n",
      "Anti-TNF-α Exposure During Pregnancy: Impact on the Neonate’s Immune System\n",
      "24-hour Activity Profiling in People Living with Arthritis: Habits Matter\n",
      "Using External Data to Estimate Omitted Variables in Observational Data: A Plasmode Simulation Study Investigating the Relationship Between Osteoarthritis and Cardiovascular Diseases to Compare Alternative Approaches in Imputing the Body Mass Index Variable\n",
      "Casting a Wide Net: Comparing Strategies for Recruiting 18-35-year-olds with Rheumatic Disease as Study Participants\n",
      "Use of Minimal Important Difference (MID) in Randomized Clinical Trials of Pain in Osteoarthritis\n",
      "LOU064: A Highly Selective and Potent Covalent Oral BTK Inhibitor with Promising Pharmacodynamic Efficacy on B Cells for Sjoegren’s Syndrome\n",
      "Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren’s Syndrome – Open-label Extension Phase of a Randomized Controlled Phase III Trial\n",
      "Evaluation of Pharmacokinetics and Immunogenicity Following Subcutaneous Administration of Abatacept in Primary Sjogren ’s Syndrome (pSS) and RA Patients\n",
      "ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Associated with Sjögren’s Syndrome\n",
      "A Phase 2a Study of MEDI5872 (AMG557), a Fully Human Anti-ICOS Ligand Monoclonal Antibody in Patients with Primary Sjögren’s Syndrome\n",
      "Tofacitinib Inhibits Increased Inflammatory Marker Expression in a Human Salivary Cell Line Deficient in Autophagy: A Model of Sjögren’s Syndrome\n",
      "An ex-vivo Assay to Evaluate the Efficacy of Different Treatments for Inhibiting B Lymphocytes Activation by Salivary Gland Epithelial Cells in Sjögren’s Syndrome\n",
      "Role of T Follicular Helper Cells and T Peripheral Helper Cells in the Activation of B Cells in Sjögren Syndrome\n",
      "Circulating CCR7loPD-1hi Follicular Helper T Cells Indicate Disease Activity and Glandular Inflammation in Patients with Primary Sjögren’s Syndrome\n",
      "Increased Apoptosis and Compromised Suppressive Capacity of Regulatory T Cells in Primary Sjögren’s Syndrome\n",
      "In Primary Sjogren’s Syndrome (pSS) IL7 Promotes the Crosstalk Between T Lymphocytes and Salivary Gland Epithelial Cells and Participates to IFN Signature\n",
      "RORγt Antagonist Attenuates Experimental Sialadenitis Like Sjögren’s Syndrome via Inhibition of CD25 Expression on CD4+ T Cells\n",
      "The anti-Ro52 Prevalence in the Sjögren’s Syndrome Picture: A Single Center Cross Sectional Study\n",
      "Distinct Clinical Characteristics of Anti-Ro/SSA Negative Primary Sjögren’s Syndrome: Data from a Cohort for Sjögren’s Syndrome in Korea\n",
      "The Positivity for Anti-centromere Antibody Makes Distinct Clinical Features in Primary Sjogren’s Syndrome : Data from a Prospective Korean Nation-wide Cohort\n",
      "Serum Myositis Specific/associate Autoantibodies Help Identify Early Connective Tissue Diseases Relevant Interstitial Lung Diseases: A Medical Center Experience\n",
      "Zipcode-Binding Protein 1 (ZBP1) Facilitates Ro60 Surface Translocation, Cellular Growth and Autoimmune Sequelae\n",
      "Detection and Clinical Significance of Circulating M3 Muscarinic Acetylcholine Receptor Reactive Th17 Cells in Patients with Primary Sjögren’s Syndrome\n",
      "Extracellular Vesicles in Primary Sjögren’s Syndrome: A Promising Source for Novel Proteomic Biomarkers\n",
      "Thymic Stromal Lymphopoietin (TSLP) as a Biomarker of Primary Sjögren’s Syndrome (pSS) and Related Lymphoma: Results in Independent Cohorts\n",
      "Fatigue in Primary Sjögren’s Syndrome as a Manifestation of Heavier Disease Activity of Mucosa-Associated Lymphoid Tissue (MALT)\n",
      "Risk of Lymphoma and Thyroid Cancer in Primary Sjögren’s Syndrome Measured Using the Korean Health Insurance Claims Database\n",
      "Data Driven Prediction Lymphoma Model and 10-year Overall Survival Rates of a Large Harmonized Cohort of Patients with Primary Sjögren’s Syndrome Associated Lymphomas\n",
      "The Salivary Glands as the Key Site of Inflammation and Lymphoproliferation Leading to Lymphoma in Primary Sjögren’s Syndrome: Relevance for Dedicated Scoring, Biomarker Development and Lymphoma Prevention\n",
      "Autoantibodies from Sjögren’s Syndrome Enhance NLRP3 Inflammasome Activation and IL-18 Production in Human Salivary Gland Cell Line A-253\n",
      "Autoantibody Mediated Salivary Gland Hypofunction in Sjögren’s Syndrome Involves Activation of Innate Immunity and Endothelial Cells\n",
      "Development of a Biomarker Panel for Prediction of Disease Flares in Systemic Lupus Erythematosus\n",
      "Hydroxychloroquine Is a Modifiable Predictor of Durable LLDAS\n",
      "Time to Lupus Low Disease Activity State: Role of African-American Ethnicity\n",
      "Cenerimod, a Potent, Selective and Orally Active Sphingosine 1-phosphate Receptor 1 Modulator, Reduced Blood Antibody-secreting Cells in Patients with SLE\n",
      "Treatment of SLE Patients with the Immunoproteasome Inhibitor KZR-616: Results from the First 3 Cohorts of an Open-Label Phase 1b Dose Escalation Trial\n",
      "Rituximab Treatment Is Not Associated with Increased Risk of Infection or Mortality in Refractory SLE Patients: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)\n",
      "Frequency and Early Prediction of Hydroxychloroquine Induced Retinopathy in SLE\n",
      "Contemporary Prescription Opioid Use and Predictors Among Patients with Systemic Lupus Erythematosus\n",
      "24-Month Outcomes Associated with Belimumab in Black/African-American Patients with Systemic Lupus Erythematosus in a Clinical Practice Setting in the United States\n",
      "Within-Trial Cost Analysis of Flares from a Phase 3 Clinical Trial Evaluating Subcutaneous Belimumab for the Treatment of Systemic Lupus Erythematosus\n",
      "Antimalarial Agents Improve Physical Functioning in Patients with Systemic Lupus Erythematosus\n",
      "Cytokine and Autoantibody Profiles During Treatment with Belimumab in Patients with Systemic Lupus Erythematosus\n",
      "Effect of Additional Administration of HCQ on Pro-inflammatory Cytokine Expression, Especially in Lupus Nephritis\n",
      "Safety of Chloroquine and Hydroxychloroquine During Pregnancy: A Systematic Review and Meta-Analysis\n",
      "Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of KZR-616, a Selective Inhibitor of the Immunoproteasome\n",
      "Low Vitamin D Is Associated with Miscarriage and Preterm Birth in SLE with a U-shaped Relationship\n",
      "Effect of Treatment on Antiphospholipid Antibodies in SLE\n",
      "Hydroxychloroquine Increases Low C3 in SLE\n",
      "Vitamin D Reduces Cardiovascular Risk Factors in SLE\n",
      "Identifying Subgroups of SLE Patients with Differential Responses to a BLyS Inhibitor: Application of a Machine Learning Algorithm to Clinical Trial Data\n",
      "Distribution and Predictors of Whole Blood Hydroxychloroquine Levels in Clinical Rheumatology Practices in the United States\n",
      "Influential Factors in Promoting Treat-to-Target for Systemic Lupus Erythematosus via Empowering Patients: A Cohort Study from China by Smart System of Disease Management (SSDM)\n",
      "Importance of Serum Phosphatidylserine-Specific Phospholipase A1 (PS-PLA1) as a Novel Disease Activity Biomarker of Systemic Lupus Erythematous\n",
      "Patient Perception of Benefit and Risks Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus (SLE)\n",
      "Impact of IL34, IFN-α and IFN-λ1 on Disease Activity of SLE Patients in Egypt\n",
      "Pharmacokinetics of Hydroxychloroquine in Systemic Lupus Erythematosus Patients with Renal Impairment\n",
      "An Updated Meta-Analysis of the Efficacy and Safety of Mycophenolate Mofetil in the Induction Treatment of Chinese Patients with Lupus Nephritis\n",
      "Meta-Analysis Examining the Clinical Significance of Monitoring of Hydroxychloroquine Levels in SLE\n",
      "Results of the Open-label, Non-randomized 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment with Belimumab in Patients with SLE\n",
      "Belatacept in Systemic Lupus Erythematosus (SLE) Kidney Transplant Patients\n",
      "Clinician’s Simple Opinion of SLE Disease Progress: Used in a Clinical Trial\n",
      "Safety Results of 50% Enrollment from a Multicenter, Randomized, Double‑blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Repository Corticotropin Injection in Patients with Systemic Lupus Erythematosus Despite Moderate‑dose Corticosteroid Use\n",
      "Abatacept Failed to Demonstrate Efficacy in an SLE Trial with Low Placebo Response Rates, Although Global Assessments Indicated Less Flare Severity\n",
      "Population Pharmacokinetics of Atacicept in Systemic Lupus Erythematosus (SLE) – an Analysis of Three Clinical Trials\n",
      "Impact of Pathogenic and Protective Environmental Exposures on Autoimmune Disease—The Microbiome Effects on Lupus (MEL) Study\n",
      "Validity and Reliability of Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Tests (CAT) in a Canadian Cohort of Patients with Systemic Lupus Erythematosus\n",
      "Design and Development of an Online Intervention for Lupus Self-Management Based on the Transtheoretical Model of Change\n",
      "Prescription Opioid Use and Osteoporotic Fractures in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology & Surveillance (MILES) Cohort\n",
      "Do All Patients Who Achieve Lupus Low Disease Activity State Have Similar Outcomes?\n",
      "Antimalarial-Induced Cardiomyopathy: Outcome in 10 Patients\n",
      "Histologic Findings from Paired Renal Biopsies and Clinical Outcomes: Results from a Single Site in the Phase III Study of Abatacept in Patients with Proliferative LN\n",
      "Proton Pump Inhibitor Induced Subacute Cutaneous Lupus Erythematosus: Clinical Characteristics and Outcomes – Case Control Study\n",
      "Profiling of Gene Expression, Immune Cell Subtypes, and Circulating Protein Biomarkers in Systemic Lupus Erythematosus Patients Treated with the Selective Immunoproteasome Inhibitor, KZR-616\n",
      "A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of Anifrolumab in Adults with Systemic Lupus Erythematosus\n",
      "Factors Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus Patients with End Stage Renal Disease\n",
      "Deep Remission During Induction Therapy for Lupus Nephritis Prevents Damage Accrual and Associates with the Baseline Proportions of Peripheral Treg, CD8+ T Cells, and NKT-like Cells\n",
      "Glucocorticosteroid Usage and Major Organ Damage in Patients with Systemic Lupus Erythematosus – Meta-analyses of Observational Studies Published Between 1979 and 2018\n",
      "PK/PD, Safety and Exploratory Efficacy of Subcutaneous Anifrolumab in SLE: A Phase-II Study in Interferon Type I High Patients with Active Skin Disease\n",
      "Adherence to Hydroxychloroquine Influences the Incidence of Organ Damage During Follow-up in Patients with Systemic Lupus Erythematosus\n",
      "Pharmacokinetics and Exposure-response of Intravenous Belimumab in Children with Systemic Lupus Erythematosus\n",
      "Polypharmacy and Potentially Inappropriate Medication Use in Young versus Older Adults with SLE\n",
      "Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates\n",
      "Iguratimod Is an Alternative Option for Refractory Lupus Nephritis: A Preliminary Observational Study\n",
      "Guidelines on Prescribing and Monitoring Antimalarials in Rheumatic Diseases: A Systematic Review\n",
      "Urinary Cellular Profile as a Biomarker for Proliferative Lupus Nephritis\n",
      "Early Improvement in SLEDAI-2K Responder Index-50 Predicts SRI-4 Response in a Randomized Placebo-Controlled Trial of Ustekinumab (UST) in Systemic Lupus Erythematosus\n",
      "Efficacy Analysis of Patients with Systemic Lupus Erythematosus Treated with Belimumab or Placebo Plus Standard Therapy in Phase 3 Trials by Baseline Levels of BLyS mRNA and Type 1 Interferon Inducible Gene Signature Status\n",
      "Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus: Comparison of Whole Blood and Serum Levels\n",
      "Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of BIIB059, a Monoclonal Antibody Targeting BDCA2 Following Administration of Subcutaneous Single Doses in Japanese Healthy Volunters\n",
      "Electronic Monitoring of Medication Adherence in Young Adults with Childhood-Onset Systemic Lupus Erythematosus over 12 Weeks\n",
      "Clinical Evidence Supporting Therapeutic Potential of Activating the Immune Checkpoint Receptor BTLA in SLE\n",
      "SLE Disease Activity May Be Associated with Choroidal Thickness\n",
      "Effect of Omega-3 Fatty Acids on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis\n",
      "A Quality Improvement Project in Determining If Cardiac Enzymes Play a Role in Surveillance of Possible Hydroxychloroquine Induced Cardiotoxicity\n",
      "Pharmacotherapies Targeting Type 2 SLE Symptoms\n",
      "Clinical Impact of Decreasing Hydroxychloroquine Dose According to the 2016 American Academy of Ophthalmology Guidelines in Patients with Systemic Lupus Erythematosus\n",
      "Incidence of Antimalarials-Induced Retinopathy in Inflammatory Rheumatic Diseases, Using OCT and Visual Field Test : A Systematic Review and Meta-analysis\n",
      "Prevalence and Risk Factors of Herpes Zoster Reactivation in Patients with Biopsy Proven Lupus Nephritis Undergoing Immunosuppressive Therapies\n",
      "Management of Cutaneous Manifestations of Lupus Erythematosus: A Systematic Review\n",
      "A Comparison of Risk of Ovarian Failure Following Intravenous Cyclophosphamide Therapy in Juvenile versus Adult Systemic Lupus Erythematosus\n",
      "Higher Genetic Risk Load in Patients with More Diverse Manifestations in a Korean Systemic Lupus Erythematosus Cohort\n",
      "Analysis of Gene Expression from Systemic Lupus Erythematosus Synovium Reveals Unique Pathogenic Mechanisms\n",
      "Gene-Expression Analysis of Male and Female SLE Patients Reveals Candidate Pathogenic Pathways\n",
      "Genetics of Longitudinal Kidney Function in Children and Adults with Systemic Lupus Erythematosus\n",
      "Ancestry Influences the Gene Expression Profile in Systemic Lupus Erythematosus and Contributes to Transcriptomic Heterogeneity in Lupus Patients\n",
      "MicroRNA-27a Can Contribute to Interferon Signatures in Systemic Lupus Erythematosus via the Suppression of Tripartite Motif-containing Protein 27\n",
      "Dysregulation of Granulopoiesis in Systemic Lupus Erythematosus\n",
      "Inhibited Expression of Hematopoietic Progenitor Kinase 1 in Tfh Cells Contributes to Autoimmunity in Systemic Lupus Erythematosus\n",
      "Aberrant H3K9me3 Modification in Promoter Region Up-regulates cAMP Response Element Modulator Alpha in Systemic Lupus Erythematosus\n",
      "Staphylococcus Aureus Colonization Is Increased on Lupus Skin Lesions and Is Promoted by Interferon-Mediated Barrier Disruption\n",
      "Interferon Alpha Promotes Caspase-Dependent Apoptosis Independently of Reactive Oxygen Species in Ultraviolet B-Exposed Keratinocytes\n",
      "Enhanced IFN a Production and STING Pathway in Monocytes in Systemic Lupus Erythematosus Is Suppressed by the Inhibition of mTOR Activation\n",
      "IRAK4 Inhibition Suppresses TLR7, TLR9, and SLE Serum-Induced IFNA Production in Primary Human Plasmacytoid Dendritic Cells\n",
      "Identification of IL-17+ and IL-10+ TCRαβ+ CD4- CD8- Double Negative (DN) T Cell Subsets in Lupus-prone Mice and Patients with SLE and Their Significance in Predicting Renal Involvement\n",
      "Systemic Lupus Erythematosus (SLE) Is Caused by Expanded DOCK8-Positive Autoantibody-Inducing CD4 T (aiCD4 T) Cell\n",
      "Mitochondrial DNA: A Potential Trigger of Cyclic GMP-AMP Synthase Activation in Systemic Lupus Erythematosus\n",
      "Understanding Langerhans Cell ADAM17 Levels in Systemic Lupus Erythematosus: Potential Contributor to Photosensitivity\n",
      "Antibodies to Malondialdehyde-acetaldehyde (MAA) Protein Adduct as a Biomarker for Cardiovascular Manifestations in Systemic Lupus Erythematosus\n",
      "High Prevalence and Disease Correlation of Autoantibodies Against p40 Encoded by Long Interspersed Nuclear Elements (LINE-1) in SLE\n",
      "BATF2 Contributes to Interferon Dysregulation in SLE Keratinocytes\n",
      "Epigenome-wide Association Study Reveals Differential DNA Methylation in Systemic Lupus Erythematosus Patients with a History of Ischemic Heart Disease\n",
      "Intestinal Microbiota Alters Th1/Th17 Balance but Is Dispensable for the Development of Systemic Autoimmune Disease in BXD2 Mice\n",
      "Large Joint Arthritis in Systemic Lupus Erythematosus Is Characterized by TH17 Cells Rather Than B Cell Accumulation\n",
      "Expression of SLAMF6 and Its Functional Significance in Podocytes of Lupus Nephritis: Report with Consideration Based on the Results of Microarray Analysis in Podocytes of MRL/lpr Mice\n",
      "RNA Sequencing of Plasma and Urine-derived Extracellular Vesicles from Lupus Nephritis Patients Identifies Disease-associated Small RNA Signatures and Putative Therapeutic Targets\n",
      "NMR Spectroscopy Reveals Alterations of Urinary Acetate and Citrate Levels Following Cyclophosphamide Therapy in Patients with Lupus Nephritis\n",
      "Cardiovascular Impact of Hyperuricemia in Patients with Psoriatic Arthritis\n",
      "Bone Mineral Density in Psoriatic Arthritis: Results from a Longitudinal Study\n",
      "Rates of Treated Depression Among Patients with Psoriatic Arthritis Treated with Apremilast, Biologics, DMARDs, and Corticosteroids in the US MarketScan Database\n",
      "The Relationship Between Fatigue and Disease Activity as Determined by Different Indices in Patients with Psoriatic Arthritis (PsA)\n",
      "A Gender-based Analysis of Disease Activity and Its Relationship with Anxiety, Depression, Fatigue, and Fibromyalgia in Psoriatic Arthritis\n",
      "Real-world Treatment Patterns Among Patients with Psoriatic Arthritis Treated with Biologic Therapies\n",
      "Enthesitis, Dactylitis, and Axial Disease in Psoriatic Arthritis (PsA): Impact on Patient Quality of Life and Work Productivity\n",
      "Gender Differences in Psoriatic Arthritis – Impact on Tumor Necrosis Factor Inhibitors Persistence and Response\n",
      "Characteristics of Psoriasis Patients with Subclinical Signs of Musculoskeletal Involvement Detected by Fluorescence Optical Imaging and Confirmed by MRI-assessment\n",
      "Factors Associated with Discordance Between Patient and Rheumatologist Assessment of Disease Activity in Psoriatic Arthritis Considered in Remission\n",
      "Assessing Risk of PsA Progression: Results from a Combined Psoriasis-PsA Center Cohort\n",
      "The Paradoxical Effect of Depression on Psoriatic Arthritis Outcomes in a Combined Psoriasis-Psoriatic Arthritis Center\n",
      "Rates of Myocardial Infarction, Stroke, and Revascularization Among Patients with Psoriatic Arthritis Treated with Apremilast, Biologics, DMARDs, and Corticosteroids in the US MarketScan Database\n",
      "The Performance of a Multi-marker Genetic Test to Identify Patients with Psoriatic Arthritis Among Psoriasis Patients\n",
      "Static and Longitudinal Construct Validity of PROMIS CAT and Profile29 for Assessing Pain Interference, Physical Function and Fatigue in Psoriatic Arthritis\n",
      "PROMIS Profile29 Differentiates Active Disease from Treat-to-Target State in Psoriatic Arthritis\n",
      "Impact of Enthesitis on Patient Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey\n",
      "Validity of Patient-reported Cardiovascular Events in a Large Longitudinal Cohort of Patients with Psoriatic Arthritis and Psoriasis\n",
      "Increased Prevalence of Systemic Lupus Erythematosus Co-morbidity in Patients with Psoriatic Arthritis: A Population-Based Case-Controlled Study\n",
      "Predictors of Structural Progression in Psoriatic Arthritis: Clinical versus Systemic Inflammation\n",
      "Effect of Obesity and Surgical Weight Loss on Joint Surgery Hospitalizations in Psoriatic Arthritis: Data from National Inpatient Sample\n",
      "Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Database\n",
      "Clinical Presentation and Treatment of Oligoarticular Psoriatic Arthritis in Canada: High Frequency of Smaller Joint Involvement\n",
      "Use of Complementary and Alternative Medicine (CAM) in a Psoriatic Arthritis Cohort\n",
      "Body Composition and Fat Distribution in Patients with Psoriasis or Psoriatic Arthritis\n",
      "Multidisciplinary Unit of Psoriatic Arthritis: Clinical Results\n",
      "Reliability and Validity of the Self‐Administered Comorbidity Questionnaire in Psoriatic Arthritis\n",
      "Evolution of Health-Related Quality of Life in Psoriatic Arthritis Patients\n",
      "Pain and Anxiety Are Independent Factors Associated to Sleep Impairment in Psoriatic Arthritis: A Multicentric Study in 14 Countries\n",
      "JAK-STAT Signaling System in Pannus Formation of Psoriatic Arthritis: A Therapeutic Target\n",
      "Diversity of Poly-Functional T Cells in Psoriatic Arthritis and Rheumatoid Arthritis and Its Therapeutic Significance\n",
      "Relationship Between Serum Calprotectin Level and Presence of Subclinical Atherosclerosis and Arterial Stiffness in Patient with Psoriatic Arthritis\n",
      "Regional Difference in Disease Burden Among Patients with Psoriatic Arthritis: A Multi-Center Study\n",
      "The Role of Ultrasound for the Assessment of Psoriatic Arthritis Patients with Fibromyalgia – Interim Analysis\n",
      "Implementing the Psoriatic Arthritis Disease Activity Score (PASDAS) in Routine Clinical Practice: (im)possible?\n",
      "Impact of Multidomain Disease Presentations on Overall Disease Burden Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry\n",
      "Prevalence of Disease Domain Presentations Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry\n",
      "Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA\n",
      "Burden of Disease at Treatment Initiation Among Biologic-Naïve Patients with Oligoarticular versus Polyarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry\n",
      "Enthesitis Frequency and Treatment Patterns in Patients with Psoriatic Arthritis in Europe and Japan\n",
      "Unmet Treatment Needs in Patients with Psoriatic Arthritis\n",
      "Opioid Use Surrounding Diagnosis of Inflammatory Arthritis\n",
      "Uveitis in 320 Patients with Psoriatic Arthritis. Epidemiology, Clinical Features and Biological Treatment: Study from a Single University Center\n",
      "Differences and Similarities According to Gender in Patients with Psoriatic Arthritis Initiating Biological Therapy\n",
      "Comparison Between Composite Activity Indices to Assess Clinical Response to Biological Therapy in Patients with Psoriatic Arthritis\n",
      "Gender Influence on Treatment Effectiveness in Psoriatic Arthritis\n",
      "Red Cell Distribution Width Positively Correlates with Atherosclerotic Cardiovascular Disease Risk Score in Psoriatic Arthritis and Decreases with BDMARD Therapy\n",
      "Evaluation of Clinical and Functional Parameters by Joint Involvement and Remission in Psoriatic Arthritis\n",
      "Identification of Circulating MicroRNA Signatures in Patients with Psoriasis and Psoriatic Arthritis to Develop Novel Strategies for Early Diagnosis of a Bone and Joint Involvement\n",
      "MDA Versus DAPSA: Applicability in a Real World\n",
      "Differences in Clinical Characteristics, Quality of Life, Disability, and Work Productivity in Psoriatic Arthritis Patients by Gender: Findings from a Cross-sectional Survey in the US and Europe\n",
      "The Cutaneous Microbiome of Psoriatic Disease Is Influenced by Disease Susceptibility HLA Alleles but Not Clinical Phenotype\n",
      "Predictors of DAPSA28 Remission at 6 Months in Bio-Naive Patients with Psoriatic Arthritis Starting a TNF Inhibitor in Clinical Practice– Results from the EuroSpA Collaboration\n",
      "Efficacy and Safety of Disease-Modifying Drugs in Psoriatic Arthritis (PsA): A Systematic Literature Review\n",
      "IL-6 and TNF-α Influence on Clinical Manifestations, Activity and Comorbidity in Psoriatic Arthritis Patients\n",
      "Comparison of Comorbidity in Spondyloarthritis: Influence on Inflammatory Activity in Patients with Psoriatic Arthritis\n",
      "Oligoarticular Psoriatic Arthritis\n",
      "Serum Metabolomic Analysis of Psoriatic Arthritis Using Solid Phase Microextraction – Liquid Chromatography – High-Resolution Mass Spectrometry Identifies Putative Disease Activity Markers\n",
      "Description and Prevalence of Spondyloarthritis in Unselected Patients with Psoriasis, Acute Anterior Uveitis, and Inflammatory Bowel Disease Presenting with Undiagnosed Back Pain\n",
      "Incidence and Predictors of Heart Failure in Patients with Psoriatic Disease – a Cohort Study\n",
      "Predicting Risk of Developing Psoriatic Arthritis (PsA) in Siblings of Patients with Psoriatic Arthritis\n",
      "Current Smoking Status Increases the Risk of Axial Psoriatic Arthritis: An Explanation to Smoking Paradox\n",
      "The Association Between Metabolic Syndrome and Radiographic Damage in Psoriatic Arthritis\n",
      "Normalization of Inflammatory Gene Expression and Cellular Markers by Abatacept in the Skin Lesions of Psoriatic Arthritis Patients: A Biopsy Substudy of a Phase III Study\n",
      "Achilles Tendon Enthesitis and Disease Burden in Psoriatic Arthritis and Axial Spondyloarthritis: Baseline Results from a Randomized Controlled Trial\n",
      "Differential Expression of Human Endogenous Retroviruses in Psoriatic Disease\n",
      "Can Biologics “Prevent” the Development of Psoriatic Arthritis in Psoriasis Patients? Data from a Large University Hospital Cohort in Argentina\n",
      "The ‘Severity of Nail Psoriasis Score’ (SNAPS) Is Feasible, Reliable and Demonstrates Construct Validity Against the mNAPSI in an Observational Cohort of Patients with Psoriatic Arthritis\n",
      "The Impact of Psoriasis Severity on Outcomes Among Psoriatic Arthritis Patients Receiving Adalimumab\n",
      "Large Joint and Lower Extremity Involvement Has Higher Impact on Disease Outcomes in Oligoarticular PsA\n",
      "Psoriasis Impact on Patient-Reported Outcomes in Psoriatic Arthritis in a Real-World Setting: Results from the APOPSIS Study\n",
      "Validation of the Modified Stokes Ankylosing Spondylitis Spinal Score (mSASSS) as a Tool to Assess Axial PsA\n",
      "What Influences Patients’ Opinion of Remission and Low Disease Activity in Psoriatic Arthritis? Principal Component Analysis of an International Study\n",
      "A Qualitative Study of Clinicians’ Perspectives on Barriers to Implementation of Treat to Target in Psoriatic Arthritis\n",
      "Relationships Between Psoriatic Arthritis Disease Activity Score and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies\n",
      "Relationships Between Minimal Disease Activity and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies\n",
      "Disease Activity Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Psoriatic Artrhitis\n",
      "Clinical Characteristics and Survival in Systemic Sclerosis-mixed Connective Tissue Disease and Systemic Sclerosis-overlap Syndrome\n",
      "Prognostic Role of Measurement of Renal Resistive Index in Systemic Sclerosis\n",
      "Myositis-specific and -associated Antibodies in Systemic Sclerosis: Prevalence and Clinical Associations\n",
      "Searching the Calcinosis Signature: A Case Control Study Analyzing Limited Systemic Sclerosis Female Patients with and Without Calcinosis, Paired by Disease Duration, Age and Body Mass Index\n",
      "Computer Vision Applied to Dual Energy Computed Tomography Images for Precise Calcinosis Cutis Quantification in Patients with Systemic Sclerosis\n",
      "Hospitalization Among Incident Cases of Systemic Sclerosis: Results from a Population-based Cohort (1980-2016)\n",
      "Longitudinal Changes in Health-related Quality of Life in Systemic Sclerosis Treated with Autologous Hematopoietic Stem Cell Transplant Compared to Standard of Care\n",
      "Cyclophosphamide for the Treatment of Skin Fibrosis in Systemic Sclerosis: A Systematic Review\n",
      "Associations Between Antibodies to the Angiotensin II Type 1 Receptor and Endothelian-1 Type a Receptor and the Incidence of Vascular Complications in Early Diffuse Systemic Sclerosis\n",
      "Asymptomatic Scleroderma Antibody Positivity and Progression to Systemic Sclerosis\n",
      "The Contribution of Left Heart Disease in Patients with Systemic Sclerosis-associated Pulmonary Hypertension Having Normal Pulmonary Artery Wedge Pressure\n",
      "Prevalence and Clinical Associations of Degos Lesions in Systemic Sclerosis\n",
      "Different Treatment Backgrounds Do Not Influence Aminaphtone Efficacy in Primary and Secondary Raynaud’s Phenomenon\n",
      "Body Composition and Nailfold Videocapillaroscopy Patterns in a Cohort of Systemic Sclerosis Patients\n",
      "‘If You Don’t Use It, You Lose It’: Rehabilitation of Finger Dexterity and Ability to Perform Activities of Daily Living in Systemic Sclerosis\n",
      "Trabecular Bone Score and Malnutrition in a Cohort of Systemic Sclerosis Patients\n",
      "Changes in Fecal Microbiota Composition After Fecal Microbiota Transplantation in Systemic Sclerosis\n",
      "Course of Progressive Lung Fibrosis in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) in the EUSTAR Database\n",
      "Pain Chronification and the Important Role of Non-disease Specific Symptoms in Patients with Systemic Sclerosis\n",
      "Men and Black Persons Die at Younger Ages from Systemic Sclerosis: A Nationwide Population-based Study\n",
      "Evolution of Systemic Sclerosis-Related Interstitial Lung Disease After Autologous Hematopoietic Stem Cell Transplantation\n",
      "Ultrasound Detection of Calcinosis and Correlation with Ulnar Artery Occlusion in Patients with Systemic Sclerosis\n",
      "Subsets in Systemic Sclerosis-ILD: Working Towards Consensus-Based Definitions\n",
      "Anti-angiogenic VEGF-A165b Is Associated with Systemic Sclerosis Peripheral Vasculopathy\n",
      "Relationship Between Parenchymal and Vascular Features in Systemic Sclerosis-Interstitial Lung Disease: Results from Quantitative Analysis of Chest Computed Tomography\n",
      "Mesenchymal Stem Cells in Scleroderma: A Systematic Review\n",
      "Minocycline for Refractory Calcinosis in Systemic Sclerosis: A Single-Centre Observational Cohort Study\n",
      "Hsp90 as a Potential Biomarker of Lung and Skin Involvement in Patients with Systemic Sclerosis\n",
      "Association of Body Composition in Scleroderma Patients with Disease Activity, Serum Levels of Inflammatory Cytokines and Parameters of Nutrition and Lipid Metabolism\n",
      "Cumulative Incidence, Survival and Predictors of Pulmonary Arterial Hypertension in Disease Subsets of Systemic Sclerosis: PAH Is Not Increased in Limited vs Diffuse Patients by Adjusted Competing Risk Analysis\n",
      "Forced Vital Capacity Trajectories for Systemic Sclerosis-associated Interstitial Lung Disease—Analysis from the University of Michigan Scleroderma Cohort\n",
      "Responsiveness to Change of the Modified Rodnan Skin Score in a Phase I/II Double-Blind Randomized Placebo-Controlled Trial\n",
      "Anti-RNPC-3 Antibodies Are Associated with Nuclear Speckled Immunofluorescence Pattern and Enriched in Triple Negative Systemic Sclerosis Patients\n",
      "Rituximab for Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review of Observational Studies\n",
      "Effects of Tofacitinib Suppressed Pulmonary Vascular Remodeling of Allergic Vasculitis in a Murine Model\n",
      "Association Between Outcome Renal, Clinical Variables and Findings of Renal Biopsy in Patients with ANCA Vasculitis\n",
      "A Single Center Retrospective Analysis of Efficacy and Safety Between Low-Dose versus High-Dose Rituximab as Remission Induction Therapy with ANCA-Associated Vasculitis\n",
      "Abnormality of Percentages and Absolute Numbers of CD4+ Memory and Regulatory T Subset Cells in ANCA-associated Vasculitis\n",
      "Comparison Between Long-Term and Conventional Rituximab-Maintenance Treatments: Results of a Placebo-Controlled Randomized Trial\n",
      "Predictors of Advanced Chronic Kidney Disease in Patients with ANCA Vasculitis and Renal Involvement\n",
      "Cell-free Mitochondrial DNA Levels in Granulomatosis with Polyangiitis\n",
      "Association of Work Productivity Assessed by Absenteeism and Presenteeism with Disease Activity, Damage and Health-related Quality of Life in Patients with ANCA-associated Vasculitis\n",
      "Mortality Predictors in ANCA-associated Vasculitis: Experience of a Brazilian Monocentric Cohort of a Rheumatology Center\n",
      "Urinary Inflammatory Cell Analysis Reflects the Renal Histopathology in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis\n",
      "A Dutch Consensus Statement on the Diagnosis and Treatment of ANCA Associated Vasculitis\n",
      "Increased Risk of Acute Coronary Artery Disease and Ischemic Stroke in Patients with Eosinophilic Granulomatosis with Polyangiitis\n",
      "Changing Trends in the Management of ANCA-associated Vasculitis at an Academic Medical Center\n",
      "Efficacy of Remission Induction Regimens in Elderly Patients with ANCA-Associated Glomerulonephritis\n",
      "ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients\n",
      "Accuracy of Self-Reported Diagnosis of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis\n",
      "Cluster Analysis for Classification of Japanese Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Subgroup Analysis of Nationwide Cohort Studies\n",
      "Urine Complement Ba Levels During Flares of Renal Disease in Patients with ANCA-Associated Vasculitis\n",
      "The Cumulative Burden of Damage for Patients with Eosinophilic Granulomatosis with Polyangiitis\n",
      "Comparison of Patient Self-reported Data to Physician-driven Cohorts in Patients with Eosinophilic Granulomatosis with Polyangiitis\n",
      "Performance of Berden’s Classification and ANCA Renal Risk Score for the Prediction of End-Stage Renal Disease in ANCA-associated Vasculitis\n",
      "Clinical Characteristics of a Cohort of Patients with a Self-Reported Diagnosis of Granulomatosis with Polyangiitis or Microscopic Polyangiitis\n",
      "ANCA Testing: Final Diagnoses in Cases with Positive Immunofluorescence and Negative ELISA\n",
      "Comparative Study of Renal Transplantation Due to Rapidly Progressive Glomerulonephritis (RPGN): Study of 42 Patients from a Single Tertiary Centre\n",
      "Ultrasound to Monitor Treatment Response in Large Vessel Giant Cell Arteritis\n",
      "The Anteromedial Ultrasound Examination of the Large Supraaortic Vessels Identifies Higher Rates of Large Vessel Involvement Than Previous Reported in Patients with Giant Cell Arteritis\n",
      "Survival of Large Vessel Giant Cell Arteritis in Northern Italy During a 26-year Period : No Correlation with Demographical, Clinical, Laboratory and Imaging Data\n",
      "Flares and Long-term Remission in Large-vessel Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-term Follow-up Study\n",
      "Association Between Specimen Length and Number of Sections and Diagnostic Yield of Temporal Artery Biopsy: A Retrospective, Single Center Experience over a 21 Years’ Period\n",
      "Comparison of Biopsy Proven Giant Cell Arteritis in North America and South Europe: A Population-Based Study\n",
      "Predictors of Relapse in Giant Cell Arteritis: Data from an International Collaboration\n",
      "Are There Phenotypic Overlaps Between Giant Cell Arteritis Subgroups?\n",
      "Comparison Between Transmural and Isolated Periadventitial And/or Adventitial Inflammation at Temporal Artery Biopsy: A Single Center Cohort of Biopsy-Positive GCA with Long Term Follow-up\n",
      "Adventitial Fibroblast, an Important Actor in Giant Cell Arteritis\n",
      "Comparison of Aortitis and Non-Inflammatory Thoracic Aortic Aneurysms Undergoing Open Surgical Repair\n",
      "Large Vessel Vasculitis: Diagnosis Is Very Frequent with Ultrasound Examination and Shows Responsiveness to Treatment\n",
      "The Veterans Health Administration (VHA) National Database Cohort: Incident Ophthalmic Complications in Giant Cell Arteritis (GCA) Patients with a Negative Temporal Artery Biopsy\n",
      "The Association Between Bisphosphonates and Giant Cell Arteritis: A Retrospective Cohort Study\n",
      "Giant Cell Arteritis Diagnostic Workup Among Medicare Beneficiaries\n",
      "Giant-Cell Arteritis Associated with Myeloproliferative Neoplasms: A Retrospective Case–Control Study\n",
      "Rationalizing the Use of MRI of the Scalp Arteries in the Diagnosis of Giant Cell Arteritis Through Multivariable Predictive Modelling\n",
      "A Ten-Year Retrospective Review of Temporal Artery Biopsy Lengths in Alberta\n",
      "Temporal Artery Biopsy Lengths in Alberta: Which Surgical Subspecialty Achieves Optimal Biopsy Lengths?\n",
      "Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial\n",
      "Color Doppler Ultrasound for the Diagnosis of Giant Cell Arteritis in Montreal: A Canadian Single Center Experience\n",
      "Clinical Outcomes of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica Symptoms Treated with Tocilizumab in Routine Clinical Practice\n",
      "Development and Outcome of Aortic Complications During Tocilizumab (TCZ) Treatment of GCA and Histopathologic Evidence of Residual Inflammation\n",
      "Efficacy and Safety of Tocilizumab in Giant Cell Arteritis: A Monocentric Real-life Experience\n",
      "Pharmacokinetics and Pharmacodynamics of Tocilizumab in Combination with Prednisone Tapering in Patients with Giant Cell Arteritis: 3-Year Results from a Randomized Controlled Phase 3 Trial\n",
      "Survival Trends in Giant Cell Arteritis: A Population-based Cohort Study\n",
      "Giant Cell Arteritis with Intracranial Vasculitis: A Case Series\n",
      "PET/CT Vascular Findings at Baseline and Six Months in Patients with Newly Diagnosed Giant Cell Arteritis\n",
      "Ultrasonography in the Diagnosis of Giant Cell Arteritis\n",
      "Presentation and Management of Giant Cell Arteritis in a Real-World Setting (Artemis Study)\n",
      "Clinical Symptoms and Associated Vascular Imaging Findings in Takayasu’s Arteritis Compared to Giant Cell Arteritis\n",
      "Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a US-based Electronic Health Records Database\n",
      "Cardiovascular Treatment and the Incidence of Giant Cell Arteritis (GCA) – a Population-Based Case-Control Study\n",
      "Healthcare Resources Utilization in Giant Cell Arteritis – a Population-Based Study\n",
      "Response to Tocilizumab in Patients with Giant Cell Arteritis, According to Ischemic vs Systemic Symptoms\n",
      "Tocilizumab in Giant Cell Arteritis: Route of Administration: Intravenous or Subcutaneous\n",
      "Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Real Life Study of 134 Patients\n",
      "Tocilizumab in Giant Cell Arteritis: The Safest and Most Effective Initial Dose of Prednisone\n",
      "Efficacy of Tocilizumab in Giant Cell Arteritis, Independent of the Time of Disease Evolution\n",
      "Visual and Quantitative Assessment of Cranial Arteries on FDG-PET/CT Can Reliably Diagnose Cranial Giant Cell Arteritis\n",
      "Real-world Comparative Study of Methotrexate vs Tocilizumab in Patients with Giant Cell Arteritis with Large Vessel Involvement\n",
      "Factors Contributing to Capturing Positive Findings on Temporal Artery Biopsy: An Australian Experience from Two Rheumatology Referral Centers\n",
      "Real Life Data over 4 Years from a Fast Track GCA Pathway in Coventry\n",
      "Clinicopathologic Associations in a Large International Cohort of Patients with Giant Cell Arteritis\n",
      "Comparisons of Strategies for Diagnostic Assessment in Giant Cell Arteritis: Results from an International Observational Cohort\n",
      "GM-CSF Pathway Signature Identified in Temporal Artery Biopsies of Patients with Giant Cell Arteritis\n",
      "Fast Track Clinic (FTC) for Giant Cell Arteritis (GCA) – the United States Experience\n",
      "Treatment Patterns, Disease Burden and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica\n",
      "Coronary Artery Disease in a Population-Based Cohort of Biopsy-Proven Giant Cell Arteritis in Southern Sweden\n",
      "Mitochondrial Contribution to Juvenile Dermatomyositis Pathogenesis\n",
      "Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients with Active Ankylosing Spondylitis\n",
      "Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Primary Results from a Phase 3 Trial\n",
      "Efficacy and Safety of Romosozumab vs Placebo Among Patients with Mild-to-Moderate Chronic Kidney Disease\n",
      "Decomposition Analysis of Spending and Price Trends for Biologic Anti-Rheumatic Drugs in Medicare and Medicaid\n",
      "The Relationship Between Gout and Cardiovascular Disease Outcomes: A Health Data Linkage Study of 1 Million New Zealanders Using Population-level Cardiovascular Risk Prediction Equations\n",
      "Inhibition of Neutrophil Elastase Reduces Autoantibody Levels and Renal Inflammation in Murine Lupus\n",
      "Signaling Lymphocytic Activation Molecule Family (SLAMF) Receptors Deregulation Is Implicated in the Altered Function of NK Cells in Systemic Lupus Erythematosus\n",
      "Response Gene to Complement -32 Exerts Proinflammatory and Profibrotic Effects in Immune Complex Gediated Glomerulonephritis\n",
      "Mucosal-associated Invariant T Cells Can Be Therapeutically Targeted in Lupus\n",
      "HIF-1α and miR-210 Differential and Lineage-specific Expression in Systemic Lupus Erythematosus\n",
      "Differential Methylation of Peripheral Blood Adaptive Immune Cells in Individuals at High Risk for RA and with Early RA Compared with Controls Identifies Pathways Important in Transition to Arthritis\n",
      "Skin Disease Activity and Autoantibody Phenotype Are Major Determinants of Blood Interferon Signatures in Dermatomyositis\n",
      "Takayasu Arteritis Associated Risk Locus in IL6 Represses the Anti-inflammatory Gene GPNMB Through Chromatin Looping and Recruiting MEF2-HDAC Complex\n",
      "Integration of Single Cells from Inflammatory Disease Tissues Reveals Common and Unique Pathogenic Cell States\n",
      "Toward a Liquid Biopsy for Lupus Nephritis: Urine Proteomic Analysis of SLE Identifies Inflammatory and Macrophage Signatures\n",
      "Characterizing the Epigenomic Landscape of Psoriasis Patients Destined to Develop Psoriatic Arthritis\n",
      "Development and Preliminary Validation of a Novel Lung Ultrasound Interpretation Criteria for the Detection of Interstitial Lung Disease in Patients with Systemic Sclerosis\n",
      "Very Low Prevalence of Ultrasound Determined Tendon Abnormalities in Healthy Subjects Throughout the Age Range: An Outcome Measures in Rheumatology (OMERACT) Ultrasound Minimal Disease Study\n",
      "Successfull Evaluation of a Predefined Set of Anatomic Sites in the Pelvis of Patients with Polymyalgia Rheumatica Showing Extracapsular Inflammation as Visualized by Contrast Enhanced Magnetic Resonance Imaging\n",
      "Major Salivary Gland Ultrasound: Pilot Study of Findings and Feasibility in Childhood-Onset Systemic Lupus Erythematosus (cSLE)\n",
      "AxSpA Patients with Symptom Onset < 30 Years Have More Structural Lesions on MRI of the Sacroiliac Joints When Fulfilling the Modified New York Criteria\n",
      "Assessing the Sensitivity to Change of the OMERACT Ultrasound Structural Gout Lesions During Urate-Lowering Therapy\n",
      "Subcutaneous Tanezumab versus NSAID for the Treatment of Osteoarthritis: Joint Safety Events in a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study\n",
      "Clinical Effectiveness of Ultrasound-guided Intra-articular Corticosteroid and Local Anaesthetic Injections for Hip Osteoarthritis: A Randomised Controlled Trial (HIT)\n",
      "Nortriptyline in Knee Arthritis (Nortika): A Randomised Controlled Double Blind Trial of Nortriptyline for Pain in Knee Osteoarthritis\n",
      "Stopping NSAIDs for Arthritis Pain (SNAP): A Randomized Withdrawal Trial Comparing NSAIDs to Cognitive Behavioral Therapy\n",
      "A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200-1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)\n",
      "Cartilage Thickness Modification with Sprifermin in Knee Osteoarthritis Patients Translates into Symptomatic Improvement over Placebo in Patients at Risk of Further Structural and Symptomatic Progression: Post-Hoc Analysis of a Phase II Trial\n",
      "The Preparation and Recovery Experience from Total Knee Replacement of Patients with Osteoarthritis: A Qualitative Study\n",
      "What Disease Do You Have? – Assessment and Predictors of Accurate Illness Naming in Rheumatology\n",
      "Medication Necessity and Concerns Beliefs Are Distinct, Interactive Predictors of Treatment Adherence in Rheumatoid Arthritis\n",
      "Assessing the Impact of Digital Health Coaching on Quality Adjusted Life Years, Symptom Severity and Disease Activity in Patients with Rheumatoid Arthritis\n",
      "Patient Preferences for Attributes of Treatments for Chronic Pain Associated with Osteoarthritis Pain and Chronic Low Back Pain That Differentiate Nerve-Growth Factor Inhibitors, Nonsteroidal Anti-inflammatory Drugs, and Opioids in the United States: A Discrete-Choice Experiment\n",
      "Importance of Discussing RA Treatment Goals: Patients Report Providers Seldom Discuss Treatment Goals and Outcomes Improve When Goals Are Discussed\n",
      "Changes in B Cell Profile as a Marker of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis\n",
      "The Pre-Treatment Gut Microbiome Predicts Early Response to Methotrexate in Rheumatoid Arthritis\n",
      "Towards the Lowest Efficacious Dose (ToLEDo): Results of a Multicenter Non-Inferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis Patients in Remission\n",
      "A Phase I, Randomized, Double-blind, Placebo-controlled, Single Center, Single-dose Escalation to Investigate the Safety, Tolerability, and Pharmacodynamics of Subcutaneously Administered DEN-181 in Adult Patients with ACPA+ Rheumatoid Arthritis on Stable Methotrexate\n",
      "Clinical and Biological Changes in Rheumatoid Arthritis Patients Exposed to an Anti-inflammatory Diet\n",
      "Individually Tailored Predictions of Flare Probability for Rheumatoid Arthritis Patients on Biologic DMARDs Based on Machine Learning Stacking Meta-Classifier\n",
      "Identification of SLE Subgroups at Risk for Poor Outcomes After Hydroxychloroquine Taper or Discontinuation\n",
      "Risk of Cardiovascular Disease Associated with the Use of Glucocorticoids in Patients with Incident Systemic Lupus Erytematosus: A Population-based Study\n",
      "Comparative Risks of Cardiovascular Disease Among SLE Patients Receiving Immunosuppressive Medications\n",
      "Hydroxychloroquine Blood Levels and Risk of Thrombotic Events in Systemic Lupus Erythematous\n",
      "Alterations in Inflammatory, TNF-Superfamily, and IFN-Associated Chemokines Precede Clinical Changes in SLEDAI After Methylprednisolone Treatment of SLE Patients\n",
      "Cancer Risk in a Large Inception SLE Cohort: Effects of Age, Smoking, and Medications\n",
      "Cluster-based Spondyloarthritis Phenotypes Defined at Baseline Are Predictive of Different Severity Outcomes at 5-Year in the DESIR Cohort\n",
      "Pregnancy Rates and Outcomes in Early Axial Spondyloarthritis: Analysis of the DESIR Cohort\n",
      "5-years Treatment Effect of TNF Alpha Inhibitor in Early Axial Spondyloarthritis and Associated Factors: An Inverse Probability Weighting Analysis of the DESIR Cohort\n",
      "What Is Axial Spondyloarthritis? A Latent Class and Transition Analysis in the SPACE and DESIR Cohorts\n",
      "Alcohol Consumption as a Predictor of the Progression of Spinal Structural Damage in Axial Spondyloarthritis: Data from the Catholic Axial Spondyloarthritis COhort (CASCO)\n",
      "Higher Disease Activity Is Associated with More Spinal Radiographic Progression in Patients with Axial Spondyloarthritis Independently of Prior Exposure to TNF Inhibitors\n",
      "Altered Expression of CD52 Facilitates Adhesion of Circulating CD14+ Monocytes in Systemic Sclerosis\n",
      "Iguratimod Treated Scleroderma with Interrupted Egr1/TGF-β Loop\n",
      "Dimethyl Fumarate Ameliorates the GATA6 Deficiency-Induced Pulmonary Hypertension by Normalizing Oxidative and ER Stress\n",
      "Identification of Naturally Presented Peptides of the Autoantigen Topoisomerase-I Reveals a Common Pathogenic Mechanism in Patients with Systemic Sclerosis\n",
      "Cracking a Novel Profibrotic Molecular Mechanism: lncRNA H19X and DDIT4L Crosstalk\n",
      "Long Non-coding RNA HOTAIR Induces Myofibroblast Activation in Systemic Sclerosis Through EZH2 Dependent De-repression of NOTCH Signalling Pathway Activation\n",
      "Renal Histopathological Classifications Predict the Renal Outcomes of Plasma Exchange-Treated ANCA-Associated Vasculitides with Renal Failure\n",
      "Predictors of Renal Involvement in ANCA-Associated Vasculitis\n",
      "Longitudinal Changes in the Nasal Microbiome and Disease Activity in Patients with Granulomatosis with Polyangiitis\n",
      "Neutrophil Extracellular Traps Induce Tissue-Invasive Macrophages in Granulomatosis with Polyangiitis Dominated by Ear, Nose and Throat Manifestations\n",
      "Platelet Mediates Neutrophil Extracellular Traps Formation via TLR Signaling in ANCA-associated Vasculitis\n",
      "Treatment Response Criteria for Anti-neutrophil Cytoplasmic Antibodies (ANCA)-vasculitis: Results of a Scoping Review\n",
      "Trajectories of Opioid Filling Patterns After Total Knee Replacement\n",
      "Does Early Anterior Cruciate Ligament Reconstruction Prevent Further Meniscal Damage? Secondary Analysis of a Randomized Controlled Trial\n",
      "Five Year Structural Changes in Patients with Meniscal Tear and Osteoarthritis from an RCT of Arthroscopic Partial Meniscectomy vs. Physical Therapy\n",
      "Optimal Threshold of Walking Speed Predictive of Mortality Risk over 9 Years in Knee Osteoarthritis: Data from Osteoarthritis Initiative\n",
      "High Intensity Interval Training for Knee Osteoarthritis: A Pilot Study\n",
      "Efficacy of a 3-Month Wearable-enabled Physical Activity Counselling Program for People with Knee Osteoarthritis\n",
      "The Need for Personalized, Non-Pharmacological Intervention Programmes in Autoimmune Connective Tissue Disorders: Results of a EULAR-Funded Scoping Review with a Nested, Descriptive Meta-Analysis\n",
      "Methotrexate Intolerance: A Qualitative Descriptive Study of the Adult Rheumatoid Arthritis Patients’ Perspectives\n",
      "Predictors of Incident and Worsening Lumbar Spine Degeneration: The Johnston County Osteoarthritis Project\n",
      "Patterns of Ambulatory Health Care Utilization and Medication Adherence Among Transition-Age Youth with Systemic Lupus Erythematosus\n",
      "The Association Between Omega-3 Supplementation and Disease Activity in a Rheumatoid Arthritis (RA) Observational Cohort\n",
      "Exploring Possible Predictors of Physical Activity in Knee Replacement Patients\n",
      "Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial\n",
      "A Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), Telitacicept (RC18), in Systemic Lupus Erythematosus (SLE): Results of a Phase 2b Study\n",
      "Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjögren’s Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients\n",
      "A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naïve Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks\n",
      "Secukinumab 150 mg Significantly Improved Signs and Symptoms of Non-radiographic Axial Spondyloarthritis: Results from a Phase 3 Double-blind, Randomized, Placebo-controlled Study\n",
      "Tofacitinib for the Treatment of Polyarticular Course Juvenile Idiopathic Arthritis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Withdrawal Study\n",
      "Depression and Subsequent Risk for Incident Seronegative Rheumatoid Arthritis Among Women\n",
      "Progression to Inflammatory Arthritis After Screening Autoantibody Positive in a Non-Clinical Setting\n",
      "Antibiotic Use and the Development of Rheumatoid Arthritis (RA) and Risk of RA Flares: Case-Control and Self-Controlled Case Series Studies in Two National Electronic Patient Databases (SIDIAP and CPRD)\n",
      "Provider Variability in Glucocorticoid Prescribing for Patients with Rheumatoid Arthritis and Impact on Chronic Glucocorticoid Use\n",
      "Risk of Serious Infections in Tofacitinib versus Other Biologic Drug Initiators in Patients with Rheumatoid Arthritis: A Multi-database Cohort Study\n",
      "Weight Fluctuation and Risk of Cardiovascular Events in Patients with Rheumatoid Arthritis\n",
      "Neutrophil Passage Through the Megakaryocyte Cytoplasm via Emperipolesis Modulates Neutrophil Migration\n",
      "Natural Killer Cells Gene Expression Can Differentiate Rheumatoid Arthritis Patients from Healthy Controls\n",
      "Single Cell RNA-sequencing Reveals Distinct Macrophage Subsets in the Joint with Differing Ontogenies During Steady-state and Arthritis\n",
      "Activation of the STING Pathway Is a Shared Feature of Salivary Gland and Lung Inflammation in Sjogren’s Syndrome\n",
      "Linking Toll-Like Receptor Signaling and Type I Interferons to Inflammation and Fibrosis in a Macrophage/Fibroblast Model of Congenital Heart Block\n",
      "Single-Cell RNA Sequencing of Murine Neutrophils Identifies a Transcriptional Continuum (“Neutrotime”) Across Biological Compartments\n",
      "Implementing the BP Connect Systems-Based Blood Pressure Follow-Up Protocol with Community Rheumatology Clinic Teams\n",
      "Improving SLE Care by Enhancing Medication Adherence Using a Tailored Clinic Intervention: HCQ-Crosswalk\n",
      "Treatment Delays Associated with Prior Authorization for Infusible Medications: A Cohort Study\n",
      "Cracks in Your Referral Process? Find Your Sustainable Solution Here\n",
      "Using a Learning Collaborative to Develop an RA Disease Activity Communication Tool to Promote Shared Decision-Making in Treat to Target\n",
      "Shared Decision Making in Routine Clinical Practice: An Assessment of Audio-recorded Consultations with Rheumatoid Arthritis Patients\n",
      "Assessing the Risk of Gout with Sodium Glucose Co-Transporter-2 Inhibitors: A Population-Based Cohort Study\n",
      "A Burden of Missense Genetic Variants in Urate Secretory Genes Is Associated with Inadequate Response to Allopurinol in People with Gout\n",
      "Do Serum Urate-associated Genetic Variants Differentially Contribute to Gout Risk According to Body Mass Index? Analysis of the UK Biobank\n",
      "Asymptomatic Monosodium Urate Crystal Deposition Associates with Increased Expression of Pro-Inflammatory Genes\n",
      "The First Phase 2a Proof-of-Concept Study of a Selective NLRP3 Inflammasome Inhibitor, Dapansutrile™ (OLT1177™), in Acute Gout\n",
      "Association of a Gout Polygenic Risk Score with Disease Severity Phenotypes Amongst Caucasian Gout Patients in Three Independent Cohorts\n",
      "Reliability, Validity and Responsiveness of PROMIS PF-20 in Patients with Inflammatory Myopathy\n",
      "A Double-Blind, Placebo-Controlled, Phase 2 Trial of a Novel Toll-Like Receptor 7/8/9 Antagonist (IMO-8400) in Dermatomyositis\n",
      "Paraoxonase 1 Activity Is Abnormal in Patients with Idiopathic Inflammatory Myopathies and Associates with Poor Disease Control\n",
      "Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects\n",
      "Predictive Factors for Mortality in Anti-melanoma-associated Gene 5 Antibody-associated Interstitial Lung Disease\n",
      "Pain Patterns in Idiopathic Inflammatory Myopathy (IIM): Associations with Disease Activity Measures (Muscle Enzymes, Manual Muscle Testing 8), Patient-Reported Quality of Life (HAQ) and Pain Scales (Widespread Pain Index (WPI), Symptom Severity Index (SSI) and Visual Analogue Scale)\n",
      "Outcomes over the First 5 Years of Follow up in a Very Early Rheumatoid Arthritis (RA) Cohort Recruited over 20 Years: Most of the Improvement Occurred Before the 2011 Implementation of Treat-to-Target (T2T)\n",
      "Testing Different Thresholds for Patient Global Assessment in Defining ACR-EULAR Boolean Remission Criteria for RA\n",
      "Semiquantitative Assessment of Synovial Inflammation on US-Guided Synovial Membrane Biopsy Is Contingent to Disease Phase, Autoimmune Profile and Treatment Response in Rheumatoid Arthritis: Large Single Center Experience (SYNGem Cohort)\n",
      "Radiographic Progression During a 10-Year Follow-Up : Results from the French Cohort ESPOIR\n",
      "Exploring Heterogeneity in Rheumatoid Arthritis: Outcomes up to 4 Years of Follow-Up in Patient Clusters Identified by Data-driven Analysis of the BRASS Registry\n",
      "Limiting Factors of Reaching ACR/EULAR Boolean Remission in Early RA Patients Treated According to Current Recommendations\n",
      "Does Loss-of-function Variants in SAT1 Cause X-linked Pediatric Lupus?\n",
      "The IRE1α Pathway Mediates Neutrophil Stress and NETosis in Lupus\n",
      "A New Role for Selectins in Systemic Lupus Erythematosus\n",
      "Pentameric, but Not Monomeric C-reactive Protein, Limits the SnRNP-immune Complex Triggered Type I Interferon Response: Implications for Lupus Pathogenesis\n",
      "Methionine Commits Immunometabolism and Epigenetic Regulation of BACH2 Loci in B Cells, Resulting in Biases Toward Plasmablast Differentiation in the Pathogenesis of SLE\n",
      "Lower IL-4R in IgD+ Naïve B Cells Is a Pre-disposing Factor for Development of T-bet+ DN2 B Cells in Systemic Lupus Erythematosus\n",
      "Shared and Differing Risk Factors for PsA, Psoriasis, AS, and RA: A Series of Case-control Studies\n",
      "The Pattern of Musculoskeletal Complaints in Patients with Suspected Psoriatic Arthritis and Their Correlation with Physical Examination and Ultrasound\n",
      "Delay Between the Onset of Psoriasis and Arthritis in PsA Patients from the PsART International Cohort\n",
      "Clinically Relevant Patient Clusters Identified by Machine Learning Tools in a Large Database from the Secukinumab Psoriatic Arthritis Clinical Development Program\n",
      "Drug Retention of Biological DMARDs Targeting IL-12/IL-23 or IL-17 versus TNF Inhibitors, After a First Line TNF Inhibitor, in Patients with Psoriatic Arthritis – an Analysis in the Swiss SCQM Register\n",
      "Decision Tree Analysis to Identify Inflammatory Arthritis Patient Subgroups with Different Levels of Treatment Persistence with First-Line Subcutaneous TNF-alpha Inhibitors\n",
      "An Expanded Granzyme K+ CD8 T Cell Population Induces Inflammatory Responses in Rheumatoid Arthritis Synovium\n",
      "Lysosomal Placement of the Energy Sensors AMPK and mTORC1 Controls Tissue Inflammation in Rheumatoid Arthritis\n",
      "Differences in the Phenotypic Landscape and Antigen Specificity of CD4+ T Cells Are Present in CCP+ Subjects Before the Onset of Rheumatoid Arthritis\n",
      "The Transcription Factor MAF Controls the Ability of T Peripheral Helper (Tph) Cells to Help B Cells\n",
      "Calcium/ Calmodulin – Dependent Protein Kinase IV Associates with Phosphofructokinase to Promote Glycolysis and Limit IL-2 Production\n",
      "Clonal Expansion of a Specific Subset of Cytotoxic CD4+T Cells and Tissue Apoptosis in Patients with IgG4-related Disease\n",
      "Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: An Across-Trial Comparison with the Adult Belimumab Studies\n",
      "Application of Bayesian Statistics to Support Approval of Intravenous Belimumab in Children with Systemic Lupus Erythematosus in the United States\n",
      "Factors Associated with Cardiac Dysfunction in a Longitudinal Follow-Up of Neonatal Lupus\n",
      "Nocturnal Blood Pressure Dipping as a Marker of Endothelial and Cardiac Function in Pediatric-onset Systemic Lupus Erythematosus\n",
      "Baseline Clinical and Serological Findings in Pediatric-Onset Discoid Lupus Erythematosus: Analysis of a Multicenter Retrospective Cohort Study\n",
      "Access to Care and Diagnostic Delays in Juvenile Dermatomyositis\n",
      "Persistence of B Cell-rich Synovitis Following Conventional Synthetic Disease Modifying Anti-Rheumatic Drug Treatment in Early Rheumatoid Arthritis Is Associated with Radiographic Progression Independently of Clinical Response\n",
      "Advances in Treatment of Rheumatoid Arthritis: ACPA-positive Patients Benefited More Than ACPA-negative Patients; 25 Year Results of a Longitudinal Cohort Study\n",
      "Risk of 30-day Readmission and Adverse Events After Primary Hip or Knee Arthroplasty: A Comparison of Patients with Rheumatoid Arthritis versus Osteoarthritis Using the Nationwide Readmission Database\n",
      "Antimicrobial Use Is High in Patients with Rheumatoid Arthritis, and Further Increases with First-Line TNFi Therapy – Nationwide Results from Iceland\n",
      "Comparison of Malignancy and Mortality Rates Between Tofacitinib and Biologic DMARDs in Clinical Practice: Five-Year Results from a US-Based Rheumatoid Arthritis Registry\n",
      "Effects of Filgotinib on Anemia, Thrombocytopenia and Leukopenia: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biological DMARDs\n",
      "The Role of Bradykinin Receptor B1 and Its New Ligand Soluble CD13 in Rheumatoid Arthritis and Inflammatory Arthritis Mouse Model\n",
      "Citrulline Reactive B Cells Are Present in the Lungs of Early Untreated RA\n",
      "Perturbation of the Human Gut Microbiome by Methotrexate Contributes to the Resolution of Inflammation and Autoimmune Disease\n",
      "Lung-Related Factors Are Associated with Transitions from Systemic Anti-CCP Antibody Positivity to Classified RA\n",
      "Hypoxia Resistant Pathogenic B Cells Accumulate in the RA Synovial Tissue in a CXCR3 Dependent Manner\n",
      "Increased Expression of Extracellular Matrix Proteins in Human Fibroblast Synoviocytes and Lung Epithelial Cells Following Malondialdehyde-Acetaldehyde Adduct (MAA)/Citrullinated Protein Stimulation\n",
      "Prospective Demonstration That Attainment of the Lupus Low Disease Activity State Is Associated with Improved Health Related Quality of Life\n",
      "Systemic Lupus Erythematous Risk Alleles Drive Autoimmune Features in a Population Without Diagnosed Autoimmune Diseases\n",
      "Combined Trajectories of Fatigue and Disease Activity in an Inception Cohort of Lupus Patients over 10 Years\n",
      "An Integrated Gut Microbiomic and Plasma Metabolomic Analysis in Patients with Four Systemic Autoimmune Diseases\n",
      "Prevalence of Systemic Lupus Erythematosus in the United States: Preliminary Estimates from a Meta-Analysis of the Centers for Disease Control and Prevention Lupus Registries\n",
      "Cell-bound Complement Activation Products in Combination with Low Complement C3 or C4 Have Superior Diagnostic Performance in Systemic Lupus Erythematosus\n",
      "Go-Dact: A Phase 3b Randomized Double-Blind Placebo-Controled Proof-Of-Concept Trial, of Golimumab Plus Methotrexate (MTX) versus MTX Monotherapy, in Improving Dactylitis, in MTX Naïve Psoriatic Arthritis Patients\n",
      "Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor in Patients with Active Psoriatic Arthritis\n",
      "Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis\n",
      "Efficacy and Safety of Low-dose IL-2 in Rebuilting Immunity Re-equilibrium of Psoriatic Arthritis Patients\n",
      "Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDs: Primary Analysis of Phase 3 Trial\n",
      "Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study\n",
      "Deriving Accurate Prednisone Dosing from Electronic Health Records: Analysis of a Natural Language Processing Tool for Complex Prescription Instructions\n",
      "From a Potential Solution to Part of the Problem: Analysis of Spending and Price Trends for Brand-Name and Generic Colchicine and Other Gout Medications\n",
      "The Effect of Rheumatoid Arthritis and Biologics on the Acquisition of Subsequent Diseases and Adverse Events: A Matched Longitudinal Population Study\n",
      "Cost-effectiveness of Duloxetine for Knee OA Patients Whose Pain Can’t Be Controlled by NSAIDs\n",
      "Model-based Cost-Effectiveness Analyses Comparing Combinations of Urate Lowering Therapy and Anti-Inflammatory Treatment in Newly Diagnosed Gout Patients\n",
      "Long-term Clinical and Economic Benefits of a Short-term Physical Activity Intervention Among Inactive Knee Osteoarthritis Patients in US: A Model-based Evaluation\n",
      "Interferon Signature Predicts Response to Tofacitinib in Haploinsufficiency of A20\n",
      "Anakinra Treatment in Patients with Familial Mediterranean Fever: A Single-center Experience\n",
      "The Use and Safety of Rituximab in Connective Tissue Disease Associated Interstitial Lung Disease\n",
      "Cryopyrin-Associated Periodic Syndrome Treated with Canakinumab – Long-Term Follow-up Data Documents Sustained Safety and Remission\n",
      "Rituximab as Rescue Therapy in Treatment-Refractory CTD-ILD\n",
      "Rilonacept in Recurrent Pericarditis: Efficacy and Safety Data from an Ongoing Phase 2 Pilot Clinical Trial\n",
      "DMARD-free Remission in Established Rheumatoid Arthritis: 2 Year Results of the TARA Trial\n",
      "Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response\n",
      "Remission in Patients with Rheumatoid Arthritis Receiving Triple Therapy Compared to Biological Therapy – A Swedish Nationwide Register Study\n",
      "Efficacy and Safety of the Selective Interleukin-1 Receptor Associated Kinase 4 Inhibitor, PF-06650833, in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate\n",
      "Improving the Efficiency of Clinical Trial Recruitment Using Electronic Health Record Data, Natural Language Processing, and Machine Learning\n",
      "A Randomised, Open Labelled Clinical Trial to Investigate Synovial Mechanisms Determining Response – Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis Patients Failing TNF Inhibitor Therapy\n",
      "CD6-ALCAM Signaling Is Upregulated in Kidneys with Lupus Nephritis and Is Associated with Disease Activity\n",
      "Complement Protein CL-K1 at High Concentrations Protects Against the Development of Lupus Nephritis\n",
      "The Role of Alterations in the Splicing Machinery in the Pathogenesis of Lupus: Does It Impact Lupus Nephritis?\n",
      "Increased CD69+ Tissue-resident Memory T (TRM) Cells and STAT3 Expression in Cutaneous Lupus Erythematosus Patients Recalcitrant to Antimalarials\n",
      "Evaluation of the Transcriptome of Non-Lesional, Non-Sun Exposed Skin in Patients with Lupus Nephritis\n",
      "Transcriptomic Meta-analysis of Lupus Affected Tissues Reveals Shared Immune, Metabolic, and Biochemical Dysregulation\n",
      "Predictive Factors for Treatment Related Mortality and Event-Free Survival After Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: Results of a Long Term Follow-up Multi-centre Study\n",
      "Serum Interferon Score Predicts Clinical Outcome at 12 Months in Diffuse Cutaneous Systemic Sclerosis as Measured by Global Ranked Composite Score (GRCS) and Composite Response Index in SSc (CRISS)\n",
      "Predictors to Develop Definite Systemic Sclerosis (SSc): Results from an International Multicentre Study on Very Early DiagnOsis of Systemic Sclerosis (VEDOSS)\n",
      "Machine-learning Classification Identifies a Subset of Patients That Improve on Abatacept via Modulation of a CD28-Related Pathway\n",
      "Ancestry-Specific Classical HLA Alleles Define Phenotypic Subsets in the African American Scleroderma Population\n",
      "Geographic Disparities in Systemic Sclerosis Mortality in the United States: 1999 to 2017\n",
      "Metabolic Signatures of Pathogenic T Cells in Medium and Large Vessel Vasculitis\n",
      "Endothelial Protein C Receptor and Scavenger Receptor Class B Type 1 Negatively Regulate Vascular Inflammation and Are Major Autoantigens in Takayasu Arteritis\n",
      "Comparison of Arterial Patterns of Disease in Takayasu’s Arteritis and Giant Cell Arteritis\n",
      "High Resolution 3D Fast Spin-Echo T1 Black-Blood Imaging for the Diagnosis of Giant Cell Arteritis\n",
      "Imaging Acquisition Technique Influences Interpretation of Positron Emission Tomography Vascular Activity in Large-Vessel Vasculitis\n",
      "Clinical Subsets in Giant Cell Arteritis\n",
      "Does the Degree of Decline in Walking Speed Predict Mortality Risk Beyond the Present Level of Walking Speed in Knee Osteoarthritis?\n",
      "The Effects of Leisure Time Sitting and Sitting at Work on Worsening Radiographic Knee Osteoarthritis over Two Years: Data from the Osteoarthritis Initiative\n",
      "Knee Injury and Transitions Among States of Knee Osteoarthritis in the Johnston County Osteoarthritis Project: A Multi-State Time-To-Event Modeling Approach\n",
      "Dietary Patterns and Symptomatic Progression of Knee Osteoarthritis: Data from the Osteoarthritis Initiative\n",
      "Associations of Socioeconomic Status with Rheumatoid Arthritis (RA) Progression in African Americans with Early Disease\n",
      "Cannabis Use Among Patients in a Large US Rheumatic Disease Registry\n"
     ]
    }
   ],
   "source": [
    "for i in range(len(subsessionxl)):\n",
    "    print(subsessionxl[i])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "e4b774db",
   "metadata": {},
   "outputs": [],
   "source": [
    "temp = pd.ExcelFile('ACR_2019.xlsx').parse('Sheet1')\n",
    "names=temp['NAMES']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "128935f1",
   "metadata": {},
   "outputs": [],
   "source": [
    "conf_names=[]\n",
    "for i in range(len(names)):\n",
    "    conf_names.append('American Society of Abdominal Radiology, SAR - 2019')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "0533eb0f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "24951"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(conf_names)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "98b4a8f1",
   "metadata": {},
   "outputs": [],
   "source": [
    "Initial=[]\n",
    "First=[]\n",
    "Middle=[]\n",
    "Last=[]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "0a26e329",
   "metadata": {},
   "outputs": [],
   "source": [
    "def NameDivider(Name):\n",
    "    inti=\"\"\n",
    "    first=\"\"\n",
    "    last=\"\"\n",
    "    midd=[]\n",
    "    temp=Name.split(\" \")\n",
    "    for i in range(len(temp)):\n",
    "        if(len(temp[i])==2 and i==1):\n",
    "            if(temp[i][1]=='.'):\n",
    "                inti=temp[i][0]\n",
    "            continue\n",
    "        if(i==0):\n",
    "           first=temp[i]\n",
    "           continue\n",
    "        if(i==len(temp)-1):\n",
    "           last=temp[i]\n",
    "           continue\n",
    "        else:\n",
    "           midd.append(temp[i])\n",
    "    if(midd==[]):\n",
    "           mid=\"\"\n",
    "    if(midd!=[]):\n",
    "           mid=\" \".join(midd)\n",
    "    return inti,first,mid,last\n",
    "\n",
    "\n",
    "for j in range(len(names)):\n",
    "    inti,first,mid,lst=NameDivider(names[j])\n",
    "    Initial.append(inti)\n",
    "    First.append(first)\n",
    "    Middle.append(mid)\n",
    "    Last.append(lst)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "816cab0e",
   "metadata": {},
   "outputs": [],
   "source": [
    "k=pd.DataFrame()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "4942fad1",
   "metadata": {},
   "outputs": [],
   "source": [
    "k['Conference Name']=conf_names\n",
    "k['Initial']=Initial\n",
    "k['First Name']=First\n",
    "k['Middle Name']=Middle\n",
    "k['Last Name']=Last"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "1a97c0c5",
   "metadata": {},
   "outputs": [
    {
     "ename": "IndexError",
     "evalue": "index 5 is out of bounds for axis 0 with size 5",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mIndexError\u001b[0m                                Traceback (most recent call last)",
      "Input \u001b[1;32mIn [34]\u001b[0m, in \u001b[0;36m<cell line: 1>\u001b[1;34m()\u001b[0m\n\u001b[1;32m----> 1\u001b[0m k\u001b[38;5;241m=\u001b[39mk\u001b[38;5;241m.\u001b[39mdrop(\u001b[43mk\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcolumns\u001b[49m\u001b[43m[\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;241;43m5\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m]\u001b[49m,axis\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m1\u001b[39m)\n",
      "File \u001b[1;32mC:\\ProgramData\\Anaconda3\\lib\\site-packages\\pandas\\core\\indexes\\base.py:5055\u001b[0m, in \u001b[0;36mIndex.__getitem__\u001b[1;34m(self, key)\u001b[0m\n\u001b[0;32m   5048\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m com\u001b[38;5;241m.\u001b[39mis_bool_indexer(key):\n\u001b[0;32m   5049\u001b[0m     \u001b[38;5;66;03m# if we have list[bools, length=1e5] then doing this check+convert\u001b[39;00m\n\u001b[0;32m   5050\u001b[0m     \u001b[38;5;66;03m#  takes 166 µs + 2.1 ms and cuts the ndarray.__getitem__\u001b[39;00m\n\u001b[0;32m   5051\u001b[0m     \u001b[38;5;66;03m#  time below from 3.8 ms to 496 µs\u001b[39;00m\n\u001b[0;32m   5052\u001b[0m     \u001b[38;5;66;03m# if we already have ndarray[bool], the overhead is 1.4 µs or .25%\u001b[39;00m\n\u001b[0;32m   5053\u001b[0m     key \u001b[38;5;241m=\u001b[39m np\u001b[38;5;241m.\u001b[39masarray(key, dtype\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mbool\u001b[39m)\n\u001b[1;32m-> 5055\u001b[0m result \u001b[38;5;241m=\u001b[39m \u001b[43mgetitem\u001b[49m\u001b[43m(\u001b[49m\u001b[43mkey\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m   5056\u001b[0m \u001b[38;5;66;03m# Because we ruled out integer above, we always get an arraylike here\u001b[39;00m\n\u001b[0;32m   5057\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m result\u001b[38;5;241m.\u001b[39mndim \u001b[38;5;241m>\u001b[39m \u001b[38;5;241m1\u001b[39m:\n",
      "\u001b[1;31mIndexError\u001b[0m: index 5 is out of bounds for axis 0 with size 5"
     ]
    }
   ],
   "source": [
    "k=k.drop(k.columns[[5]],axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "16d640fb",
   "metadata": {},
   "outputs": [],
   "source": [
    "k.to_excel('append.xlsx')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "0165ce02",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
